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ABSTRACT 
The principal target of antibodies that can neutralise HIV- I infection in vitro is the 
surface envelope protein, encoded by the envelope gene (env). The env gene evolves 
rapidly during the course of infection, producing a multitude of variants, many of 
which show different sensitivities to neutralisation by antibodies. The work described 
in this thesis, examines the hypothesis that the selection of antibody-resistant variants 
of the env gene is a strong force shaping the evolution of the env gene, a process that 
allows the virus to persist in the face of a strong immune response. 
In order to examine the antibody-response to the env gene, 19 HIV- I clones were 
constructed by replacing the env gene of the infectious molecular clone pHIXB2-D, 
with homologous env sequences obtained from a single individual. The 19 env genes 
were obtained directly from patient peripheral blood mononuclear cell DNA using the 
polymerase chain reaction. The sequences of the env genes represent the predominant 
types found in the plasma at seroconversion and in five subsequent years of infection 
within this individual. No inactivating mutations were found following the partial 
sequencing of each env clone. 
Following the introduction of the recombinant proviral clones into human T-cell 
cultures, only five of the 19 showed evidence of the production of high-replicating 
viruses. Viruses from these clones induced cell-to-cell fusion (or syncytia), and were 
capable of growth in a variety of human T-cell lines. With the remaining 14 clones, 
three showed evidence low level replication in human peripheral blood mononuclear 
cells, but failed to replicate in T-cell lines and did not induce the formation of syncytia. 
The remaining 11 clones but did not show evidence of productive infection. 
In conclusion, despite being taken directly from an infected patient, only a small 




MCS 	multiple cloning sites 
T-cell 	T-lymphocyte 
MAb 	monoclonal antibody 
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1.1 Impact of HIV on World Health 
The human immunodeficiency viruses cause a chronic, debilitating infection which 
results in a profound loss of the immune system, culminating as the acquired 
immunodeficiency syndrome (or AIDS). 
Although the first cases of AIDS were only reported as recently as 1981, HIV 
infection has caused an escalating pandemic. The World Health Organisation has 
estimated that in 1993, over 15 million people had been infected with HIV, and over 
three million had developed AIDS, most of whom have died. By the end of the 
century, the estimated number of cases of HIV infection, world-wide, is 30 to 40 
million. In many large cities in the United States, AIDS is currently the commonest 
cause of death in young men. However, the situation is worse in the developing 
world, particularly in Sub-Saharan Africa and Southeast Asia, where the estimated 
number of cases is greater than 9 million and 2 million, respectively. 
At present, there is no antiviral drug therapy capable of eliminating HIV-infection, 
nor is there a vaccine against HIV. Since its discovery in 1983, there has been an 
unprecedented effort of biomedical research, aimed at understanding the pathogenesis 
of HIV infection, the development of antiviral therapies, and vaccine research. 
Although HIV is one of the most intensively studied viruses, much remains to be 
understood of the pathogenic mechanisms of HIV infection from both a viral and 
immunological standpoint before effective treatment and vaccines can be developed. 
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1.2. The Natural History of HIV Infection 
Although the course of HIV infection may vary between individual patients, a 
common pattern of disease development has been recognised, and may be divided 
into three stages: primary infection, asymptomatic infection, and symptomatic 
infection. 
Primary Infection 
The course of HTV infection begins with primary infection, which in the majority of 
cases (50 to 70%) is associated with an acute viral syndrome - a period of rapid virus 
replication, and the presentation of clinical illness which may include fever, rash, and 
in some cases hospitalisation may be required (Daar et al, 1991; Clark et a!, 1991). 
However, many cases of primary infection will not produce any clinical symptoms. 
During this period, the levels of infectious virus in the peripheral blood, can reach 
iO cell infectious doses per 106  cells, with plasma-associated HIV RNA levels of 
greater than 107  molecules/ml (Piatak et al, 1993). Viral core antigen (p24) can be 
detected slightly after the detection of plasma viraemia and may reach levels of 10'-
103 pg/ml (Clark et al, 1991). There follows a rapid decline in plasma viraemia, 
coincident with the first detectable anti-p24 antibodies. Cytotoxic T-lymphocytes have 
been detected as the first antiviral immune response (Koup et a!, 1994), with 
neutralising antibody responses occurring later, from between two weeks, to as long 
as 11 months after primary infection (Albert et al, 1990, Arendrup et al, 1992, 
Ariyosha et al, 1992 and Moore et al, 1994b). 
Asymptomatic Infection 
Following the down-regulation of virus production in the peripheral blood, the patient 
enters a period of clinical latency, or asymptomatic infection. During this period, viral 
infection appears to be confined to the lymphoid tissues and peripheral blood - where 
viral replication can be detected (Pantaleo et al, 1993;  Michael et al, 1992; Zhang et 
al, 1991, Ho et al, 1989). 
During the course of asymptomatic infection, the viral load increases, and the number 
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of CD4 T cells slowly declines (Levy, 1993). 
The mean duration of the asymptomatic stage of infection is 10 years (Rutherford et 
a!, 1990). However, in a very small number of patients, there is no period of clinical 
latency, and AIDS may develop within weeks of primary infection. At the other 
extreme, some patients, termed long term survivors, have a more protracted 
asymptomatic stage, in which levels of CD4+ T-lymphocytes may remain stable and 
within the normal range for fourteen years or longer (Haigwood et al, 1993; Cao et 
al, 1995). 
Symptomatic Infection 
After the asymptomatic phase of infection, the patient begins to show constitutional 
symptoms of viral infection - characterised by fever, night sweats, weight loss and 
in some cases, neurological disfunction. The hall-mark of AIDS is a dramatic 
reduction in the number of circulating CD4-positive T-lymphocytes, however, other 
immune dysfunctions can be detected (Miedema, 1992; Levy, 1993). The resultant 
profound immunodeficiency results in the appearance of opportunistic infections and 
the development of neoplasms. Death usually occurs within two years of developing 
AIDS. 
During the period of symptomatic infection, viral replication can increase to 106  RNA 
copies/ml in the peripheral blood (Piatak et al, 1993, Zhang et al, 1991). At 
postmortem, high levels of virus can be detected in both lymphoid and non-lymphoid 
tissues (Donaldson et al, 1994a). 
The Centers for Disease Control (CDC), has introduced, mainly for epidemiological 
purposes and clinical reporting, a four stage classification system for HIV-induced 
disease: 
CDC I, acute infection; 
CDC II, asymptomatic infection; 
CDC ffi, persistent generalised lymphadenopathy; 
CDC IV; other clinical symptoms of HIV-infection. 
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Groups I, If and ifi, are regarded as pre-AIDS conditions, which may or may not, 
progress to AIDS. Group IV, is subdivided into five groups, of which a subset are 
considered to constitute frank AIDS. In 1993, the CDC expanded its definition of 
AIDS to include HIV-infected persons with CD4 lymphocytes counts of less than 200 
per ul. 
1.3. The Virus 
1.3.1. HIV Classification 
The human immunodeficiency viruses belong to the retrovirus family, and to the 
lentivirus subfamily. 
Retroviruses are characterised by the possession of a single-stranded RNA genome 
which is 'reverse-transcribed' into a DNA copy, through the virus-encoded enzyme 
reverse-transcriptase (Weiss et al, 1985b; Varmus, 1988). However, the possession 
of a reverse-transcriptase is not unique to retroviruses, the so-called 'para-
retroviruses', such as the hepatitis B virus, also contain a reverse-transcriptase (- the 
replication of the double-stranded genome of Hepatitis B Virus occurs through an 
RNA intermediate which is reverse-transcribed). Retroviruses are distinguished 
additionally, by virion morphology and composition, and by the structure of the viral 
genome. 
Historically, the retrovirus family has been subdivided into three taxonomic groups, 
based primarily on the disease manifestations caused on infection of the host, and on 
the in vitro consequences of infection. These groups are: 
- the oncovirus subgroup, specific members of which can cause neoplastic disease 
in the infected host. This group includes Rous sarcoma virus, murine and avian 
leukaemia viruses, human and bovine T-cell leukaemia viruses; 
- the spumavirus subgroup, which produce a 'foamy' cytopathic effect in vitro but 
are not clearly associated with disease in vivo. This group includes the human foamy 
virus; 
- the lentivirus subgroup, of which, specific members may cause a chronic infection 
in which the disease state emerges in a slow fashion (ie. after many years of 
infection). This group includes the Equine Infectious Anaemia Virus (EIAV), Visna 
Virus of sheep, the closely related Caprine Arthritis Encephalitis Virus (CAEV) and 
the recently-discovered immunodeficiency viruses - which are found in many 
mammalian groups: human, simian, bovine, and feline. 
There are two distinct types of the human immunodeficiency virus: type 1 (HIV-1) 
whose infection is found globally, and type 2 (HIV-2), whose infection appears to be 
confined to Western Africa. Both HIV subtypes can lead to AIDS, although there is 
evidence that the pathogenic course of HIV-2 is longer (Marlink et al, 1994). 
Despite their name, a number of lentiviruses can cause a rapid, acute disease in the 
host, especially under experimental conditions infecting a new host species. For 
example, infection of pigtailed macaques with an highly pathogenic strain of SIV 
from sooty mangabeys (SIVs , PBl4) can cause death within eight days of inoculation 
(Fultz et al, 1989). Primary infection with the human immunodeficiency viruses 
frequently results in an acute viral syndrome - which is then followed by a more 
characteristic, slow progressive disease. 
It has been argued that for comparative purposes, the retrovirus family should be 
classified according to the complexity of the retroviral genome. In this way common 
patterns of viral life-cycle and modes of infection and pathogenesis may be 
recognised. Cullen, 1991, has suggested that the retrovirus family be classified into 
two groups: simple and complex retroviruses. Simple retroviruses, such as the murine 
leukaemia virus, contain three genes: gag, poi and env, common to all retroviruses. 
Complex retroviruses contain additional regulatory genes, allowing a more complex 
pattern of gene expression. All lentiviruses and the human T-cell leukaemia viruses 
would fall into this latter group. 
The morphology of the virus, as viewed under the electron microscope, has also been 
used to subclassify the retrovirus family. In this system, four subgroups have been 
identified: types -A, -B, -c and -D. The members of each subgroup have a 
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characteristic extra-cellular (virion) and intra-cellular form. This classification system 
is consistent with the genetic classification and has allowed the relatively rapid 
identification of unknown viral isolates (Weiss et a!, 1985b). 
1.3.2. The Virion 
H]V is a small, enveloped virus, the characteristic features of which are depicted in 
figure 1.1. 
The virion contains an inner core, or capsid (CA), whose cone-shape is characteristic 
of the lentivirus subfamily (Gelderbiom, 1991). The capsid contains the viral nucleic 
acid, which is present as two copies of positive-sense RNA, and, in addition, contains 
the viral proteins necessary for the early replication steps, such as the reverse-
transcriptase (RT) and integrase (IN) enzymes. The capsid is surrounded by a 
membrane-associated matrix protein (MA), which is thought to stabilise both the 
capsid and the viral envelope. The virion envelope is a lipid-bilayer derived from the 
host cell during the process of viral budding, and contains the virus-encoded envelope 
surface (SU) and transmembrane (TM) proteins, and also contains host-cell-derived 
proteins, in particular, there is an abundance of the immune-system molecules class 
I and II HLA and 132-microglobulin (Arthur et a!, 1993). 
7 

Figure 1.1 A Schematic Representation of the HIV-1 Virion 
gp4l and gpl2O - virus envelope proteins; p7, p17, p24 - viral core proteins 
RT - virus reverse transcriptase enzyme; RNA - positive-sense, diploid viral RNA genome 
lipid bilayer - virion envelope derived from the host cell 
host proteins - include MHC class I and II molecules and 3-microglobulin 









1.3.3. The HIV Life-Cycle 
The life-cycle of HIV and other lentiviruses, is similar to that of the more simple 
retroviruses (Varmus, 1988). The main differences reside in the regulation of viral 
gene expression; lentiviruses have additional genes which are potent regulators of 
gene expression. In HIV-1 these are the tat and rev genes (Felber and Paviakis, 
1993). 
The first step occurs when the virion encounters and binds to a susceptible host cell - 
the CD4+ T lymphocyte, or the monocyte/macrophage - through a high-affinity 
receptor on the host cell, which for HIV-1 is the CD4 molecule (Dalgleish et al, 
1984; Klatzman et al, 1984b; Maddon et a!, 1984). Two second receptors have been 
identified recently: CC-CKR-5 and fusin (Dragic et al, 1996; Deng et al, 1996; Feng 
et a!, 1996). CC-CKR-5 is required for entry of certain strains of HIV-1 (those with 
a macrophage and T-cell tropism). Fusin is required for entry into the cell of T-cell 
line-tropic strains of HIV-1. This is discussed further in sections 1.3.10 and 1.4, 
below. 
Following binding, the viion is internalised by a process of direct-fusion of virus and 
cell membranes, or by receptor-mediated endocytosis and subsequent fusion of 
membranes intra-cellularly (Maddon et al, 1984; McClure et al, 1988) 
The viion is then uncoated by the complete or partial loss the envelope proteins and 
viion membrane. The virus particle remains in the host-cell cytoplasm as a 
nucleoprotein complex, where the first stages of reverse-transcription occur. The 
diploid, single-stranded RNA genome is copied into a (double-stranded) DNA copy, 
through the complex process of reverse-transcription. 
In the activated, proliferating T-cell, the nucleoprotein (pre-integration) complex is 
then translocated into the host-cell nucleus, and the double-stranded genome maybe 
inserted into the host-cell genome, where it resides as a provirus. 
The provirus is transcribed by the host-cell RNA polymerase II and associated 
transcription factors. The early gene products are the virus regulatory proteins (Tat, 
Rev and Nef) which in turn, promote the synthesis of structural, enzymatic and 
maturation proteins of the virion (Gag, Pol, Vif, Vpu, Vpr, and Env). New viral 
particles are assembled below the host cell membrane, and released by budding from 
the cell. 
Most retroviruses depend upon cell proliferation for replication. At mitosis the 
nuclear envelope breaks down allowing the pre-integration complex to interact with 
the host-cell genome (Lewis and Emerman, 1994). However, lentiviruses can infect 
non-replicating cells, such as macrophages and resting T-cells. HIV-1 contains 
nuclear localisation signals on the viral matrix (p17) and Vpu proteins, which directs 
the pre-integration complex into the nucleus (Bukrinsky et al, 1993; Heinzinger et al, 
1994; Zack et al, 1990). In terminally-differentiated macrophages, and cells arrested 
at G1/S or G2, reverse-transcription, integration and viral replication may then occur 
(Weinberg et al, 1991). 
However, following infection of resting T-lymphocytes - those at G0 of the cell cycle 
- complete reverse-transcription does not occur, and extra-chromosomal partial 
reverse-transcripts can be found (Zack et a!, 1990; Stevenson et a!, 1990a). These 
may direct the expression of gag and env genes (Stevenson et a!, 1990b), although 
this has not been confirmed. Following T-cell activation, integration, and viral gene 
expression can occur. 
1.3.4. The HIV-1 Genome 
The unusual life-cycle of the retrovirus involves two forms of the viral genome: a 
diploid, single-stranded RNA form, which is present in the extra-cellular virion, and 
a double-stranded DNA, or proviral form - which describes the viral genome when 
it is integrated into the host-cell genome. The proviral form also exists as intra-
cellular, unintegrated, circular or linear forms, of which the latter is the normal pre-
integration intermediate (Weiss et at, 1985b). 
The process of reverse-transcription results in the partial duplication of cis-acting 
control elements found at the ends of the RNA form necessary for viral replication 
(elements 'R' and 'U5' at the 5' end, and 'U3' and 'R' at the 3' end). This produces 
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(elements 'R' and 'U5' at the 5' end, and 'U3' and 'R' at the 3' end). This produces 
two identical structures (or long-terminal repeats) at the ends of the provirus, 
containing both U3, R and U5 (figure 1.2). 
Genetic Elements Other Than Coding Regions 
The long terminal repeats (LTRs) contain the essential cis-acting elements defining 
the start-site of RNA-transcription and the polyadenylation site, common to all 
mRNA species, and elements controlling the level of RNA expression. These 
elements include the binding-sites of ubiquitous cellular transcription factors Spi and 
TFIID - the Spi binding site and the TATA box (which are common to all 
retroviruses) (Garcia et al, 1987; Jones et al, 1986). The LTRs also contain binding 
sites for the inducible host transcription factor NF-i'zB, whose activity is induced 
following stimulation of the cell (by mitogens and antigens; Nabel and Baltimore, 
1987; Gruters et al, 1991). The LTR also contains the TAR element (IransActivator 
Response region), through which the viral trans-activator protein, Tat, mediates its 
effect. 
Other recognised genetic elements include a multitude of RNA splice -donor and - 
acceptor sites, of which there are several sets for the smaller regulatory genes 
(Schwartz et al, 1990a, 1990b). There is the Rev-Response Element, or RRE, lying 
at the 3' end of the genome, which is a regulatory element associated with the viral 
Rev protein. 
Coding Sequences 
The HIV- 1 genome encodes nine genes, whereby 'gene' refers to the region encoding 
a primary protein product. Six of the nine genes are referred to as 'essential genes', 
each of which is required for growth of the virus in vitro. These are gag, poi and env 
genes, which are common to all retroviruses, and the three regulatory genes vif, tat 
and rev. There are, in addition, three 'non-essential genes'; vpr, vpu and nef, which 
are not required for establishing viral cultures, although some may be required for 
growth in specific cell culture systems (section 1.4.6, below). 
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Figure 1.2 The HIV-1 Genome 
shaded boxes represent open reading-frames 
TAR transactivator response region 
RRE Rev-responsive region 
LTR long terminal repeat 
opposite page 12 
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1.3.5. Non-Human Primate Immunodeficiency Virus Genome 
Organisation 
The experimental infection of various non-human primate (simian) species with SIV 
or HIV, arguably produce the most relevant animal models in which to investigate 
the pathogenesis of FHV, or SIV infection, and with which to carry out vaccine 
research. Based upon genetic sequence analysis, used to determine the relatedness of 
the primate lentiviruses, four discrete groups are now recognised (Myers et al, 1992): 
- HIV- 1/SIVcpz (wild caught chimpanzee) group; 
- SIVsmm (captive and feral sooty mangabeys)IHIV-2/SIVmac (captive macaques); 
- SIVagm (wild caught African green monkeys); 
- SIVmnd (wild caught mandrills). 
Together, the four groups contain seven 'auxiliary' genes, which are not found in 
other retroviruses. These are: tat, rev, nef, vif, vpr, vpu and vpx. 
- four out of the seven are common to all four primate lentivirus groups: tat, rev, nef 
and vif. 
- vpu is unique to the (HIV-1/SIVcpz) group. 
- vpx is found in the SlVagm and (SIVsmm/HIV-2/SIVmac) groups. 
- vpr is found in the (HIV- l/SIVcpz) group, the (SlVsmm/HTV- 1/SIVmac) group, and 
the SIVmnd group. 
Nucleotide similarity suggests that vpx is a duplicated vpr gene. Thus the absence of 
vpr in the SIVagm group may be compensated by vpx, and the absence of vpx in the 
(HIV-1/SIVcpz) group may be compensated by vpr. vpu stands out as unique to the 
(HIV-1/SIVcpz) group (Myers et al, 1992). 
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1.3.6. The Pattern of HIV-1 Gene Expression 
HIV-1 produces a complex set of mRNA molecules from the alternative splicing of 
a full-length precursor mRNA, initiated from a common position in the 5' LTR 
(figure 1.3). 
The transcripts may be classified into two groups, according to the regulation of their 
expression, and the stage of the viral life-cycle at which they are produced: 
unspliced and partially-spliced, RRE-containing; these are Rev-dependent for their 
expression. These transcripts are produced late in the viral life-cycle, and include 
the messages for the gag, p01, vpu, vpr, vif and env genes. 
small, multiply-spliced mRNAs, that lack the RRB and are Rev-independent. 
These transcripts are produced early in the viral life-cycle and include the messages 
for the regulatory genes tat, rev, and nef. 
The pattern of gene expression is also regulated at the protein level, with many 
transcripts encoding for more than one protein, thus maximising the coding potential 
of the viral genome. Differential gene expression at the protein level may, for 
example, be the result of ribosome frameshifting (gag and poi expression; Wilson et 
a!, 1988), or the use of alternative translation start-sites (vpu and env; Schwartz et al, 
1990b). Post-translational proteolytic cleavage also results in the production of 




Figure 1.3 Principal mRNAs Produced from the HIV-1 Genome 
This figure is adapted from Schwartz et al, 1990a, 1990b. 
Shaded boxes represent open reading-frames 
RRE-i- mRNAs that contain the RRE, and are Rev dependent for their expression 
RRE- mRNAs that have the RRE spliced out, these are Rev-independent for their 
expression. 
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1.3.7. The Function of the Genes of HIV-1 
- gag 
In common with other retroviruses, the Gag and Pol proteins are translated from an 
unspliced gag-pol transcript (figure 1.3), with Pol translation resulting from ribosome-
frameshifting (Wilson et al, 1988). The gag gene encodes a 53kD Gag precursor 
polypeptide (p55a) which is cleaved by the virus-encoded protease to produce the 
p24 capsid (CA) protein, the p17 matrix (MA) protein, and p9 and p7 Gag proteins 
of ill-defined function (figure 1.1). 
The matrix protein, p17, contains a nuclear localisation signal, which directs the pre-
integration complex to the nucleus. This allows the establishment of HIV-infection 
in macrophages, which are terminally-differentiated cells, and resting T-cells (von 
Schwedler et al, 1994; Bukrinsky et al, 1993). 
-pOl 
The poi gene encodes a Pol precursor protein which is cleaved sequentially to yield 
the reverse-transcriptase (RT), protease (PR) and integrase (IN) enzymes. The 
reverse-transcriptase contains a DNA-dependent DNA polymerase, an RNA-dependent 
DNA polymerase and an RNaseH activity, each of which is utilised during reverse 
transcription of the RNA genome into a double-stranded DNA version. RT exists as 
a heterodimer containing a p66 and p55 subunit from the same coding region. The 
integrase is responsible for the integration of the viral DNA into the host genome to 
form the provirus, and the protease is responsible for the post-translational 
modification (maturation) of the viral proteins. 
-tat 
The Tat protein is an 86 amino acid nuclear protein, that acts as a powerful trans-
activator of HIV gene expression, increasing the efficiency of transcription by over 
1000-fold (Marciniak et al, 1990). Tat is required for replication of IIIV in vitro, with 
mutations in tat destroying infectivity (Fisher et al, 1986). The mechanism of the 
action of Tat is unresolved, but appears to be primarily by preventing premature 
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termination, through binding to the RNA transcript itself (Laspia et al, 1989). Trans-
activation by Tat requires a cis-acting target sequence known as the trans-activation 
response element, or TAR element, which is situated just down stream of the 
transcription initiation site, and is therefore common to all HIV transcripts (figures 
1.2 and 1.3). The TAR element forms a stem-loop structure with which Tat, in 
association with cellular factors, interacts directly to exert trans-activation. 
- rev 
The Rev protein controls the pattern of I-IIV mRNA expression, promoting the 
transition from 'early' regulatory gene expression to 'late' structural gene expression 
(Malim et al, 1988). Rev is an early gene product, translated from multiply-spliced 
mRNA (figure 1.3), and is essential for viral replication in vitro. Experiments using 
rev-defective proviruses show that Rev is required for the detection of unspliced 
mRNA and singly spliced RNA. Analysis of the localisation of I-IIV- 1 RNA reveals 
that unspliced and singly-spliced mRNA are retained in the nucleus (Chang and 
Sharp, 1989). Thus it appears that Rev is required for transport of these late mRNAs 
into the cytoplasm. 
The mechanism by which Rev acts is not clear. However, like Tat, Rev exerts its 
effect on the mRNA itself, through a cis-acting target sequence, the Rev-responsive-
element, or RRE, which is situated within the env-coding region (Heaphy et al, 1990, 
Malim et al, 1990, 1991). The RRE is therefore present in the late mRNAs, but is 
spliced out of the early transcripts (figure 1.2). The late transcripts, containing the 
RRE, require the presence of Rev for their expression, ie. are RRE/Rev dependent. 
The early transcripts do not contain the RRE, and are therefore Rev/RRE 
independent. 
- tev 
The tev transcript has been identified as a minor HIV transcript from analysis of in 
vitro cultures of certain HIV-1 strains (for example, the HIV-1 strain FHV- 1 Shaw 
et al, 1984). However, sequence analysis has shown that tev is not present in all HIV 
strains. Tev protein has both Tat and Rev activities and can replace both these 
essential genes (Benko et al, 1990). 
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-vii 
The Vif protein is a late-gene product, produced from singly-spliced mRNA (figure 
1.3). The vif gene is present in all four groups of primate lentiviruses, implying the 
importance of this gene. vif mutants of HIV-1, have dramatically-reduced replicative 
capacity in vitro, the magnitude of which, is dependent upon the cell system used 
(Gibbs et al, 1994). The mechanism of action of the Vif protein is not known, but 
it appears necessary for cell-free viral infection, but not for direct cell-to-cell 
transmission. Vif appears to play a role in the formation of virus particles, however, 
Vif itself is only found at trace amounts in the virion. Vif-defective viruses produce 
virions, but these have an improperly packed nucleoprotein core (Hogland et al, 
1994) and fail to synthesise proviral DNA (von Schwedler et al, 1993). 
-vpu 
Vpu is a l6kD protein, expressed from a bi-cistronic mRNA along with the env 
coding region (Strebel et al, 1988, Schwartz et al, 1990b), which implies a role for 
the co-ordinate expression of the env and vpu genes. Despite this, Vpu is dispensable 
for viral replication in vitro. The main action of vpu in T-lymphocyte culture appears 
to be to promote the export of viral particles from the cell, but Vpu does not have 
a profound effect on the replication rate in this cell type (Klimkait et at, 1990). 
However, it appears that Vpu may be essential for virus growth in cultures of 
monocyte-derived macrophages, where vpu-defective viruses show a block to 
replication, or severely impaired growth, but may be rescued by co-cultivation with 
T-lymphocytes (Westervelt et al, 1992b, Kawamura et at, 1994). The role of vpu on 
growth in monocyte-derived macrophage cultures appears to be complementary to 
role of vpr, such that one of these genes need be functional for replication in this cell 
Two apparently unlinked roles have been described for the Vpu protein; firstly, a 
CD4-independent role, in which Vpu is involved in promoting the release of virus 
particles from the plasma membrane (Terwilliger et al, 1989, Klimkait et al, 1990), 
and secondly, a role in the intra-cellular degradation of CD4, with a consequent 
reduction in the delivery of CD4 to the plasma membrane (Geraghty et al, 1993). The 
down-regulation of the receptor molecule is a common feature of retroviral infection, 
where its role may be to prevent super-infection by additional viruses. 
In the infected cell the HIV-1 envelope precursor protein, gp160, binds to the CD4 
molecule in the endoplasmic reticulum (ER), forming a gpl6O-CD4 complex, which 
results in a reduced delivery of CD4 to the cell surface. Vpu appears to induce the 
degradation of CD4 within the gpl60-CD4 complex, releasing gp160, which is 
subsequently processed into gp120 and gp4l and delivered to the cell surface (Bour 
et al, 1995; Lenburg and Landau, 1993). The biological significance for HIV-1 
infection in vivo of the down-regulation of CD4 and the release and processing of 
gp 160, however, remain to be elucidated. It is of interest that vpu is absent from the 
three other primate immunodeficiency virus groups (section 1.3.3), whose envelope 
proteins have been shown to have a lower affinity for CD4 than the HIV- 1 envelope 
protein (Moore, 1990). This suggests that HIV-1 may have acquired the Vpu protein 
to prevent the formation of the CD4-gp 160 complex, thereby releasing a block to 
gp 1 20-gp4 1 production. 
-vpr 
Vpr is a 12-15kD protein synthesised from a singly-spliced mRNA, late in infection. 
The Vpr protein is incorporated into the virion, where it is associated with the Gag 
precursor protein (p558 ). Vpr contains a nuclear localisation signal to direct the pre-
integration complex into the nucleus. The connection to the nuclear import pathway 
is necessary for viral infection of non-dividing cells: macrophages and resting T-cells 
(Heinzinger et al, 1994). 
Vpr is a non-essential gene, in that laboratory-adapted viruses defective in vpr are 
able to replicate in T-lymphocyte cultures, with equal efficiency to vpr viruses. Some 
researchers have found that vpr-defective proviruses are unable to grow in cultures 
of the monocyte-derived macrophage lineage (Westervelt et al, 1992b). Others, 
however, have found that vpr-defective proviruses show only a small decrease in the 
replication level in this cell type (Kawamura et al, 1994). 
The requirement of vpr in the replication of HIV- 1 in monocyte-derived macrophages 
appears to be complemented by the vpu gene, such that the presence of a functional 
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copy of either of these genes allows the viral replication in monocyte-derived 
macrophages culture (Westervelt et al, 1992b). The HIV-2 vpr gene has similarly 
been shown to be required for replication in monocyte-derived macrophage cultures, 
but dispensable for growth in T-lymphocytes (Hattori et a!, 1990). 
-nef 
The nef gene is found in all primate lentiviruses. Nef is dispensable for viral 
replication in vitro (Terwilliger et al, 1986), but appears essential for pathogenesis 
in vivo following the experimental infection of Rhesus macaques with SIVmac 
(Kestler et al, 1991). 
The in vivo role of nef was demonstrated by experiments of Kestler et a!, 1991, who 
showed that infection of Rhesus macaques with a nef-deleted clone of SIVmac results 
in low titre virus infection, and a stable CD4 count. In contrast, infections of 
macaques with the isogenic nef-intact SIVmac virus results in the rapid progression 
to a severe immunodeficient state, similar to the human AIDS. Furthermore, a strong 
selective pressure for nef function in vivo was shown by the reversion to a fully-
encoding nef gene, of the previously nef-mutant viruses within two weeks of infection 
of the inoculated animals. These animals exhibited high levels of viraemia and 
subsequently developed AIDS. 
The in vitro function of the Nef protein remains ill-defined; it gained its name as a 
negative factor for viral replication. Others, however, have found nef-defective viruses 
to replicate more rapidly, or at least equally-well as nef-intact viruses (Kin et a!, 
1989). 
The nef gene from many isolates appears to down-regulate the surface levels of the 
CD4-receptor molecule (Mariani and Skowronski, 1993). Aiken et al, 1994, have 
shown that the Nef protein promotes the endocytosis of CD4, where it is 
subsequently degraded in lysosomes. The down-regulation of CD4 by Nef occurs at 
early stage, prior to the envelope protein-mediated receptor interference (described 
under the section on vpu, above). 
PTO 
Nef also appears to enhance virus infection and replication, a function independent 
of CD4 down-regulation (Miller et al, 1994; Spina et al, 1994); this may arise by 
enhancing the reverse-transcription process (Schwartz et al, 1995). 
-env 
The env gene of HIV-1 encodes the viral envelope (ENV) proteins. The viral 
envelope proteins play a pivotal role in the viral life cycle: the initial binding of the 
virion to the host cell, and subsequent internalisation of the virion. The envelope also 
plays a role in cell-to-cell transmission of the virus, and is the major target of 
antibodies capable of neutralising viral infectivity. 
The env gene is initially translated as a glycoprotein precursor of molecular weight 
160 kdaltons, designated gp160. gp160 is cleaved intra-cellularly to produce the 
surface (SU) glycoprotein gp120, and the transmembrane (TM) protein gp4l, a step 
essential for viral infectivity (McCune et al, 1988, Willey et al, 1988). Both the 
precursor and mature cleavage products are highly glycosylated, with almost half the 
native molecular weight of gp160 and gp120 attributable to asparagine- (N-) linked 
carbohydrate (Putney, et al, 1986, Leonard et al, 1990). 
After their cleavage, gp120 and gp4l are exported to the surface of the cell where 
they associate via non-covalent interactions. On the surface of the virion, the gp120-
gp4l complexes are associated as heterodimers, forming oligomeric spike structures 
that are visible under the electron microscope (Gelderblom, 1991). The strength of 
the gp120-gp4l association varies between different virus isolates. For cell-line 
adapted strains, such as 1-HV-1IIIB (Shaw et al, 1984), the association is weaker than 
for primary isolates. gp120 can be lost from the surface of the virion, a property that 
correlates with loss of infectivity (McKeating et al, 1991). 
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1.3.8. The Structure of the HIV-1 Envelope Surface Protein gp120 
The surface envelope protein, gpl20, is folded into a complex three-dimensional 
structure, held together by disulphide bonds, whose number are invariant between 
widely divergent isolates (Myers et al, 1991). The assignment of the intra-chain 
disulphide bonds was carried out by Leonard et al, 1990, using a recombinant form 
of gpl20, produced by expression in Chinese hamster ovary cells. This study has 
produced a definitive two-dimensional structure for gpl2O, which is depicted in figure 
1.4. 
The disulphide bonds delineate several domains of gpl20, which are necessary for 
the correct folding of the molecule into a structure capable of binding the cellular 
receptor molecule CD4. The domains delineated by the disulphide bonds coincide 
with those defined as conserved or variable, according to sequence comparisons of 
divergent isolates of HIV-1 (Starcich et al, 1986, Modrow et al, 1987). Sequence 
comparisons have defined five hypervariable regions in gpl20, designated Vl to V5 
(figures 1.4 and 1.6). Interspersed between the hypervariable regions, are four 
conserved regions, designated Cl to C4. 
The Vi and V2 hypervariable regions form a complex double-loop disulphide-bonded 
structure. The V3 and V4 hypervariable regions exist as single loop structures, 
formed by a single disulphide bond at the base of each. Computer-assisted modelling 
predicts that each of the hypervariable domains will be exposed at the surface of the 
molecule and potentially antigenic (Modrow et al, 1987). The V2 and V3 loops do 
indeed form important targets for antibodies found during the course of natural 




(A) The HIV-1 Surface Envelope Protein gp120 
This figure is taken from Leonard et al, 1990, and shows the position of the cysteine 
bonds, and sites of N-linked glycosylation determined for CHO-cell produced 
recombinant gp120, from the HXB2 clone. 
Roman numerals (I to V) indicate cysteine-bonded loops. 
Boxed regions indicate hypervariable regions (Vito V5), defined by Modrow et al, 
1987. N-linked glycosylation sites are shown. 
(B) The HIV-1 Transmembrane Protein gp4i 
This figure is taken from Ratner, 1992 and shows the primary structure of the mature 
gp4l predicted for the HXB2 clone. 
The region important for fusion (the fusion peptide), and the location of potential N-
linked glycosylation are shown. 
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The C4 region has been shown to contain residues important for binding the receptor 
molecule, CD4 (Lasky et al, 1987). However, the testing of panels of gpl20 mutants 
for their ability to bind soluble, recombinant CD4 has shown that other regions of 
gpl20 are important for binding CD4, especially sites C2 and C3 (Olshevsky et al, 
1990). 
The three-dimensional structure of gp120 has not yet been elucidated, due in part to 
the high glycosylation of this molecule, which has precluded the formation of a 
crystal form of gpl20. In consequence, an immunochemical approach has been 
undertaken by many researchers to determine in more detail the structure of gpl20 
(Sattentau et at, 1989, Moore et al, 1993a, 1993b, 1994a). 
This approach has revealed that the conserved regions of gpl20 are inaccessible to 
anti-gp 120 monoclonal antibodies (MAbs) on the native protein. In contrast, the 
variable regions of the envelope are accessible to MAbs and are therefore exposed 
on the protein surface, although MAbs were found to be frequently masked by 
carbohydrate moieties (Moore et at, 1994a). In addition, the Cl and C5 portions of 
gpl20, which are located at the amino terminal and carboxyl-terminal of gpl20, 
respectively, were found to be exposed on a monomeric form of gpl20. However, 
when complexes of gpl20 and gp4l were probed with MAbs, these regions were 
found to be inaccessible, implying that these regions are hidden by contact with gp4l 
(Moore et at, 1994a). 
The examination of panels of recombinant gpl20 proteins altered by site-directed 
mutagenesis, has been a means of determining further the interactions of the different 
domains of gpl20. Amino acid changes in the Cl domain of gpl20 affect the binding 
of MAbs mapping to the C2 domain, implying a functional interaction between Cl 
and C2. Similarly, mutations in C4 enhance the access of MAbs to the V1/V2 
structure. Mutations in C4 also affect the binding of MAbs to the V3 loop, suggesting 
that there is an interaction between C4 and both the V3 loop and the V1/V2 structure 
(Moore et at, 1993a, 1993b). There is also a structural relationship between the V3 
loop and residues in C2 and C4, which contribute to the CD4-binding site (Wyatt et 
al, 1992). 
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1.3.9. The Structure of the HIV-1 Envelope Transmembrane Protein 
gp4l 
gp4l consists of three domains: a hydrophobic external domain at the N-terminal, a 
membrane spanning domain, and an intracellular domain which consists of an 
extensive cytoplasmic tail (figure 1.4B). 
The external domain of gp4l interacts with gpl20 via non-covalent bonds. Genetic 
data suggest that there are two or more contact points between gpl20 and gp4l 
(Gallaher, 1987; Gallaher et al, 1989, Helseth et al, 1990b, Ivey-Hoyle et al, 1991). 
Computer modelling predicts that one of the contact-points in the surface proteins 
(SU) of divergent lentiviruses and oncoviruses forms a structurally-conserved pocket 
(Schulz et al, 1992). This pocket could accommodate a knob-like protrusion formed 
by the transmembrane (TM) immunodominant region. Thus the SU-TM linkage is 
predicted to be a 'knob and socket' structure. 
The external domain also contains the fusion domain, which mediates fusion of the 
viral envelope with the plasma membrane of the host cell (Freed et al, 1990). 
Mutations within this region, can alter fusion in a cell-type specific manner (Bergeron 
et a!, 1992). 
The cytoplasmic domain of gp4l associates with the matrix protein (MA) pl7. 
Deletions in the gp4l cytoplasmic tail block incorporation of the envelope 
glycoproteins into virions, a block that is mediated by p17 (Freed and Martin, 1996). 
1.3.10. Virus Entry into the Host Cell 
Identification of the CD4 Molecule as the Cellular Receptor for 
HIV-1 
The selective tropism displayed by HIV-1 for the subset of T-lymphocytes expressing 
the surface glycoprotein CD4, and the selective depletion of this cell-type in patients 
presenting with AIDS, indicated that the CD4 molecule was the cellular receptor used 
by HIV-1 for entry into the cell (Klatzman et al, 1984a). 
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Dalgleish et al, 1984, identified receptor-positive cells by assaying for the induction 
of syncytia following infection, and assaying the susceptibility of different cell types 
to infection by vesicular stomatitis virus (VSV) pseudotypes carrying the envelope 
molecules from HIV-1. Monoclonal antibodies directed at the CD4 molecule were 
found to block infection byHIV-1, and to block infection with VSV pseudotypes, and 
in addition, to block the formation of syncytia in HIV-1 infected cells (Dalgleish et 
al, 1984, Klatzmann et al, 1984b). 
Further confirmation that the CD4 is the receptor for HIV- 1 has come from the work 
of Maddon et al, 1984, who transformed various human and murine cell lines of 
lymphoid and non-lymphoid origin, with a cDNA clone of the human CD4 gene. The 
expression of the CD4 gene on the majority of human cell lines rendered these 
susceptible to infection by HIV-1. The introduction of the human CD4 gene into 
murine cells, however, did not render these cells permissive for HIV-1 infection, 
indicating the requirement for an additional factor present in human cells but absent 
from murine cells. 
The CD4 molecule is found on a subset of T-lymphocytes (those of the helper 
subset), and on cells of the monocyte-macrophage lineage (Sattentau et al, 1989; 
Maddon et a!, 1984). 
Identification of Second Receptors for HIV-1 Entry into CD4+ T-
Cells 
The receptor molecule CC-CKR-5 has been identified as a second receptor required 
for the entry into CD4+ T-cells of certain strains of H1V-1 (Deng et a!, 1996; Dragic 
et a!, 1996). Co-expression of CC-CKR-5 and CD4+ on cells previously non-
permissive for HIV-1 infection, enables infection by HIV-1 strains that have a 
macrophage-tropic, non-syncytium-inducing phenotype (which will be described 
below). The CC-CKR-5 gene is expressed in T-cell lines HUT78 and PM1, T-cells 
and monocyte/macrophages from peripheral blood (Deng et a!, 1996). 
Another receptor molecule, fusin (also called CKR4, LESTR or HUMSTR), is 
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required along with CD4, for the entry of T-cell-line adapted strains of HIV-1 into 
T-cells (Feng et a!, 1996). 
Mechanism of Viral Entry 
Enveloped viruses enter the host cell by fusion of the viral envelope with the plasma 
membrane of the host cell, leading to the release of the nucleocapsid into the 
cytoplasm. With some enveloped viruses such as the Sendai virus and the 
paramyxoviruses, fusion occurs at the cell surface by direct fusion of the virus 
envelope and the cell membrane. Alternatively, with other viruses, such as the 
Semliki Forest virus, influenza type A virus, mouse mammary tumour virus and 
vesicular stomatitis virus, the virion may first undergo receptor-mediated endocytosis 
into acidic vesicles, where the envelope glycoprotein undergoes a requisite low-pH-
dependent conformational change that facilitates fusion with the endosomal membrane 
(reviewed by White, 1990). 
Viruses that enter the cell by receptor-mediated endocytosis often show a pH-
dependent membrane fusion process, whereby, a low pH causes a conformational 
change in the envelope protein which activates its fusion potential. Virus entry may 
be perturbed by treatment of the cells with lysosomotropic agents such as ammonium 
chloride and chloroquine, which neutralise the endosomal compartments (McClure 
et a!, 1988). In contrast, viruses that enter the cell by direct fusion at the plasma 
membrane show a pH-independent entry into the cell. 
There is evidence to suggest that HIV-1 can enter the host cell by both direct fusion 
at the plasma membrane and by receptor-mediated endocytosis. For example, Maddon 
et a!, 1984, observed a 95% inhibition of viral infection in cells treated with 
ammonium chloride, consistent with a mechanism of viral entry into the cell by 
endocytosis and low-pH-dependent fusion. However, others have shown that HIV-1 
infection is not affected by treatment of the cells with lysosomotropic compounds 
(McClure et a!, 1988). In addition, Pelchem-Matthews et al, 1995, have shown that 
inhibiting endocytosis of CD4 has no effect on the rate of HIV- 1 infection. 
Viruses that show entry into the cell by direct fusion at the plasma membrane, such 
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as, Sendai virus, lentiviruses, paramyxoviruses, and some herpesviruses, exhibit a 
syncytium-inducing property, whereby infected cell and non-infected cells fuse 
through the interactionbetween the viral envelope expressed on infected cells and the 
receptor molecule expressed the uninfected cells. In contrast, viruses that undergo 
fusion within endocytotic vesicles will not be syncytium-inducing. 
Some isolates of HIV-1 form syncytia on infection of peripheral blood mononuclear 
cells, or T-cell lines. In contrast, some isolates are unable to form syncytia (Tersmette 
et al, 1988; Fenyo et al, 1989). The ability to induce syncytia in vitro is a property 
of the env gene: only a small number of amino acid changes are required to change 
a viral clone from a syncytium-inducing type to a non-syncytium-inducing virus 
(section 1.4). It is tempting to speculate that the envelope protein of syncytium-
inducing isolates allows entry into the cell, via attachment to the appropriate second 
receptor by direct fusion at the cell surface. In contrast, the envelope of non-
syncytium-inducing isolates may requires endocytosis for viral entry, in a process 
requiring the second receptor. This is discussed further in section 1.4. 
1.4. Biological Properties Displayed by HIV-1 In Vitro 
Three biological properties displayed by HIV-1 in vitro have been used to classify 
FHV-1 isolates: 
- the replication rate: isolates may be classified as rapid/high, or slow/low, 
according to the rate and level of virus production (Fenyo et al, 1988, 1989; Asjo et 
al, 1986). 
- the cytopathic effect: isolates may be classified as syncytium-inducing (SI), or non-
syncytium inducing (NSI), dependent upon the ability of the virus to induce 
multinucleated cells, or syncytia (Tersmette et al, 1988). 
- the cellular host range: HIV-1 isolates are often described as either 
monocytotropic, or T-cell line tropic, according to the ability of the virus to infect 
cells of the monocyte-macrophage lineage, or CD4+ transformed cell lines 
(Schiutemaker et al, 1991; Cheng-Mayer et al, 1989; Connor et al, 1994). 
Variation in these properties is found between isolates taken from different 
individuals, and in isolates taken at different time points from the same individual 
(Cheng-Mayer et al, 1988, Tersmette et al, 1988). The analysis of the viruses present 
in individual isolates, examined through the production of biological or molecular 
clones, reveals that isolates frequently contain a multitude of variants, each of which 
may show distinct biological properties (Sakai et a!, 1988, Schuitemaker et al, 1992, 
Connor et a!, 1993a). 
1.4.1. The Replication Rate 
The distinction between slow/low and rapid/high isolates was first shown by Asjo et 
a!, 1986, who examined the growth properties of primary HIV-1 isolates by co-
cultivation of patient peripheral blood mononuclear cells (PBMCs) with donor 
PBMCs. The term rapid/high was assigned to isolates able to replicate efficiently in 
PBMCs. Conversely, slow/low isolates were defined as those only able to yield low 
amounts of virus after a prolonged time in culture. 
Rapid/high and slow/low isolates can also be distinguished by their ability to induce 
syncytia and their transmission to CD4+ cell lines. Rapid/high isolates are generally 
found to induce syncytia and replicate in CD4+ cell lines, whereas slow/low isolates, 
in general, do not induce syncytia (Fenyo et a!, 1988, 1989). 
Although this classification system has facilitated the description of viral isolates, the 
differences in replication rate between the rapid/high and slow/low isolates, in reality, 
form a continuum, with no distinct cut-off between the two groups (Fenyo et al, 
1989). 
1.4.2. The Cytopathic Effect 
There are two main cytopathic effects of HP! infection that can be observed in cell 
cultures of HIV-1 isolates. The first is the formation of syncytia, or multinucleated 
giant cells, caused by cell fusion (Fenyo et a!, 1988, 1989; Tersmette et al, 1988). 
The second is single-cell death in the absence of syncytia, which is believed to be 
due to pycnosis and degradation (Fenyo et a!, 1988 and 1989). 
The induction of syncytia, and associated 'cell-ballooning,' which are readily 
observed under the light microscope, is frequently used to classify viral isolates into 
two groups: syncytium-inducing (SI), or non-syncytium-inducing (NSI) (Tersmette 
et al, 1988; Fenyo et al, 1989). The degree and number of syncytia produced by 
different isolates may vary but appears to be independent of the replication rate 
(Tersmette et al, 1989b; De Jong et al, 1993a). 
In order to standardise measurements, a definition of syncytium-inducing capacity 
based upon the induction of syncytia in the T-cell line MT2, has been proposed (Koot 
et al, 1992). In this classification scheme, isolates are considered as syncytium-
inducing if syncytia are observed upon infection of MT2 cells, and non-syncytium-
inducing if no syncytia are observed. 
1.4.3. The Cellular Host Range 
HIV- 1 shows a requirement, or a strong preference, for replication in cells expressing 
the CD4 receptor molecule (Klatzmann et al, 1984a). The most commonly used 
experimental cell culture systems are peripheral blood mononuclear cells (PBMCs) 
obtained from seronegative donors. PBMCs may be fractionated to obtain cultures of 
CD4+ T-lymphocytes, or cultures of monocyte-derived macrophages, both of which 
are permissible to HIV-1 infection (Schuitemaker et al, 1991; Cheng-Mayer et al, 
1988). In addition, CD4-positive transformed cell lines of lymphoid or monocytoid 
origin are widely used (McKeating et al, 1989; Tersmette et al, 1988). Specific 
human cell lines transfected with the human CD4 molecule, such as HeLa CD4, are 
also permissive for FillY infection (Chesebro et al, 1991). 
HIV- 1 isolates show a differing ability to replicate in these different CD4+ cell types, 
which allows a measure of the cellular host-range, or 'cell tropism'. In general, most 
HIV-1 isolates grow in cultures of PBMCs and CD4-positive lymphocytes (Asjo et 
al, 1986; Schuitemaker et al, 1991). Marked variation, however, is seen in the ability 
of different isolates to replicate in CD4-positive transformed cell lines and monocyte-
derived macrophages (Gendelman et al, 1990). 
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In general, HIV- 1 isolates that are capable of growth in cultures of monocyte-derived 
macrophages fail to infect transformed T cell lines. These isolates are described 
variously in the literature, as monocytotropic, MT-tropic (for macrophage and T-
lymphocyte), or of broad host-range, or dual tropic (Moore and Ho, 1995). 
Conversely, isolates capable of growth in CD4-positive cell lines are generally unable 
to replicate in monocyte-derived macrophage cultures. These isolates are referred to 
as T-cell-line tropic, or occasionally as simply T-tropic, or of narrow-host range - 
referring to their loss of ability to grow in macrophages. 
However, many researchers have found that all primary isolates can replicate in 
monocyte-derived macrophages (Cheng-Mayer et al, 1988; Valentin et al, 1994; 
Connor et al, 1993b, 1994, Fiore et al, 1994). Valentin et al, 1994, who found that 
even established T-cell-line tropic strains, such as lilV-1 	and HIV-1SF2, could 
replicate in macrophages, have suggested that it is the method of isolation and 
culturing that explains the discrepancy between different laboratories in the ability to 
propagate isolates in monocyte-derived macrophages. 
The relative ability of different isolates to replicate in CD4+ T-lymphocytes 
compared to monocyte-derived macrophages varies widely. For example, the isolate 
HIV-1 shows a 1000-fold preferential ability to infect T-lymphocytes compared to 
infection of monocyte-derived macrophages. In contrast, the FIIV-1 isolates HW-l A 
and HTV-1BAL, show a 70-fold, and 10-fold increased infectivity, respectively, for 
monocyte-derived macrophages compared to T-lymphocytes. However, the prototype 
macrophage isolates, HIV- 'SF162  and FHV-l jR.FL, show a 10-fold greater infectivity for 
T-lymphocytes compared to monocyte-derived macrophages (Cohn et al, 1994). 
There is a correlation between the three biological properties displayed by HIV-1 
isolates, leading to a broad classification of viral strains into two groups: firstly, 
slow/low replicating isolates which have a non-syncytium-inducing phenotype, and 
are unable to grow in transformed cell-lines, but are capable of growth in monocyte-
derived macrophages; secondly, rapid/high replicating isolates which are generally 
syncytium-inducing, capable of growth in transformed cell lines but not in monocyte- 
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derived macrophages. There are, however, exceptions to this classification, in 
particular, there have been reports of rapidly replicating, syncytium-inducing isolates 
capable of infecting iiiacrophages (Coliman et al, 1992; Connor et al, 1994; Valentin 
et a!, 1994). 
1.4.4. The Relationship between the Biological Phenotype of HIV-1 
Isolates and Disease Status of the Host 
Early studies with isolates of HIV-1 showed that the biological characteristics of an 
isolate are closely related to the severity of the disease in the infected individual. In 
cross-sectional studies, isolates from patients with a more severe disease were often 
found to have a high replicative capacity, and were able to grow in transformed 
CD4+ T-cell lines. In contrast, isolates with lower replicative capacity were isolated 
from patients in the asymptomatic stage of disease, and these generally could not 
grow in transformed CD4+ T-cell lines (Asjo et al, 1986; Fenyo et al, 1988; 
Tersmette et a!, 1988). 
In longitudinal studies, patients who remained asymptomatic during the time period 
studied were found to have low replicating, non-syncytium-inducing isolates that 
could not be transmitted to T-cell lines. Patients who progressed slowly to AIDS had 
higher replicating, non-syncytium-inducing isolates that could not be transmitted to 
T-cell lines. In contrast, patients that showed a rapid progression to AIDS had high 
replicating, syncytium-inducing variants that could be transmitted to T-cell lines 
(Tersmette et a!, 1989b; Connor et a!, 1993b; Oka et a!, 1994). 
Subsequent studies have shown that the emergence of T-cell line tropic, syncytium-
inducing variants, is associated temporally with a rapid CD4+ T-cell decline and the 
development of AIDS in 50% of patients (Koot et a!, 1993). It has been speculated 
that the emergence of these more cytopathic variants is the cause of the decline in 
CD4 cell count and leads to the progression of AIDS; in other words, that a more 
'virulent' strain of HIV-1 emerges during the course of infection (Tersmette et a!, 
1989b, Schuitemaker et a!, 1992). However, whether the emergence of these more 
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cytopathic variants is a cause or consequence of immune system breakdown is not 
known. In particular, 50 % of patients that progress to AIDS do not have syncytium-
inducing (SI) variants, and SI variants can often be found at times much earlier than 
the time of progression to AIDS (Tersmette et al, 1988; Fiore et al, 1994). In 
addition, isolates that are cytopathic in vitro may not be cytopathic in vivo (Mosier 
et al, 1993). 
Whilst many of the early studies correlating viral phenotype in vitro and disease 
progression have highlighted the importance of syncytium-inducing, T-cell line tropic 
variants, other more recent studies have shown the importance of macrophage-tropic 
isolates in HIV-1 infection (Connor et al, 1993b; Gartner and Popovic, 1990; Cheng-
Mayer et al, 1988, 1989). 
Many authors have shown that isolates taken in later stages of disease retain their 
ability to replicate monocytes-derived macrophages (Gartner and Popovic, 1990; 
Connor et al, 1993b, 1994), and may show an increased replicative ability in this cell 
type compared to earlier isolates (Connor et al, 1993b, 1994, Cheng-Mayer et al, 
1988). These later isolates, in addition, frequently acquire the ability to form syncytia 
and the ability to grow in T-cell lines, in agreement with earlier studies (Tersmette 
et al, 1989a, 1989b; Schuitemaker et al, 1992). 
Macrophage-tropic isolates can be found in the peripheral blood at all stages of 
disease, despite the emergence of variants with a greater ability to grow in T cell 
lines, which generally lose their ability to grow in macrophages (Schuitemaker et al, 
1991, 1992). It has been suggested that infection of macrophages with HIV-1 enables 
the persistence of HIV-1 and its spread outside the peripheral blood. Indeed, the 
macrophage appears to be the most important cell harbouring HIV-1 in tissues of 
non-lymphoid origin (Koenig et al, 1986; Wiley et al, 1986). Viruses isolated from 
tissues appear to have a higher ability to grow in cultures of monocyte-derived 
macrophages than do peripheral blood-derived isolates (Schuitemaker et a!, 1992; 
Cheng-Mayer et a!, 1989). 
Isolates taken around the time of primary infection are frequently macrophage-tropic 
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(Schuitemaker et al, 1992; Zhu et al, 1993; Fiore et al, 1994; Kliks et al, 1994). It 
has been suggested that following primary infection, for both sexual and vertical 
transmission, macrophages present in the mucosa and placental tissues may be the 
first target cells encountering Buy-i (Miedema, 1992; Braathen et al, 1987). 
However, it has been suggested that SI variants are suppressed by the immune system 
during the first years of asymptomatic infection and this may delay the pathogenic 
process of infection (Schuitemaker et a!, 1992). In a second study, individuals in 
which variants with a rapid/high phenotype were present on primary infection, 
showed a more rapid CD4 decline than those infected with slow/low viruses (Fiore 
et a!, 1994). In this study also, all isolates were capable of replication in monocyte-
derived macrophages. 
The macrophage is also an important cellular target of ungulate lentiviral infections - 
specifically Visna virus of sheep, and caprine arthritis encephalitis virus of goats. 
Disease is characterised by virus-infected macrophages in several target organs, such 
as the lung, joints and CNS, where they initiate inflammatory responses which result 
in extensive organ damage (Haase, 1986). 
Insight into the possible importance of the infection of macrophages in the 
pathogenesis of HIV-1 has come from work with the experimental infection of 
chimpanzees with HIV-1 (Schuitemaker et a!, 1993). It is known that chimpanzees 
may be infected long-term with HIV-1, but do not develop clinical symptoms. In the 
infected animals systemic immune dysfunction does not occur; antigen-presenting 
function remains intact, T-cells have normal proliferative capacity with no evidence 
of programmed cell death, which are often cited as evidence of immune dysfunction 
in infected humans. Low viral loads can be demonstrated in the peripheral blood at 
levels of 1 in 103  to iO infected cells. Virus may be isolated from the peripheral 
blood of these animals; however, these isolates show an exclusive tropism for 
chimpanzee peripheral blood lymphocytes, and are unable to replicate on either 
chimpanzee or human monocytes. The lack of ability of HIV-1 to infect chimpanzee 
monocytes is believed to result in an absence of immune dysfunction, and the ability 
to control viral replication. However, these experiments were conducted with the T-
cell line adapted isolate fflV-1 (Shaw et a!, 1984), which is unable to replicate in 
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monocyte-macrophages, or to very low levels (Valentin et at, 1994). 
1.4.5. Mapping the Determinants of Viral Phenotype 
Studies with recombinant proviral clones generated by swapping different subgenomic 
regions of clones with distinct phenotypes, have shown that the principal determinant 
of viral replication rate, cytopathic effect and cellular host-range, resides in the env 
gene (O'Brien et at, 1990; Helseth et al, 1990b; York-Higgins et al, 1990; Cheng-
Mayer et al, 1991; Chesebro et al, 1991; Westervelt et al, 1991; Shioda et at, 1991; 
Groenink et at, 1992; Cann et at, 1992; Fujita et al, 1992; Sullivan et at, 1993; 
Stamatatos et al, 1994). 
In many cases, only a few amino acid substitutions within the V3 loop were 
sufficient to change the phenotype of resultant clones. Amino acid substitutions in the 
V3 loop can alter the syncytium-inducing capacity of molecular clones (De Jong et 
at, 1993a, 1993b), and the cellular tropism (Takeuchi et al, 1991; Hwang et at, 1991; 
Shimizu et al, 1994; Stamatatos et al, 1994; Wiley et at, 1994). 
However, other regions of the env gene have been found to influence the phenotype. 
For example, the Vi and V2 regions act in combination with the V3 loop to alter 
syncytium-inducing ability and replication rate (Andeweg et a!, 1993; Groenink et al, 
1992, 1993; Sullivan et at, 1993; Koito et al, 1994). In addition, the cellular tropism 
can be altered by single mutations in the Vi region (Boyd et al, 1993). 
Other genes, or genomic regions, also affect virus phenotype. For example, the 
replication rate in different T-cell lines may be altered by changing the sequences of 
the Rev-responsive element (Dayton et a!, 1993), or by mutations in tat gene (Cheng-
Mayer et al, 1991). The cellular host-range may be narrowed by the absence of a vpu 
or vif gene, which are required in conjunction with specific env sequences for 
replication in monocyte-derived macrophage cultures (Westervelt et at, 1992b, Du et 
a!, 1993). However, the LTR does not appear to be involved with in vitro phenotype 
in HIV-1 (Hirsch et a!, 1990; Pomerantz et a!, 1991) 
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1.4.6. The Relationship between the Amino Acid Sequence of the V3 Loop and 
the In Vitro Viral Phenotype 
Whilst studies with recombinant clones have demonstrated the influence of specific 
amino acids or regions of the env gene on the phenotype, each used artificially-
constructed recombinant viruses; the effect of these changes may be influenced by 
the background of the virus used. Perhaps more relevant to determining the 
phenotype of isolates obtained from infected patients are studies of panels of HIV-1 
isolates which aim to correlate specific sequence-motifs, or amino acid substitutions, 
with a given phenotype (Fouchier et al, 1992; Milich et al, 1993). 
An early indication that T-cell line tropic and macrophage-tropic viruses may 
constitute two different groups according to the amino acid sequence of their V3 loop 
was provided by Chesebro et al, 1992. In this study, it was observed that the V3 loop 
of macrophage-tropic isolates showed a more restricted set of mutations as compared 
to T-cell-line tropic variants. 
Fouchier et al, 1992, showed through comparisons of the V3 loop amino acid 
sequence from a panel of sequential biological clones that there is a correlation 
between the acquisition of basic amino acids (K and R) at positions 11 and 25 in the 
V3 loop and the transition from an NSI to an SI phenotype (figure 1.5). The presence 
of a basic amino acid at one or both of these sites has been shown experimentally to 
confer an SI-phenotype on the resultant viral clone (De Jong et al, 1993b). 
In a more extensive study, Mulch et al, 1993, examined a large data set consisting 
of well-characterised FIIV- 1 isolates for which the sequence of the V3 loop was 
known. A correlation was found between both the charge of the V3 loop - in terms 
of the presence of basic amino acids at specific residues - and the sequence 
heterogeneity of the loop - and the in vitro phenotype. All T-cell-line tropic viruses 
had basic amino acids (K and R) in at least one of the four positions: 11, 24, 25 32, 
which was generally associated with a change away from an acidic residue (BID) at 
position 25. In contrast, no macrophage-tropic isolates had a basic substitution at any 
of these positions. In addition, isolates with basic amino acid substitutions, showed 
a two-fold greater number of amino acid differences from the North American 
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The V3 loop of HIV-1 
(subtype B consensus sequence) 
p 0 R 
F 
I 	 Y 
H T 
	
I 	 T 











Residues underlined are the sites whose charge is important in determining the 
syncytium-inducing ability and cellular host-range (see text for details). 
(subtype B) V3 loop consensus sequence (Myers et a!, 1991). 
A further analysis along the same lines by Donaldson et a!, 1994b, showed that in 
combination the net charge of the V3 loop and number of amino acid differences 
from the subtype B consensus sequence produces an almost complete separation of 
published variants into two groups. The first contains the NSI/macrophage-tropic 
isolates, which have a low net charge and greater similarity to the subtype B 
consensus. The second contains the SIlT-cell-line tropic variants, which are of higher 
charge and greater heterogeneity. 
1.4.7 The Role of Second Receptors in HIV-1 Tropism 
The CC-CKR-5 molecule is a co-receptor with CD4, allowing fusion and entry of 
NSI, macrophage and T-lymphocyte-tropic strains into T-lymphocytes (T-cells) (Deng 
et a!, 1996; Dragic et al, 1996). In contrast, the receptor molecule, fusin, is required 
for fusion and entry of T-cell line-tropic, SI strains (Feng et a!, 1996). 
A model for receptor usage and cell tropism has been proposed by Deng et a!, 1996. 
The envelope protein of isolates found early in infection, that is, NSI, T-cell and 
macrophage-tropic, may have a high binding affinity for CC-CKR-5 which is 
expressed in macrophages and T-cells. In contrast, the switch to a T-cell-line tropic 
virus, seen during the course of infection, or following prolonged passage in vitro, 
may be due to changes in envelope configuration, allowing the use of fusin, as well 
as, or instead of CC-CKR-5. Fusin is presumed to be expressed on T-cells and T-cell 
lines. 
1.4.8 Possible Role of the V3 Loop in Viral Life-Cycle 
Whilst there is convincing evidence demonstrating the role of the V3 loop in 
determining the cellular host range and syncytium-inducing ability of FHV-1, the 
mechanism and the stage in the viral life-cycle at which the V3 loop exerts its 
effect(s) is currently not known. 
The V3 loop resides outside the CD4-binding site, and the hydrophobic fusion peptide 
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which resides in gp4l. Antibodies to the V3 loop which act to prevent viral infection, 
act at a step after the binding of the virion to CD4 (Page et al, 1992). This suggests 
a role for the V3 loop in a post-CD4-binding step of viral entry. 
It is known that the envelope protein undergoes a conformational change following 
binding to CD4 (Sattentau and Moore, 1991). Upon binding, the V3 loop adopts a 
more exposed position on the envelope complex (Sattentau et al, 1995). This change 
in conformation, which may be influenced by the structure and charge of the V3 
loop, is believed to trigger or activate the fusion potential of the virus. 
With the recent discovery of different co-receptors for entry of T-cell line SI strains, 
and NSI macrophage strains, it has been speculated that a post-CD4 binding 
conformational change in the HIV- 1 envelope may expose a co-receptor binding site. 
This co-receptor binding site may contain the V3 loop or be influenced by its 
conformation (Deng et al, 1996; Dragic et a!, 1996). Binding to the appropriate co-
receptor, may induce further conformational changes activating the fusion domain in 
gp4l. 
1.5. The Genetic Variation of HIV 
1.5.1. The Quasispecies 
One of the most important properties displayed by HIV is its genetic variability. 
Indeed, it is now recognised that most viral species, especially the RNA viruses, 
which display a high mutation rate, consist of a genetically complex population that 
comprises multiple variants. 
The term quasispecies has often been used to indicate the heterogeneity of a virus 
population. A quasispecies, however, is more than an heterogeneous population of 
virus genomes, but a mathematically-defined distribution of mutants generated by a 
mutation-selection process (Eigen et a!, 1988). The term was originally used in 
theoretical work on the origin of life, to describe a cluster of closely related 
molecular species, produced by errors in the self-replication of the molecules. For 
example, in the situation where there are no errors during self-replication, and an 
array of mutants with different replication rates, a homogeneous population will arise 
by Darwinian selection, consisting of the fastest-roplicating variant. However, when 
the error-rate is high - such as for RNA viruses - a distribution of mutants is 
generated (the quasispecies), which will eventually reach an equilibrium. At the 
population equilibrium, a consensus (or 'master') sequence is produced, around which 
the mutants are distributed. This has been experimentally documented for in vitro 
systems (Domingo et al, 1978). 
The importance of the quasispecies is that the target of selection is the mutant 
distribution, rather than a single sequence. In the case of a population of RNA 
viruses, many different phenotypic variants may co-exist in the quasispecies. These 
may then be the target of selection: for example - resistant forms that are no longer 
recognised by the host's immune system - as has been found for influenza A virus 
(Fitch et al, 1991), and proposed for lentiviral infections (Carpenter et a!, 1987; 
Albert et al, 1990; Burns et al, 1993), and for the development of drug resistant 
mutants - such as AZT resistance in HIV- 1 infection (Larder et al, 1989). There may 
be the potential for the selection of more virulent or pathogenic forms, both within 
the individual, as has been postulated for HIV- 1 and -2 (Tersmette and Schuitemaker, 
1993, Nowak and May, 1993), and within the infected population as a whole - such 
as has occurred in myxoma virus infection of rabbits (Fenner and Kerr, 1994). 
Demonstration of Genetic Variability of HIV-1 
HIV-1 shows considerable variation across the whole genome. However, the rate of 
substitution, is not uniform, but is particularly high in the env gene and the regulatory 
genes tat, rev, nef, vif and vpr. The gag gene encoding the virion structural proteins, 
and the poi gene encoding the viral enzymes, show an approximately ten-fold lower 
rate of nucleotide substitution (Li et al, 1988). 
Variation in the env gene, which shows the highest rate of substitution, is not 
uniform. Early studies, comparing env gene sequences from different isolates, 
revealed the presence of five hypervariable regions, designated Vi to V5, which 
show less than 25% conservation of amino acid sequence (Modrow et a!, 1987, 
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Starcich et al, 1986). These hypervariable regions map to the surface glycoprotein 
(gp120) portion of the env gene (figures 1.4 and 1.6). Interspersed between the 
hypervariable regions are more conserved regions, designated the conserved regions 
Cl to C5. The transmembrane protein (gp4l) does not contain any defined 
hypervariable regions, but does show extensive variation between different HIV-1 
sequences (Myers et al, 1991). 
Source of Variation 
A major source of the genetic variation of HIV is from the error-prone viral 
polymerase enzyme - reverse transcriptase. This enzyme lacks a 5'->3' exonuclease 
or 'proof-reading' ability, and therefore cannot repair nucleotide mismatches 
introduced into the sequence during the synthesis of the viral DNA. The frequency 
of the introduction of point-mutations into the genome has been estimated as 2x10 3 
to 5x10 3 per nucleotide per replication cycle (Preston et a!, 1988, Roberts et al, 
1988). However, Mansky and Temin, 1995, found an 'in vivo' error rate using an 
HIV-1 based shuttle vector replicating in BeLa cells, to be 3 .4x i0 5, 100-fold lower 
than the in vitro rate. This figure is, however, 3 to 7 times higher than those reported 
for other retroviruses. 
Other mutational processes have been described for HIV- 1. For example, the process 
of hypermutation, has been described, whereby a predominance of G to A transitions 
occurs (Goodenow et al, 1989). The mechanism for this is unclear, but appears to be 
due to a property of the reverse transcriptase. In addition, during the viral life cycle, 
the provirus is transcribed by the cellular RNA polymerase II, which is another error-
prone polymerase, providing a further source of mutation. 
Recombination between non-identical viral genomes present in the same virion can 
occur under experimental conditions. During reverse-transcription, template-switching 
by the reverse-transcriptase enzyme may result in the generation of a 'hybrid' double-
stranded DNA version that is recombinant between the two RNA molecules (Hu and 
Temin, 1990). There is evidence of recombination occurring during the course of 
natural infection with HIV-1 (Clavel et a!, 1989, Howell et al, 1991, Simmonds et 
a!, 1991, Diaz et al, 1995). 
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Figure 1.6 
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The Different Levels at which the Genetic Variation may be Examined 
The genetic variation and evolution of HIV can be examined at several levels. The 
genetic differences between the human and primate immunodeficiency viruses can be 
used to determine their evolutionary relationships - which may shed light on the 
origin of HIV-1 and HIV-2 (Myers et at, 1992; and Bigen and Nieselt-Struwe, 1990). 
Comparisons of the rates of amino acid changes in human and simian 
immunodeficiency viruses, have been used to examine the evolution of viral virulence 
(Shpaer and Mullins, 1993, Nowak and May, 1993). 
The use of genetic relatedness of HIV sequences (presented as a phylogenetic tree), 
can be used to trace the spread of HIV - globally (Louwagie et at, 1993; Charneau 
et al, 1994), within a community (Holmes et al, 1995; Ou et al, 1992), or indeed, 
within the different tissue compartments of an infected individual (Donaldson et al, 
1994b; Korber et at, 1994). This type of analysis is known as molecular 
epidemiology. 
1.5.2. The HIV Subtypes 
HIV-1 Subtypes 
In order to characterise the global diversity of HIV- 1, isolates from different parts of 
the world have been examined. Extensive molecular epidemiology studies, using both 
sequence information and genetic heteroduplex analysis, have shown that isolates of 
HIV-i fall into two genetic clusters, which appear to be the result of two independent 
introductions of primate lentiviruses into the human population (Louwagie et al, 
1993; Myers et at, 1991; Deiwart et at, 1994). 
The first cluster has been named group M, for (major group) (Charneau et at, 1994) 
and contains the majority of HIV-1 isolates found world-wide. The second cluster 
which has been named group 0 (for Qutgroup) was discovered recently, with a small 
number of cases from infected patients in Cameroon and more recently of a French 
woman who had never travelled outside Europe, nor identified a sexual partner from 
Africa, nor had received any known blood transfusion. (Charneau et al, 1994). 
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Group M is further divided into 8 distinct genetic lineages (or clades), on the basis 
of both gag and full-length env sequence data (Louwagie et al, 1993), differing by 
10 to 13% in their nucleotide sequence. The genetic lineages define 8 HIV-1 
subtypes, denoted A to H. A ninth subtype I, has recently been recognised, from 
patients in Cyprus (Kostrikis et al, 1995). 
The global distribution of the subtypes is complex, with some subtypes showing a 
restricted distribution, whilst others are distributed in many continents, and as a 
consequence many locales, such as Central Africa, have multiple subtypes (table 
below). 
Table 1. Summary of the global distribution 
of HIV-1 subtypes from group M 
Subtype Predominant distribution 
A Central and Western Africa 
B North America and Europe, Brazil 
C South and Central Africa 
D Central Africa 
E Northern Thailand, South and Central 
Africa 
F Brazil, Rumania, Zaire 
G Gabon and Zaire 
H Gabon 
I Cyprus 
The subtypes have been used to study the epidemiology of HIV-1 infection world-
wide (reviewed by Leigh Brown and Holmes, 1994). Each subtype has been shown 
to eventually cause AIDS and to date, there is no evidence to suggest a difference in 
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the rate of pathogenesis of the different subtypes. 
In terms of vaccine design, extensive serological research is being undertaken with 
the eventual aim of quantifying the number of different epitopes required to produce 
a vaccine capable of counteracting infection with the diverse range of variants that 
may be encountered in the field (Gao et al, 1994 & 1996; Moore et al, 1994c & 
1996). In a study to determine the extent of neutralisation serotypes, Moore et al, 
1996, found that although the different neutralisation serotypes did not correspond to 
the genetic subtypes, some sera were found to neutralise across clades. This raises 
hope for the development of a broadly effective vaccine. 
HIV-2 Subtypes 
The extent of genetic diversity of HIV-2 has been studied by Gao et al, 1994, who 
obtained viral sequences from West African HIV-2 sero-positive asymptomatic and 
AIDS patients from whom virus isolation had repeatedly been unsuccessful. 
Phylogenetic analysis using gag, poi and env sequence data, revealed five distinct 
genetic lineages, denoted, by analogy to HIV-1, subtypes A to E. 
There are some preliminary indications that there may be significant differences in 
the biology of the different HIV-2 subtypes: viruses from type A were able to grow 
to high titre in cell culture, whereas all attempts to obtain isolates from type C, D and 
B, as well as the majority of subtype B failed (Gao et al, 1994). However, greater 
numbers of patients will be required to demonstrate whether the inability to isolate 
is a genuine phenomenon or a biased result due to the small number of patients 
studied. 
1.5.3. The Evolution of HIV-1 During the Course of Natural Infection 
The degree of genetic variation of the env gene of HIV-1 within an infected 
individual varies according to the disease status of the patient. Three phases of 
evolution: I, II and ifi, have been identified (McNearney et al, 1990 and 1992; Leigh 
Brown, 1991; Wolfs et al, 1992; Zhang et al, 1993; Zhu et al, 1993). These coincide 
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with the three clinical phases of H]1V infection: primary infection, the asymptomatic 
phase and the symptomatic phase. It believed that the three phases of sequence 
evolution are a result of different selective processes acting upon the virus population 
at these time points. 
Phase I: the sequence diversity observed upon primary infection, prior to the 
development of the anti-viral immune response. A number of researchers have found 
that there is a restricted diversity within the env gene on primary infection (Wolfs et 
al, 1992; McNearney et at, 1990; Ait-Khaled and Emery, 1993; Zhu et al, 1993; 
Zhang et al, 1993). This restricted diversity is seen following either one of the three 
main routes of transmission: sexual intercourse (Kuiken et a!, 1993; Zhu et al, 1993), 
transmission via blood or blood products (Cichutek et al, 1991; McNearney et a!, 
1992; Zhang et al, 1993), and mother-to-child transmission (Wolinsky et al, 1992; 
Scarlatti et al, 1993; Mulder-Kampinga et a!, 1993). 
In the study of Zhang et al, 1993, no sequence variation was found in the V3 and V4 
regions of the env gene within any of the infected patients. In addition, the amino 
acid sequences of the V3 loop were extremely similar in different patients, many of 
whom showed epidemiologically unlinked infections (Holmes et al, 1995). This was 
in marked contrast to the sequences of the gag gene, which showed diversity in a 
number of patients. A similar result was found by Zhu et a!, 1993, although in this 
case, less similarity was found in the V3 loop sequence. Again, a greater diversity 
was found in the sequences of the gag genes, suggesting a constraint on the env gene 
diversification. 
This restriction in diversity in the env gene, which is not observed for the gag gene, 
may be the consequence of a strong selective force acting during primary infection, 
or during transmission. The result of this force produces extremely homogeneous V3 
loop sequences within the individual (Zhang et a!, 1993) and similar sequences 
between patients (Kuiken et a!, 1993; Zhang et al, 1993). 
The majority of V3 loop sequences found at primary infection are very similar to 
those of macrophage-tropic isolates (Wolinsky et a!, 1992; Mulder-Kampinga et a!, 
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1993; Scarlatti et a!, 1993; Zhu et al, 1993; Zhang et al, 1993). In accordance with 
this, many virus isolates taken at primary infection are macrophage-tropic and NSI 
(Schuitemaker et a!, 1992; Zhu et al, 1993), but not exclusively so (Clark et al, 1991; 
Fiore et al, 1994). 
It is conceivable that the macrophage is the most efficient cell at transmitting the 
virus, or that macrophages provide the primary target for virus infection after 
transmission to the new host. However, it is conceivable that the limited 
heterogeneity found at primary infection could be due to a sequence bottleneck 
occurring during transmission, with infection initiated by a very few random variants. 
However, if this were so, we would not expect to see such a high degree of diversity 
in gag. 
Phase II: This is the phase of asymptomatic infection in which there is continual 
viral replication in the peripheral blood and lymph nodes, despite the presence of a 
strong anti-viral immune response (Zhang et al, 1991; Piatek et al, 1993; Michael et 
al, 1992). Several studies have demonstrated that in the peripheral blood at this time 
the virus population shows a high degree of genetic heterogeneity and, in addition, 
there is a rapid turnover of sequence variants with time (Hahn et al, 1986; Meyerhans 
et al, 1989; Howell et al, 1991; Simmonds et a!, 1990a, 1991; Wolfs et al, 1990, 
1992; Holmes et al, 1992; Cichutek et a!, 1992; Kusumi et a!, 1992; McNearney et 
al, 1992; Deiwart et al, 1994; Lukashov et a!, 1995). 
Similar studies with experimentally-infected monkeys have shown that rapid sequence 
diversity arises over the course of infection (Burns and Desrosiers, 1991; Baler et al, 
1991, Johnson et a!, 1991). 
Much of the variation in the Vito V5 of the env gene results in amino acid changes 
at specific sites, and these are frequently found to alter the number of N-linked 
glycosylation sites. In addition, there is considerable change in the length of the 
hypervariable regions, although the length of the V3 loop is relatively conserved at 
35 amino acids (Simmonds et a!, 1990b, 1991; Holmes et a!, 1992; Howell et at, 
1991; Cichutek et at, 1992). These changes may represent variation that results in the 
45 
generation of antigenically-distinct variants. 
Phylogenetic analyses have shown that the evolution of the env gene during the 
asymptomatic period is complex. In the hypervariable regions, often two or more 
distinct viral populations exist at any one time. These populations will often differ 
by a number of point mutations, and/or the length of the variable region (Howell et 
al, 1991; Simmonds et al, 1991; Holmes et al, 1992; Cichutek et al, 1991). The 
distinct populations evolve in parallel, so the sequence evolution does not follow a 
simple linear path where one variant is replaced by its descendants; distinct variants 
arising from the other population will also be present. This process of evolution is 
discussed in detail in chapter 5 of this thesis. 
Amino acid substitutions in the V3 loop observed at this time are often at sites that 
alter antibody recognition when synthetic peptides representing the V3 loop are used 
to assay antibody-binding (Wolfs et a!, 1991; Zwart et al, 1991). Indeed, Wolfs et al, 
1991, have shown that the V3 sequence variants which emerge during the course of 
infection are accompanied by the emergence of a new population of V3-specific 
antibodies. 
The argument that selection is a dominant force driving sequence evolution during 
this phase of infection can be made by determining the proportion of synonymous 
nucleotide substitutions (Ks) to non-synonymous substitutions (KA), expressed as the 
KS/KA ratio (Simmonds et al, 1990b; Wolfs et al, 1992). In these studies, the Ks/KA 
ratio of the V3 region, was found to be less than 1, which is indicative of positive 
selection. A similar predominance of non-synonymous substitutions was found by 
Burns and Desrosiers, 1991, who examined the evolution of SW in experimentally-
infected rhesus monkeys. 
Together, these data strongly suggest that the variants within the env gene evolve 
under selection pressure from the immune system. 
Phase ifi: This stage begins at the time when the immune system breaks down and 
the patient progresses to AIDS. There is an increase in viral burden at this time, 
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presumably due to the loss of constraint on viral replication from the immune system. 
HIV-1 infection, which during the asymptomatic phase is limited to the lymphoid 
tissues and peripheral blood, spreads to many other organs of the body, including 
tissues of non-lymphoid origin such as the brain, lung and muscle (Donaldson et al, 
1994a). By analogy to phase I, which occurs before the immune response develops, 
it has been predicted that in the absence of immune control, the fastest replicating 
viruses will predominate, and this will reduce the variation observed (Nowak et a!, 
1990). 
A limited variation was seen in the env gene of two infected neonatal patients who 
rapidly progressed to AIDS following blood transfusion (McNearney et al, 1990). 
However, in a study of four patients who died of AIDS-defining illness, a wide range 
of sequence variation was observed in the V3 loop of sequences taken from 
peripheral blood cells, lymph nodes and non-lymphoid organs (Donaldson et a!, 
1994b). This sequence diversity was equal to that seen in three asymptomatic 
patients, who died of non-AIDS-related causes. 
1.5.4. Sequence Variation and Tissue Tropism In Vivo 
HIV has been found to infect cells of both lymphoid and non-lymphoid origin - such 
as the central nervous system, lung, small and large intestine (Levy, 1993). 
In the peripheral blood, the predominant cell type infected is the memory CD4+ 
lymphocyte (Schnittman et a!, 1990), although others have reported the presence of 
HIV sequences in monocytes and dendritic cells, but these appear to be infected at 
a lower frequency than CD4 lymphocytes (Macatonia et a!, 1990; Yamashita et al, 
1994). In the lymph nodes HIV-1 is found in CD4+ lymphocytes and macrophages, 
and associated with follicular dendritic cells (FDCs) - where it is thought virions are 
trapped by cellular processes of the FDCs (Embretson et al, 1993; Pantaleo et al, 
1993). 
In contrast, HIV infection of non-lymphoid tissue appears to be mainly limited to 
tissue macrophages. For example, in the brain the most predominantly infected cell 
47 
is the macrophage and microglial cells (Koenig et al, 1986; Wiley et al, 1986). 
Infection in the lung is also associated with macrophages, although there is some 
evidence of lymphocytic infiltration of lung tissue in AIDS patients which may 
harbour HIV (Donaldson et al, 1994b; Bell et al, 1993). 
Based upon sequence analysis, a number of researchers have found that the non-
lymphoid tissues harbour different viral populations than the peripheral blood or 
lymphoid tissue (Epstein et al, 1991; Pang et al, 1991; Ball et a!, 1994; Itescu et a!, 
1994). 
Some have addressed the question of whether there is a specific adaptation of HIV 
variants for different cell types, and whether these sequence differences reflect the 
differences found between in vitro macrophage or T-cell line tropic variants. This 
approach was taken by Donaldson et al, 1994b, who examined proviral DNA 
sequences from a number of organs, both lymphoid- and non-lymphoid, taken at post 
mortem from three patients who died while in the asymptomatic stage of infection, 
and four patients who died with AIDS-defining illness. In patients dying of AIDS, 
there were distinct populations of HIV in different organs, but there was no consistent 
segregation of variants with specific V3 sequences into different cell types. For 
example, variants with the same V3 loop were found in proviral sequences recovered 
from the brain and lymphoid tissue. In other cases, there were distinct populations at 
different sites within a single organ, suggesting a random component in the 
distribution of env sequences in vivo. The inferred phenotype of the V3 sequences of 
variants from lymphoid tissue and non-lymphoid tissue was NSI for all but 3 
sequences, in both the symptomatic and asymptomatic individuals. Indeed, the V3 
loop was found to be relatively invariant compared to the regions flanking the V3 
loop and in the V4 region (an observation made by Zhang et al, 1993). 
A similar result was found in the study of Korber et a!, 1994 who found that 
sequences derived from the brain of six AIDS patients taken at postmortem showed 
a low net charge, similar to that described for macrophage tropic isolates. There was 
significantly less sequence variation between sequences obtained from the brain 
compared to those derived from peripheral blood. This suggests there may be a 
constraint on the sequence diversity due to strong selection for sequences capable of 
growth in macrophages. In four of the patients, the brain-derived sequences clustered 
into a separate phylogenetic group from the blood derived sequences, suggesting 
tissue-specific compartmentalisation of the viruses. However, in two of the six 
patients, brain-derived sequences clustered together with those derived from the 
blood, suggesting in these cases that there was no compartmentalisation of the virus, 
and the possibility of trafficking between the two tissues. 
Indeed a number of studies have found that the V3 loop sequence of variants in non-
lymphoid tissues are relatively homogeneous (compared to the population found in 
peripheral blood or lymphoid organs) and show similarity to the macrophage (subtype 
B) consensus sequence (Power et al, 1994; Itescu et al, 1994, Ball et al, 1994; Li et 
al, 1992). 
1.6. The Humoral Immune Response to HIV-1 Infection 
1.6.1 The Immune Response to Viral Infections 
The immune response to viral infections has three principal components: i) the 
destruction of virus-infected cells; ii) the neutralising of the infectivity of the viions, 
and; iii) the production of interferons (White and Fenner, 1994). Cytotoxic T-
lymphocytes are responsible for the destruction of infected cells, thus eliminating 
virus from its reservoirs in the body. Neutralising antibodies neutralise the infectivity 
of cell-free virus, preventing infection from being established or disseminated. The 
relative contribution of these three components to recovery from viral infections is 
disease-specific. Circulating antibody is believed to play a key role in recovery from 
a number of viral infections: picornavirus, togavirus, flavivirus and parvovirus (White 
and Fenner, 1994). 
Antigenic Determinants 
The regions of protein molecules which interact with specific antibody molecules are 
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described as epitopes (or antigenic determinants). X-ray crystallography has shown 
that epitopes contain between 15-22 amino acids. Early studies using polyclonal sera 
raised to a variety of proteins, led to the distinction of two classes of epitopes: 
- linear (sequential, continuous) epitopes, which require the correct linear amino acid 
sequence to be recognised. These epitopes can bind antibody when the protein is 
denatured, and can be mimicked by short peptide sequences. 
- conformational (discontinuous) epitopes, which require the native protein folding 
to bind antibody. The discontinuous epitope comprises residues that are brought 
together by the folding of the polypeptide chain or the juxtaposition of two separate 
chains of the native protein. In consequence, discontinuous epitopes cannot be 
mimicked by short peptides, and conformational epitope will be destroyed when the 
protein is denatured. 
In reality, however, most epitopes are conformational, that is, the epitope will be 
influenced by amino acids outside the epitope, which determine the conformation of 
the native protein (Benjamin et al, 1984; Layer et al, 1990). 
Neutralising Antibodies 
Antibodies bind to accessible epitopes on the surface protein of the viion. However, 
only those that bind with high avidity to particular epitopes are capable of 
neutralising viral infectivity. Neutralising antibodies are measured by their ability to 
inhibit viral infection in vitro, through the inhibition of cell-free viral infection, or the 
inhibition of cell-to-cell infection. Neutralisation is believed to occur by blocking 
attachment to the host cell, or at a post-binding stage, such as blocking the fusion of 
the viral and host-cell membranes, thus preventing release of the nucleocapsid. 
1.6.2 Characterising the Neutralising Antibody Response Following 
HIV-1 Infection 
Individuals infected with HIV-1 usually develop humoral responses to the majority 
of viral proteins (Barin et al, 1985, Robey et a!, 1985). Of these antibodies, only a 
proportion are capable of neutralising the virus. 
UCI 
The main targets of neutralising antibodies are found in the surface envelope protein, 
gpl20 (Profy et al, 1990; Rusche et al, 1988; Putney et a!, 1986). The neutralising 
antibody response elicited by HIV, is of two types: type-specific, and group-specific. 
Type-specific neutralising antibodies are capable of neutralising the strain of virus 
from which the immunogen derived, but not other divergent strains. This type of 
neutralising antibody is the form predominantly elicited following the experimental 
inoculation of animals with preparations of the virus, or with recombinant envelope 
protein (Weiss et al, 1986; Looney et a!, 1988). Group-specific neutralising 
antibodies are more broadly reactive, in that they are capable of neutralising a wider 
range of HIV-1 strains (Weiss et al, 1985a; Steimer et al, 1991; Kang et al, 1991; 
Berkower et a!, 1989). 
Both type-specific and group-specific neutralising antibody responses are found 
during natural infection. In general, in early infection the neutralising antibody 
response is type-specific, but later in infection, a group-specific antibody response 
occurs, although at lower titre (McKnight et al, 1992). 
1.6.3 The Principal Neutralising Determinant (PND) of HIV-1 
Experimental inoculation of animals with preparations of recombinant gpl20, or 
gpl20 -derived polypeptides, results in the production of type-specific antisera, 
capable of neutralising cell-free and cell-to-cell viral infection (Rusche et al, 1988). 
A single dominant epitope was found to elicit these neutralising antibodies, mapping 
to a portion of the envelope gene within the third hypervariable (V3) region (Rusche 
et al, 1988; Javaherian et al, 1989). Consequently, this region has been named the 
principal neutralising determinant (PND). This region is predicted to form a hairpin 
loop structure, which is maintained by a conserved central glycine-proline-glycine 
(GPG) motif and two flanking disulphide bonded cysteine residues (figures 14A and 
1.5, above). 
Fine-structure mapping with synthetic peptides representing regions of the V3 loop 
has revealed that the antibody binding site is 8 amino acids at the tip, or crown, of 
the V3 loop around the conserved consensus GPG motif. Type-specificity in part, can 
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be explained by the amino acid variation present in the V3 loop between different 
strains of HIV-1, which may alter antibody binding. Similarly, the presence of some 
cross-reacting neutralising antibodies, directed at the V3 loop, can be explained in 
part by sequence conservation at the crown of the loop (Javaherian et a!, 1990; 
LaRosa et a!, 1990). 
1.6.4 The Targets of Neutralising Antibodies Elicited During Natural 
Infection with HIV-1 
The first detectable neutralising antibody response after primary HIV-1 infection in 
humans can occur early, within two to six weeks of primary infection, shortly after 
seroconversion (Albert et al, 1990). In other patients, the development is slower, and 
may occur between 10 to 45 weeks post-infection. (Arendrup et al, 1992; Ariyosha 
et al, 1992; Moore et al, 1994b). 
The neutralising activity of sera taken early after infection appears to be of a type-
specific form. It has a high neutralising activity to contemporaneous autologous virus 
isolates and to a narrow range of laboratory isolates (Albert et al, 1990). Competition 
studies using synthetic peptides of the V3 loop, have shown that the majority of 
neutralising activity in early sera is directed to the V3 loop (Zwart et al, 1992; 
Bolognesi, 1993; Profy et al, 1990; Chamat et a!, 1992). 
A broader (group-specific) neutralising antibody response can be found later in 
infection (Weiss et a!, 1986). This broader neutralising antibody response appears to 
be due to the development of a new class of antibodies directed at epitopes other than 
the V3 loop, which are more conserved between different isolates. For example, in 
the case of an accidental infection of a laboratory worker with the isolate HIV-1, 
a broad neutralising antibody response was found in the sera 23 months after 
infection. Sera taken at this time could inhibit the replication of fflV-1 and the 
divergent isolate FHV-1 MB  . The neutralising activity could not be blocked by HIV-1- 
specific V3 peptides, but these antibodies were found to block binding of gpl20 to 
soluble CD4 (sCD4). A similar pattern of development of neutralising antibodies was 
seen to occur in the experimental infection of chimpanzees with HIV- 1 (Goudsmit 
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et al, 1988). Initially, high titre antibodies emerge, which are capable of neutralising 
the autologous strain, and can be blocked by HIV- l -specific V3 synthetic peptides. 
After 20 months the neutralising activity broadened to neutralise divergent strains of 
HIV- 1. Again, this set of broader-reacting antibodies were found to block the binding 
of gpl20 to sCD4. 
Studies in which HIV-1 positive sera are fractionated by affinity chromatography, 
using either native recombinant gpl2O or denatured gpl2O, or sCD4, have confirmed 
that the CD4-binding site is a major target of group-specific antibodies elicited during 
the course of natural infection and represents a conformationally-dependent epitope 
(Kang et al, 1991; Steimer et al, 1991; Berkower et al, 1989; Posner et a!, 1991; 
Thali et al, 1993; Chamat et a!, 1992). 
A neutralising epitope in the V2 loop of gpl20 has been defined monoclona]. 
antibodies (Fung et a!, 1992), and similarly for an epitope in the C2 region (Ho et 
a!, 1988). There is a single neutralising epitope in gp4l (Muster et al, 1994). p17 - 
the matrix protein elicits neutralising antibodies, and may be present on the virion 
surface (Papsidero et al, 1989). However, p17 has amino acid similarity to thymosin 
a, a human cellular protein, which may be the target of the neutralising antibodies if 
it is present on the virion surface. 
1.6.5 The Role of Neutralising Antibodies in Control of Disease 
Whilst there is clear evidence that HIV-1 elicits a strong neutralising antibody 
response, there are few reports that show the role of neutralising antibodies in 
controlling HIV-1 infection, or influencing disease progression. 
The rapid drop in plasma viraemia seen shortly after primary infection suggests a role 
for the immune system in counteracting viral replication at this stage of disease. The 
earliest detectable anti-viral immune response, is a cytotoxic T-lymphocyte response 
(CTL), with neutralising antibody responses occurring many weeks after the clearance 
of plasma viraemia (Koup eta!, 1994; Moore et al, 1994b). Similarly, in SW-infected 
macaques, a CD8+ T-cell mediated inhibition of SIVmac replication in autologous 
CD4+ T-lymphocytes was shown to precede the appearance of a neutralising antibody 
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response, and coincide with the clearance of plasma viraemia (Niu et a!, 1993). 
Despite the initial control of viral replication, high levels of virus are seen in the 
peripheral blood during the asymptomatic stages of infection, and high viral loads 
detected in the lymphoid organs (Donaldson et al, 1994a; Embretson et al, 1993). 
A number of studies have addressed the question of whether there is a correlation 
between the rate of disease progression and the levels of neutralising antibodies. For 
example, Fenyo, 1994, examined a cohort of HIV-1 infected patients, who could be 
divided into non-, or slow-progressors and fast-progressors, according to the rate of 
CD4+ lymphocyte decline over time. Virus isolates from non-, or slow-progressors, 
in 5 out of 10 cases, could be neutralised by autologous sera. Follow-up sera, taken 
3 to 56 months after virus isolation, could in the majority of cases (13 out of 14 
sera), neutralise the autologous virus isolates. In contrast, autologous neutralising 
antibodies were rarely found in the fast-progression group. These studies show that 
in fast-progressors, the ability to produce neutralising antibodies is severely impaired. 
They do not however, demonstrate a protective role for neutralising antibodies. The 
slow rate of progression in patients showing the presence of neutralising antibodies, 
may be due to another cause, such as a strong CTL response, which was not 
investigated in this study. 
In another study, Lu et a!, 1993, failed to show a correlation between the presence 
of neutralising antibodies and the rate of disease progression. In this case, 
approximately half of patients showing a stable CD4+ lymphocyte count (non-
progressors) had high neutralising antibodies, but in the remaining half neutralising 
antibodies could not be detected. The group of patients showing fast-progression 
showed undetectable levels of neutralising antibodies, but high levels of plasma 
viraemia and infected PBMCs. Perhaps surprisingly, within the group of non-
progressors, those patients showing high neutralising antibody levels showed the 
highest levels of virus both in PBMCs and plasma. In contrast, those patients with 
undetectable neutralising antibody responses had low virus levels. This led the 
authors to hypothesise that a threshold level of virus may be needed to elicit a 
neutralising antibody response, but casts doubt on the role of antibodies in controlling 
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viraemia. 
There has been some suggestion that neutralising antibodies provide protection 
against transmission of HIV-1 from mother to child. In a study of Scarlatti et al, 
1993, it was found that mothers who did not transmit to their child were more 
frequently found to have neutralising antibodies to autologous virus, in comparison 
to mothers who did transmit. Indeed, in respect to this, it has been suggested that a 
single broadly-specific neutralising antibody, or polyclonal sera, may be used for 
passive immune therapy to interrupt maternal-foetal transmission. A similar passive 
immune therapy approach has proved successful in preventing infection in 
chimpanzees (Emini et al, 1991), where the administration of V3-specific antibodies 
alone was shown to prevent infection of chimpanzees challenged with high doses of 
cell-free virus. 
1.6.6 The Generation of Antibody Escape Mutants 
One mechanism by which HIV-1 may evade the immune system is to continually 
produce novel antigenic variants, which are no longer recognised by the current 
antibody response. Such antibody-escape mutants have been generated in the 
laboratory, as will be described below. There is also some evidence that escape 
mutants arise during the course of natural infection, and in experimental infections 
of monkeys. 
The Generation of Neutralising Antibody Escape Mutants In Vitro 
Incubating virus isolates, or biological clones, with small amounts of neutralising 
antibodies will select for variants that are more resistant to neutralisation. The amino 
acid changes conferring the increased resistance can then be ascertained by 
sequencing. 
One of the first reports of the generation of antibody escape mutants was by 
McKeating et a!, 1989, who cultured virus derived from the molecular clone FHV-
1 5 in the presence of monoclonal antibodies (MAbs) directed to an epitope 
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bridging the GPG-motif of the V3 loop (figure 1.5, above). A panel of viral mutants 
was generated, each showing a reduced binding affinity for the MAbs. Four of the 
variants were found to have an amino acid change in the V3 loop itself (arginine (R) 
to glycine (G) at position 8), with the corresponding V3 loop peptides unable to bind 
the selecting antibodies. Other mutants showing reduced sensitivity to neutralisation, 
however, did not contain amino acid changes in the V3 loop. This result shows that 
neutralisation by antibodies directed at the V3 loop can be influenced by amino acid 
changes both within and outside the loop. 
In a similar study, using plaque-cloned virus and selecting with a MAb directed at 
the tip of V3 loop, resistant viruses were generated each of which had a mutation at 
the tip of the loop, (of GPGR to GGGR), which abolished MAb binding to the 
corresponding peptide (Masuda et a!, 1990). Significantly, in the acute-replicating 
conditions which were required to generate these resistant mutants, there was a large 
number of amino acid changes in clones which were not incubated in the presence 
of neutralising antibody. 
Resistant viruses can also be generated in vitro in response to selection by broadly 
neutralising antisera. For example Robert-Guroff et al, 1986, selected a mutant 
derivative of the molecular clone HXB2 (Fisher et al, 1985), by incubation with a 
broadly neutralising antisera derived from pooling the sera of HIV-1 infected 
individuals. The mutation conferring resistance was mapped to the gp4l protein, with 
a threonine (T) to adenine (A) substitution in the external domain (residues 582 of 
HXB2) (Kiasse et al, 1993). It was subsequently shown that this resistant clone was 
resistant to neutralising antibodies directed at the CD4-binding site (Thali et a!, 
1994). However, only minor differences in the binding of these antibodies to wild 
type and mutant viruses was observed, showing that the antigenic structure of gp120 
can be subtly affected by amino acid changes in gp4l, with important consequences 
for neutralisation. Similarly, Back et al, 1993, showed that neutralising resistant 
variants, arising after the experimental inoculation of chimpanzees with the isolate 
FHV-1, have mutations in the extracellular portion of gp4l. By generating 
recombinant viruses, it was shown that these mutations conferred resistance to HIV-
1 V3 MAbs. 
56 
McKeating et a!, 1993, showed that escape mutants selected by incubation with HIV-
1-positive human serum, developed resistance to CD4-binding site MAbs. The amino 
acid change conferring resistance was located in the conserved region C4. The mutant 
envelope protein had reduced affinity to C134-binding site MAbs, which is in contrast 
to the result of Thali et al, 1994, described above. Clearly, CD4-resistant viruses can 
arise by two mechanisms: one which directly reduces the affinity of the neutralising 
antibodies for gpl20, and the other which does not affect binding but may block the 
steps after binding. 
The V2 region of gpl20 can also evolve in vitro under the selection of neutralising 
antibodies (Yoshiyama, et al, 1994). In this study, the primary isolate HIV- 1. was 
incubated with a neutralising MAb directed at a conformational epitope in V2 loop. 
Three neutralising escape mutants were generated, each showing reduced affinity for 
the neutralising antibody. A mutation in the V2 loop of Y to histidine (H) (in the 
motif KEYALFY), was demonstrated as responsible for conferring the resistant 
phenotype. 
However, even in the absence of selection, there can be antigenic variation in gpl20 
following prolonged culturing. Moore et a!, 1993c, showed by examination of several 
molecular clones derived from the laboratory isolate H1V- 1, that each showed a 
distinct pattern of neutralisation to a panel of neutralising MAbs, including those 
directed at the V3 loop, the V2 loop and the CD4-binding site. A similar result was 
described by Domingo et al, 1993, who passaged plaque-purified virus in the absence 
Of antibody, and showed that virus progeny displayed considerable sequence and 
antigenic variation. 
Clearly, the high mutation rate of HIV- 1 can result in the generation of antigenically 
distinct variants in vitro, even in the absence of immune selection (Domingo et al, 
1993). 
The Development of Neutralising-Antibody Escape Mutants In Vivo 
Antigenic variation in non-primate, animal lentiviral infections has been well 
documented (Lutley et al, 1983; Thormar et a!, 1983), and is frequently quoted as an 
57 
important mechanism by which such viruses persist in their host during a chronic 
infection in the face of a strong anti-viral immune response (Leigh Brown and 
Holmes, 1994). However, even in these examples, which are often used as paradigms 
of immunological escape, the significance of antigenic variants in allowing persistent 
infection, and the role of these variants in pathogenesis has not been unequivocally 
demonstrated. 
For example, in the experimental infection of sheep with visna virus, isolates resistant 
to autologous sera are seen to emerge, but only at low frequency, and do not replace 
the infecting strain (Thormar et al, 1983; Lutley et a!, 1983). Virus can persist and 
cause tissue damage, despite the presence of high titres of neutralising antibodies. 
Burns et a!, 1993, have shown that following the experimental infection of Rhesus 
macaques with a pathogenic molecular clone of SW (S1Vm239) env gene mutants 
arise that are resistant to serum neutralisation. 
The development of neutralising antibodies following the experimental infection of 
chimpanzees with HIV-1 has been documented (Nara et a!, 1990). Virus isolated 
from chimpanzees vaccinated with gpl2O and subsequently challenged with HIV- 1, 
was found to be more resistant to neutralisation by autologous serum, than the virus 
isolated from naive animals. This suggests that the immune system, stimulated 
following vaccination, has selected for more resistant viruses in the vaccinated 
animals. In both naive and immunised animals, sequential isolates were more resistant 
to neutralisation by IilV-1-V3-specific MAbs than the parental stock. Resistance 
to V3-specific MAbs was conferred by mutations outside the V3 loop. With one 
isolate, the resistance mutation mapped to gp4l (Back et a!, 1993). 
In the case of the accidental infection of a laboratory worker with the isolate HIV-
1, variants detected one year after infection were found to be resistant to a panel 
of MAbs directed at the V3 loop (Di Marzo Varonese et a!, 1993). However, these 
variants were detected after the development of the variant-specific neutralising 
antibody response, and persisted in all subsequent isolates (Reitz et a!, 1994). This 
suggests that these variants were not selected by neutralising antibodies. 
Arendrup et al, 1992, and Albert et al, 1990, have examined the development of the 
neutralising antibody response in patients following primary infection. In the first of 
these, neutralising antibodies to isolates taken one week after seroconversion could 
be demonstrated only after between 13 to 45 weeks post-seroconversion. Virus 
isolates with reduced sensitivity to autologous sera taken at or before the time of 
isolation could be demonstrated at between 45 to 117 weeks. The patients 
subsequently developed neutralising antibodies to the 'escaped' virus isolates, but the 
titres against the later isolates were generally low compared to the titres against the 
first isolate. 
In the study of Albert et al, 1990, a low-titre neutralising antibody response could be 
detected, much earlier than the study of Arendrup et al, 1992, within 3 to 4 weeks 
after primary infection. Virus variants with reduced sensitivity to autologous sera was 
observed. However, in this case, the patients did not develop antibodies capable of 
neutralising the new variants. In a subsequent study, only a minority of the resistant 
isolates were found to have amino acid changes in the V3 loop (Wahlberg et a!, 
1991). 
1.7 Vaccine Development 
Much effort has been directed to the development of vaccines against HIV-1 and 
HIV-2, a method which has proved effective in controlling the development of 
disease in a number of other viral infections, such as polio, smallpox, rabies, 
influenza, hepatitis B and measles. 
Traditionally, there have been two major strategies of producing viral vaccines: live, 
attenuated virus (such as those for polio, measles, mumps), and chemically 
inactivated virus (such as those for polio, influenza and rabies). With the advent of 
recombinant DNA techniques, subunit vaccines are being developed to a number of 
pathogens, and have proved successful in vaccinating against the hepatitis B virus. 
With these as precedents, there are currently three main types of vaccine being 
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produced for FIIV and the animal models including STY infection of rhesus macaques: 
- subunit vaccines, using genetically engineered subfragments of the gpl20 protein, 
or synthetic polypeptide epitopes of gp120. 
- whole inactivated preparations of HIV-1, or SIVmac 
- live, attenuated strains of SIVmac (and HIV-1). 
There are several obstacles to HIV vaccine production. In particular, the nature of 
persistent infection, where HIV (and other lentivinisès) induces a chronic debilitating 
disease following long-term infection, despite an initially strong host immune 
response. It is therefore likely that an HIV vaccine will have to produce sterilising 
immunity against the initial infection, as once the virus is established, there is no 
epidemiological evidence that the immune response can influence the course of 
infection or the disease process. However, the very nature of retroviral infection, 
where a long-lived reservoir of infected cells can be generated by the integration of 
the provirus into the host genome, and the spread of virus by cell-to-cell contact, 
undisturbed by the immune defence, makes sterilising immunity following primary 
infection difficult to envisage (Sabin, 1992). 
A second barrier to HIV vaccine production is the antigenic variability displayed by 
HJIV strains. There are a large number of strains of HIV that are minimally cross-
neutralising. In consequence, the immune response to one strain may not be effective 
against the multitude of field isolates which may be encountered by the vaccinee. To 
date, it has not been possible to quantify the number of HIV strains that would be 
needed to provide broad protection against infection. 
Subunit vaccination of chimpanzees and macaque monkeys has been demonstrated 
to limited success (reviewed by Bolognesi, 1993). In experiments with chimpanzees 
in which protection has been demonstrated, protection was found to correlate with the 
induction of neutralising antibodies directed to the V3 region of gp120. However, in 
experiments with macaque monkeys, although protection was achieved, there was no 
correlation between protective immunity and protection. 
Protection has also been achieved in macaques following intravenous infection with 
inactivated SIVmac that had been grown in human T-cells. However, protective 
immunity was found to be linked to the immune response to human cellular antigens, 
specifically, HLA-DR and 3-micoglobulin, expressed upon the virion envelope, 
following their growth in human cells (Stott et al, 1991). In subsequent experiments, 
protection was not established with inactivated SIVmac that had been grown in 
macaque cell cultures. 
The most promising vaccine, produced to date, is that of an attenuated strain of 
SD/mac. Vaccination with the attenuated strain of SIVmac was shown to confer 
protection in rhesus macaques to high-dose challenge with a pathogenic SIVmac 
strain (Daniel et al, 1992). 
The development of a live attenuated SIVmac vaccine came about following 
experiments carried out to determine the role of infection in vivo of the SIVmac nef 
gene. Kestler et al, 1991, showed that six rhesus macaques infected with cloned 
SIVm239 containing a deletion in the nef gene were able to maintain an extremely low 
viral burden and normal CD4+ cell counts, despite the death of eleven out of twelve 
macaques infected with the wild-type S1Vm, 239. Four of the monkeys infected with 
the nef-deleted SW were challenged with wild-type pathogenic S1Vm2391 using 10 
cell-free infectious doses. Following challenge, these monkeys showed no signs of 
viral infection with the wild-type challenge virus: no plasma viraemia could be 
detected, and no wild-type viral sequences, representing the challenge virus, were 
detected by PCR, despite the amplification of nef-deleted sequences. It was concluded 
that the infection of these monkeys with attenuated, nef-deleted SIVm239 rendered 
them resistant to further virus challenge. 
The feasibility of developing a live, attenuated lillY vaccine, with its attendant ethical 
and safety issues, was discussed by a World Health Organisation working group. The 
main conclusions of this working group were, that the development of live attenuated 
vaccine should go ahead in parallel with other vaccine strategies. The safety issues 
discussed were the stability of such viruses, whether, with the high mutability of 
primate lentiviruses, they could mutate back to a virulent form, or whether infection 
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with such viruses will cause delayed immunosuppression, neuropathogenesis, 
oncogenesis, or other adverse effects. In terms of the efficacy of such vaccines, the 
breadth of protection against heterotypic strains must be determined, as well as the 
efficacy against challenge by various routes, dosages and cell-associated virus. In 
terms of protection, the mechanism and correlates of protection must be determined. 
The laboratory of Desrosiers, from which these experiments were first reported, have 
been constructing multiple-deletion mutants of both SIVmac and HIV-1, in order to 
render these candidate attenuated viruses, less susceptible to back mutation to the 
wild-type pathogenic form. To date, it has been shown that I-fly-i viruses carrying 
multiple deletions in the LTR, nef, vpr and vpu genes, were capable of growth in 
human CD4+ T cells (Desrosiers, 1992; Gibbs et al, 1994). 
In 1994, Desrosiers expressed the belief that live, attenuated viruses will be the only 
effectual vaccine against flY infection. However, recent work has questioned the 
safety of attenuated viruses as vaccines. In 1995, Baba et al, demonstrated that an 
attenuated strain of SIVmac is highly pathogenic to neonatal macaques following 
mucosal infection. Despite containing deletions in nef, vpr, and the negative 
regulatory element, the construct caused high levels of viraemia, haemolytic anaemia, 
thrombocytopenia, and CD4 T-cell depletion, in neonatal macaques. 
Despite multiple deletions, and their lack of pathogenicity in adult macaques, these 
constructs have retained their pathogenicity in infected neonates. As such, these 
constructs are unsuitable as candidate live, attenuated virus vaccines against AIDS. 
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1.8 The Work Presented in this Thesis 
The work described in this thesis is an experimental investigation of the hypothesis 
that the env gene sequences that emerge during the course of natural infection with 
HIV-1, represent immunological escape mutants. The work specifically addresses the 
role of the neutralising-antibody response in selecting env gene variants. 
In order to demonstrate that the env gene sequences of HIV-1 evolve in response to 
selection from neutralising antibodies, it will be necessary to show that high titres of 
sequence-specific neutralising antibodies arise subsequent to, but not before, the first 
appearance of a new variant. 
The approach I have taken is to construct a panel of recombinant viruses, expressing 
the variant env genes found over the course of natural infection from a single HIV-1-
infected patient. Chapter 3 describes the construction of an HIV-1 proviral vector, 
into which the env genes were substituted to form recombinant viruses. Chapter 4 
describes the cloning of the major env gene sequences found during a seven-year 
period of infection, and their incorporation into recombinant proviral clones. 
Chapter 5 examines the sequences of the hypervariable regions of the cloned env 
genes, and characterises these according to the env sequences previously obtained 
from this patient (Simmonds et al, 1991; Holmes et al, 1992). Chapter 6 examines 
the results of the transfection of the recombinant proviral clones into cell culture in 
order to recover a panel of recombinant viruses, differing only in the env gene. 
However, as will be found in chapter 6, the majority of these clones did not yield 
infectious viruses following transfection, and in addition, the clones that did yield 
infectious viruses, produced only low titre virus stocks, insufficient to carry out 
neutralisation assays. Chapter 7, therefore, presents a discussion of this approach, and 
the possible reasons for the failure of many of the env genes to support viral 
replication in this recombinant system. 
Chapter 2 
Materials and Methods 
2.1 Collection and Processing of Blood Samples 
2.2 HIV-1 Infectious Molecular Clones 
2.3 Plasmid Cloning Vectors 
2.4 Bacterial Strains 
2.5 DNA Manipulations and Cloning 
2.6 Preparation and Transformation of Competent E.coli Cells 
2.7 The Polymerase Chain Reaction 
2.8 Site-Directed Mutagenesis 
2.9 DNA Sequencing 
2.9.1 Manual DNA Sequencing 
2.9.2 Automated DNA Sequencing 
2.10 In Vitro Transcription and Translation 
2.11 Cell Culture Techniques 
2.12 Recovery and Propagation of Recombinant Viruses 
2.1 Collection and Processing of Patient Peripheral Blood 
Samples 
Patient 82 is a member of the Edinburgh Haemophiliac Cohort, who were infected 
with HIV-1 following treatment with a batch of contaminated Factor XIII, prepared 
from Scottish blood donations (Ludlam et al, 1986). p82  seroconverted in June 1984, 
and was asymptomatic and had not received any anti-viral therapy at the times of 
collection of the blood samples used in this study. Clinical data for this patient are 
given by Simmonds et al, 1991. 
Dates of Collection 
Five sequential PBMC samples from p82 were used in this study. The samples were 
collected in August 1987 (sample #108, year 3, 1987), January 1988 (sample #12, 
year 4, 1988), February 1989 (sample #82, year 5, 1989A), October 1989 (sample 
#123, year 5, 1989B), and April 1990 (sample #139, year 6, 1990). No PBMC sample 
was available at the time of seroconversion (year 0, 1984). 
Blood samples were processed by staff at the Centre for HIV Research, University 
of Edinburgh. PBMCs were isolated from heparmnised whole-blood by separation over 
Ficoll, and stored in liquid nitrogen (Simmonds et al, 1990a). 
Preparation of PBMC DNA 
Ampoules of stored PBMCs (not less than 5 X 106  cells) were removed from liquid 
nitrogen and allowed to thaw. The cells were washed in 20m1 RPIvII medium (Gibco), 
and resuspended in 400u1 of a lysis buffer containing 50mM EDTA, 100mM Tris-CI 
pH 7.5, and 50mM NaCl, 100mM proteinase K to 100mM, and 1% (w/v) N-
laurylsarcosine. Lysis was allowed to proceed by incubating the reaction at 65°C for 
2hr. The DNA was extracted by a standard phenol/chloroform extraction, and 
precipitated by the addition of 2.5 volumes of 100% ethanol and storage at -20°C for 
at least 2hr. The DNA was collected by centrifugation, washed with 70% ethanol and 
dried at 50°C. The DNA was resuspended in 100-200ul of dH20 and the concentration 
assessed by spectrophotometry. 
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2.2. HIV-1 Infectious Molecular Clones 
pHXB2-D 
pHXB2-D is a full-length proviral clone capable of producing infectious viruses when 
transfected in cell culture (Fisher et al, 1985). pHXB2-D was obtained from the MRC 
AIDS Reagent Project Repository, National Institutes for Biological Standards and 
Control, to which it was donated by Dr Robert Gallo of the National Institutes of 
Health, Bethesda, Maryland, USA. 
The proviral clone HXB2 was originally isolated in 1984, as a lambda clone from a 
library of recombinant bacteriophage constructed from the XbaI digested genomic 
DNA of H9 cells chronically infected with the HIV-1 isolate HIV-1 (Shaw et al, 
1984). A 12.7kb XbaI insert fragment of the lambda clone HXB2, consisting of 9.8kb 
of full-length proviral sequence and 2.7kb of cellular flanking DNA, was transferred 
into the plasmid vector pSP62 (Melton et al, 1984) to create the molecular clone 
pHXB2-D (Fisher et a!, 1985). 
The complete nucleotide sequence of HXB2 is available from GenBank, accession 
number K03455. In addition, a schematic diagram of pHXB2-D is given in figure 3. 1, 
and the restriction site co-ordinates for the proviral sequence (HXB2R) are given in 
appendix A. 
NOTE: Sequence analysis has subsequently revealed that the isolate HIV-1 
originated from the HIV-1 infected patient LAI, from which virus was originally 
isolated at the Pasteur Institute, Paris, France. It appears that virus from the isolate 
HIV-1LAI, contaminated and outgrew cultures of IllV-1 	and HIV-1BRU. In 
consequence, both isolates have been renamed HIV-1 (Wain-Hobson et al, 1991). 
However, for the purposes of this thesis, the isolate from which HXB2 was cloned 
will be referred to by its original name of HIV-1. 
pHXB2-MCS 
pHXB2-MCS is a modified version of pHXB2-D. The details of the construction of 
pHXB2-MCS are described in chapter 3, section 3.3, of this thesis. In brief, the 
12.7kb XbaI proviral and cellular flanking sequences of pHXB2-D has been 
transferred to the plasmid vector pSPThM20i& - a derivative of the plasmid vector 
pSPTBM20 (Boehringer) from which the EcoRV to SmaI fragment of the polylinker 
has been deleted. Three unique restriction sites have been engineered into the proviral 
genome: a NotI site at 5645, a BstEll site at 5875 and an XbaI site at 7624 (co-
ordinates according to HXB2R). 
pHXB2-MCSM1uI 
pHXB2-MCS.MluI is a derivative of pHXB2-MCS, containing an additional cloning 
site - MluI - at nucleotide position 7279 in the HXB2R sequence. This clone was 
modified from pHXB2-MCS by Dr Peter Balfe at The University College and 
Middlesex School of Medicine, Department of Medical Microbiology, London. 
Further details of its construction can be found in chapter 3, section 3.3. 
SF2MC and SF162Mc 
These are two full-length HP/-i proviral clones, a gift from Dr Cecelia Cheng-
Mayer at the School of Medicine, Cancer Research Institute, University of California, 
San Fransisco, USA. 
SF2MC is derived from the HIV-1 isolate HIV-1sF2, which was obtained from the co-
cultivation of PBMCs of a symptomatic HIV-1 infected individual with oral 
candidiasis, with PBMCs from seronegative donors (Cheng-Mayer et al, 1989). 
SF162MC is derived from the FIIV-1 isolate HIV-1sF162, which was obtained by the co-
cultivation of cerebrospinal fluid of an HIV-1 infected individual with neurological 
symptoms (toxoplasmosis) with PBMCs from seronegative donors (Cheng-Mayer et 
a!, 1989). 
Both full-length clones were originally obtained from libraries of recombinant 
bacteriophage constructed from the EcoRI-partially-digested genomic DNA of the 
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respective isolates. The full-length versions of the molecular clones SF2MC and 
SF162MC were divided into two fragments at unique internal EcoRI sites, at the 
midpoint of each genome. The 5' and 3' viral fragments generated after restriction 
digest with EcoRI were subcloned into a pUC19 plasmid vector at the EcoRI site 
(Cheng-Mayer et al, 1990). 
The complete nucleotide sequence of SF2MC is available from Genbank, accession 
number K02007. The nucleotide sequence of the 3' half of the SF162MC genome is 
available from GenBank accession number M38428. 
2.3 Plasmid Cloning Vectors 
pB Iuescriptll(KS-) 
pBluescriptllKS(-) (Short et al, 1988, Alting-Meese and Short, 1989) is a 2.96kb 
plasmid cloning vector and was purchased from Stratagene Ltd. This vector contains 
a Co1EI origin for autonomous replication in the E.coli host, and an fl filamentous 
phage origin of replication, allowing recovery of single stranded copies of the 
plasmid sequence (- the antisense strand of the lacZ gene - encoded by the vector), 
on infection with helper phage. pBluescriptllKS(-) has a T7 RNA polymerase 
promoter flanking the polylinker. The complete sequence of pBluescript is available 
from GenBank accession number X52329. 
pSPTBM2O 
The plasmid cloning vector pSPTBM20 was purchased from Boehringer Mannheim. 
pNBXXenv 
pNBXXenv is an env gene subclone of pHXB2-MCS. Its construction is described 
in chapter 3, section 3.6. In brief, the NotI to XhoI fragment of pHXB2-MCS (nts 
5645-8443 HXB2R) was subcloned into pBluescriptllKS(-) at the Nod and XhoI sites 
in the vector polylinker, generating the construct pNBXX. A deletion of 428bp was 
made in the env gene by double digestion with Stul (nt5952 HXB2R) and NdeI 
(nt6380 HXB2R) followed by filling-in the 3' overhangs with Klenow and self- 
ligation. 
pHXB2-MCSenv 
pHXB2-MCSenv is a deletion-derivative of pHXB2-MCS. A 428bp deletion was 
made within the env gene - from Stul (nt5952 HXB2R) to NdeI (nt6380 HXB2R). 
Transfection of pHXB2-MCSenv into cell culture results in the production of p24 
antigen, but does not generate infectious viruses (chapter 6, section 6.2.2). 
2.4 Bacterial Strains 
The E.coli strains used in this study are given in table 2.1 below. 
Bacterial Stocks 
Bacteria were maintained short-term on solid medium (generally, 2xTY agarose plates 
see appendix B), at 4°C. For longer-term storage, DMSO stocks were prepared, and 
could be stored for over a year at -20°C or -70°C. These were prepared by adding 
imi of a freshly saturated culture to an equal volume of 7% (v/v) DMSO solution. 
Fresh colonies were obtained by streaking bacteria from single colonies on existing 
plates, or by streaking a loop-full from the frozen stock onto a fresh plate and 
incubating overnight at 37°C The presence of the F' episome, required for the 
infection of R408 M13-derived helper phage, was ensured by streaking colonies on 
2xTY plates with supplemented with tetracycline. 
Storage of Plasmid DNA 
Plasmid DNA constructs were stored with their E.coli host at -20°C, and as DNA 
preparations at -20°C. Due to the instability of HIV-plasmid constructs in their E.coli 
hosts, and the poor viability of strain DL655, plasmids were also stored as ethanol 
precipitates at -20°C. 
Table 2.1 E.coli Strains 
Strain Genotype Source Reference 
DL655-F' hsdR, leu, mcrA, mcrB, pro, reeD DL655 was a Chalker et al, 
1009, sbcC201, supE, thi-1, tsx, (dcm, gift from 1988 
dam) recA::Cmr  [F' proAB, David Leach Bullock et al, 
Tn10(tet')] at ICMB, 1987 (XL1- 
DL655-F' is DL655 transfected with University of Blue) 
the F episome of XL1-Blue Edinburgh. 
(Stratagene Ltd). 
SURE e14 (mcrA), A(mcrCB-hsdSMR- Stratagene Greener et a!, 
mrr)171, sbcC, recB, recJ, Ltd 1990 
umuC: :Tn5(kanr),  uvrC, supE44, lac, 
gyrA96, relAl, endAl [F' proAB, 
lacF'ZMvI 15, Tn l0(tee)] 
XL1-Blue endAl, hsdRl7, supE44, thi-1, recAl, Stratagene Bullock et a!, 
gyrA96, relAl, lac, [F'proAB, Ltd 1987 
!acF'ZEM15, TnlO(tetT)] 
CJ236 dutl, ungl, thi-1, relAlIpCJ105(CmT), Invitrogen Joyce and 
[F' proAB, lacIqZAM15, TnlO(tet')] Grindley, 1984 
70 
2.5 DNA Manipulations and Cloning 
Small-Scale Preparation of Plasmid DNA 
The boiling method of Holmes and Quigley (Homes and Quigley, 1981), was used to 
prepare small amounts (2-3ug) of plasmid DNA from E.coli. 
An overnight culture of E.coli, carrying the required plasmid, was prepared by 
inoculating 5m1 of 2xTY-broth plus ampidilhin with a single bacterial colony, and 
incubating at 37°C overnight with vigorous aeration. 1 .5ml of the culture was 
centrifuged for 30s to pellet the cells. The supernatant was poured away, and the pellet 
resuspended in 300u1 STET solution (see appendix B) and placed on ice. To this was 
added 30u1 of a freshly-prepared 10mg/mi lysozyme solution (Boehringer). The reaction 
was incubated on ice for 2min and heated to 100°C for 90s. Immediately after this, the 
sample was centrifuged at 1500g for 15mm. The resultant flocculant pellet of bacterial 
debris was removed with a sterile toothpick. 0.7 volumes of isopropanol and 0.1 volume 
of 3M NaAc was added, and the sample stored at -20°C for 20min to precipitate the 
DNA. The precipitate was collected by centrifugation at 1500g for lOmin, washed in 
70% ethanol and allowed to air-dry. The DNA was resuspended in 50ul of 'FE. The 
concentration was determined by agarose-gel electrophoresis of a 5ul aliquot. 
Restriction Digests 
Restriction digests were carried out using between 0.2 and lOug of the appropriate DNA 
preparation. Between 5 to 10 units of restriction enzyme, were used according to the 
amount of DNA to be digested, with the restriction enzyme buffer recommended by the 
manufacturer (Boehringer, Stratagene or Promega). Digests were allowed to proceed for 
at least 60 min, at the recommended optimum temperature for the enzyme. When two 
or more enzymes were used to digest the DNA, the broad-specificity buffer KGB was 
used, at the recommended concentration (McClelland et al, 1988). When necessary, for 
subsequent enzymatic steps, restriction enzymes were inactivated by heating at 65°C for 
15 min for heat-sensitive enzymes. For heat-stable, phenol resistant enzymes (such as 
XhoI), the enzyme was removed by purification of the DNA using a 'Magic DNA 
Clean-up' column (Promega). 
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Agarose-Gel Electrophoresis 
Agarose gels were prepared with standard electrophoresis grade agarose (Sigma), or 
with low melting point agarose (LMP; Sigma) when high percentage gels (>2.5%) were 
required and when DNA was to be recovered from the gel. Gels were prepared by 
dissolving the required amount of agarose in TBE buffer. Once the molten gel had 
cooled to below 50°C, ethidium bromide was added to lug/mi. Ficoll stop buffer was 
added to the DNA sample prior to electrophoresis. Electrophoresis was carried Out at 
a voltage appropriate to the application. For the optimum separation of fragments within 
the range of 1 to 3kb, required routinely in this project, the voltage applied was 
1 .5V/cm. For more rapid separation, voltages up to 5V/cm were used. 
Recovery of DNA from Agarose Gels 
The majority of the subcloning carried out in this study, involved the isolation and 
purification of specific restriction fragments. This was achieved by first resolving the 
restriction fragments by agarose-gel electrophoresis, then recovering the required 
fragment from the agarose-gel. 
To obtain optimum resolution of the DNA fragments (which in the majority of cases 
were in the range of 0.8 to 2.5 kb), electrophoresis was carried out with 0.5% LMP 
agarose gels, at between 0.3 and 1 volt/cm. Following electrophoresis, the required 
bands were excised from the gel using a clean scalpel blade, (or in the case of 
infectious clones, using a plastic knife), illuminating the DNA under long-wave UV to 
minimise UV-induced damage to the DNA. The gel-slice was incubated at 65°C until 
the agarose had completely melted. Purification of the DNA was achieved by treatment 
with 'Gene-Clean' (Bio 101 i), according to the manufacturer's instructions, or 
through the use of a 'Magic DNA clean-up' column (Promega). The recovery of the 
DNA was assayed by running one tenth of the recovered volume on an agarose gel. 
Ligations 
The relevant vector and/or insert DNA was prepared by digesting approximately 2-1Oug 
of the plasmid construct with the appropriate restriction enzymes as described above. 
In general, the cohesive ends produced from the restriction digests of the vector were 
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compatible with the cohesive end of the insert DNA to be cloned. In situations where 
it was necessary to fill-in incompatible recessed 3' termini, the Kienow fragment of 
E.coli DNA polymerase I was used. In such cases, lunit of Kienow (Boehringer) was 
added to the reaction on completion of the digest, and dNTPs (Boehringer) to 1mM. 
The reactions were incubated for 30min at 37°C and subsequently terminated by heating 
to 750C for 10mm. The required DNA fragments were then isolated and purified by 
agarose-gel electrophoresis (as described above). 
The relevant vector and insert fragments were ligated in reactions that contained a 2-
to 5- molar excess of insert to vector DNA. Due to the low transformation efficiency 
of E.coli strain DL655F, approximately 300ng of vector DNA were required to recover 
colonies from each ligation reaction. Ligations were carried out in as small a volume 
as possible (generally between 10-30u1) with lunit of T4 DNA polymerase 
(Boehringer), in the presence of 0.5x KGB (McClelland et al, 1988; appendix B), ATP 
to 1mM, or with lx T4 DNA ligase buffer supplied by the manufacturer (Boehringer, 
appendix B). Reactions were incubated on ice contained within a glass beaker which 
was left for l6hr on the open bench, allowing the ice to melt and reach room 
temperature (15-20°C). The entire ligation reaction was used to transform competent 
cells of E.coli strain DL655F' (table 2.1, above). In this manner, between 20-100% of 
recovered transformant colonies contained the required recombinant plasmids. 
Screening of Recombinant Clones 
Two methods were used to screen transformant bacterial colonies for the presence of 
plasmids successfully incorporating the required insert fragment. The first was to 
prepare plasmid DNA from overnight E.coli cultures initiated from single transformant 
colonies and analyse the DNA by restriction digest. The second method used was the 
direct screening of transformant colonies by the polymerase chain reaction (PCR). The 
PCR-based method described below has taken the cloning of PCR-amplified env genes 
of lengths 1.7kb and 2.5kb, into the plasmid vector pNBXXAenv as the example. The 
same method was also used to screen for the correct transfer of the cloned env genes 
into the proviral vector pHXB2-MCSAenv. 
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The Direct Screening of Transformant Colonies by PCR 
The screening of transformant colonies for the incorporation of the PCR-amplified DNA 
fragment takes the advantage of the difference in size between the cloning vector 
pNBXXAenv, and the recombinant derivatives which have successfully incorporated the 
PCR fragment. pNBXXL\env contains the entire HXB2 env gene minus 428bp at the 
5'end of the gene. Recombinant clones incorporating the PCR-amplified env gene 
fragments should have a full-length env gene. Transformant colonies will therefore be 
of two types: there will be those carrying the reconstituted or incompletely digested 
vector; and secondly those carrying the required PCR-derived env gene fragment. These 
can be distinguished by specifying PCR-primers that amplify across the deletion of 
pNBXXLenv and using these in a PCR to amplify the DNA directly from the 
transformant colonies. The primers for the PCR-amplification are '313' and '403' - 
whose specification is given below in section 2.7. The PCR-product of the reaction will 
be of length 140bp for pNBXXEenv, and of approximately 560bp for full-length insert-
bearing plasmids. 
For each screening, PCR buffer was prepared for the appropriate number of replicate 
reactions, and 20ul was distributed into each PCR tube. Reactions contained 0.33mM 
each dNTP, lOOnM of each primer, 0.025 units/ui Taq polymerase (Promega), 50mM 
KC1, 10mM Tris-Cl (pH 8.0), 1.5mM MgC12, 0.1% Triton X-100. Single colonies were 
inoculated firstly into the PCR tube and then immediately into 2m1 2xTY broth plus 
ampicillin. The cultures were initiated by incubating at 37°C with vigorous aeration. The 
PCR was carried out with 25 heat-cycles each consisting of 25s at 94°C, 35s at 50°C, 
and 150s at 68°C, followed by an extension step of lOmin at 68°C. The PCR products 
were analysed by agarose-gel electrophoresis on 2.5% agarose gels. For colonies 
yielding the correct sized PCR-product (560bp), plasmid DNA was extracted from the 
cultures initiated from the colonies and further characterised by restriction digest. 
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2.6 Preparation and Transformation of Competent E.coli Cells 
Preparation of Competent Cells 
The preparation of competent cells was carried out by the method of Hanahan (1983). 
Bacteria are rendered susceptible to the uptake of DNA by treating log-phase cultures 
to heavy metal ions. 
Cells were plated onto 2xTY agarose plates (appendix A) and incubated overnight at 
37°C. A single colony was used to inoculate lOmi of 2xTY broth, and the culture 
incubated for 2hr at 37°C. 5ml were subcultured into 95m1 of 2xTY broth and incubated 
at 37°C until the cells had reached an optical density at wavelength 550nm of between 
0.5 and 0.6. The culture was chilled on ice for 5min before aliquoting the contents into 
pre-chilled corex tubes and chilling on ice for a further lOmin. The cells were pelleted 
by centrifugation at 6,000rpm for 5min in a cold Sorvall centrifuge. The supernatant 
was discarded and the cells resuspended in lOml TfbI solution (appendix A). The cells 
were incubated for 15min on ice and centrifuged at 6,000rpm for 5mm. The supernatant 
was again discarded and the cells resuspended in imi of TfbII solution (appendix B). 
The cells were incubated for 15min on ice before aliquoting 100-300u1 into pre-chilled 
Eppendorf tubes contained on ice. The cells were then snap-frozen in liquid nitrogen 
and stored at -70°C for subsequent use. 
The efficiency of transformation of the competent cells prepared by this method was 
assessed by transforming an aliquot of cells with a known amount (between 0.lng and 
lOng) of supercoiled plasmid DNA. The efficiency of transformation of competent cells 
of E.coli strain DL655F' used routinely in this project was 104/ug supercoiled DNA, 
whereas the same method produced an efficiency of transformation of 106/ug 
supercoiled DNA from more robust strains such as XL1-Blue (Stratagene). 
Transformation of E.coli with Plasmid DNA 
Aliquots (100 to 300u1) of competent cells were removed from storage at -70°C and 
thawed on ice. The cells were mixed gently and lOOul aliquoted into pre-chilled 1 .5m1 
Eppendorfs. The appropriate DNA for transformation was chilled on ice and added to 
the competent cells. The reactions were incubated on ice for 30 to 45mm, and heat- 
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shocked by placing at 45°C for 45s. Immediately after heat-shock the cells were 
returned to ice for 2mm. 0.5m1 of 2xTY broth pre-heated at 37°C was added to the cells 
which were then incubated at 37°C for ihr. After this time, the cells were plated onto 
2xTY plates supplemented with ampicilhin and incubated overnight at 37°C. 
2.7 The Polymerase Chain Reaction (PCR) 
PCR Primers 
PCR primers were specified to amplify five regions of the FIIV-1 env gene: 
the V1/V2 region (278bp); 
the V3 region (289); 
a 1.7kb fragment (cassette-1); 
a 2.5kb (cassette-2); and 
a 1.4 kb region (cassette-3) 
- with the first four using a nested PCR. The lay out of the primers is shown in figure 
2.1. The primers were specified at conserved regions of the HIV- 1 genome, using the 
consensus sequence derived from the Los Alamos Database of HIV-1 subtype B 
sequences (Myers et al, 1991). 
V1/V2 Hypervariable Region 
outer: 
4015' GAG GAT ATA ATC CAG TTT ATG G (+, 6107) 
3335 GTA CAT TGT ACT GTG GTG ACA (-, 6493) 
inner: 
4025' GAT CAA AGC CTA AAG CCA TG (+, 6126) 
4035' CAA TAA TGT ATG GGA AAT TGG (-, 6404) 
V3 Hypervariable Region 
outer: 
3325' TAC AAT GTA CAC TGG AAT T (+, 6503) 
308 5' ATT ACA GTA GAA AAA TTC CCC (-, 6908) 
OR 
inner: 
3065' TGG CAG TCT AGC AGA AGA AG (+, 6572) 
307 5' AAT TFC TGG GTC CCC CTC CTG AGG (-, 6861) 
Cassette-1: 1.7kb (BstEII to XbaI) 
outer: 
365 5' GAT GTT GAT GAT CTG TAG (+, 5856) 
3665' TCC AGG TCA TGT TAT TCC AA (-, 7636) 
inner: 
313 5' TGG GTC ACC GTC TAT TAT (+, 589 1) BstEll 
367 5' GGA GTA ATA AAT GTC TAG ATG (-, 7630) XbaI 
Cassette-2: 2.5kb (BstEII to XhoI) 
outer: 
365 5' GAT GTT GAT GAT CTG TAG (+, 5856) 
638 5' GAT GAA CAC TAA CGA GGT AC (-, 8462) 
inner. 
313 5' TGG GTC ACC GTC TAT TAT (+, 5891) BstEll 
g1999 5' GTC TCG AGA TAC TGC TCC (-, 8432) XhoI 
Cassette-3: 1.4kb (BstEII to MInI) 
313 5' TGG GTC ACC GTC TAT TAT (+, 589 1) BstEll 
MluI 5'TGC ACC ACG CGT CTC TTF GCC (-, 7270) MluI 
(The restriction sites located within the primers are underlined) 
Limiting-Dilution Nested PCR 
The limiting-dilution nested PCR was carried out according to Simmonds et al, 1990a. 
A series of dilutions of the PBMC DNA were made (usually from 1:10 to 1:1000) and 
these were amplified in replicate in a nested PCR with primers specified to amplify the 
V1/V2 hypervariable region of the env gene (as given above). The amplifications were 
repeated with different PBMC DNA concentrations until the end-point dilution was 
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reached where less than 20% of the PCR reactions yield amplified DNA. 
The primary and secondary reactions contained 0.33mM each dNTP, lOOnM of each 
of the appropriate primer pair, 0.025 units/ui Taq polymerase (Promega), 50mM KC1, 
10mM Tris-Cl (pH8.0), 1.5mM MgCl2, 0.1% Triton X-100. For each primary reaction 
lul of diluted PBMC DNA was amplified in a 20u1 volume. For the secondary reaction 
lul from the primary reaction was transferred into a 20u1 volume. Each set of 
amplifications was set up in parallel with 5 negative controls in which the DNA was 
omitted. For each round of amplification, 25 heat-cycles were used, each consisting of 
25s at 94°C, 35s at 50°C, and 150s at 68°C, followed by an extension step of 10min at 
68°C. The products of the secondary reaction were analysed by agarose gel 
electrophoresis. 
PCR Amplification with Pfu-Polymerase 
To amplify the cassettes from single proviral molecules directly from PBMC DNA, a 
nested PCR with lul of PBMC DNA at the end-point dilution calculated from the 
V1/V2 PCR was employed. The primary and secondary rounds of amplification were 
carried out with lOOuM each dNTP, 0.025units/ul Pfu polymerase (Stratagene), 20mM 
Tris-Cl (pH 8.8), 10mM KC1, 6mM (NH4)SO4, 1.5mM MgC12 and 0.1% Triton X-100 
and lOOnM each of the appropriate primer pair. Amplifications were carried out by 25 
heat-cycles of 94°C for 35s, followed by 45°C for 35s and 72°C for 4mm. After the 25 
cycles the reaction were held at 72°C for lOmins to allow completion of strand 
synthesis. 
The primary round of amplification was carried out in a 20u1 volume. On completion, 
lul was transferred to the secondary round amplification. The initial secondary round 
amplification - for the purpose of screening for the presence of amplified DNA - was 
carried out in a 20ul reaction. The PCR products were analysed by subjecting the entire 
20u1 volume to agarose gel electrophoresis on 0.8% agarose gels. Reactions containing 
amplified DNA of the appropriate size were re-amplified from lul of the corresponding 
primary reaction in a lOOul volume. Following the secondary PCR, lOul was analysed 
by agarose gel electrophoresis and the remaining 90u1 cloned as described below. 
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When sequences were amplified from cloned material, a single round of PCR with the 
appropriate inner primers was used, in a lOOul volume containing lOng of the 
appropriate cloned DNA. 
Cloning of PCR Products 
Immediately following the completion of the PCR cycles, the reactions were placed on 
ice to minimise the exonuclease activity present in Pfu polymerase. The paraffin oil was 
removed by the addition of 400u1 chloroform, and extracting the aqueous layer. 
Optimum cloning efficiencies were obtained by purifying the DNA through a simple 
ethanol precipitation. This was achieved by adding 0.1 volume of 3M NaAc pH 4.5, and 
2.5 volumes of 100% ethanol and, to facilitate precipitation, lug glycogen was added 
to the reaction (Tracy, 1981) and the sample stored at -20°C for at least 20mm. The 
precipitate was collected by centrifugation at 1500g for 10mm, washed twice with 70% 
ethanol and allowed to air dry. The DNA was resuspended in a lOul volume with 5 
units of the appropriate restriction enzyme (XhoI, XbaI or MluI) and KGB restriction 
enzyme buffer to a 1X concentration (McClelland et al, 1988). Incubation of the sample 
was carried out at 37°C for 2hr. After this time, the reaction was pulse-centrifuged to 
collect any condensation on the sides of the tube, and 5units of BstEll was added, the 
sample overlaid with paraffin oil and incubated at 65°C for lhr. 
Approximately half of the reaction was used to ligate into the plasmid vector 
pNBXXienv. The entire ligation reaction was used to transform competent cells of 
E.coli strain DL655F'(as described above). 
2.8 Oligonucleotide-Directed Mutagenesis 
Oligonucleotide-directed mutagenesis was carried out by an adaptation of the original 
method of Kunkel, 1985. An oligonucleotide is specified to contain the desired 
nucleotide sequence changes. These are incorporated into a cloned DNA sequence by 
priming the in vitro synthesis from a single-stranded form of the cloned sequence with 
the oligonucleotide. The synthesised strand containing the specified changes is 
recovered by transformation of E.coli. The efficiency of recovery of the mutant over the 
wild-type strand can be enhanced by selecting against the parent strand. With the 
method of Kunkel, selection is achieved by preparing the template construct from the 
E.coli strain CJ236 (Joyce and Grindley, 1984), (dut, ung, table 2.1). This strain 
incorporates a small number of uracil residues in place of thymine. dut mutants lack the 
enzyme dUTPase and contain raised levels of dUTP, which competes with dTTP for 
incorporation into DNA; ung mutants lack uracil glycosylase which would normally 
remove uracil from DNA. Following transformation of uracil-containing DNA into a 
wild type E.coli host, the uracil residues will be removed by the action of N-uracil 
glycosylase, leaving the DNA susceptible to nuclease degradation, and consequently 
rendered biologically inactive. The mutant strand, lacking uracil should have greater 
survival in the wild type host. 
Preparation of a Uracil-Containing Single-Stranded DNA Template 
E.coli strain CJ236 (table 2.1) was transformed with 20ng of the appropriate plasmid 
construct. A single transformant colony was inoculated into 5m1 2xTY-broth plus 
ampicillin, supplemented with 0.25ug/ml uridine (Boehringer), and incubated at 37°C 
with vigorous shaking for 60min to allow expression of the F' episome contained on 
the plasmid. 50ul of R408 helper phage (Russel et al, 1986) at 10"pfu/ml (Stratagene) 
was added and incubation continued overnight. 1 .5ml aliqouts of the culture were 
centrifuged for lOmin at 4°C to pellet the cells. 200ul of a 15% PEG/2.5M NaCl 
solution was added to lml of the supernatant and the mixture left at room temperature 
for 20mm, to allow the phage particles to precipitate. The phage were pelleted by 
centrifugation at 1500g for lOmin and resuspended in lOOul TB. The DNA was 
extracted by a standard phenol/chloroform extraction followed by ethanol precipitation, 
and resuspended in 20ul TB. The yield was determined by agarose-gel electrophoresis 
of a 5u1 aliquot. 
In Vitro Synthesis of Mutant Strand 
200ng of uracil-containing, single-stranded DNA template was annealed with 20ng of 
the appropriate phosphorylated primer (see below), in a lOul volume containing 10mM 
Tris-Cl (pH 7.5), 2mM MgC12 and 50mM NaCl. Annealing was carried out by heating 
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the reaction to 75°C followed by gradual cooling to room temperature, over a period of 
1 hour. Synthesis of the mutant strand was carried out by the addition of lul of a lox 
synthesis buffer (4nIvI dNTPs, 10mM ATP, 200mM Tris-Cl pH 7.5), 40mM MgC12 and 
150 mM DTF, 5 units Sequenase (USB) and 1 unit T4 DNA ligase (Boehringer). The 
reaction was incubated on ice for 5mm, followed by 5 min at 25°C and 37°C for 60mm. 
The DNA was ethanol precipitated after addition of 20ng glycogen (Boehringer) to 
facilitate DNA precipitation. The DNA was collected by centrifugation, washed in 70% 
ethanol and allowed to air dry. A further ligation step was carried out by resuspending 
the DNA in 20u1 of 0.5x KGB (appendix A) with 1 unit T4 DNA ligase (Boehringer), 
ATP to 1mM and incubating for 60min at room temperature. 
Recovery of Mutant Clones 
One quarter of the ligation reaction was used to transform competent cells of E.coli 
strain SURE ung+ (Stratagene) (table 2.1). Colonies were screened for mutant clones 
by digestion of miniprep DNA, prepared from single transformant colonies. 
Primers for Oligonucleotide Mutagenesis 
The following primers were specified for oligonucleotide mutagenesis: 
- NotI: 5' GTA GCA TTA GCG GCC GCA ATA ATA ATA GC 3' (5645 HXB2R) 
- BstEll: 5' TGG GTC ACC GTC TAT TAT G 3' (5891 HXB2R) 
- XbaI: 5' GAA GTA ATA AAT GTC TAG ATG 3' (7630 HXB2R) 
The nucleotide sequences were specified to be identical to the sense strand of the HXB2 
sequence, except for the appropriate substitutions to generate the three respective 
restriction sites. 
Phosphorylation of Oligonucleotide Primers 
Primers synthesised by Oswell contain neither a 3'or 5' phosphate group. In order to 
improve the efficiency of the ligation of the newly synthesised strand produced during 
in vitro mutagenesis, the oligonucleotide primers were first phosphorylated at the 5' 
end. 
15 pmoles primer were phoshphorylated in a 20u1 volume, by incubating with 2 units 
of T4 polynucleotide kinase (Boehringer) in the presence of 1mM ATP, and T4 
polynucleotide kinase buffer (Boebringer) to the final, recommended, concentration of 
50 mM Tris.Cl pH8.2, 10mM MgCl2, 0.1 mM EDTA, 5 mM DTT and 0.1 mM 
spermidine, at 37°C for 30mm. Reactions were terminated by heating to 65°C for 10 
mm. 
2.9 DNA Sequencing 
2.9.1 Manual Sequencing 
DNA sequencing was carried out using the dideoxy-chain termination method of Sanger 
et al, (Sanger et al, 1977). The reaction conditions followed those recommended by the 
Sequenase version 2.0 sequencing protocols (USB), with the addition of 10% DMSO 
to the annealing and termination reactions according to Winship, 1989. 
Primers for Manual Sequencing 
For the position of the primers along the env gene, see figure 2.1 
Hypervariable Regions Vi and V2 
4025' GAT CAA AGC CTA AAG CCA TG (+, 6126) 
403 5' CAA TAA TGT ATG GGA AAT TGG (-, 6404) 
Hypervaraible Region V3 
3065' TGG CAG TCT AGC AGA AGA AG (+, 6572) 
307 5' AAT TFC TGG GTC CCC CTC CTG AGG (-, 686 1) 
Hypervaraible Region V4 and Conserved Region C4 
407 5' GGG GAA TTT TFC TAC TGT AAT (+, 6928) 
Hypervariable Region V5 
405 5' CTF CTC CAA TFG TCC CTC ATA (-, 7192) 
5' End of gp4i 
3675' GGA GTA ATA AAT GTC TAG ATG (-, 7630) 
Denaturation For each reaction approximately 1-3ug of plasmid DNA was denatured 
by treatment with alkali, by incubating in a 50u1 volume containing 0.2M NaOH and 
0.2mM EDTA, for 20min at 37°C. The reaction was neutralised by the addition of 0.1 
volume of 3M NaAc pH 4.3. The DNA was precipitated by adding 2.5 volumes 100% 
ethanol, and storing at -20°C for at least 20mm. The DNA was collected by 
centrifugation for 10 min at 1500g, washed with 70% ethanol and allowed to air dry. 
Annealing Annealing of template and primer was carried out by resuspending the DNA 
in a lOul volume containing 200mM Tris-Cl pH 7.5, 100mM MgCl2,  250mM NaCl, 
10% DMSO and lOng of the relevant primer, and incubating at 37°C for 20mm 
Labelling Reaction lul 0. 1M DTT, lul 1 .5uM each dNTP (Boehringer), 2 units 
Sequenase enzyme (USB) and 5uCi of 35S-labelled nucleotide triphosphate (>1000 
Ci/mM; Amersham) were added to the annealing reaction and incubated for 5min at 
room temperature. The labelled nucleotide triphosphate was chosen according to the 
composition immediately 3' to primer binding site. 
The termination step was carried out by aliquoting 3.7u1 of the labelling reaction into 
each of 4 termination mixtures, each containing 80uM of the 4 dNTPs, 8uM of either 
(dideoxy-)ddGTP, ddATP, ddTTP or ddCTP, contained within a 2.5u1 volume. 
Reactions were allowed to proceed at 37°C for 5 mm, before adding stopping the 
reaction by the addition of 4u1 of loading buffer (95% formamide, 20mM EDTA, 0.05% 
bromophenol blue, and 0.05% cyanoiFF). 
Polyacrylamide-Gel Electrophoresis The sequencing reactions were resolved on 8% 
denaturing polyacrylamide gels, (BRL model S2 electrophoresis apparatus). Gels were 
prepared with 8% (w/v) 20:1 acrylamide:bisacrylamide (BDH), 0.1% (w/v) ammonium 
persuiphate (Sigma) and 1xTBE. Gentle heat was applied to dissolve the reagents, and 
the solution allowed to cool. Prior to pouring the solution, TEMED (N,N,N',N'-
tetramethylethylenediamine, Sigma) was added to 10%. Samples were heat denatured 
at 90°C for 2min prior to loading onto the sequencing gel. Electrophoresis was carried 
out with 1xTBE as the running buffer, at 75 watts, until the bromophenol blue present 
in the loading buffer had egressed from the gel. 
Following electrophoresis, gels were fixed with 5% acetic acid (BDH) and 5% methanol 
(BDH). The gels were dried under vacuum at 80°C for 2 to 3hr, and autoradiography 
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carried out for 16 to 24hr, using Kodak XAR-2 Xray film. 
Sequence Analysis Sequence analysis was performed on a VAX computer, using the 
University of Wisconson GCG package (Devereux et al, 1984). 
2.9.2 Automated DNA Sequencing 
Automated DNA sequencing was carried out using the model 373A DNA sequencing 
system of Applied Biosystems Inc. 
The automated sequencing method, as with the manual sequencing, is based upon the 
di-deoxy chain termination method of Sanger et al, 1977. With the automated 
sequencing employed in this laboratory we use 17 DNA polymerase with dye-labelled 
terminators. The di-deoxynucleotides are labelled with a dye molecule each of which 
emits light at a different wavelength when excited by a laser which continually scans 
the gel while it is moving. A photon multiplier tube detects the fluorescent light and 
converts it to an electrical signal. The signal are transmitted to the computer and stored 
for eventual processing. 
DNA sequencing of cloned material with an automated sequencer involves the following 
four steps: 
- Amplification of the DNA by PCR, with a primer pair, of which, one is biotinylated. 
- Purification of single-stranded DNA using a Dynabead biomagnetic separating system 
(Dynal AS). 
- DNA sequencing. 
- Data collection and analysis. 
For the automated sequencing described in this study, the first three steps were carried 
out by Alexander Cleland (Centre for HIV Research, University of Edinburgh). 
PCR Amplification 
Single-stranded DNA is prepared for sequencing by the PCR-amplification of the 
required region with a primer pair of which one is biotinylated. The DNA strand primed 
from the biotinylated primer will incorporate the biotin at its 3' end. 
RR 
Primers were specified to amplify a 1.7kb portion of the env gene, as three overlapping 
regions of 780, 690 and 51Obp respectively. These are denoted 1, 2 and 3 in figure 2.2, 




36635' AGC AGA AGA CAG TGG CAA TG (+, 5773) 
36645' TTC TGC TAG ACT GCC ATT (-, 6554) 
Sequencing: 
365F 5' GAT GTF GAT GAT CTG TAG (+, 5856) 
0185 5' CAT GGC TTT AGG CTT TGA TC (-, 6108) 
4025' GAT CAA AGC CTA AAG CCA TG (+, 6126) 
3664 as above 
Region 2 
Amplifcation: 
3325' TAC AAT GTA CAC ATG GAA TT (+, 6503) 
405 5' CTF CTC CAA TFG TCC CTC ATA (-, 7192) 
Sequencing: 
332 as above (non-biotinylated) 
405 as above 
307 5' CTG GGT CCC CTC CTG AGG (-, 686 1) 
4065' TCA GGA GGG GAC CCA GAA ATT (+, 6883) 
Region 3 
Amplification: 
3893 5' OCT ATT AAC AAG AGA TGG (+, 7143) 
3662 5' TFC TCT GTC CCA CTC CAT CC (-, 7653) 
Sequencing: 
3893 as above 
3661 5' CAG CAG GAA GCA CTA TGG GC (+, 7363) 
38945' CTG CTT GAT GCC CCA GAC (-, 7478) 
3675' GGA GTA ATA AAT GTC TAG ATG (-, 7630) 
50ng of the appropriate DNA plasmid were amplified in a 50u1 volume reaction, as 
described in section 2.7, with primers in molar ratio of lQpmol of biotinylated primer 
to 30pmol of non-biotinylated primer. Following the PCR, lOul were analysed by 
agarose-gel electrophoresis to ensure the correct yield of DNA. The remaining 40u1 of 
PCR product were taken forward into the two strands separated and purified as 
described below. 
Preparation of Single-Stranded DNA For each sequencing reaction 20u1 of dynabeads 
coated with streptavidin (Dynal AS) were prepared in 40u1 of 0.1% bovine serum 
albumen and resuspended in 40u1 of extraction buffer (10mM Tris-Cl pH7.5, 1mM 
EDTA, 20mM NaCl) to a final concentration of Sug/ml. To this was added 40u1 of PCR 
product, the solution mixed thoroughly and incubated at 48°C for 30mm. Following 
incubation, the reactions were placed in a magnetic separator (Dynal AS) and the 
supernatant discarded. The beads were then washed in 40u1 extraction buffer and 
resuspended in 8u1 0.1M NaOH and incubated at room temperature for lOmin to 
denature the non-biotinylated complementary strand. The reactions were then returned 
to the magnetic separator and the supernatant containing the unbound complementary 
strand was removed and neutralised by the addition of 4u1 0.2M HC1 and lul 1M Tris-
Cl pH7.5. The solution was then made up to 14u1 with dH20 and stored for subsequent 
sequencing. The beads containing the captured biotinylated DNA strand were washed 
three times, firstly, with 50u1 NaOH, then 50u1 extraction buffer, followed by 50u1 TE 
buffer. The beads were then resuspended in 14u1 dH20. 
DNA Sequencing The materials for the sequencing reactions were obtained from the 
'PRISM Sequenase terminator' single-stranded sequencing kit (Applied Biosystems Inc). 
14u1 of single-stranded DNA template, prepared as described above, were mixed with 
lul of the appropriate sequencing primer (figure 2.2) at 0.8uM. To this was added 5u1 
of a freshly prepared 5x MOPS buffer (0.2M MOPS pH7.5, 0.25M NaCl and 0.05M 
MgC12, 25% glycerol, 25mM MnC12, and 0.075M isocitrate) were added. The reaction 
was incubated at 65°C for 2min and allowed to cool slowly to room temperature. 
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4u1 'T7 Dye Terminator Mix' (as supplied in the sequencing kit) was added to the 
annealedtemplate reactions and pre-warmed at 37°C for 2mm. After this time lul (1.5 
units) of T7 DNA polymerase was added, the reaction mixed and incubated at 37°C for 
10mm. The reactions were then placed on ice and spun briefly to collect any 
condensation. 
The excess dye was removed from the reactions containing the biotinylated strand by 
placing the tube in the magnetic separator, removing the supernatant and washing the 
DNA-bead complex twice with 50u1 dye-terminator wash buffer (0.01M Tris-Cl pH8.0 
and 0.1% Tween-20) and once with 50ul TB. The excess dye terminator was removed 
from the non-biotinylated strand by precipitating the DNA by the addition of 29.5u1 8M 
NH4Ac, 150u1 95% ethanol. The precipitate was collected by centrifugation at 1500g 
for 20mm, the supernatant removed and the pellet dried by heating to 90°C for 2mm. 
Both the biotinylated and non-biotinylated samples were resuspended in 3ul 
formamide/EDTA solution (5:1 deionised formamide:50mM EDTA pH8.0). The 
sequencing products were resolved by electrophoresis on 6% polyacrylamide gels, 
within the 373A automatic sequencer, according to the manufacturer's instructions. 
Collection and Processing of Sequence Data 
The data from the sequencing run was collected on a Macintosh computer using the 
ABI data collection programme (ABI Inc). 
Data in the form of ABI sequence files were transferred to a SUN Sparcstation 
computer via CAP (Columbia Appletalk Package). The data was processed through a 
preliminary editor TED (which forms part of the Staden computer package, see below), 
using the Seqprocess script (written by Chris Wade, Centre for HIV Research, Division 
of Biological Sciences, University of Edinburgh, Edinburgh, EH9 3JN). The data were 
then entered into the Xbap data base (Staden package) using the Seqedit script (Chris 
Wade, address as above). 
TED and Xbap are two programs that form part of the Staden Package, written by 
Roger Staden and Simon Dear, MRC Laboratory of Molecular Biology, Hills Road, 
Cambridge CB2 2QH). 
Sequences from both strands of the DNA, covering the entire region of gpl20 
sequenced from each clone, were aligned and contiguous sequences (contigs) assembled 
within the Xpab program. The full-length gpl20 sequence was then edited by eye, With 
reference to the sequence trace data. The consensus gpl20 sequence was output from 
Xpab and transferred to a VAX computer, where it was analysed using the GCG 
package. The sequencing data are collected and analysed by Macintosh ilci computer. 
Two programs are utilised Data Collection and Analysis. Sample files created from the 
preliminary analysis of data were transferred to a Sun Sparkstation computer and 
subsequently analysed using TED and Xbap. 
2.10 In Vitro Transcription and Translation 
In vitro transcription was carried out using 'phage T7 RNA polymerase, initiating 
transcripts from the T7 promoter sequence present in pBluescript (- located upstream 
of the env gene - see section 2.3 and chapter 3, section 3.6). In vitro translation was 
carried out using the following systems purchased from Promega: The Wheat Germ 
Extract System and the Rabbit Reticulocyte Lysates. The protocols followed were those 
recommended and detailed in the 'Promega Protocols and Applications Guide'. These 
will be summarised briefly below. 
In Vitro Transcription 
For each reaction 5ug of the appropriate plasmid construct were digested to completion 
with 10 units of XhoI (section 2.5). Following digestion the DNA was extracted once 
with phenol and once with chloroform and purified by ethanol precipitation. The DNA 
was resuspended in dH2O and 2ug was used to direct in vitro transcription with T7 RNA 
polymerase (Promega). Each transcription reaction contained lx transcription buffer 
(40mM Tris-Cl pH7.5, 6mM MgCl2, 2mM spermidine and 10mM NaCl), 10mM DTT, 
100u rRNAsin (Promega), 0.5mM rNTPs, 15U T7 RNA polymerase, 2ug DNA, made 
up to 100u1 with nuclease-free dH20. The reactions were incubated for 120mins at 37°C. 
Following incubation, the reactions were treated with DNaseI (Promega) at 1 unit per 
ug template DNA, by incubating the reaction at 37°C for 15mm. The RNA was purified 
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by phenol/chloroform extraction and ethanol precipitation. The RNA pellet was washed 
with 70% ethanol and allowed to air dry. The RNA was resuspended in nuclease-free 
dH20 and stored at -70°C. 
In Vitro Translation 
Prior to assembling the reaction components (either from the Wheat Germ Extract 
System, or the Rabbit Reticulocyte Lysates; Promega) the RNA was denatured by 
heating at 67°C for 10mm. Each reaction contained 25u1 of wheat germ extract, 40units 
RNasin, 1mM amino acid mixture (minus methionine), 1M potassium acetate, lug RNA 
substrate, and 2.5u1 [35S]methionine (1,2000Ci/mmol; Amersham) at lOmCi/ml, and was 
made up to 50u1 with dH20. The reactions were incubated at 25°C for 60mm, and on 
completion were stored at -70°C. 
SDS Gel Analysis of Translation Products 
Discontinuous gel electrophoresis under denaturing conditions in the presence of 0.1% 
SDS, a method described by Laemmli (1970), was carried out. Vertical slab minigels 
with a 12% SDS polyacrylamide separating gel and a 5% stacking gel were prepared 
for the Mighty Small II SE250 (Hoefer Scientific Apparatus). 
5u1 of wheat germ translation product were prepared for electrophoresis by adding 20u1 
loading buffer (containing 10% glycerol, 10% SDS, 2.5% B-mercaptoethanol), boiling 
for 5min and centrifugation for 5min. lOul were loaded onto the gel along side 14C-
labelled Rainbow protein markers (Amersham) ranging from 14,000 to 200,000 daltons. 
Electrophoresis was carried out at lOmA whilst the samples were migrating through the 
stacking gel, and at 20mA when samples were migrating through the separating gel. 
Once the bromophenol blue present in the loading buffer had reached the end of the gel, 
electrophoresis was stopped and the gel removed and fixed in 30% methanol, 10% 
glacial acetic acid, and stained with Coomassie Blue for 30mm. After a series of 
destaining in 30% methanol and 10% acetic acid, the gel was dried onto a sheet of 
Whatman 3MM paper, using gel drying apparatus. Autoradiography was carried out 
using 'AGFA curix RP1' X-ray film (Kodak), exposing the film for 12-16hr. 
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2.11 Cell Culturing 
The following two sections, 2.11 and 2.12, describe the experimental procedures for 
cell-culturing and the recovery of recombinant viruses. These were developed and 
carried out by Dr Robert Walker, with assistance from Mrs Elizabeth Harvey. 
Cell Lines 
COS-1 - an established simian cell line transformed with the simian virus SV40 
(Gluzman, 1981). This cell line has a single integrated copy of the complete early 
regions of SV40 DNA and expresses the SV40 transforming T-antigen. This cell line 
was a gift from Dr Myra McClure, London. 
The following cell lines were obtained from the MRC AIDS Reagent Project 
Repository, National Institute for Biological Standards and Control, Blanche Lane, 
South Mimms, Potters Bar, Herts EN6 3QG, UK: 
C8166 - a CD4-positive T cell line 
This cell line derives from the transformation of human umbilical cord blood 
lymphocytes with Human T-Cell Leukemia Virus type 1 (HTLV-1) (Salahuddin et al, 
1983). 
H9 - a CD4-positive T cell line 
The H9 cell line is a clonal derivative of a T cell line designated HT (Mann et al, 
1989). HT is a sublime of the continuous T cell line HUT-78, established from a human 
cutaneous T-cell lymphoma (Gazdar et al, 1980). 
Sup-Ti - a CD4-positive T cell line 
This cell line was established from a non-Hodgkin's T-cell lymphoma (Smith et al, 
1984). 
Jurkat 111 - a CD4-positive T cell line, expressing the HIV-1 tat gene 
The Jurkat cell line, established from a Human T-cell leukaemia, has been transformed 
with the HIV-1 tat gene. This cell line is reported to support the growth of poorly 
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replicating primary HIV-1 strains (Fenyo et al, 1988). 
U937 - an histiocytic cell line with monocyte-like characteristics 
This cell line derives from an histiocytic lymphoma, and phenotypic characteristics of 
the histiocyte-monocyte series (Sundstrom and Nilsson, 1976). 
Isolation and Culture of Peripheral Blood Mononuclear Cells 
Whole blood was obtained from normal healthy HIV-1 seronegative donors. Peripheral 
blood mononuclear cells (PBMCs) were isolated by density centrifugation (400g for 
30mm) on sodium metrizoate/Ficoll (Lymphoprep; Nycomed Limited, Birmingham, UK) 
and washed twice in RPMI medium (HyClone Europe Ltd, Cramlington, UK). PBMCs 
were resuspended at 2xlO6cells/ml in RPMI-complete medium; (RPMII supplemented 
with 2mM L-glutamine (HyClon), penicillin (50U/ml; GIBCO BRL, Paisley, Scotland), 
streptomycin (50ug/ml; GIBCO) and 10% foetal calf serum (FCS; Advanced Protein 
Products Ltd, Brierley Hill, UK). Cultures were stimulated with phytohaemagglutinin 
(PHA; 5ug/ml; Sigma Chemical Company Ltd, Poole, UK) for 72hrs and then 
maintained in RPMI-complete medium further supplemented with 30U/ml recombinant 
human interleukin-2 (IL-2; Advanced Protein Products). 
Maintenance of Cell Lines 
The immortalized CD4t T cell lines; H9, C8166, SupTi, Jurkat tat., and MT2 and the 
myeloid cell lines: U937, HL60 and THP1 were maintained in RPMI-complete medium 
and sub-cultured twice weekly. COS-1 cells were maintained in Dulbecco's Modified 
Eagle's medium (DMEM) supplemented as with RPMJ-complete medium. 
2.12 Transfection and Culture of Recombinant Virus 
Preparation of DNA 
DNA of full-length proviral clones were prepared for transfection from small-scale 
(3m1) cultures of E.coli, using commercially available DNA purification columns, either 
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from Promega (the 'Magic Miniprep' purification system), or plasmid purification 
columns from Qiagen. These systems allow the preparation of small amounts of DNA 
(3-5ug) of sufficient purity for transfection, without resorting to conventional 
purification by caesium chloride-gradient centrifugation, which would have resulted in 
the handling of larger amounts of potentially infectious material. 
For each transfection, 2ug of plasmid DNA from the purification columns was sterilised 
by ethanol precipitation. The DNA was collected and washed with 70% ethanol and 
allowed to air-dry under sterile conditions (by storage within a Class II biosafety 
cabinet). The DNA sample was resuspended in 21u1 sterile dH20. lul was assayed by 
agarose-gel electrophoresis to ensure there was efficient recovery of the DNA following 
the ethanol precipitation. 
To recover virus from the two molecular clones SF2MC and SF162MC, 5ug of each DNA 
from the 5' and 3' subclones was linearised by digestion with EcoRI and co-precipitated 
with ethanol. The DNA pellet was air-dried and resuspended in sterile distilled H20. 
DNA Transfection 
Cos cells (1-2x105) were seeded into 6 well plates (Nunc, GIBCO) 24hrs prior to 
transfection. Plasmid DNA (5-10ug) in lOOul OPTI-MEM medium (GIBCO) was mixed 
with lipofectin reagent (GIBCO; 15ug in lOOul OPTI-MEM) for 15min at room 
temperature (RT). COS-1 cell monolayers were gently washed twice with OPTI-MEM 
and overlaid with 0.8m1 OPTI-MEM. Lipofectin-DNA mixture was added to the COS -1 
cells and incubated for 6hrs at 37°C, 5% CO2. after which 2m1 DMEM-complete 
medium (20% FCS) was added. Alternatively, cell suspensions (3x106 cells in 0.8m1 
OPTI-MEM) of immortalized CD4 T cells or myeloid cells were combined with the 
lipofectin-DNA mixture as above and subsequently cultured in RPMT-complete medium 
(20% FCS). After 24hrs, 5x106 PHA stimulated PBMCs or 3x106 cells from transformed 
T cell and myeloid cell cultures were co-cultivated with transfected COS-1 cell 
monolayers to enable spread and amplification of any resultant recombinant virus 
progeny. 72hrs later PBMCs and transformed cells of co-cultures were transferred to 
T25 flasks and monitored for viral production. Additional PHA stimulated PBMCs or 
appropriate cells from immortalized cell cultures were added to transfected cultures as 
required. 
Assessment of Viral Production 
Transfected cultures were monitored twice weekly for 4-6 weeks post- transfection for 
production of virus. At each time, imi of culture was clarified by centrifugation (250g 
for 10mm) to obtain the supernatant which was filtered (0.45um) and stored at -70°C 
for subsequent determination of p24 antigen levels by an enzyme-linked immunosorbent 
assay (ELISA). Recovered cells were stained for gag core antigens by direct 
immunofluorescence. 
Direct Immunofluorescence on Fixed Cells 
Cell pellets were washed twice in phosphate buffered saline (PBS; pH7.5) and 
permeabilized by hypotonic shock (PBS:distilled H20; 1:1). Duplicate aliquots (15u1) 
were spotted onto PTFB coated multiwell microscope slides (C.A.Hendley Ltd, 
Loughton, UK) and allowed to air dry for 45mins. Slides were fixed in 
acetone: methanol (1:1) for lOmin at RT. Cell preparations were stained with FJTC-
conjugated mouse anti-HIV-1 p24  monoclonal antibody (MAb; Coulter Clone KC57-
FITC, Coulter Immunology, Luton, UK) and an isotype control (Coulter Clone MsIgGl-
FITC). MoAbs were diluted 1:200 in PBS containing 1% bovine serum albumin 
(Sigma) and incubated for 45min at RT. Slides were washed in PBS (3 changes over 
10min period) and briefly (30sec) counterstained in 0.05% Evans Blue (BDH 
Laboratory Supplies, Glasgow, Scotland). Following mounting in glycerol containing 
an anti-fading agent (Citifluor, Canterbury, UK) slides were examined under a Nikon 
OPTIPHOT microscope with episcopic-fluorescence attachment (Nikon Ltd, Kingston, 
UK). 
p24 Antigen ELISA Supernatants were assayed for p24 antigen using affinity purified 
sheep anti-p24 antibody as capture antibody (Aalto BioReagents, Dublin, Eire), 
biotinylated mouse anti-p24 MAb as detector antibody (MRC AIDS Directed 
Programme) followed by streptavidin-horseradish peroxidase (Sigma) and o-
phenylenediamine dihydrochioride (OPD; Sigma) for chromogenesis. Briefly, lOOul 
capture antibody (1mg/mi) was diluted 1:100 with coating buffer (150mM NaHC031  
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pH9.0) and lOOul dispensed to 96 well high binding microelisa plates (Costar, High 
Wycombe, UK) and incubated overnight at RT. After washing in Tris buffered saline 
(TBS; 144mM NaCl, 25mM Tris, pH7.5) plates were blocked for 30min at RT using 
200u1/well of 2% Marvel milk solution, then washed in TBS. Following heat 
inactivation (56°C for 45mm) viral lysates prepared from culture supernatants treated 
with Empigen (0.1% final concentration; Calbiochem, La Jolla, CA), and p24 standards 
(1-1000ng/ml; Baculovirus-derived p24., American Bio-Technologies Inc, Cambridge, 
MA) were added to plates and incubated overnight at RT. Plates were washed in 
TBS/Tween (0.05%; Sigma) and lOOul biotinylated mouse anti-p24 MAb (diluted 
1:1000 in TBS/0.05% Tween/20% FCS) added and incubated at RT for 2hr. Subsequent 
addition (lOOul) and incubation (lhr at RT) of Extravidin-horseradish peroxidase(diluted 
1:4000 in PBS/0.05% Tween) followed washing in TBS/0.05% Tween. A final wash 
in TBS/0.05% Tween preceded addition (lOOul) and incubation (15-20mm) of OPD 
(lmg/ml in 0.05M phosphate citrate buffer with urea, pH5.0; Sigma). Reaction was 
stopped by addition of lOOul 5N H2SO4. Absorbances at 492nm were read using a 
Multiskan Bichromatic microplate reader (Life Sciences International Ltd, Basingstoke, 
UK) and data analysed using GENESIS software package (Life Sciences). 
Viral Stock Production and Infectivity Determination Cells from p24 
antigen positive cultures were mixed 1:4 with uninfected cells from CD4 T cell lines 
for 72hr. Supernatants were harvested following centrifugation (300g for 10mm), 
filtered (0.45um), mixed 1:1 with FCS and stored in liquid N2. The infectivities of 
supernatants were determined by performing sextuplet replicates of 4-fold serial 
dilutions of virus (50ul) and incubating with SOul of C8166 cells (4x105/ml) in 96 well 
flat bottomed microtitre plates (Costar) at 37°C, 5%CO2 for 7-10 days. Plates were 
scored for the formation of syncytia and the 50% tissue culture infective dose (TCJD) 
calculated by the Reed & Muench method. 
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3.1. Introduction 
It is possible to produce infectious HIV-1 virions by the introduction of full-length, 
proviral clones into cell cultures (Levy et a!, 1986, Adachi et al, 1986). This property 
may be exploited to examine the function of viral genes, or specific regions of the 
viral genome. Through the use of recombinant DNA techniques, specific genes, or 
genomic regions of the proviral genome, may be mutated, or exchanged for different 
allelic versions. By examining the phenotype of the resultant viruses, the function of 
the mutated gene, or exchanged genomic region, may be determined (Fisher et a!, 
1985, and 1986). 
There have been many reports describing the construction of HIV-1 recombinant 
molecular clones for purposes of mapping the determinants of viral phenotype. (For 
example: Fisher et al, 1985; Cheng-Mayer et al, 1990; Groenink et a!, 1991; Hwang 
et a!, 1991). These were carried out by exchanging regions of the env gene between 
infectious molecular clones with differing phenotype, or by exchange of regions of 
the env gene from non-infectious clones into the backbone of an infectious clone. 
In these reports, the regions exchanged were limited to restriction-fragments common 
to both clones. 
However, the region of interest may not be bounded by restriction sites shared 
between the clones. In such cases, it is possible to engineer additional restriction sites 
into the cloned sequence, for the exchange of more precisely-defined regions. The 
modified infectious clone may then be thought of as a 'cassette-vector', in which a 
defined region of the genome, that is, the 'cassette', can be replaced with variant 
sequences from another source. Indeed, it is possible to take advantage of the 
polymerase chain reaction (Mullis et a!, 1987, Saiki et al, 1988), and design primers 
at the regions of the newly-specified restriction sites, that is, the cassette-boundaries, 
and so amplify sequences from a variety of sources, both cloned, and uncloned 
sequences, in a form in which they can be easily substituted into the vector. For 
example, there have been several reports of the engineering of infectious molecular 
clones to allow exchange of the V3-domain of gpl20 - to study cellular tropism, 
cytopathic effect and neutralisation properties (De Jong et al, 1993a; Chesebro et a!, 
as the V2-loop, and an epitope in the external domain of gp4l (Fung et al, 1992, 
Muster et al, 1994). 
The majority of these epitopes are conformationally-dependent - the neutralising 
sensitivity of the epitope is influenced by both the primary sequence and the 
conformation of the epitope, which in turn, can be influenced by amino acid changes 
distant to the epitope. 
The conformational nature of these epitopes is seen clearly when neutralising-
antibody escape mutants are found to map to regions of the protein that are outside 
the defined epitope. For example, antibody-escape mutants to the V3-loop epitope 
have been found to map outside the V3 loop - in some cases mapping to distant sites 
in gpl20, and in gp4l (McKeating et al, 1989; Back et al, 1993). This is similarly 
the case for the complex CD4-binding site epitope, where resistant mutations are 
found to map outside this site (McKeating et al, 1993; Thali et al, 1994). 
Ideally, to reproduce an HIV- 1 envelope protein with the correct antigenic properties 
requires both gp120 and gp4l subunits of the envelope protein to be expressed, so 
they can assemble into their oligomeric, native form (Moore, 1993). This argues for 
the exchange-region of the proviral vector to contain the whole of the env gene. 
However, another major factor influencing the design of a cassette-vector, where one 
sequence is to be replaced by a variant of it, is the organisation of the HIV- 1 
genome, which consists of many overlapping reading-frames (figure 3.1). The result 
of such overlapping reading frames is that the replacement of the coding sequence 
of one gene will result in the alteration of the coding capacity of any overlapping 
genes. 
In this way, any resulting changes in given phenotype conferred by sequence changes 
in one gene cannot be attributable solely to that gene, the contribution of changes to 
the overlapping genes must be considered. 
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Figure 3.1. The Proviral Clone pHXB2-D 
R EcoRI; S Sail; B BamHI; Xh XhoI; Xb XbaI 
a - start env coding region; ,b - end of vpu coding region; 
c - gp 160 cleavage site; d - start of tat and rev 3' coding exon; 
e - end of env coding region; f - start of nef coding region 
co-ordinates according to HXB2R 
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The HIV- 1 env gene overlaps with the vpu gene and the 3' coding exons of the 
regulatory genes tat and rev. To study the contribution to the sensitivity of the virus 
to neutralising antibodies, or indeed, to any other phenotypic properties, of changes 
limited to the env gene, the region exchanged should include only env gene 
sequences, and not those of vpu, tat and rev. Such a region lies in the intervening 
sequences between the overlapping reading frames of vpu, tat and rev (from nt 5876 
to 7924 HXB2R). This region is 2.0kb and includes the sequence of the env gene 
encoding for the whole of gp120, and the majority of the extracellular portion of 
gp4l. This region contains the major neutralising epitopes of gp120 and gp4l. 
A third region of the env gene was also considered as important for investigating the 
neutralising sensitivities of the virus envelope: the region of the env gene encoding 
for surface protein, gp120. The main reasons for exchanging gp120 alone is to 
prevent the formation of a hybrid gp4l, and to exclude from the exchange region the 
Rev response element (RRE) which lies within the env gene (figure 3.1). The RRE 
is the cis-acting element for the viral regulatory protein Rev (Malim et al, 1990). It 
is conceivable that different RRE sequences contained within exchanged variants of 
the env gene may not function optimally with the HXB2 Rev protein. Omitting the 
RRE from the region exchanged should control for this type of variation. 
In summary, we would like to design a cassette-vector with three exchange-regions: 
1) the whole of the env gene (from 5771 to 8341 HXB2R); ii) the region of the env 
gene lying between the overlapping coding sequences of vpu, tat and rev (from 5856 
to 7924 HXB2R); and iii) the region of the env gene encoding for gp120 but not for 
gp4l (from 5771 to 7303 HXB2R). 
The proviral clone, pHXB2-D, contains a number of unique restriction sites which 
could act as cloning sites (for example Sail at 5332 , BamHJ at 8021, and NheI at 
6806, and XhoI at 8443; figure 3. 1, and appendix B). The XhoI site at 8443, provides 
a suitable 3' cloning site for the exchange of the entire env gene. However, there are 
no unique restriction sites at the 5' end of the env gene, nor are there sites at the 5' 
end of the overlapping reading frames of tat and rev, nor at the gpl20-gp41 cleavage 
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site. 
In consequence, three unique restriction-enzyme sites were engineered into the HXB2 
sequence. A BstEll site has been engineered at the 5' end of the env gene (at 5875), 
114 nucleotides into the env gene. An XbaI site has been engineered at 7623, 300 
nucleotides upstream of the tat and rev splice-acceptor site. An MluI has been 
engineered at 7279, 24 nucleotides upstream of the gpl20-gp4l cleavage sites. In 
addition, a NotI site, at 5645, in the vpu gene, was also engineered into the HXB2 
sequence, to act as an additional cloning site. 
These unique restriction sites have been used to define three cassettes that can be 
readily exchanged for homologous sequences amplified from patient material: 
- cassette-1: from the BstEll site to the XbaI site (5875 to 7624; figure 3.2). This is 
a 1.7kb fragment of the env gene, encompassing the whole of gpl20 (minus six 
highly conserved amino acids at the N-terminal), and the first 300 amino acids of 
gp4l, including approximately three quarters of the external domain. This fragment 
lies entirely between the overlapping reading frames of tat and rev, and as such, the 
exchange of this fragment will not alter the coding capacity of these genes. 
- cassette-2: from the BstEll site to a naturally occurring XhoI site in the nef gene 
(5875 to 8443; figure 3.2). This is a 2.5kb fragment of the proviral genome 
encompassing the whole of the env gene. Although this fragment encodes for the 
whole envelope protein, exchange of this fragment will also result in changes to the 
tat, rev and nef genes, which may have a contributory effect to the viral properties 
in vitro. 
The XhoI site, defining the 3' boundary of this cassette-region is in a highly 
conserved region of the nef gene, and in consequence, is found in 80% of isolates 
found in the Los Alamos data base. It is, in addition, rare to HIV-1 genomes, and 
therefore unlikely to be found in the env genes amplified from patient-material. 
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Figure 3.2. The Cassettes Specified in pHXB2-MCS. 
The structure of the 3' half of the HXB2 genome, showing the open-reading 
frames and the location of the introduced-restriction sites. 
The structure of the three cassettes in relation to the open-reading frames of the 
env and nef genes. 
The boxes indicate open-reading frames; the blue boxes indicate the open-reading 
frames encoded by HXB2, and the pink boxes indicate those parts of the open-
reading frames that will be exchanged on replacement of one of the three cassettes. 
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- cassette-3: from the BstEll site to the MluI site (5875 to 7279; figure 3.2). This is 
a 1.4kb fragment of the env gene, encoding for all of gpl20 (minus 6 highly 
conserved amino acids at the N-terminal and five, highly conserved amino acids 
upstream of the gpl20-gp4l cleavage site). Exchange of this region will therefore 
produce a recombinant envelope protein, whose gpl20 is encoded by sequences 
obtained from the patient, and whose gp4l encoded by the vector. In addition, the 
Rev-responsive-element which lies within the gp4l part of the env gene, in constructs 
generated by exchange of this region, will be encoded by the vector, and therefore 
acted on by its own Rev protein. 
The BstEll and XbaI site are each one synonymous nucleotide change away from the 
HXB2 sequence, and the MluI site is two synonymous nucleotide changes away from 
the HXB2 sequence (table 3.1). As a result of this, the engineering of these 
nucleotide changes into the HXB2 sequence, should not alter the coding capacity of 
the vector. In addition, each of these sites is rarely found in the env gene of diverse 
HIV-1 isolates, (as determined by examining the sequences found in the Los Alamos 
data base of HIV-1 sequences (Myers et a!, 1991). As such, these sites are unlikely 
to be found in the env genes of sequences amplified from patient material; the 
presence of an internal site for one of these enzymes would render such sequences 
extremely difficult to clone into the vector. 
The changes from the HXB2 sequence required to generate the NotI site result in two 
conservative amino acid changes of valine to alanine in vpu gene (table 3.1). 
However, these changes are unlikely to effect the growth properties of the resultant 
virus, as the vpu gene is not expressed in HXB2 due to the absence of a methionine 
start codon (Schwartz et a!, 1990b). 
In this study, the majority of recombinant clones were generated through the 
exchange of cassette-1, because of the practical constraints of amplifying sequences 
from PBMC-DNA. It was found to be relatively straight-forward to amplify by PCR 
the 1.7kb fragment - the region defined by cassette-1, but it was extremely difficult 
to amplify cassette-2 which is of 2.5 kb in length. 
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Table 3.1. Nucleotide Changes made to pHXB2-D in the Construction 
of the Cassette-Vector, pHXB2-MCS. 
BstEllat5875 GGTC ACA HXB2 
G'GTCACC G G T C A C C MCS 
A -> C at 5881 V 	T amino acid 
Xba1at7624 TCT CTGGAA HXB2 
T'CTAGA TCT CTAGAA MCS 
G -> A at 7627 S 	L 	E amino acid 
M1u1at7279 AAGAGTG HXB2 
A'CGCGT A C G C G T G MCS 
A -> C at 7280 R 	V amino acid 
A -> C at 7282 
Not1at5645 GTAGTAGC HXB2 
GC'GGCCGC V 	V amino acid 
T->Cat5645 GCGGCCGC MCS 
A -> G at 5646 A 	A amino acid 
T -> C at 5648 
A -> C at 5649 
Co-ordinates according to HXB2R (Myers et al, 1991) 
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3.3. Cloning Steps Undertaken to Construct the Cassette-Vector 
pHXB2-MCS. 
The manipulations carried to create the cassette-vector pHXB2-MCS from pHXB2-D 
are given in outline in figures 3.3(a) and (b). A more detailed representation of 
pHXB2-D and pHXB2-MCS may be found in figures 3.1 and 3.5, respectively. 
Firstly, in order to carry out site-directed mutagenesis to introduce the three 
restriction sites, the EcoRJ to XhoI fragment (5289 to 8443) of pHXB2-D was 
subcloned into the plasmid vector pBluescriptll(KS-) at the EcoRI and XhoI sites in 
the vector polylinker. The resultant clone, designated pRX, contains the entire env 
gene coding sequence and, in addition, the coding sequences of tat, rev and vpu. The 
three unique restriction sites for NotI, BstEll and XbaI were introduced sequentially 
into pRX by oligonucleotide-directed mutagenesis (chapter 2, section 2.8). 
Prior to replacement of the HXB2 env gene with the modified sequence from 
pRNBXX, it was first necessary to transfer the XbaI proviral insert fragment of 
pHXB2-D into a different cloning vector. The proviral sequence of pHXB2-D is 
contained in the plasmid vector pSP62 (Melton et a!, 1984). However, this vector was 
unsuitable for constructing the cassette-vector, because it contains a number of 
'unwanted' restriction sites; these include the sites chosen as cloning sites for the 
cassettes, XhoI, XbaI, and others which may be useful for other manipulations of the 
HXB2 sequence, such as Sail which has a single site in HXB2. The sequence of 
pSP62 is not available on the database, which confounds the removal of these sites 
by conventional genetic manipulations. 
Therefore, the HXB2 provirus and cellular flanking sequences were transferred to 
another vector, pSPTBM20E. The manipulations involved are shown schematically 
in figure 3.4. The XbaI fragment of pHXB2-D (which includes the entire provirus and 
cellular flanking sequences) was isolated and cloned into the NheI site of the plasmid 
pSPTBM20, a deletion-derivative of pSPTBM20. pSPTBM20A was created by 
removing the majority of the polylinker (including the XbaI, XhoI and Sail sites), by 
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double-digestion with EcoRV and Smal, followed by self-ligation. By cloning into 
the NheI site of pSPTBM20D, both the NheI and XbaI sites are lost. The resultant 
recombinant molecular clone, pHXB2-SPT, has an insert fragment which is identical 
to that of pHXB2-D, excepting the removal of the XbaI site at the cloning junction. 
In the final step to create pHXB2-MCS, the SalI-BamHI fragment of pHXB2-SPT 
(5332 to 8443) was exchanged for the Sall-BamHI fragment of pRNBXX (figure 
3.3(b)). In pHXB2-MCS, the restriction sites defining the cassette-boundaries (BstEII, 
XbaI and XhoI) are unique (figure 3.5), thus allowing the direct exchange of these 
regions with sequences amplified from PBMC DNA, when amplified with primers 
specified to incorporate these restriction sites in frame with the env and/or nef genes 
(chapter 4). 
The MluI site specified as the 3' boundary of cassette 3, was introduced into pHXB2-
MCS by Dr Peter Balfe, at Middlesex Medical School, London, using the site-
directed mutagenesis method described by De Jong et al, 1992b. This construct was 
used only towards the end of this study, where it was employed for the construction 
of a single recombinant clone (see chapter 4, section 4.2.2). As a consequence, this 
vector will be referred to as pHXB2-MCS.MluI to distinguish it from pHXB2-MCS. 
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Figure 3.3 A Schematic Representation of the Steps Involved in 
Engineering the Proviral Cassette-Vector pHXB2-MCS 
The subcloning of the env gene of pHXB2-D and the introduction of a NotI, BstEH 
and XbaI site, and 
the replacement of the env gene of pHXB2-SPT with the modified version. 
The relevant DNA fragments are shown schematically and the restriction sites given. 
The env gene coding sequence and the proviral LTRs are indicated by open boxes. 
The restriction sites are noted in abbreviated form: 
R (EcoRIl), S (Sail), N (NotI), Bs (BstEll), Xb (XbaI), Bm (BamHI) and X (XhoI). 
A more detailed representation of pHXB2-D and pHXB2-MCS may be found in 
figures 3.1 and 3.5, respectively. 
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Figure 3.4 A Schematic Representation of the Steps Involved in 
Generating pHXB 2-S PT 
The thin lines represent the proviral sequence, with thicker lines representing the 
cellular-flanking sequences. The proviral LTRs are shown as open boxes. Circles 
indicate the plasmid vector sequences. 
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3.4. Construction of Vectors pHXB2-MCSenv, pNBXX and 
pNBXXAenv 
Three derivatives of pHXB2-MCS were generated in this study for cloning and 
expression purposes. 
- pNBXX (5.7kb) - an env gene subclone of pHXB2-MCS. The NotI to XhoI 
fragment (5645 to 8443) of pRNBXX (figure 3.3) was subcloned into the plasmid 
vector pBluescript, at the NotI-XhoI sites in the vector polylinker (figure 3.6). 
- pNBXXAenv - (5.3kb) a deletion-derivative of pNBXX (figure 3.6), formed by 
removing the NdeI-StuI fragment (5952 to 6380). This is a 428bp fragment of the env 
gene encoding the Vi, V2 and C2 regions. It was removed by digesting pNBXX with 
Stul and NdeI, gel-purifying the vector fragment, filling in the 3' overhangs with 
Kienow and self-ligating. 
- pHXB2-MCS&nv - a derivative of pHXB2-MCS, used as the cloning-vector to 
construct the full-length, recombinant, proviral clones of this study (figure 3.5). 
pHXB2-MCSi\env was constructed by replacing the BstEII-XbaI fragment of pHXB2-
MCS, with that of the 428bp-deletion-containing BstEll-XbaI fragment of 
pNBXXAenv (see above). 
The 428bp deletion in the env gene of pHXB2-MCSenv allows the full-length, 
recombinant derivatives formed by substitution of one of the cassettes to be 
distinguished from it by size. In addition, pHXB2-MCSAenv is a defective provirus, 
and therefore safer to handle. 
112 
Figure 3.5. The Proviral Clone pHXB2-MCS 
R EcoRI; S Sail; B BamHI; Xh XhoI; N Nod; Bs BstEII; St Stul; Nd NdeI; 
Xb-fNh- XbaI & NdeI sites removed; M*  MluI only present in pHXB2-MCS.MluI 
zXenv fragment is deleted in pHXB2-MCSzenv 
co-ordinates according to HXB2R 
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Figure 3.6. The Cloning Vector pNBXX 
B BamHI; Xh XhoI; N NotI; Bs BstEll; St StuI; Nd NdeI; 
Aenv fragment is deleted in pHXB2-MCSAenv 
co-ordinates according to HXB2R 
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3.5. Verification of the Sequence Changes made to Create 
pHXB2-MCS 
The incorporation of the three restriction sites, NotI, BstEll and XbaI, into pHXB2-
MCS, at the correct position in the proviral sequence was verified by extensive 
restriction mapping (data not shown). In addition, the nucleotide sequence changes 
made to create the BstEll site and the XbaI site were verified by sequencing pHXB2-
MCS at the site of the changes. 
Solid phase sequencing and sequence-data analysis was carried out using an ABI 
automatic sequencing machine, as described in chapter 2, section 2.9.2. A copy of the 
chromatogram, showing the nucleotide sequence of pHXB2-MCS at the BstEll and 
XbaI site, is given in figure 3.7a and 3.7b, respectively. At the BstEll site there is a 
single A to C substitution from the parental (pHXB2-D) sequence, and at the XbaI 
site there is a single T to C substitution, with no other changes observed. 
115 
GGTCACA - pHXB2-D 
a) 
G G T C A C C- pHXB2-MCS 
T T C T 6 C C T C A C C C T C T A T T A T 
b) 	 TCCAGA - pHXB2-D 
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3.6. Verification of the Infectious Nature of pHXB2-MCS 
Following the construction of pHXB2-MCS, the growth properties of virions 
produced from this clone were compared to the growth properties of virus produced 
from the unmodified clone, pHXB2-D. This work was carried out by Dr Jane 
McKeating, at the Chester Beatty Laboratories, London. 
Three proviral clones were used in these experiments: pHXB2-SPT, pHXB2-MCS 
and pNL4-3, which is an additional clone derived from the FllV-1 isolate (Adachi 
et al, 1986). Virus was recovered by DNA-transfection into the CD4-positive 
transformed cell line H9, as described in McKeating et a!, 1991. Three different 
preparations of virus from pHXB2-MCS were used in these experiments, namely: 
MCS, MCS2 and MCS10 (figure 3.8). 
Two growth experiments were conducted using two different viral inocula, of 200pg 
and 20pg per 106  cells, respectively, as determined by Sephacryl S1000 
chromatography (McKeating et al, 1991). Virus production was monitored over a 10 
day period of infection in C8166 cells by monitoring for the production of p24 in the 
culture supernatant by ELISA (McKeating et a!, 1991). 
As can be seen from figures 3.8a and 3.8b, the growth curves are virtually identical 
between the three pHXB2-MCS preparations and the parental virus pHXB2-SPT. This 
confirms the infectivity of the new construct and that the nucleotide changes made 
to create the cassette-vector have no detectable effect on the kinetics of virus 
production. 
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Figure 3.8 The Time Course of p24 Production Following the Infection 
of C8166 Cells with Virus Produced from Clones pHXB2-SPT, pHXB2-
MCS and pNL4-3 
The time course following inoculation with 200pg virion p24, and 
inoculation with 20pg virion p24 (*) 
MCS, MC2 and MCS 10 refer to the virus derived from three separate viral stocks 
produced from the transfection of pHXB2-MCS into C8166 cells. 
HXB2 refers to virus derived from pHXB2-SPT. 
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4.1. Introduction 
In this chapter, the cloning of env gene sequences found over the course of infection 
in a single HIV-1-infected individual is described. I have chosen to clone the env 
gene sequences from patient 82, a haemophiliac infected in 1984 (Ludlam et al, 
1985), because two previous studies have characterised the sequence evolution of the 
env gene within this patient, over a 7-year period of infection (Simmonds et al, 1991; 
Holmes et al, 1992). This characterisation has allowed the major env gene sequences 
to be identified and cloned in this study. 
I have used five peripheral blood mononuclear cell (PBMC) DNA samples to obtain 
the env gene sequences. Although our previous knowledge of the turnover of viral 
variants was obtained from variants found in the plasma, we observed that most 
sequences seen in the plasma subsequently appear in PBMC DNA (Simmonds et al, 
1991). It is not currently feasible to amplify full-length env gene sequences from 
single RNA genomes, but I was able to amplify all major sequences from PBMC 
DNA, and these were generally intact coding sequences. 
Abundance of HIV-1 Target Sequences in Peripheral Blood 
HIV sequences are generally in very low abundance in peripheral blood (Brinchman 
et al, 1991; Simmonds et al, 1990a; Ho et al, 1989). During the asymptomatic phase 
of infection, proviral DNA copy numbers in peripheral blood generally range from 
1 copy per 500 PBMCs to as low as 1 copy 200,000 PBMCs. The proviral load is 
higher at primary infection and increases to a similarly high level during the 
symptomatic phases of ARC and AIDS (Bieniasz et al, 1993, Haigwood et al, 1993, 
Clark et a!, 1991; Daar et al, 1991). These levels are generally not sufficient to 
enable cloning of the viral DNA without a method of amplification of the proviral 
copy number. There are a few exceptions, for example Li et al, 1992, were able to 
clone HIV-1 proviral sequences directly from brain tissue of a post-mortem sample 
from an AIDS patient, where proviral load was exceptionally high. 
In consequence, many HIV-1 clones have been derived from DNA prepared from 
viral isolates and not directly from patient material (Shaw et a!, 1984; Levy et a!, 
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1986; Adachi et al, 1986; Saiki et al, 1988; Cheng-Mayer et al, 1989; Groenink et 
al, 1991; Gao et al, 1996). Virus isolates are produced by culturing the patient PBMC 
sample with uninfected PBMCs or with a CD4+ immortalised cell line. Virus present 
in the infected PBMCs should be stimulated to replicate, increasing the viral copy 
number to sufficient levels for cloning through conventional means of screening 
genomic libraries constructed from cellular genomic DNA obtained from the viral 
isolate. 
This method has the advantage of increasing the proportion of infectious proviral 
sequences (Sabino et at, 1994). However, culturing results in a marked reduction in 
the number of variants that were present in the original material (Meyerhans et at, 
1989, Kusumi et at, 1992, Sabino et al, 1994). If there is genetic variation in the 
patient sample which confers differential replicative abilities on the viruses in culture, 
the subset with the highest replication rate will predominate. For the same reasons, 
variants that grow to low levels in culture will be under-represented in an isolate. 
Therefore, to obtain a representative sample of the spectrum of variants present in 
vivo, the variants must be obtained without prior culturing. This can be achieved by 
using the polymerase chain reaction (Saiki et at, 1985, Mullis and Faloona, 1987) 
amplifying proviral sequences directly from the PBMC DNA (Ou et at, 1988, 
Meyerhans et al, 1989, Simmonds et a!, 1990a). The polymerase chain reaction is an 
in vitro method for the enzymatic synthesis of specific DNA sequences in which two 
oligonucleotide primers that flank the region of interest in the target DNA are used 
to initiate DNA synthesis. A repetitive series of cycles involving DNA template 
denaturation, primer and template annealing, and the extension of the annealed 
primers by DNA polymerase, results in the exponential accumulation of copies of the 
target sequence whose termini are defined by the 5' ends of the primers. The PCR 
is sufficiently sensitive to allow the direct amplification of viral sequences from 
uncultured patient material. 
Although the spectrum of variants obtained by PCR-amplification of sequences 
directly from uncultured material should not be biased towards a specific subset of 
variants, there are problems concerning the accuracy of the amplification. There are 
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two main sources of sequence error associated with the PCR: firstly, the mis-
incorporation of nucleotides during synthesis of the target sequences (Ennis et al, 
1990); and secondly, the formation of artefactual hybrid sequences by PCR-
recombination between different target sequences amplified in the same reaction 
(Meyerhans et al, 1990). 
Errors Introduced by PCR Amplification 
Misincorporation The heat-stable DNA polymerase, Taq polymerase, is the most 
commonly used DNA polymerase for PCR. Taq polymerase does not contain a 3'-
>5 'exonuclease, or 'proof-reading', ability, and therefore has a relatively high mis-
incorporation rate. The misincorporation rate has been measured as 1 in 400 (Saiki 
et al, 1988) to 1 in 1800 (Ennis et al, 1990), depending on the individual reaction 
conditions. A means of reducing, or controlling for, this high error-rate is important 
when the amplified sequence is to be cloned and expressed, as is the case in this 
study, as these errors may lead to an aberrant or defective protein being expressed. 
In Vitro Recombination In addition, the amplification of a heterogeneous population 
of sequences, such as the population of viral genomes found in vivo, (Saag et al, 
1988, Alizon et a!, 1986, Hahn et al, 1986, Balfe et al, 1990), can result in the 
production of artefactual recombinant molecules, due to recombination between 
different sequences occurring during the PCR (Meyerhans et al, 1990, Ennis et al, 
1990). These false-recombinant sequences are thought to arise from the premature 
termination of Taq polymerase in one cycle, and the hybridisation of this unfinished 
strand to a heterologous strand in the next cycle. Following the subsequent extension 
and completion of the strand a hybrid sequence will be produced. This process is 
illustrated in figure 4.1. 
A high rate of in vitro recombination was described by Meyerhans et al, 1990, with 
1 in 5 sequences being an artificial recombinant after 25 cycles, amplifying a 300bp 
stretch of DNA from reactions containing two different cloned variants of the HIV- 1 
tat gene. It is to be expected that the frequency of false-recombinants will increase 
with an increase in length of the amplified fragment, as there will be an 
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Figure 4.1. A Schematic Representation of the Formation of 
Recombinant Sequences during PCR 
- 






Two variants (blue and red) of a given genomic fragment are shown. 
Following a round of PCR (denaturation, annealing  and elongation), some 
incomplete strand synthesis occurs. 
In a subsequent round of PCR, annealing of incomplete strands to 
heterologous templates, followed by elongation, will generate hybrid 
sequences. 
3. A further round of PCR will generate recombinant sequences. 
increase in the probability of incomplete strand synthesis. It is therefore necessary to 
control for, or reduce, the generation of artefactual recombinant sequences in order 
to amplify sequences accurately by PCR. 
In the amplification of env gene sequences in this study, two modifications to the 
standard PCR were carried out to reduce the errors inherent in the PCR-amplification 
of sequences. Firstly, each amplification was carried out from a single target 
molecule. Amplification from a single molecule avoids the possibility of producing 
artefactual recombinants by recombination in vitro. Recombination may occur 
between strands, but template-switching, in this case, will have no effect on the end 
sequence, as all templates are derived from the same initial molecule. 
Secondly, an alternative thermostable DNA polymerase, Pfu polymerase, was used 
which has a proof-reading ability, and consequently, a misincorporation-rate, 
measured as 12-fold lower than Taq polymerase (Lundberg et al, 1991, Mathur et a!, 
1992). 
In addition, by starting from a single target sequence, it has been possible to calculate 
the number of errors by sequencing of two or more clones derived from the same 
amplification and examining these for sequence differences. 
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4.2. Results 
4.2.1. Single-Molecule Amplification of env Gene Sequences 
In this study the limiting-dilution, nested-PCR of Simmonds et a!, 1990a was used 
to amplify from single molecules, the 1.7kb (cassette-1) and the 2.5kb (cassette-2) 
env gene fragments. 
In this method, the PBMC DNA is diluted before amplification and distributed into 
a number (usually 30 to 50) of replicate reaction tubes. At a specific 'end-point' 
dilution (dependent on the proviral copy number and the concentration of the DNA 
sample), only a small proportion of the reactions will contain a target sequence and 
so yield amplified DNA. By assuming a random distribution of proviral sequences 
in the reaction tubes, it is possible to calculate, by reference to the Poisson 
distribution, the probability that each PCR-positive amplification was initiated from 
a single molecule. In this laboratory, we consider the DNA sample to be sufficiently 
dilute, ie. at its end-point dilution, when the frequency of PCR-positive amplifications 
is 0.2 or less. At this value, there is a 90% probability that each reaction initiated 
from a single molecule (Simmonds et a!, 1990a). 
A critical factor in the accuracy of the limiting-dilution method, is the ability to 
detect the DNA following amplification from a single target molecule. In this 
laboratory, we employ a nested-PCR, in which two rounds of cycling is carried out 
with the primers for the second round located within the first round pair. This second 
round increases both the yield and specificity of the product. It was demonstrated by 
Simmonds et al, 1990a, that a nested-PCR, amplifying a 278bp fragment of the env 
gene across the V1-V2 hypervariable regions, is capable of amplifying to detectable 
levels, visible by agarose gel-electrophoresis, from single target molecules. 
To obtain an amplification of the 1.7kb and 2.5kb fragments of the env gene from 
single molecules, the PBMC DNA samples were first titrated to the end-point 
dilution, using the V1-V2 nested-PCR described above, previously demonstrated to 
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be sufficiently sensitive to amplify from single target molecules. Once the end-point 
dilution was reached, this dilution was used in a nested-PCR with the primers 
specified to amplify the 1.7kb or 2.5kb fragment. By altering the reaction conditions, 
that is, conducting the annealing step at 45°C and allowing DNA extension to proceed 
for 4 mins, two rounds of 25 cycles were capable of amplifying the 1.7kb fragment 
to detectable levels, visible by agarose gel electrophoresis. The 2.5kb fragment could 
not, however, be amplified consistently from single molecules. Therefore, the 
majority of env gene sequences examined in this study were of the 1.7kb fragment. 
Table 4.1. shows the end-point dilutions calculated for each of the 5 PBMC DNA 
samples used in this study, with the frequency of PCR-positives obtained from the 
nested-PCR amplifying with the V1-V2 primers. This is compared to the frequency 
of PCR-positives generated by amplifying the DNA at its end-point dilution with the 
1.7kb PCR. For each DNA sample, the number of positives generated in both PCRs 
was similar, demonstrating that the 1.7kb PCR can efficiently amplify from single 
molecules. The frequency of PCR-positive reactions was in all cases 0.2 or less, 
which, as described above, gives a probability that 90% of these were initiated from 
a single molecule. 
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Table 41. A Comparison of the Efficiency of Amplification of the Vi -V2 
(278bp) Region and the 1.7kb Fragments of the env Gene 
PBMC 	 no. of PCR-positives/total no. of reactions 
sample PBMC DNA end-point 
'ti 'i'b 	 1 '11 
date 	sample number 	dilutlona 	v i- v .L 1. /K() 
1987 	#108 	1/15 	7/30(0.23) 	3/30(0.01) 
5/28 (0.18) 
1988 	#12 	1/50 	1/5 (0.20) 	2/25 (0.08) 
1989A 	#82 	1/500 	2/10(0.20) b3/25 (0.12) 
5/30 (0.17) 3/25 (0.12) 
1989B 	#123 	1/200 	1/5 (0.20) 2/25 (0.08) 
0/20(0.00) 3/25 (0.12) 
3/25 (0.12) 
1/25 (0.04) 
1990 	#139 	1/50 	1/5 	(0.20) 3/25 (0.12) 
1/25 (0.04) 4/25 (0.16) 
The figures in brackets refer to the frequency of positive reactions. 
a  at the end-point dilution each PCR contains lul of the DNA dilution given for each 
PBMC DNA sample 
b  Taq amplified 
Pfu amplified 
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Note on the Nomenclature of the env Gene Clones 
The remaining sections of this chapter describe the cloning of the PCR-amplified env 
gene variants and their subsequent incorporation into pHXB2-MCS. 
A complex naming-scheme was adopted to identify each amplified env sequence, and 
the clones derived from it. This naming-scheme has been maintained in this chapter 
to facilitate the descriptions of the cloning steps, and to allow identification of each 
clone in future work. 
The complex naming-scheme is as follows: 
each amplified env gene sequence (ie. each PCR-positive) is referred to by two 
numbers (w.x). The first number (w) identifies the PBMC DNA sample from which 
the env sequence was amplified; the second number (x) distinguishes each 
individually-amplified env gene sequence from that DNA sample. For example, in 
table 4.2, '082.03' refers to env sequence number 03, amplified from PBMC DNA 
sample #82. '082.06' refers to env sequence number 06, from PBMC DNA sample 
#82. 
env gene subclones are referred to by a prefix 'p', followed by three numbers 
(p.w.x.y). The first number (w) gives the PBMC sample number; the second number 
(x) the number of the amplified env sequence; the third (y) distinguishes each clone 
obtained from the amplified env sequence. For example, p082.03.03 refers to clone 
number 03, derived from the cloning of env sequence number 03, amplified from 
PBMC DNA sample #82. p082.03.05  refers to clone number 05, derived from the 
same amplified env sequence. As such, these two clones should be identical if there 
has been no PCR errors. 
recombinant proviral clones - generated following the substitution of env 
gene clones into pHXB2-MCSenv - are denoted by a prefix 'H' followed by four 
numbers (H.w.x.y.z). The first number (w) gives the PBMC sample number; the 
second (x), the number of the amplified env sequence; the third (y) distinguishes each 
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clone obtained from the amplified env sequence; the fourth number (z) distinguishing 
each recombinant proviral clone recovered from the transfer of the cloned env 
sequence into the cassette-vector. For example, H.082.03.05.01 refers to recombinant 
proviral clone number 01, obtained from the incorporation of the env gene from 
subclone p082.03  .05 into the cassette-vector pHXB2-MCSienv. 
I have also adopted a more simplified nomenclature whereby each env sequence is 
given a letter (A to S) followed by a number (1 to 3) to show its length (1=1.7kb; 
2=2.5kb; 3=1.4kb). 
All env clones and full-length proviral clones generated in this study are 
summarised in table 4.8, at the end of this chapter. 
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4.2.2. Cloning and Characterisation of 1.7kb env Gene Sequences 
a) Taq Polymerase-Derived Clones 
The preliminary amplification of 1.7kb env gene sequences was carried out with Taq 
polymerase, from patient PBMC DNA sample #82 (1989A). At the end-point dilution, 
three out of a total of twenty-five amplification reactions were positive, each yielding 
a single band of DNA at 1.7kb (table 4.1). The details of experimental conditions are 
given in chapter 2, section. 
The products of these three positive PCR reactions were digested with BstEll and 
XbaI and cloned in the plasmid vector pNBXXLenv (chapter 3, section 3.6), by 
replacement of the deletion-containing 1.3kb BstEll-XbaI vector env fragment. Two, 
eleven and four clones were recovered from the three amplified env sequences, 
respectively (table 4.2). 
Assessment of Taq Amplification Errors 
The number of errors arising from the PCR-amplification was assessed by sequencing 
two clones from each of the three amplified env gene variants. Each clone was 
sequenced across a 150bp stretch of the third hypervariable (V3) region and across 
a 200bp region encompassing the fourth and fifth hypervariable regions and the 
fourth conserved region C4 (V4-C4-V5). Errors were detected by comparing the 
sequence of clones derived from the same env variant. 
A total of four nucleotide differences were found between all comparisons made 
between clones derived from the same env variant. These differences are summarised 
in table 4.3; the actual nucleotide sequences are given in appendix D. 
No nucleotide differences were found between clones p082.03.03 and p082.03.05 in 
either the V3 or V4-C4-V5 region. Three nucleotide differences were found between 
clones p082.06.11 (L.1) and p082.06.12 (Md). Two of the these differences - C and 
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Table 4.2 Taq-Amplified 1.7kb env Gene Sequences 
PBMC env total number clones examined 
sample variant clones obtained further 
#82 082.03 2 p082.03.03, -05 
(1989A) 082.06 11 p082.06.11, -12 
082.10 4 p082.10.13, -22 
Table 4.3 Nucleotide Differences Between Taq-Amplified Clones Derived from the 
same PCR Amplification. 
region 	V3 	V4-C4-V5 
env 
variant clones nucleotide 
position 	7184 	7220 	7531 	7561 
082.06 (Li) p082.06.11 A (Q) 	C (I) 	- 	A (I) 
(M.1) p082.06.12 T (R) T (I) - G (I) 
082.10 (N.1) p082.10.13 - 	- 	T (I) 	- 
(W.1) p082.10.22 - - A (N) - 
The nucleotide position of the observed differences are given according to HXB2R. 
The letters in brackets refer to the amino acid residue at each site. Where '-' is 
marked no differences were found. 
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T (position 7220) and A and G (at 7561) - are synonymous codon changes. The third 
nucleotide difference - A or T (at 7184) - results in an amino acid difference - 
aspartate (Q) or arginine (R) in the deduced sequence. One nucleotide difference was 
observed between clones p082.10.13 (N.1) and p082.10.22 (W.1) - T to A (at position 
7531) which results in a codon change of I to asparagine (N). 
There are two possible reasons for the sequence discrepancies between clones derived 
from the same PCR-amplification. Either, despite amplifying at the endpoint dilution, 
there are two variants in the original reaction, or alternatively, the differences are the 
result of nucleotide misincorporation by Taq polymerase. 
Two of the four nucleotide differences result in amino acid residues that have not 
been observed before in sequences in the data sets from patient 82 (Simmons et a!, 
1991; Holmes et a!, 1992; Zhang, 1993). Firstly, an A at position 7184 (L.1 or 
p082.06.1 1) - which results in an arginine (R) amino acid residue at position 25 of 
the V3 loop sequence is not seen in 87 V3 sequences derived from this patient 
(Zhang, 1993). Secondly, the T at 7531 (N.l or p082.10.13) which results in an 
asparagine (N) residue in the conserved region C4 is not found the data set of 114 
V4-C4-V5 sequences obtained by Zhang, 1993. The absence of these nucleotides in 
the patient 82-data set of Zhang, 1993, provides evidence that suggests that they are 
the product of mis-incorporation by Taq-polymerase. 
Assuming each of the four nucleotide differences in sequence between clones 
amplified from the same reaction are Taq-induced errors, then four nucleotides mis-
incorporations have occurred over a length of 2200 nucleotides examined (or a mean 
of 1 error per 525 nucleotides). If just two of these (the nucleotides resulting in an 
unusual amino acid) are Taq-induced errors, then the mean number of errors is 1 per 
1050 nucleotides amplified and cloned. 
These values are in agreement with other published work. For example Saiki et a!, 
1988 found 1 error per 400 nucleotides, and Ennis et a!, 1990 found 1 error per 1800 
nucleotides. 
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The high number of errors produced following amplification with Taq polymerase 
means that Taq is unsuitable for amplifying sequence variants for their subsequent 
expression, as on average no cloned variant will represent the original sequence found 
in vivo. All subsequent PCR amplifications were carried out using Pfu-polymerase, 
from which I detected less than 1 error per 16kb of amplified and cloned sequence, 
as will be described below. 
4.2.2. Cloning and Characterisation of 1.7kb env Gene Sequences 
(Continued) 
b) Pfu Polymerase-Derived Clones 
A total of 29 single molecules were isolated by limiting-dilution from 5 PBMC 
samples from p82, and amplified over the 1.7kb region of the env gene with Pfu 
polymerase (table 4.1). To obtain representative examples of the major V3 forms 
identified at each of the 7 time points studied in an earlier longitudinal study of V3-
variability in this patient (Holmes et al, 1992) 13 of the 29 isolated molecules were 
cloned (table 4.4). (The characterisation of these clones according to the sequence of 
their V3, V4 and V5 hypervariable regions is given in the chapter 5). 
Each amplified proviral variant was digested with BstEll and XbaI and cloned into 
the plasmid vector pNBXXEenv, replacing the deletion-containing 1.3kb BstEll/XbaI 
vector env fragment. Between one and twelve clones were recovered from each 
proviral variant, according to individual cloning efficiencies (table 4.4). 
133 
Table 4.4 1.7kb Single-Molecule Derived, PJ1-Amplified env Gene Variants 
This table shows the 13 env gene variants amplified with PJii-polymerase and the 
number of clones obtained from each. 
opposite page 134 
total 
year PBMC env number clones examined 
sample variant clones further 
obtained 
1987 #108 108.18 (A.1) 2 p108.18.27, .28 
108.11 (B.1) 2 p108.11.03, .07 
108.10 (C.1) 3 p108.10.04, .06, .07 
108.15 (D.1) 2 p108.15.01, .04 
108.17 (B.1) 2 p108.17.32, .33 
108.19 (P.1) 3 p108.19.04, .05, .06 
1988 #12 012.08 (T.1) 1 p012.08.10 
012.16 (U.1) 3 p112.16.03, .04, .14 
1989A #82 082.24 (G.1) 12 p082.24.01, .04 
1989B #123 123.14 (H.1) 3 p123.14.09, .10, .11 
1990 #139 139.05 (Li) 6 p139.05.01, .02, .16,.20 
139.06 (V.1) 6 p139.06.08, .10, .11 
139.6b (J.1) 6 p139.6b.09, .12 
Assessment of Pfu Amplification Errors 
To determine the number of errors resulting from amplification, and to ensure that 
clones, where expected, were derived from the same proviral molecule, multiple 
clones derived from the amplification reaction were sequenced across at least four out 
of the five hypervariable regions of the env gene, and also across a 200bp stretch 
within the gp4l coding region. Table 4.5 summarises the regions sequenced from 
each env clone. (The actual nucleotide sequences are given in appendix D). 
The number of errors was calculated by making sequence comparisons between 
clones derived from the same proviral variant. However, no sequence differences 
were detected between clones derived from the same proviral variant, despite there 
being sequence variation between the individual proviral molecules. The length 
compared covered a total of 16.32kb of cloned sequence (table 4.5). From this we 
can conclude that Pfu polymerase has a very low error rate and should be suitable to 
amplify 1.7kb env gene sequences without the introduction of errors. 
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Table 4.5 Summary of the Numbers of Clones from Each env Variant Sequenced in 
One or More of Five Regions of the env Gene 
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number of clones sequenced 
region V1/V2 V3 V4/C4 V5 gp4l 
env variant 	 length (bp) 180 200 200 90 200 
108.18 (A.1) 2 2 2 1 2 
108.11 (B.1) 2 2 2 2 1 
108.10 (C.1) 2 2 3 1 0 
108.15 (D.1) 2 1 1 0 2 
108.17 (E.1) 1 1 2 1 2 
108.19 (F.1) 1 2 2 1 1 
012.08 (T.1) 1 1 1 1 1 
012.16 (U.1) 2 2 3 1 3 
082.24 (G.1) 1 1 1 1 1 
123.14 (H.1) 2 3 3 2 1 
139.05 (1.1) 1 4 4 1 4 
139.06 (V.1) 0 3 5 1 3 
139.6b (J.1) 0 2 4 1 2 
total number of clones 18 27 34 14 23 
total length sequenced (kb) 3.24 5.40 6.80 1.26 4.60 
total number of clones compared 12 22 29 4 18 
total length compared (kb) 2.16 2.60 5.8 .36 3.6 
Total length sequenced = 21.3kb 
Total length compared (between clones derived from the same amplification) = 
16.32kb 
4.2.2. Cloning and Characterisation of 1.7kb env Gene Sequences 
(Continued) 
c) Characterisation of Pfu-Amplified Clones by Restriction-Mapping 
The thirteen Pfl-amplified env variants were characterised by restriction-mapping in 
the pNBXX-background. Several restriction enzymes were used ( BamHI, BsmI, 
HindJll, KpnI, MluI, NdeI, NheI, NotI, SalT, XbaI, XhoI, EcoRI, and SspI). Multiple 
clones derived from the same amplification were restriction-mapped. With each 
variant env gene, clones from the same amplification produced identical restriction 
patterns, further demonstrating that each amplification was initiated from a single 
proviral sequence (data not shown). 
Eleven clones, as expected, showed the correct sized insert fragment of 1.7kb. Two 
(T.1 and U.1), however, contained anomalous bands which had not been detected 
earlier. In consequence, no futher analysis was carried out with these two clones. 
Four restriction enzymes: BsmI, Hindu, KpnI and SspI, were found to show different 
cleavage patterns (restriction-site polymorphism) between the panel of clones (table 
4.6). BsmI shows two polymorphic sites: one at nucleotide 306 (where co-ordinate 
1 is the start of the cassette at the BstEll site), and one at 1731. Hindffl shows a 
single polymorphic site at 237. KpnI shows two polymorphic sites: one at 22 and 
approximately 1000, although the site at 1000 was found in only one variant: 1.1. 
SspI shows two polymorphic sites: one at 1251, which was present in nine out of the 
13 clones, and the other polymorphic site at approximately 1700, although this site 
is only seen in variant 1.1. 
In total, the four restriction enzymes produced nine different restriction patterns for 
the set of eleven env variants (table 4.6). Six clones (C.1, D.1, F.1, 1. 1, V.1 and J.1) 
and pNBXX, show a unique restriction pattern (patterns 3, 4, 5, 7, 8, 9 and 1, 
respectively). Variants G.1 and H.1 show the same restriction pattern (pattern 6); and 
restriction pattern 2 is shared between three clones A.1, B.1 and E. 1. 
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Table 4.6 Restriction-Enzyme Recognition Sites 
1  co-ordinate 1 is the BstEII site at the 5'end of the cassette 
+ presence of site, - absence of site 
opposite page 138 
BsmI 	I HindIll I 	KpnI 	I 	SspI 
pattern 
number 306' 	1731 237 22 	1000 1251 	1700 clones 
1 - + - + - + - pNBXX 
2 + + - + - + - A.1, B.1, E.1 
3 - + - + - + - C.1 
4 + + - - - + - D.1 
5 + + + + - + - F. 
6 + + + + - + - G.1, H.1 
7 - + - - + - + 1.1 
8 + + + + - - - V.1 
9 - - + + - + - J.1 
4.2.2. Cloning and Characterisation of 1.7kb env Gene Sequences 
(Continued) 
d) Examination of Coding Potential by In Vitro 
Transcription/Translation 
The technique of in vitro transcription followed by in vitro translation was applied 
to screen the panel of env gene clones for an intact reading frame. 
The design of the plasmid vector, pNBXXEenv, into which the env variants were 
cloned, is such that the entire env gene can be transcribed using T7 RNA polymerase 
from the 17 promoter, which is located upstream of the env gene (chapter 3, section 
3.6). The first start codon of the transcripts is that of the env gene, and as such, can 
be used to direct in vitro translation. 
Despite numerous attempts, this technique was successful on only one occasion. The 
succesful experiment was conducted with three clones: pl23.14..09, p123.14.10 and 
p123.14.11 - which are clones of the same env variant H.l or 123.14 (table 4.4) - and 
the control plasmid pNBXX. Each clone was linearised by digestion with XhoI, and 
transcribed with 17 RNA polymerase. The resultant transcripts were added to a 
wheat-germ translation system, the details of which can be found in chapter 2, section 
2.10. 
An autoradiograph of the translation products is shown in figure 4.3. The control 
clone pNBXX, and clones p123.14.10 and p123.14.11, produced a translation product 
of approximately lOOkDa (arrow), the size of non-glycosylated gp160. Clone 
p123.14.09, however, produced a shorter product of approximately 8OkDa, which may 
be the result of a truncated env gene. If so, this mutation was not picked up during 
sequencing this clone (section 4.2.2, above). The autoradiograph also shows the 
presence of many shorter protein products, which may have resulted from one of the 
following three processes: proteolysis, internal ribosomal initiation, or premature 
termination of translation. 
Figure 4.3. Autoradiograph Showing the Result of In Vitro Transcription/Translation 
of env Clones 
Lane 1: pNBXX; lane 2: p123.14.09; lane 3: p123.14.10; lane 4: p123.14.11 
The arrow indicates the presence of a protein of approximately lOOkDa. 
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As this technique did not produce a clear predominant band of the expected size, and 
was difficult to repeat, I proceeded with the next cloning step of substituting the env 
variants into pHXB2-MCSzenv and determining their infectivity following 
transfection (as will be described in chapter 6). 
4.2.3. Incorporation of 1.7kb env Genes into pHXB2-MCSAenv 
With the Pfu-Amplified Clones 
Ten of the thirteen PJ1-derived 1.7kb env genes (A.1 to J.1) were transferred to the 
cassette-vector pHXB2-MCSienv (a description of which was given in chapter 3, 
section 3.6), to construct ten full-length recombinant proviral clones (table 4.8 (1) 
below). 
The ten variants were chosen on the basis of their V3 loop sequences to include the 
major V3 sequence types detected in the plasma over the course of infection within 
patient 82. The sequence of the clones will be discussed further in the next chapter. 
Each clone was digested with BstEll and XbaI, the 1.7kb env fragment was isolated 
and purified by agarose-gel electrophoresis. The purified fragments were then ligated 
into the vector pHXB2-MCSzenv, replacing the shorter 1.3kb BstEll-XbaI vector 
fragment. 
The identity of the env variant in the pHXB2-MCS background was confirmed by 
restriction-mapping with the same panel of enzymes that were used to generate the 
maps in the pNBXX background (table 4.6, above). 
With the Taq-Amplified Clones 
In addition to the Pji-derived env sequences, four Taq-amplified variants, K.1, L.1, 
M.1, and N.1 (table 4.2, above), were used to construct recombinant clones in the 
pHXB2-MCS background. This was carried out to obtain additional clones that have 
a V3-loop sequence predictive of an syncytium-inducing phenotype (chapter 5). No 
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additional clones were available from the Pfu amplified clones, therefore, the Taq 
variants were taken despite the high error rate associated with the amplification with 
Taq polymerase. 
The four clones were constructed in an identical manner to the Pjii-derived clones: 
first they were digested by BstBll and XbaI, the 1.7kb env frgament gel-purified, and 
cloned into pHXB2-MCSAenv, replacing the shorter 1.3kb BstEJJJXbaI vector 
fragment (table 4.8 (1)). 
c) 'Reconstruction' of pHXB2-MCS 
A single preparation of the BstEll-XbaI digested and purified vector pHXB2-
MCSAenv was used to construct all the 1.7kb recombinant full-length clones 
described in this study. Following the construction of the above 14 recombinant 
proviral clones, an aliquot of the BstEll/XbaI digested pHXB2-MCSAenv was tested 
to ensure it was fully-intact and capable of forming an infectious provirus. To do this, 
the 1.7kb BstEll-XbaI fragment of pNBXX was isolated and cloned into pHXB2-
MCSAenv, replacing the shorter BstEll-XbaI 1.3kb vector fragment - thus 're-
creating' pHXB2-MCS. This proviral clone was found to be capable of producing 
infectious virus on transfection into cell culture, confirming its viability (data not 
shown). 
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4.2.4. Substitution of 2.5kb env Variants into pHXB2-MCSenv 
In addition to the construction of the fourteen recombinant viruses with the 1.7kb 
fragment of the env gene derived from PBMC-DNA, amplification of cassette-2 
(2.5kb) encoding the entire env gene, and part of tat, rev and nef, was attempted from 
single proviral molecules. 
Despite the relative efficiency at which the 1.7kb fragment could be amplified, the 
2.5kb fragment proved extremely difficult to amplify from PBMC DNA at its end-
point dilution. After many attempts, one sequence, P.2 (108.42), was amplified across 
the 2.5kb region, from PBMC sample #108. The PCR product was digested with 
BstEll and XhoI and cloned into pNBXXAenv, replacing the shorter BstEll-XhoI 
2.3kb vector fragment. A single clone, p108.42.18, was recovered. This was partially-
sequenced and restriction mapped (see below). The 2.5kb env variant was then 
transferred to the cassette-vector pHXB2-MCSienv, replacing the shorter 2.1kb, 
vector, BstEll-XhoI fragment (table 4.8 (2)). 
Three additional clones were also constructed with 2.5kb env gene fragments from 
PBMC DNA sample #82. It was not possible with this PBMC DNA sample to 
amplify the 2.5kb region from single molecules. Therefore, a bulk nested-PCR 
amplification of the PBMC DNA was carried out, by amplifying lul of PBMC DNA 
with cassette-2 outer primers, in a single reaction. From the limiting-dilution 
calculation for this PBMC sample given in table 4.1, above, this PCR reaction will 
contain approximately 500 proviral molecules. Following the second round of PCR 
with the BstEll/XhoI inner primers, a single DNA band of 2.5kb was produced (data 
not shown), and was digested with BstEll and XhoI and cloned directly into the 
proviral vector pHXB2-MCS\env, replacing the shorter 2.1kb BstEll/XhoI vector 
fragment. Three recombinant proviral clones were recovered from the cloning. These 
were designated Q.2, R.2, and S.2 (table 4.8 (2)). 
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Restriction-Mapping of 2.5kb env Clones 
Variants P.2, Q.2, R.2 and S.2 were restriction mapped with BsmI, HindJll, KpnI and 
SspI to characterise each variant. The location of the restriction sites given in table 
4.7. The same polymorphic sites were seen for these clones as for the 1.7kb clones, 
namely, two polymorphic sites for BsmI, one at 306 and one at 1731; one HindJJJ 
polymorphic site at 237; one polymorphic site for KpnI at 22; and one polymorphic 
site 1239 for SspI. In addition, there is a polymorphic SspI site at 2110, absent in the 
pHXB2-MCS sequence but present in the four 2.5kb PBMC-derived clones. There 
is also a BamHI site at 2100 in pHXB2-MCS, which is not present in each of the 
four 2.5kb clones. These sites for SspI and BamHI map outside the 1.7kb fragment 
of the clones described above (section 4.4.2). 
Only one of the three 2.5kb-clones obtained from PBMC sample #82, R.2, has been 
sequenced (chapter 5, section 5.3). The restriction patterns produced from these three 
clones reveals that the three clones clearly consist of two variants, with Q.2 and S.2 
producing the same pattern (map 12), which is distinct from the restriction pattern of 
R.2 (map 13). The patterns also demonstrate that although clones Q.2 and S.2 have 
not been sequenced, they are very similar to the maps of the other clones, providing 
evidence that they are indeed amplified from patient 82 DNA, and not the product 
of contamination. 
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Table 4.7 Restriction Enzyme Recognition Sites 
1  co-ordinate 1 is the BstEII site at the 5' end of the cassette 
+ presence; - absence 
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BsmI 	I HindIIII I KpnI I 	SspI 	I BamHI 
pattern 
number 306' 	1731 237 22 1251 	2110 2100 clones 
10 - + - + + - + HXB2 
11 - + + + + + - P.2 
12 + + + + + + - Q.2, S.2 
13 + - + - + + - R.2 
4.2.5 Subcloning of 1.4kb env Variant A into pHXB2-MCSM1uI 
The proviral cassette-vector pHXB2.MCS.MluI (chapter 3) was used to construct a 
single recombinant proviral clone, A.3 (H.108.18.27.MluI), by exchange of the vector 
BstEll to MluI fragment with that from env clone A. 1 or p108.18.27 (table 4.8 (3)). 
The BstEll to MluI fragment (from 5875 to 7279 HXB2R) is a 1.4kb fragment of the 
env gene and includes that part encoding for gpl20 only (chapter 3). 
The 1.4kb fragment was amplified from lOng of p108.18.27 (A.1) DNA, in a single 
round of PCR with primers specified at the BstEll and MluI sites, using Pfu 
polymerase. The amplification product was digested with BstEll and MluI and cloned 
into pHXB2-MCSM1uI, replacing the BstEll/MluI vector fragment. The identity of 
the clone was confirmed by restriction digest with enzymes BsmI, KpnI, HindJll and 
SspI. 
4.2.6 Substitution of 1.7kb and 2.5kb env fragments from HIV-
1SF2MC into pHXB2-MCSAenv 
Two recombinant proviral clones were generated by substituting the 1.7kb, and the 
2.5kb fragment of pHXB2-MCSenv with the equivalent regions amplified from the 
T-cell-line tropic infectious molecular clone SF2MC (Cheng-Mayer et al, 1989). 
To construct the two recombinant viruses, 50 ng of the molecular clone SF2MC were 
used in a PCR with Pfu polymerase, with either the BstEll/XbaI primers for the 1.7kb 
fragment, or the BstEll/XhoI primers for the 2.5kb fragment. The PCR products were 
digested with the appropriate combination of restriction enzymes and cloned into 
pHXB2-MCSenv, replacing the vector fragment. The identity of the recombinant 
proviral clones recovered from each of the two cloning experiments were confirmed 
by restriction-enzyme analysis (data not shown). The clones were designated 
HXSF2.1 and HXSF2.2 (table 4.8(4)). 
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Table 4.8 Summary of the Construction of the HIV-1 Recombinant 
Proviral Clones 
n.d. not done: env gene variant was not incorporated into a proviral clone 
opposite page 147 
(1) Recombinant for Cassette-i - the 1.7kb fragment of the env gene 
- With Flu-Amplified env Sequences 
PBMC 
sample env variant env subclone recombinant proviral name 
date clone 
1987 108.18 p108.18.27 H.108.18.27.02 A.1 
108.11 p108.11.07 11.108.11.07.10 B.1 
108.10 p108.10.07 H.108.10.07.02 C.1 
108.15 p108.15.04 H.108.15.03.44 D.1 
108.17 p108.17.03 H.108.17.33.03 E.1 
108.19 p108.19.04 H.108.19.04.05 F. 1 
1988 012.08 - n.d. (T.1) 
012.16 - n.d. (U.1) 
1989A 082.24 p082.24.01  H.082.24.01.36 G.1 
1989B 123.14 p123.14.10 H.123.14.10.02 11.1 
1990 139.05 p139.05.20 H.139.05.20.05 1.1 
139.06 - n.d. (V.1) 
139.6b p139.6b.09 H. 139.6b.09.09 J. 1 
- With Taq-Amplified Env Sequences 
PBMC 
sample env env subclone recombinant proviral name 
date variant clone 
1989A 082.03 p082.03.03  H.082.03.03.10 K.1 
082.06.11 p082.06.11 11.082.06.11.09 1 
082.06.12 p082.06.12 11.082.06.12.04 1 
082.10 p082.10.13  11.082.10.13.23 N.1 
Recombinant for Cassette-2 - the 2.5kb fragment of the Env gene 
PBMC 
sample env env subclone recombinant name 
date variant proviral clone 
1987 108.42 p108.42.18 H.108.42.18.35 P.2 
1989A 82.13 n.d. H.082.13 Q.2 
82.14 n.d. H.082.14 R.2 
82.17 1n.d. H.082.17 S.2 
Recombinant for Cassette-3 - the 1.4kb fragment of the Env gene 
PBMC 
sample env env subclone recombinant proviral name 
date variant clone 
1987 108.18 p108.18.27 H.108.18.27.MluI A.3 
Recombinant for Cassette-i (1.7kb) and Cassette-2 (2.4kb) - with Em' gene 
fragments from SF2MC 
env gene recombinant proviral 
variant clone 
SF2MC (1.7kb) HXSF2.1 
SF2MC (2.4kb) HXSF2.2 
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5.1. Introduction 
Two previous studies have characterised in detail the evolution of the virus 
population within patient 82. In the first study, Simmonds et a!, 1991, have described 
the evolution of the V4 and V5 hypervariable regions of the env gene of the PBMC-, 
and plasma-associated viral populations, over a 6 year period of infection. In the 
second study, Holmes et al, 1992, have described the sequence evolution of the V3 
hypervariable region, of virus found in the plasma from the time of seroconversion, 
and in 7 subsequent years of infection. 
The results show firstly, that there is considerable variation within each sample, at 
both the nucleotide and amino acid levels, and a rapid turnover of variants with time. 
Despite the high level of variation, the V4, V5 and V3 sequence variants can be 
classified by phylogenetic analysis into a small number of discrete lineages. By 
following the turnover of the different lineages with time, the patterns and process 
of env gene evolution can be examined. 
In this chapter, I begin by reviewing these results, and show how the results of these 
studies can be used to classify the PBMC-derived env gene clones to ensure that each 
of the most predominant V4, V5 and V3 types is represented. In addition, the 
knowledge of the timing of the expression of the variants in the plasma has been used 
to determine when sequences very similar to the clones were actively expressed. 
Subsequently, a description of the Vi and V2 hypervariable regions of the clones is 
presented, and the full-sequence of three clones, which have been examined for the 
presence of any inactivating mutations. 
Finally, I will discuss the in vitro phenotype inferred from the V3 loop amino acid 
sequence of each clone. 
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5.2 A Review of the Sequence Evolution within Patient 82 
5.2.1 Analysis of the V4 and V5 Sequence Evolution: the 
Identification of Distinct Sequence Types 
Simmonds et a!, 1991, obtained sequences of the V4 and V5 regions from serial 
samples, from both PBMC, and plasma-associated populations, taken over 6 years. 
The sequences showed a high variation within each sample, including both a variation 
in amino acid sequence and a variation in length of the hypervariable region. The 
relationships between the V4 variants, and between the V5 variants was determined 
by phylogenetic analysis. The V4 sequences grouped into three distinct lineages, 
named A, B and C. Sequences of the V5 region also clustered into a number of 
discrete lineages, this time five groups could be distinguished, named A to E, 
although four sequences fell between the groups and could not be grouped according 
to this classification. 
The grouping based upon the nucleotide sequences was also reflected in the deduced 
amino acid sequences of the variants. The V4 and V5 regions of each lineage showed 
a characteristic pattern of amino acid sequence, and of the pattern of sites of potential 
N-linked glycosylation and also, a discrete pattern of length variation. This is 
illustrated in table 5.1, which shows the consensus sequence of each of the V4 and 
V5 lineages, and the sequence of the four unclassified VS sequences. (Specific 
examples of the V4 and V5 types can be found in table 5.3, which shows the V4 and 
V5 sequences of the clones obtained in this study). Within both the V4 and V5 
regions, sequences within each lineage rarely differ from each other by more than 
two or three amino acids. The sites and spacing of N-linked glycosylation sites within 
the each lineage are relatively constant, as is the variation in length of members 
within the same group. The length of the V4 consensus sequence, between the 
conserved flanking regions (of L#FSTW --- <V4> --- TLPCR), is 16, 17 and 18 amino 
acids, for V4A, V4B and V4C, respectively. The length of the V5 consensus 
sequences, between the conserved flanking regions (of DG --- czV5> --- PGGG) is 10, 
11, 15, 11 and 11 amino acids, for the V5 lineages A to E, respectively. As will be 
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Table 5.1. The Consensus Sequences of the Deduced Amino Acid 
Sequences of the Different V4 and V5 Lineages 
This table is adapted from Simmonds et al, 1991. 
Residues that are invariant within each lineage are shown in uppercase. Variant 
residues are shown with the consensus amino acid in lower case. (#) represent sites 
of potential N-linked glycosylation. Dots have been introduced to allow sequence 
alignment between the lineages. 
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lineage consensus sequence 
V4A L#FSTW... #StQ1#STW#steE#iTLPOR 
V4B LF#STW. #Ys#gtW?StQhnTeE#ITLPCR 
V4C LF#STW#STWDLtq1#stqnkee#ITLPCR 
V5A DGG .....#gSeTEIFRPGGG 
V5B DGg.... #nTertE1FRPGGG 
V5C DGGNsG#ks#dTtEtFrPGGG 
V5D DGGN.... rn#TTEiFrPGGG 
V5E DGG .....DTSNTTEifrPGG 
DGG#... KSKNDPETPRPGGG 
unclassified DGG# .....TSTTEIFRPGGG 
V5 DGGN .... R##TTETRRPGGG 
DGG#.... TSKTTEIFRPGGG 
described below, the characteristic amino acid pattern for each of the V4 and V5 
lineages was used to classify the cloned variants obtained in this study. 
Frequencies and Turnover of the V4 and V5 Types in the Plasma 
and PBMC Populations 
By classifying the V4 and V5 sequence variants into the lineages described above and 
calculating their frequencies in each year, Simmonds et al, 1991, have shown how 
the viral population changes over time. The frequencies of the V4 and V5 lineages 
in the plasma, and PBMC populations, at each time point is illustrated in figures 5.1 
and 5.2. 
V4 Sequence Turnover (figure 5.1) 
In the seroconversion sample of 1984, all 9 plasma-derived variants were of type 
WA, while in the following sample of 1987, only type V4B were found. In the 
following sample of 1988, sequence type WC were most predominant, and had 
completely replaced type V4B in the two 1989 samples. In 1990 and 1991, type WC 
again predominated, but variants of type V4B re-emerged but at low frequency. A 
similar turnover of sequences was found in the PBMC populations. WA and V4B 
sequences were found in 1987, while in the following year, the sequences were 
almost all of type V4B. Replacement of type V4B sequences with WC occurred over 
the subsequent 2 years. 
VS Sequence Turnover (figure 5.2) 
A comparable turnover of sequences was found for V5 variants. In the plasma, only 
V5A sequences were found in the seroconversion sample of 1984. These were 
replaced by types V5B and V5C in 1987, and by type V5C in the following year. 
Type V5D and WE arose in the two 1989 samples, with the continued presence of 
type V5C sequences. A similar succession of sequence types was found in the PBMC 
population, although type V5C dominated the data set. V5A, V5B and V5C were 
found in 1987, with type V5B and V5C predominating in 1988. V5D and WE, 
appeared in 1989, to be replaced completely by type V5C in 1990. V5A sequences 
re-emerged in 1989A although at low frequency. 
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Figures 5.1(a) and 5.1(b) Frequency of Detection of V4 Sequence Types 
from Patient 82 
plasma population 
PBMC population 
Similar histograms were originally published by Simmonds et al, 1991. Additional 
plasma-derived V4 sequences were added to these from the data of Zhang, 1993, and 
V4 PBMC sequences were added to by the variants sequenced in this study. 
The sample dates are as follows: 1984 (March 1984); 1987 (June 1987); 1988 
(January 1988); 1989A (February 1989); 1989B (October 1989); 1990 (April 1990); 
1991 (January 1991). 
The relative frequencies of each type (A, B and C) was calculated by dividing the 
number of each sequence type, by the total number of sequences at each time point. 
The total number of-sequences at each time point was: 
V4 plasma: 1984 n=09; 1987 n=18; 1988 n=19; 1989A n=13; 1989B n=40; 1990 
n=14; 1991 n=11 
V4 PBMC: 1987 n=14; 1988 n=13; 1989A n=09; 1989B n=15; 1990 n=03 
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Figures 5.2(a) and 5.2(b) Frequency of Detection of V5 Sequence Types 
from Patient 82 
plasma population 
PBMC population 
Similar histograms were originally published by Simmonds et al, 1991. Additional 
V5 PBMC sequences were added to by the variants sequenced in this study. 
The sample dates are as follows: 1984 (March 1984); 1987 (June 1987); 1988 
(January 1988); 1989A (February 1989); 1989B (October 1989); 1990 (April 1990); 
1991 (January 1991). 
The relative frequencies of each type (A to E) was calculated by dividing the number 
of each sequence type by the total number of sequences at each time point. The total 
number of sequences at each time point was: 
V5 plasma: 1984 n=02; 1987 n=08; 1988 n=08; 1989A n=13; 1989B n=07 
V5 PBMC: 1987 n=12; 1988 n=11; 1989A n=10; 1989B n=14; 1990 n=03 


















84 87 88 89A 893 90 
year 
Differences in the Rates of Sequence Turnover in Plasma and PBMC 
Populations 
Simmonds et a!, 1991, have shown from statistical analysis of the frequencies of the 
V4 and V5 variants, and from further data derived from the analysis of multiple 
length variants representing the V4 and V5 types, that there is a significant difference 
in frequencies of the different V4 and V5 types in the plasma compared to the PBMC 
population of the same time point. For example, in the 1987 PBMC sample, there 
were both V4 sequences of type A and B, but in the corresponding 1987 plasma 
sample, only type B was found (figure 5.1a). Similarly, for V5 region, in the 1987 
PMBC sample 3 types V5A, V5B and V5C, could be found, but in the plasma 
sample only two types, V5B and V5C, were present (figure 5.1b). In 1989A, in the 
plasma WE and V5D were of approximately equal frequency, with a low frequency 
of V5C, however, in the PBMC sample of the same year, type V5C predominated, 
with a low frequency of type WE, and a re-emergence of type V5A which was not 
seen in the plasma in that year. 
These differences in the frequencies of variants found in the two populations appears 
to be the result of two differences in the evolution of the variants in the plasma 
compared to that in the PBMCs. Firstly, in general, variants appear first, or at a 
higher frequency in the plasma and only in subsequent years do they reach high 
frequency in the PBMCs. Secondly, there is a more rapid turnover of sequence 
variants in the plasma than PBMCs. For example, in the 1987 plasma population V5 
types B and C had completely replaced type A found in 1984, however, in the same 
year, type A, still persisted and formed a substantial proportion of sequences in the 
PBMC population. Persistence of the V4 seroconversion sequence is also seen in the 
1987 PBMC population at a time when it had been completely replaced in the 
plasma. Similarly, the relative frequencies of types V4B and WC in 1987, 1988 and 
1989 plasma samples compared to the frequencies found in the PBMCs, could be 
interpreted as a more rapid transition from V4B to WC in the plasma. 
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5.2.2 Analysis of V3 Sequence Evolution 
Evolutionary Relationships of the V3 Variants 
This section reviews the study of Holmes et al, 1992, who have analysed the 
sequence evolution of the V3 hypervariable region in patient 82, over a 7-year period 
of infection. 
A data set of 87 plasma-derived RNA sequences was obtained from six plasma 
samples, the first taken at the time of seroconversion in 1984, and remaining five 
from 5 subsequent years of infection (1987, '88, '89, '90 and '91). A phylogenetic 
analysis was carried out using sequence information from the V3-loop itself, and 
from 135 nucleotides of flanking sequence, which from its hypervariable nature, 
provided the majority of the phylogenetic information. 
The result of this analysis is depicted in figure 5.3, which shows five principal 
lineages, denoted A to F. A single sequence (denoted A), was found in all of 12 
sequences obtained from the seroconversion (1984) sample. Sequences found three 
years after seroconversion (1987) had diverged from the seroconversion sequence into 
a number of discrete lineages (denoted B, C, B and F), which were approximately 
equidistant from each other. By year four post-seroconversion (1988), two clearly 
distinct evolutionary lineages (denoted D and E) could be observed, each showing 
increasing divergence from the earlier sequences. These two lineages predominated 
for the remainder of the period of infection studied. 
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Figure 5.3 Evolutionary Framework Relating the Different Amino Acid Sequences found in the 
V3 Loop from Patient 82 
This figure is adapted from figure 2 of Holmes et a!, 1992. 
Distinct evolutionary lineages are designated by letters A to F and sequences within lineages are designated by numbers. 
Proposed evolutionary relationships are indicated by arrows. Lineages that persist through years are indicated by dashed arrows. 
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Classification of the V3 Loop Amino Acid Sequences 
Although the phylogenetic analysis used information both within the V3 loop and the 
variable flanking regions, the sequences within each lineage can be distinguished by 
their V3 loop amino acid sequence. From the data set of 87 RNA-sequences, only 
twenty-four amino acid sequences were found. These are listed in table 5.2 according 
to their lineage; sequences within each lineage are given a number (or 'genotype'). 
Genotype A, represents the single sequence type found at seroconversion, and is 
identical to the subtype B consensus sequence, and to the V3 loop sequence of 
isolates showing macrophage-tropism and a non-syncytium-inducing phenotype. 
The divergence of sequences into lineages B, C, E, and F, was characterised by 
amino acid variation at position 25 of the loop, with glutamic acid (E) of genotype 
replaced by aspartic acid (D) in genotypes B, Cl, C4, and C5; glutamine (Q) in 
genotypes C2 and C3; and glycine (G) in genotype F. Position 25, as will be 
described in section 5.7 below, is important in determining the in vitro viral 
phenotype. Genotype C4 is of note, in that it contains a non-conservative substitution 
of arginine (R) to glycine (G), at the tip of the V3 loop, producing 'GPGG', which 
is rarely found in the Los Alamos data base for subtype B sequences (Myers et al, 
1991). 
Lineages D and E, which predominate in the later stages of infection contain amino 
acids substitutions that are quite distinct between the two lineages. In particular, the 
presence of arginine (R) at position 11, valine (V) at 20, (Q) at 25 and asparagine (N) 
at position 29, distinguish sequences of lineage D. In contrast, sequences of lineage 
each contain glycine (G) at position 11, and the majority contain serine (S) at 
position 18, and alanine (A) at 23. The serine residue at 18, present in the majority 
of lineage E sequences produces an unusual 'GPGS' motif at the crown of the V3 
loop, which as with the 'GPGG' motif of C3, discussed above, is rarely found in 
subtype B isolates described in the Los Alamos database (Myers et al, 1991). In both 
of these cases, these sequences reached high frequency in the plasma (Holmes et al, 
1992), arguing that these sequences can form viable viruses. 
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Table 5.2 The Amino Acid Sequences of the 24 V3 Loop Genotypes 
found in the Plasma of Patient 82 
This data is taken from Holmes et a!, 1992. Amino acid sequences are listed 
according to their evolutionary lineage (A to F). Only residues that differ from those 
in sequence A (detected at seroconversion) are shown, with a dash denoting identical 
residues. 
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CS ------------------------ D-T-------- 
Dl-------------------V-----Q---------- 
D2---------- R -------- V --- EQ --- N------ 
D3---------- G -------- V --- EQ --- N------ 
D4---------- R-Y ------ V --- EQ --- N------ 
D5---------- R-Y ------ V --- EQ --- N------ 
D6 ---------- R-Y ------ V --- DQ---------- 
D7 ---------- R-Y ------ V --- DQ---N------ 




E4---------- G ------ S-V-A--G---------- 
E5 ----------G------S---A--G---N------ 




Frequency Changes of the V3 Loop Variants 
In a• similar manner to that described above for the V4 and V5 regions, a number of 
important observations can be made by examining the changes in frequency of each 
V3 lineage with time. The frequency changes are given graphically in figure 5.4. 
These histograms were derived from the data of Holmes et al, 1992, for the plasma 
population, and for the PBMC-population from the data of Simmonds et al, 1991, and 
the clones sequenced in this study. 
Firstly, as with the V4 and V5 regions, there is a more rapid turnover in the plasma 
population than the PBMC population. This results in the continued presence in the 
PBMCs of variants that had disappeared from the plasma, a phenomenon observed 
for the V4 and V5 data, described above. For example, genotype A persists until 
1987 in the PBMCs, where it makes up 35% (4/11) of the variants sequenced, but 
genotype A was not found in the plasma at this time point. Similarly, sequences of 
lineage C persist until 1988 in the PBMC population at a time when lineage C was 
no longer found in the plasma. 
Lineage D and B, which predominated in the later years of infection, alternated in the 
relative frequency at which they were found in each year. For example, in the 1988 
plasma sample, lineage D had the highest frequency, whereas in 1989, lineage B was 
most predominant. In year 6, 1990, both lineages were of approximately equal 
frequency, but by year 7, 1991, D again predominated. No new sequence variants 
were found in year 7, 1991, which coincides with a rapid drop in the CD4 count from 
this patient, when the immune system may be weakening (Simmonds et al, 1991). To 
explain this, it has been speculated that in the absence of immune selection, fewer 
new variants will arise. 
The frequency fluctuations are paralleled in the PBMC population, but occur one year 
behind the plasma population, such that lineage B predominates in year 6, 1989, at 
a time when lineage D predominated in the plasma. However, in 1990, there was an 
equal distribution of the two lineages D and B as was found in the plasma. 
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Figure 5.4. Frequency of Detection of V3 Sequence Types from Patient 
The sequence data used in constructing these histograms comes from Simmonds et 
al 1991, Holmes et al, 1992, and the sequences of the clones obtained in this study. 
The sample dates are as follows: 1984 (March 1994); 1987 (June 1987)); 1988 
(January 1988); 1989 (February 1989 and October 1989); 1990 (April 1990); 1991 
(January 199 1) 
The relative frequency of each sequence type was calculated by dividing the number 
of each sequence type, by the total number of sequences at each time point. The total 
number of sequences at each time point was: 
plasma: 1984 n=12; 1987 n=15; 1988 n=11; 1989 n=23; 1990 n=15; 1991 n=11 
PBMC: 1987 n=11; 1988 n=13; 1989 n=23; 1990 n=10 
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The presence over three years of infection, from 1988 to 1991, of two independent 
and distinct V3 lineages, D and E, is of interest, if these variants show different 
antigenic properties, then it is possible to speculate that sequences of lineage D, in 
1989, were suppressed by the immune system, but remained at low level until they 
evolved changes at residues that may alter their antigenicity that allowed escape from 
serum neutralisation, where they could emerge at higher frequency in the subsequent 
year. Similarly sequences of lineage B, which alternated in frequency with that of 
lineage D, may have been suppressed in 1988, but evolved amino acid changes that 
allowed their reaching higher frequency in 1989. 
The persistence of sequences such as genotype F, D8 and El, through a number of 
years (figure 5.2), may have been possible through the production of amino acid 
changes outside the loop which altered the antigenicity of the loop. Such mutations 
mapping outside the V3 loop have been observed to arise in experimental systems 
McKeating et al, 1989; Back et at, 1993). Alternatively, they may have been able to 
persist at low level, where they did not reach a sufficiently high frequency to be 
countered by neutralising antibodies. Indeed, Holmes et at, 1992, showed that the 
evolution of the V3 region shows some evidence of frequency-dependent selection. 
Sequences that reached the highest, frequency in the plasma showed the greatest 
reduction in frequency in the next year. For example, genotype A was found at a 
frequency of 100% 1984, genotype D2 reached a frequency of 45% in 1988, and E2 
reached 70% in 1989 . Variants E2 and D2 had disappeared from the plasma by the 
subsequent year (1989 and 1990, respectively) and genotype A had disappeared by 
the time of the next sample, 1987. Each of these sequences gave rise to variants with 
one or two amino acid differences in the V3 loop. These new sequences may confer 
different antigenic properties on the viruses. However, to test all these predictions and 
speculations will require the sensitivity to serum neutralisation of the variants to be 
determined. This is exactly the aim of the work described in this thesis. 
Of note, a number (3/13) of unusual V3 loop sequences were found in the 1988 
PBMC-population (described as 'others' in figure 5.3). These sequences contained an 
unusual motif of 'GPGRTV' which was not seen in any of the plasma variants. No 
attempts were made in this study to express sequences with this motif. 
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5.2.3 The Implications for this Study 
The sequence analysis of Simmonds et a!, 1991, and Holmes et a!, 1992, can be used 
to ensure each of the major env sequence types found in the plasma is represented 
by one or more of the clones obtained in this study. In addition, the V3, V4 and V5 
sequence combination of each clone can be used to date when sequences with very 
similar, or identical, V3, V4 and V5 sequences were present in the plasma. This is 
particularly important because it has been shown that the presence of a variant in the 
PBMC population, is not necessarily associated with its active expression in the 
plasma, and it is the sequences that are present in the plasma that are the targets of 
the humoral immune response. For later experiments, in which the sensitivity to 
neutralisation of the variants is determined, the knowledge of the timing of the active 
expression of each variant will be required to correlate the neutralising sensitivity of 
each variant, to its first appearance in the plasma. This correlation will be required 
in order to determine whether the variants arose in response to selection pressure 
from the neutralising antibody response. 
Therefore, although the clones obtained in this study were derived from PBMC DNA, 
comparison of their V3, V4 and V5 sequences with those sequences derived from the 
plasma derived variants can be used to show when variants with the same sequence 
types were actively expressed in the plasma. The classification of the cloned env 
variants, and the determination of when similar sequences were expressed in the 
plasma will be described in the subsequent sections. 
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5.3 Classification of the Cloned Variants 
5.3.1 Classification of the V4 and V5 Sequences 
The V4-C4-V5 amino acid sequences of the env gene clones obtained in this study 
are shown in table 5.3. The clones have been classified into the different V4 and V5 
lineages defined above, by comparison of their amino acid sequence to the data set 
of Simmonds et al, 1991 and the more extensive data set of Zhang, 1993. 
From the panel of cloned sequences representatives of all 3 V4 types: WA, V4B and 
WC, have been obtained. From the 1987 PBMC sample, A.1 is of type WA, with 
the remaining six clones of type V4B. The two clones from the 1988 PBMC DNA 
sample are V4B and WC, whilst the clones from the three subsequent PBMC DNA 
samples (1989A, '89B and '90) are all type WC. 
The clones were more difficult to classify in the VS region, reflecting the 
observations of Simmonds et al, 1991, in which a number of variants could not be 
assigned to one of the five V5 lineages (A to F). This in itself reflects the wide 
diversity of the V5 hypervariable region within p82. However, types V5B, V5C and 
WE are represented by the clones. Cloned sequences A.1, C.1, P.2 and E.1 are type 
V5B; sequence J.1 is type V5E. The remaining clones that could be classified are of 
type V5C (F.1, U.1, K.1, L.1, M.1, N.1, G.1, 1.1 and V.1). Types V5A and V5D were 
not represented, however, as has been described above, these sequence types did not 
reach high frequency in the plasma or PBMC population at any time. 
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Table 5.3. The Deduced Amino Acid Sequences of the V4, C4 and V5 Regions of the PBMC-Derived env 
Clones 
The amino acid consensus sequence is given along the top with invariant residues in upper case and variant residues in lower 
case. The hypervariable regions V4 and V5 are indicated in bold face. The residues that form part of the CD4-binding site 
(Lasky et at, 1987) are indicated by an asterisk (*) 
Amino acid residues that differ from the consensus are given. Dashes represent residues identical to the consensus. Dots 
represent gaps introduced to preserve the alignment and (#) represent sites of potential N-linked glycosylation. 
1  the lineages are assigned according to the classification of Simmonds et a!, 1991 
n.d. not done 
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PBMC <-V4 	-> 	 C4 <----V5----> 
sample * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * V4/5 
date clone F#StW#????????????n?eENITLPCRIKQIINMwQevGKAI4YAPPIrGQIRCSSnITGLLLTRDGGn????????tEtFRPGGGDM lineage' 
1987 A.1 ----- N. SPQL#NTW. . #NT--------------------------------------------------T. #.. . .GTEI A/B 
B.1 ------ YS#DTWSST . QHNT-------------------------------------------------#. . KSRA#DTEI B/U 
D.1 ----- -NYY#GTW#ST . QHNTG-------------------------------------------------. . K#ES#TTEI B/U 
P.2 ------ STWDLTQL#STRNK --------------------------------------------------- T. ........I--------B/B 
C.1 -N-Y--YSNG#WSST . QHNT------------------G------------------------------#. .NT. 	. GTEI--------B/B 
E.1 ------ YSNG#WTST . QHNT-------------------------------------------------#. .NT. . GTEI--------B/B 
F.1 ------ YS#GTWIST . QHNT--------------------------------------------------GG#KS#DTTET B/C 
1988 	T.1 	----- IYS#GTW#PT . QHNT-------------------------------------------------#.. . KSETDPET--------B/U 
U.1 ------ STWDLTQL#STQNK -------------------------------------------------- GG#KS#DTTET -------- 	C/C 
1989A 	K.1 ------STWDLTQL#STQNK-----------------------------K--------------------SG#KS#DTTEI--------C/C 
L.1 ------STWDLTQL#STQNK--------------------------------------------------SG#KS#DTTET C/C 
M.1 ------STWDLTQL#STQNK--------------------------------------------------SG#KS#DTTET C/C 
N.1 ------STWDLTQL#STQNK--------------------------------------------------SG#KS#DTTET--------C/C 
G.1 ------ STWDLTQL#STQNK ----------------------------- S -------------------- SG#KS#DTTET-------- 
R.2 n.d. 
1989B 	H.1 ------ STciDLTQL#STQDK ----------------------------- K -------------------- SG#KS#DTTEI -------- C/C 
1990 	J.1 	------ STWDLTQF ... QNE ------------------------------------------------- DTS#.... TTET--------C/E 
I.1 ------STWDLTQL#STQNK -------------------------------------------------- GG#KS#DTTET -------- 	C/C 
V.1 ------STWDLTQL#STQNK-----------------------------K-------T------------SGNKSNDTTEI--------C/C 
5.3.2 Classification of V3 Sequences 
The V3 loop amino acid sequences of the clones obtained in this study are given in 
table 5.4, along with the lineages described by Holmes et a!, 1992, assigned to them 
by comparison of their amino acid sequence. 
The panel of clones includes a representative of each of the six V3 lineages A to F. 
Lineages A, B and F, which each contain a single genotype, are represented by 
cloned sequences A.1, B.1 and P.1, respectively. From lineages C, D and E, which 
each contain five or more genotypes, the most predominant genotypes are 
represented: 'Cl' is represented by clone T.1; 'C2' by clones DA and P.2; 'C3' by 
clones C.1 and E.1; 'D2' by clones L.1, N.1 and H.1; 'D4' by clones K. 1, S.2 and 
G. 1; 'El' by clone J.1; and 'E2' by clones 1.1 and V.1. Cloned sequence M.l has a 
D-like V3 loop with a substitution of Q to R at position 25 of the loop - which may 
be a Taq-induced error (chapter 4, section 4.2.2) 
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Table 5.4. The Deduced V3 Loop Amino Acid Sequence of the PBMC-
Derived env Clones 
The amino acid sequence of clone A.1 is given. Only residues that differ from those 
in sequence A. 1 are shown, with a dash representing identical residues. The genotype 
(A to F) of each sequence is given according to the classification of Holmes et al, 
1992. 
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date clone 1 	 V3 loop 	 35 genotype 







1988 T.1 ------------P-----------D----------Cl 
U.1 ---------- G ------ S --- A--D ---------- El 
1989A L.l ---------- R -------- V --- EQ --- N D2 
M.1 ---------- R -------- V --- ER --- N ------ D-like 
K.1 ---------- R -------- V --- EQ --- N D2 
N.1 ---------- R-Y ------ V---EQ --- N D4 
R.2 ---------- R-Y ------ V --- EQ-----N D4 
G.1 ---------- R-Y ------ V --- EQ --- N D4 
1989B H.1 ---------- R -------- V --- EQ --- N D2 
1990 J.1 ---------- G ------ S --- A--D ---------- El 
I.1  ----------G------S---A--G----------E2 
V.! ----------G------S---A--G----------E2 
5.3.3 Timing of the Expression of the Cloned Sequences in 
the Plasma 
I have used the V3, V4 and V5 combination of the cloned env variants to determine 
when variants with very similar sequence types were actively expressed in the 
plasma. Table 5.5 summarises the lineages of each cloned sequence, and dates the 
expression of similar sequences in the plasma. 
Seroconversion (1984) type 
Clone A.1 has a V3 type A, which was found only in the plasma seroconversion 
sample of 1984. The V4 sequence is of type WA, which again was only found in the 
1984 plasma sample. The V5 sequence is of type V5B, which was found only in the 
1987 plasma sample. From this analysis, it appears that this clone is very similar to 
the seroconversion type, but has clearly replicated to produce a 1987 V5B sequence. 
This V3 loop sequence is also important because it is the subtype B consensus 
sequence, and is identical, or very similar to, many of the subtype B sequences found 
in vivo from a whole spectrum of patients (Zhu et al, 1993; Zhang et a!, 1993). 
Early (1987) types 
Clone B. 1  has a V3 type B and a V4 type B sequence. Each of these sequence types 
was found only in the 1987 plasma sample. This therefore dates the expression to 
1987 of sequences with very similar V3 and V4 sequences to B.1. 
Clones C.1, D.1, P.2, and E.1 have C-lineage V3 sequences, which were only found 
in the 1987 plasma sample. These four clones have V4 type B, and V5 types - B, or - 
unclassified. Sequences with this combinations of V3, V4 and V5 types were only 
found in the 1987 plasma sample. 
Clone T.1 has a V3 type Cl, found only in the 1987 plasma sample, and similarly, 
a V4 type B that was found only in the 1987 plasma sample. Therefore, although this 
clone was obtained from the 1988 PBMC sample, variants with V3 and V4 sequences 
identical to this were only found at high frequency in 1987. 
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Clone F.1 has a V3 type F, which was present at low frequency (<15%) in the 
plasma in 1987, '88 and reappeared, again at low frequency (<10%), in 1990 and 
1991. This clone has a V4 type B, and a V5 type C; these types showed the same 
pattern of expression as the V3 type F, that is, they were present in the plasma in 
1987 and '88, and reappeared in 1990 and '91. 
Later (1988-91) types: 
V3 Loop El. Clone U.1 has an El V3 genotype which was found in the plasma at 
three time points: 1987, 1990 and 1991. This clone has a V4 type C and V5 type C, 
which were found in the plasma in 1988, 1989 and 1990. Clone J.1 has the same El 
V3 type as U.1, and a similar V4 of type C. The VS of J.1 is type E which was 
found in the plasma in 1989 and 1990. These two clones represent an early and a 
later version of sequences carrying the V3 type El. This is in agreement with the 
dates of the PBMC samples from which they were cloned - U.1 was cloned from the 
1988 sample and J.1 from the sample two years later of 1990. 
V3 Loop E2. Clones 1.1 and V.1 both have E2 V3 genotypes, a V4 type C and a V5 
type C. The E2 V3 arose in 1988, but was most predominant in 1989. V4C arose in 
1988 and was also found in 1989 and 1990; V5C was found in 1987 onwards. From 
the V3 sequence, variants very similar to clones 1.1 and V.1 were most predominant 
in the 1989 plasma sample. 
1) lineage V3 Loops. Clones from the 1989A and 1989B PBMC sample (L.1, M.1, 
K.1, N.1, R.2 and H.1), each have V4 and V5 type C sequences and a V3 D-lineage 
sequence. Clones L.1, M.1, N. 1 and H. 1 have a V3 loop sequence of genotype D2, 
which was only found in the plasma in 1988. Whereas clones K.1, R.2 and G.1, have 
V3 genotype D4, which were only found in the plasma in 1989. 
With the exception of T.1, U.1 and V.1, each of these cloned sequences has been 
incorporated into the cassette vector pHXB2-MCSenv (as described in chapter 4). 
These 16 cloned sequences are each unique, and represent the breadth of sequence 
diversity in this patient, analysed by direct sequencing of virus present in the plasma. 
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Table 5.5 Summary of the V3, V4 and V5 Sequence Lineages of Clones 
and the Estimated Time of Expression in the Plasma 
n.d not done 
opposite page 171 
5.3.4 Characterisation of the Vi and V2 Sequences 
The Vl-V2 hypervariable region of 14 env gene clones are shown in table 5.6. The 
Vi region of the clones show both variation in amino acid sequence and in length, 
similar to the variation shown by the V4 and V5 regions described in section 5.2.1, 
above. In total, there are eleven different Vi amino acid sequences out of a total of 
fourteen clones sequenced. Within this region, there are a high concentration of sites 
of potential N-linked glycosylation, and variation in the number and position of these 
sites. These sites may influence the conformation of the envelope protein, or mask 
potential neutralisation sites, and so influence the sensitivity to neutralisation. 
No attempts were made to produce a phylogenetic tree from this region due to the 
extreme variability in length observed between different sequences, which makes 
sequence alignments unreliable (E. Holmes, personal communication). 
The V2 region of the 14 env gene clones shows very little sequence variation at 
either the nucleotide level, or the amino acid level. This is surprising, as variation in 
the length and number of N-linked glycosylation sites in the V2 region may influence 
the syncytium-inducing ability of the virus (Groenink et al, 1993), and substitutions 
within the V2 alter the sensitivity to neutralisation by MAbs directed at a neutralising 
epitope within the V2 loop (Fung et al, 1992). 
As such, variation in response to selection may be expected in this region, however, 
we find what appears to be a strong conservation of sequence. The V2 loop (from 
cysteine to cysteine) is conserved in both length (42 amino acids), and in the number 
of sites of potential N-linked glycosylation (two, at positions 4 and 34 of the loop). 
Ten clones show the same amino acid sequence, and four show a single difference 
in amino acid sequence. P.2 has a glutamine (Q) instead of glutamate (E) at position 
16; clones K.1 and N.1 each have a valine (V) at position 5, a site at which all other 
clones have isoleucine (I); and 1.1 has a non-conservative substitution of arginine (R) 
to methionine (M) at position 10. The unusual conservation of sequence of the V2 
region seen with the fourteen clones may be a result of such a small sample-size. 
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Table 5.6. Deduced Amino Acid Sequences of the Vi and V2 Regions of the PBMC-Derived env Gene 
Clones 
The amino acid consensus sequence is given along the top. Invariant residues of the consensus are shown in upper case, with 
variant residues in lower case. 
Residues that differ from the consensus are given in the table, with dashes representing residue identical to the consensus. Dots 
() represent gaps introduced to preserve the alignment. (#) represents sites of potential N-linked glycosylation. The 
hypervariable regions Vi and V2 are indicated in bold-face in the consensus sequence. 
n.d. not done 
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PBMC <- Vi Region 	- > <-V2 Region 	 - > 
sample 1 42 
date clone CVTLNCTD??#aTN?nn????. . ??Ssge?MRGEIKNCSFNiTTSIrDKVQKEYALFYKLDVVPIDEDNTNTSYRLISC 
1987 A.1 -------- WG# --- T#S ........ ---- T ---------- # ----------------------------- --------- 
B. 1 -------- WG# --- I## ........ ---- P ---------- - ----------------------------- --------- 
D. 1 -------- LR4t --- TN#ATNT. #S--W-K----------------------------------------#-------- 
P .2 -------- LR# --- TN#ATNT. #S----E----------------------Q-------------------------- 
C. 1 -------- WG# --- T#S ........ ---- T ---------- - ----------------------------- --------- 
1 -------- WG# --- I## ........ ---- P ---------- - ----------------------------- --------- 
1 -------- LR# --- TN#ATNT. 4S--W-P----------------------------------------#-------- 
1988 T.1 -------- LG# --- I## ........ ---- P ---------- # 
----------------------------- 
--------- 
U. 1 -------- WE#--#ATNT#ATNT#S ---- K ---------- - --------- 




N.1 -------- LR# --- A##AT#T.T.S-I--E ---------- #V  ---------------------------- #________ 
G.1 -------- VR# --- A##AT#T. T. S-I-KE------------------------------------------------- 
1989B H.1 -------- VR# --- A##AT#T . T. S-I#-E------------------------------------------------- 
1990 J.1 n.d 
I.1  --------LR#D--T##AT#I . T. S-I--E----------------M-------------------------------- 
V.1 n.d  
5.4 Examination of Sequences for Inactivating Mutations 
Partially-Sequenced Clones 
In total, 20 env clones have been obtained from patient 82 in this study. Partial 
sequence data has been obtained from 18 of these. Of these 18, the majority have 
been sequenced across each of the five hypervariable regions, and in addition, across 
the fourth conserved region and across a 200bp section encoding for part of gp4l 
(tables 4.3, 4.5, 5.3, 5.4, 5.6, and appendix A). In total, 12.47kb of sequence has been 
obtained from the 18 env clones. This is approximately one third of the total length 
of DNA cloned - 37.2kb (16x1.7kb + 4x2.5kb). 
No stop codons or frame-shift mutations have been observed over the 12.47kb of env 
sequence. This is very low frequency of inactivating mutations and in agreement with 
Balfe et a!, 1990, who found one inactivating substitution in 20kb from PBMC-
derived gag and env sequences. Others, using Taq polymerase have found a higher 
frequency. 
Although no stop-codons or frameshift mutations could be observed in the panel of 
clones, one variant, V.1, may contain an inactivating mutation in the C4 region (table 
5.3). This variant contains a threonine (T) residue instead of the highly conserved 
asparagine (N) found in all other patient 82-derived sequences, and indeed, in all 
published isolates (Myers eta!, 1991). The highly conserved asparagine suggests that 
threonine at this site will be an inactivating substitution. This mutation was observed 
in all 5 clones derived from the amplification of sequence V.1 (139.06), thus it is 
likely that this mutation was present in the original proviral sequence rather than a 
Pfr-amplification error. Due to this potentially-inactivating mutation, this clone was 
not expressed in the cassette-vector. 
Two other residues within the C4 are variant in the panel of clones obtained in this 
study (table 5.3). In clone N.1, there is a substitution of glycine (G) in place of 
glutamate (E), and in clones K. 1 and J. 1 there is a lysine (K) in place of arginine (R), 
and in G.1, serine (S) in place of arginine (R) at the same site. However, these sites 
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are highly polymorphic with a wide range of different residues amongst published 
isolates. Each of the variant residues found in the clones is represented amongst 
published isolates, suggesting that these will not be inactivating mutations. 
Three Fully-Sequenced Clones 
The coding-capacity of three of the twenty clones obtained in this study was 
determined by sequencing the entire (1.7kb) region of the env gene amplified from 
the PBMC DNA. It was beyond the scope of this study to sequence the entire 1.7kb 
(or 2.5kb) of amplified sequence from each clone, therefore, I chose to sequence the 
entire 1.7kb from three clones, A.1, D.1 and G.1. Two of these clones, A.1 and B.1, 
represent early variants, and the third, G. 1, represents a later sequence. In addition, 
the sequence encoding for almost the all of gpl20 and the N-terminal part of gp4l 
(1.54kb) was obtained from clone P.2, another early variant. This clone, however, 
contains a 2.5kb fragment amplified from PBMC DNA (see chapter 4, section 4.2.4). 
Therefore, approximately two thirds of the sequence has been obtained from this 
clone. 
The deduced amino acid sequences of these four clones and for comparison that of 
the HXB2 sequence, are given in figure 5.5. The three completely sequenced clones 
(A.1, D.1 and G.1) each contain a full open reading frame, with no frameshift 
mutations or stop codons. The partial sequence from P.2 also encodes an open 
reading frame over the region sequenced. 
The amino acid sequences of the four clones have been examined for the conserved 
features common to the envelope proteins of all published subtype B HIV-1 isolates 
(Myers et al, 1991 & '92). The 17 cysteine residues, invariant between highly 
divergent HIV-1 isolates, are all present in each the clones (in bold-face figure 5.4). 
In addition, over this stretch of the envelope protein there are 9 highly conserved 
sites of potential N-linked glycosylation. These sites are conserved in the four clones. 
Within the five conserved regions (Cl to CS) of gpl20, the clones show amino acid 
residues characteristic of those of subtype B isolates (Myers et al, 1991). Where there 
are variable residues between the clones, each of the variant residues observed has 
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been reported in one or more published isolates. For example, at residue 186 there 
is a valine (V) residue in A.1 and D.1, and an isoleucine (I) residue in G.1 and P.2. 
Both valine and isoleucine, which are of similar polarity, are found in published 
isolates, although valine is the most common. This is similarly the case for non-
conservative substitutions, for example, at position 207, clone G. 1 and HXB2 have 
a asparagine (N), whereas clones A.1 and P.2, have arginine (R) and D.1 has lysine 
(K) which are positively charged. Asparagine, lysine and arginine are all seen at this 
position in published isolates, although asparagine predominates (Myers et al, 1991). 
There are two exceptions these observations: clones A.1 and D.1, each contain a 
single site at which there is an amino acid residue, or amino acid insertion, which has 
never been observed in published isolates. The first is asparagine (N) at residue 253 
in clone A. 1. This site does, however, show extreme variation between the published 
isolates (Myers et a!, 1991). The second exception, is an insertion of two amino acids 
at 332 to 335, in clone D. 1 Variation is seen at this location, however, this particular 
combination of amino acids has not been reported. It appears to be the result of the 
duplication of the nucleotide motif TGGAAA. 
In conclusion, at this stage of the study, sequence analysis has shown that there are 
no obvious inactivating mutations, out-of-frame insertions or deletion, nor any in-
frame stop codons. 
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Figure 5.5 Deduced Amino Acid Sequence of the env Gene 
The amino acid sequence of G.l is given, with differences from this sequence shown. 
Dashes represent residues that are identical. Dots are gaps introduced to preserve the 
alignment. 
The five hypervariable regions (Vi to V5) are indicated in boldface. Conserved 
regions (Cl to C5; according to Modrow et al, 1987) are indicated. 
# represent conserved sites of potential N-linked glycosylation. 
Conserved cysteine residues are in boldface: C. 
The fusion domain of gp4l is indicated. 
n.d. not done. 
The first amino acid (1) given is at the start of the cassette (5 amino acids down 
stream of the gpl20 signal sequence. The last amino acid (606) is at the end of 
cassette 1, one third of the way into gp4 1. 
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51 - - - - - - - - - - - - - - - - - - - - - - - - - ><-
G.1 PQEVVLE#VT ENFNMWKNNM VEQMHEDVIS LWDQSLKPCV KLTPLCVTLN 
A.1 -- -------- ---------- ---------- ---------- ----------
D.1 ---------- ---------- ---------- ---------- ---------- 
P.2 n.d 
HXB2------ V --- --- D ---- D - ---------- ---------- ------- S-K 
101 ----V1REGION - - - - - > < - - - - - - - - - 
G. 1 CTDVRNATNA NNATNTTSSI GKEM. . RGE I K#CSF#ITTS IRDKVQKEYA 
A.1 --- W ...... G ----- #--S -ET-..----  ET-..------------------------ -----# ---- ---------- 
D. . 1 --- L ----- T ------It--S WEK ------- -----It-------------- 
P .2 1-----T ------It--S GEE-..---- ------It----------- - # -  Q__ 
HXB2 --- LK ..... 	.-D --- #--S  GRMIK --- ----- #-S-- --G ------- 
151 V2 REGION ---------------------C2-
G.1 LFYKLDVVPI DEDNT#TSYR LISC#TSVIT QACPKISFEP IPIHYCTPAG 
A.1 ---------- ----- It ---- --N ------- ----- V ---- ----------
D.1 ---------- ----- * ---- ---------- ----- V ---- ----------
P.2 ---------------It----------------------------------
HXB2 F-----II-- -N-..T --- S -T------------------------A---
201 - - - - - - - - - - - - - - - - - - - - - - - - - - - 
G.1 FAIIKCNDKK FNGTGPCTNV STVQCTHGIR PVVSTQLLL# GSLAEDGVVI 
A.1 --LL--R --- ---------- ---------- ---------- ----------
D.1 
 




HXB2 --- L --- N-T -----------------------------------EE---
251 ------------><-------V3 REGION - - 
G.1 RSS#FTDNAK TIIVQL#ESV VITCTRPNItN TRKRIYI. .G PGRAVYTTEQ 
A.1 --N ------- ------ K --- E-# ------- --- S-H ---- ----F---GE 
D.1 ---------- ------ K --- -- - ------- --- S-P -. . ---- F --- GQ 
P.2 ---------- ------ Q --- E-# ------- --- S-P -. . ---- F --- GQ 
HXB2 --V ------- ------ #T-- E-# ------- ----- R-QR - ---- FV-IGK 
301 - - - - - > <--------------- C3 -----
G.1 IIGNIRQA3C #ISRAKW#ET LKQIVIKLP,E QF. .EItKTIV FKQSSGGDPE 
A.1 ---D------ -----------------L-- --. . G ----- ----------
D. 1 --- D ------ # --------- -- ----- LG- --GNG ----- ----------
P.2 ---D------ -- -------- ------- L-- --..G ----- - N --------
HXB2 
G - --- -  
.---M 	# ------- N- ----DS-L-- --GN.----I ---------- 
351 --------><------v4 REGION ---------
G.1 IVMHSFNCGG EFFYC#STQL FNSTW.NSTW DLTQLNST.Q NKEENITLPC 
A.1 --T ------- ---------- -----. ----- . SP --- N-WN -T--------
D. 1 --T ------- ----- N-A -- --------- Y YNGTW --- QH NTG-------
P.2 ---------- ----- N ---- -----. ------------. R ----------
HXB2 --T ------- ---------- -----F---- STEGS-N-.. EGSDT----- 
401 - C4 	 - ><-V5REGION 
G.1 RIKQIINMWQ EVGKANYAPP ISGQIRCSS# ITGLLLTRDG GNSGNKSNDT 
A.1 ---------- ---------- - - -------- ---------- ------- TNG 
D.1 	---------- ---------- - - -------- ---------- -- KNE..SNT 
P.2 ---------- ---------- - - -------- ---------- ------- TNG 
11X32 ---------- K --------- ---------- ---------- -------- NE 
451 -----------C5 ------------>gpl2O/gp4l 
G.1 TETFRPGGGD MRDNWRSELY RYKVVKIEPL GVAPTKAKRR VVQREKRAVG 
A.1 --I ------- ---------- K --------- ---------- ----------
ID. 1 --I ------- ---------- K --------- ---------- ----------
P.2 --I ------- ---------- K --------- ---------- ----------
HXB2 S-I--L ---- ---------- K --------- ---------- ---------- 
< -----FUSION DOMAIN------> 
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G.2 AIGALFLGFL GAAVSTMGAA ANALTVQARS LLSGIVQQQN NLLRAIEAQQ 
A.1 T---M--------G------S--------L ---------- ----------
D. 1 T---M--------G------S--------L ---------- ----------
P.2 T---M--------G------S--------L ---------- ----------
HXB2. ------------G------S--------Q ---------- ---------- 
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G.1 HLLQLTVWGI KQLQARVLAV ERYLKDQQLL GIWGCSGKLI CTTAVPW#AS 
A.1 ---------- ---------- ---------- ---------- --- T ------
D.1 ---------- ---------- ---------- ---------- ----------








5.8. Predicted Phenotype of the Cloned Variants 
The examination of panels of HIV-1 isolates and genetic mapping studies using 
recombinant molecular clones of I11V-1, have shown that the V3 loop is a major 
determinant of viral phenotype. The cellular host range, syncytium-inducing ability, 
and replicative capacity of HIV-1 strains, have been shown to be determined by the 
sequence of the V3 loop (O'Brien et a!, 1990; Shioda et al, 1991, Hwang et a!, 
1991). 
Fouchier et al, 1992, have shown by analysis of a large panel of isolates, that a 
strong correlation exists between the presence of positively charged amino acid 
residues at positions 11 or at 25, and a fast-replicating, syncytium-inducing 
phenotype. It has also been observed that the V3 loop of non-syncytium-inducing 
(NSI) and macrophage-tropic variants differ little, if at all, from the subtype B 
consensus sequence. In contrast, syncytium-inducing (SI) and T-cell line-tropic 
variants that are highly divergent (Chesebro et al, 1992). 
These two measures of net charge of the V3 loop, and amino acid divergence from 
the subtype B consensus, can be combined, as described by Milich et a!, 1993 and 
Donaldson et a!, 1994b, to provide an almost complete separation of published 
isolates into the two groups: SI[F-cell line tropic isolates have a net positive charge 
of between 4 and 8, and a difference from the consensus of between 5 and 12 amino 
acids. In contrast, NSllmacrophage tropic isolates show a net positive charge of 
between 3 and 4, and a difference from the consensus of between 0 and 5 amino 
acids. 
The charge of the amino acid residues at position 11 and 25, described by Fouchier 
et a!, 1992, and the combination of net charge of the V3 loop and the number of 
amino acid differences from the consensus, has been calculated for each clone, in 
order to predict the phenotype of viruses derived from these clones. These data are 
given in table 5.7. 
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All seven clones obtained from the 1987 PBMC DNA sample are predicted to have 
an NSllmacrophage tropic phenotype, as are the two clones from 1988A, and the 
three clones from 1990 PBMC DNA samples (table 5.4). Each of these clones 
contains a neutral of negatively charged amino acid residue at position 11 and 25, 
and have a similar net V3 charge and number of amino acid differences from the 
consensus as that associated with NSlfmacrophage-tropic isolates. In contrast, all six 
clones from 1988B and the single clone obtained from 1989, are predicted to be SI 
and T cell-line tropic. Each of these clones contains the positively charged residue 
arginine (R) at position 11, and have a similar net charge and number of amino acid 
differences from the consensus as SI/T cell-line tropic variants. 
Of interest, the division of the V3 loop variants according to their predicted 
phenotype, is also paralleled by the division of variants into the different V3-
phylogenetic lineages described above. The sequences that fall into lineages A, B, C, 
B and F, which are found predominantly in early infection, are all predicted to be 
NSJ/macrophage tropic. The majority of sequences of lineage D, found later in 
infection (from year 4 post-infection), are predicted to be SIlT-cell line tropic. In 
addition to the criteria described above that predict an SI phenotype for sequences of 
lineage D, sequences of this lineage are also characterised by the presence of an 
asparagine (N) residue at position 29 of the V3 loop (tables 5.2 and 5.4). Asparagine 
(N) at this position was demonstrated experimentally by De Jong et al 1992b, to 
confer an enhanced syncytium-inducing ability on recombinant molecular clones 
containing a positive charge at position 306 and/or 320. 
The presence, early in the course of infection, of sequences predicted to confer an 
NSI/macrophage-tropic is in accordance with the studies of Schuitemaker et al, 1991 
and 1992, who demonstrated that early isolates of FHV-1 are predominantly 
macrophage-tropic and non-syncytium inducing. Similarly, the co-existence later in 
infection in patient 82, of both SIlT-cell line tropic and NSJ/macrophage-tropic 
variants, is also in accordance with the work of Schuitemaker et a!, 1992. In their 
study, SI isolates were found to emerge later in infection, and that, at these time 
points, macrophage-tropic isolates could still be isolated, but at lower frequency than 
SI isolates. 
Table 5.7 Analysis of Charge and Diversity of V3 Loop Amino Acid 
Sequences of Clones Derived from PBMC DNA 
Net charge of the V3 loop was calculated by assigning a unitary positive charge to 
lysine (K) and arginine (R) and a negative charge to glutamate (E) and aspartate (D) 
residues (see table 5.4). 
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year clone charge at position: net charge differences predicted 
V3 loop from phenotype 
11 25 consensus 
1987 A.1 0 -1 +3 0 NSI 
B.1 0 -1 +3 1 NSI 
D.1 0 0 +4 2 NSI 
P.2 0 0 +4 2 NSI 
C.1 0 0 +4 2 NSI 
E.1 0 0 +4 2 NSI 
F.1 0 0 +4 1 NSI 
1988 T.1 0 -1 +3 2 NSI 
U.1 0 -1 +3 4 NSI 
1989A K.1 +1 0 +5 6 SI 
L.1 +1 0 +5 5 SI 
M.1 +1 +1 +6 6 SI 
N.1 +1 0 +5 5 SI 
G.1 +1 0 +5 6 SI 
R.1 +1 0 +5 6 SI 
1989B H.1 +1 0 +5 5 SI 
1990 1.1 0 0 +4 4 NSI 
V.1 0 0 +4 4 NSI 
J.1 0 -1 +3 4 NSI 
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6.1. Introduction 
This chapter describes the results of the transfection of the panel of recombinant 
proviral clones into cell culture, in order to recover recombinant viruses. This work 
was carried out in collaboration with Dr Robert Walker and Mrs Elizabeth Harvey, 
who carried out the manipulations involving infectious virus. 
Overview of Transfection Method and Virus Culture 
The details of the experimental methods for transfection of proviral DNA and the 
maintenance of transfected cell cultures can be found in chapter 2, section 2.12. In 
brief, proviral DNA was introduced by lipofectin-mediated transfection directly into 
immortalised CD4-positive cell lines, or by transfection into COS-1 cells followed 
by the addition of the appropriate target cells - either PBMCs from seronegative 
donors, or immortalised CD4-positive cell lines. Transfected cultures were maintained 
by the addition of fresh uninfected cells as required, and monitored twice weekly for 
virus production. In early experiments, virus production was monitored by observing 
for the production of syncytia. Later experiments were additionally monitored for the 
production of p24 antigen, by p24 antigen ELISA of culture supernatants, and by 
immunofluorescent staining of cells with an anti-p24 monoclonal antibody. 
Four immortalised CD4-positive T-cell lines were used for transfection and virus 
propagation: H9, C8166, SupTi and Jurkat,; and one immortalised CD4-positive 
cell-line of myeloid origin: U937. PHA-stimulated PBMCs obtained from 
seronegative donors were also used (chapter 2, section 2.11). 
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6.2. Results 
I will describe in detail the time course of a representative transfection experiment. 
Subsequently, I will present the data from the transfection experiments involving the 
constructs generated in this study by summarising these parameters. In addition, 
where appropriate, the full data from a number of other transfections will be 
presented in order to illustrate specific points. 
6.2.1 Data from a Representative Transfection Experiment 
In this example, four PBMC-derived recombinant proviral clones: E.1, F.1, G.1, H.1, 
and the positive control pHXB2-MCS, were transfected into COS-1 cells, followed 
by co-cultivation with PBMCs at day 3. Figure 6.1 and table 6.1, show the data for 
supernatant p24 antigen production and for the presence of p24-positive staining cells 
cells. 
At 72hr post-transfection the transfected COS-1 cells were assayed for the presence 
of p24-positive staining cells (table 6.1). At this time point, all transfected COS-1 cell 
cultures contained p24-positive-staining cells, indicating that each transfection had 
successfully resulted in the uptake and expression of the proviral DNA. The 
efficiency of the transfection was in the range of 5.7% to 10 %, as determined by the 
percentage of p24-positive-staining COS-1 cells 72hr post-transfection. At 72hr post-
transfection, culture supernatants were also monitored for the level of p24 antigen 
(table 6.1). An initial high burst of p24-production was observed with each of the 
transfected cultures and lasted 1 to 2 days, again indicating the uptake and expression 
of the proviral DNA. The amount of p24 produced from the transfected COS-1 cells 
varied widely with each transfected culture. For example, a relatively large amount 
of p24 was produced from the transfections with clones E. 1 and F. 1, with 23 ng/ml 
and 56 ng/ml, respectively (table 6.1). The control transfection with pHXB2-MCS, 
however, produced only 7 ng/ml of p24 antigen. These values do not correlate with 
the percentage of p24-positive cells detected at the same time point. 
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Figure 6.1 and Table 6.1 p24-Antigen Production after Transfection 
into COS-1. Cells followed by Co-Cultivation with PBMCs for clones 
pHXB2-MCS, E.1, P.1, G.l and H.l 
Figure 6.1 gives the time course of p24-antigen production in culture supernatants 
Table 6.1 shows the presence p24-positive staining cells in the transfected cultures. 
+ the presence of p24-positive cells at (> 10%) 
w+ cultures with less that 10% cells staining for p24 antigen 
- cultures with no p24 staining above background 
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Transfection into COS-1 cells 
followed by co-cultivation with PBMCs 
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days post transfection 
72hr2 3 5 8 12 14 	16 	19 	21 	23 	33 
MCS +(10.0) 7.0 + + + + culture stopped 
H.i +(7.9) 9.0 + + + + + 	+ 	+ 	+ 	+ 	+ 
G.1 +(7.0) 9.4 + + + + + + + + + + 
E.1 + (6.2) 23.0 + w+ w+ w+ - 	- 	- 	- 	- 	- 
FT + (5.7) 56.0 + w± w+ - - - - - - - 
1 COS-1 monolayer, figures in brackets indicate the percentage of COS-1 cells staining positive for p24. 
2  p24  (ng/ml) in supernatant from the COS-1 transfected monolayers. 
Following the addition of PBMCs to the cultures, it was not possible to determine 
accurately the percentage of p24-positive cells on account of the mixed population 
of cells within the PBMC cultures. Therefore, following the co-cultivation of PBMCs 
p24-positive cells were scored by indicating either the presence at greater than 10% 
of p24-positive cells (+), or the absence of p24-positive cells (-). Cultures that 
showed only a few p24-positive cells (less than 10%) were recorded as weakly 
positive (w+). 
In the example in table 6.1, cultures from the three clones pHXB2-MCS, GA and 
H.1, consistently showed p24-positive cells throughout the period of culture 
monitored. For these three clones, the results of the p24-cell staining were paralleled 
by the production of p24 in the culture supernatants. Each culture produced an 
increasing amount of p24 over the course of culturing, with a maximum production 
of 1160 ng/ml for H.1, 460 ng/ml for G.1, and 54ng/ml for pHXB2-MCS. Virions 
from these clones were considered infectious, as there is a clear indication from these 
data of virus infectivity and replication. Confirmation of the infectious nature of the 
virions recovered from the clones was carried out by demonstrating cell-to-cell 
transmission of virus by co-culturing the transfected cultures with uninfected cultures 
of the T-cell line C8166. Following co-cultivation with these clones increasing levels 
of p24 antigen could be detected in the culture supernatant, and p24-positive cells 
could be observed (data not shown). 
Virions from the other two PBMC-derived clones, E.1 and F.1, show indications of 
replication in the PBMCs in the early stages of culturing, p24-positive cells could be 
detected at day 3 post-transfection, but the number of p24-positive cells slowly 
declined over time, until only a small number of cells stained p24-positive, at days 
5, 8, and 12 for E.1, and day 5 and day 8 for F.1 (table 6.1). p24-positive cells could 
not be detected on day 14 and thereafter from these two clones. Similarly, p24 
detection in the supernatant from these cultures, showed an increase between day 12 
and day 14, but subsequently, p24 levels showed a steady decline over time (figure 
6.1). The presence of infectious virions from these two clones could not be 
demonstrated when cells taken on day 6 post-transfection were co-cultivated with 
C8166 cells; no p24 could be detected in the culture supernatant and no p24-positive 
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cells could be observed over a two-week period of culturing monitored (data not 
shown). 
6.2.2. Transfection of an env-Defective Proviral Construct 
pHXB2-MCSzenv 
In order to facilitate the interpretation of results, three transfections with the env-
defective proviral construct pHXB2-MCSenv were carried out in order to determine 
the background levels of p24 production resulting from the expression of a defective 
provirus. 
Four transfections were carried with this construct: three directly into H9 or C8166 
cultures, and third into COS-1 cells followed by co-cultivation with H9 cells (table 
6.50v)). The first three transfections were monitored by observing for the production 
of syncytia. In each case, no syncytia were observed over a three-week period of 
monitoring the cultures, indicating that this clone does not produce viable virions. 
The fourth transfection, which was into COS-1 cells followed by co-cultivation with 
H9 cells, was monitored by assaying for the production of p24. The data from this 
experiment are given in figure 6.2 and table 6.2. The initial transfection produced 
high levels of p24 (24ng/ml) in the supernatant and 2.8% p24-positive staining COS-
1 cells. Following the addition of H9 cells, p24 levels in the supernatant declined 
steadily over time to reach <lng/ml at day 22. No p24-positive H9 cells could be 
detected at any of the time points post-transfection. In a simultaneous transfection, 
the parental clone pHXB2-MCS produced sustained levels of p24 in the culture 
supernatant and p24-positive staining H9 cells. 
The results of this experiment would suggest that transfection of an env-defective 
provirus into the cell-lines used in this study (COS-1, H9 and C8166), can result in 
the expression of p24 antigen, and production of virions, as indicated by the presence 
of p24 antigen in the supernatant. However, levels of p24 in the supernatant decline 
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steadily with time, and no p24-positive staining cells can be detected in cells added 
to the cultures after transfection. This indicates that any virions produced are not 
infectious. 
By extrapolating this result to other transfections, such as in the example given above 
for clones E. 1 and F. 1, the presence of p24-positive PBMCs implies that virions from 
these clones had indeed infected the target PBMCs, and that they are minimally 
infectious. 
Figure 6.2 and Table 6.2 p24-Antigen Production after Transfection 
into COS-1 Cells followed by Co-Cultivation with H9 cells for clones 
pHXB2-MCS and pHXB2-MCSenv 
Figure 6.2 gives the time course of p24-antigen production in culture supernatants 
Table 6.2 shows the presence p24-positive staining cells in the transfected cultures. 
+ the presence of p24-positive cells at (> 10%) 
w+ cultures with less that 10% cells staining for p24 antigen 
- cultures with no p24 staining above background 













days post transfection 
clone 	72hr' 72hr2 4 8 11 15 18 22 25 29 33 
MCS +(11.4) 48.0 + + + + + + + + + 
MCS Aenv - + (2.8) 	24.0 	- 	- 	- 	- 	- 	- 	- 	- 	- 
1 COS-1 monolayer, figures in brackets indicate the percentage of COS- 1 cells staining positive for p24 
2  p24  (ngfml) in supernatant from the COS- 1 transfected monolayers. 
6.2.3 Transfections of Controls pHXB2-SPT and pHXB2-
MCS 
To assess the ability of our transfection procedure to recover infectious viruses, we 
conducted each transfections experiment in parallel with one, or both, of two control 
proviral constructs pHXB2-SPT and pHXB2-MCS, previously demonstrated to 
produce infectious virus (chapter 3, section 3.5.). 
Over the course of this study, a total of thirty-two transfections were carried out with 
either pHXB2-SPT or pHXB2-MCS (table 6.5(iv)). 
Transfections into T-cell Lines 
A total of twenty transfections with were carried out with pHXB2-SPT and pHXB2-
MCS, directly into four T-cell lines: H9, C8166, JurkaL., and SupTi, or indirectly 
into COS-1 cells followed by the addition of H9 or C8166 cells (table 6.5 (iv)) 
Sixteen out of the total of twenty transfections with these two clones resulted in the 
production of viable virus as determined by the presence of syncytia in the culture 
flasks for early experiments, and by the production of p24 antigen from the later 
experiments. In each case syncytia were detected within one week of transfection. 
The four transfections which failed to result in the production of syncytia were four 
early transfections. These initial failures were probably due to the failure to introduce 
the proviral DNA into the target cells, when we were optimising transfection 
conditions. 
The efficiency of transfection, measured as the rate and level of p24 production, 
varied widely with each transfection. Peak p24 levels reached a maximum of greater 
than 1000ng/ml with each successful transfection, but due to variation in the rate of 
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p24 production, these levels were reached between day 10 and day 30 post-
transfection. 
Transfections Directly into PBMCs 
Five transfections of pHXB2-SPT and pHXB2-MCS were carried out directly into 
PBMC cultures (table 6.5 (iv)). Only one of these transfections was successful: 
pHXB2-MCS produced infectious virions, as determined by the presence of syncytia 
at day 22 post-transfection. In consequence, the method of first transfecting into 
COS-1 cells followed by co-cultivation with PBMCs was used to recover virions in 
PBMCs for all subsequent experiments. 
In seven transfections into COS-1 followed by co-cultivation with PBMCs, virions 
were successfully recovered from six (table 6.5 (iv)). The single failure may have due 
to the variability of different batches of PBMCs to support replication of these viruses 
(Yamada et al, 1990; Spira and Ho, 1995; Iverson et al, 1995). As a consequence, 
all batches of donor PBMCs were tested for their ability to support viral replication 
of the standard laboratory isolates HIV-1 or HIV-1. 
Variation between Individual Transfection Experiments 
Although the majority of transfections into COS-1 cells followed by co-cultivation 
with PBMCs for clones pHXB2-MCS and pHXB2-SPT were successful in recovering 
virions, there was considerable variation in the rate of p24 antigen production. In 
some transfections p24 could be detected from day 3 post-transfection, whilst in 
others, p24 could not be detected until week three post-transfection. Peak p24 levels 
following virus propagation were generally in the range of 50 to 75ng/ml, an order 
of magnitude lower than in T-cell lines (data not shown). 
These variations in the rate of p24 production presumably reflect variation in the 
quality of DNA, the efficiency of the proviral DNA uptake, or the quality of the cell 
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cultures. In light of the variation of p24 production after transfection, a number of 
repeat transfections were carried out with many of the constructs generated in this 
study. 
6.2.4. Transfection of PBMC-Derived Recombinant Proviral 
Clones 
The initial transfection experiments were carried out with recombinant proviral clones 
constructed by replacing a 1.7kb region (cassette-1) of the env gene of pHXB2-MCS, 
with sequences cloned from PBMC DNA. From the results of these experiments, the 
infectivity of other constructs, generated by the exchange of a 2.5kb fragment 
(cassette-2), and 1.4kb region (cassette-3) with PBMC-derived sequences, was 
determined. 
Recombinant Clones Constructed by Exchange of Cassette-1 
At the start of the transfections conducted in this study, much of the published work 
characterising the growth properties of HIV-1 isolates concentrated on laboratory 
strains, such as the isolates IllV-i, I1V-1, and HIV-1. These isolates were 
favoured because they are capable of growth to high titre in transformed CD4+ cell 
lines. 
In a similar manner, due to the ease of handling transformed cell lines compared to 
primary cell cultures, the early transfections in this laboratory were carried out into 
transformed cell lines. In addition, the detection of virus production in transformed 
cell lines can be easily monitored, by observing for the production of syncytia. 
Transfections into T-cell-Lines 
The first transfections were carried out with the ten recombinant proviral clones 
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whose env genes were amplified from PBMC DNA using Pfu polymerase: A. 1 to J. 1 
(table 6.5 (i)). 
A total of thirty-two transfections were carried out with these ten recombinant clones 
into five different immortalised cell-lines: C8166, H9, SupTi, JurkaL and U937. 
All transfection experiments were set up in parallel with one or both of the control 
constructs pHXB2-SPT and pHXB2-MCS. A given set of transfection experiments 
was considered successful when virus could be recovered from one or both of the 
control clones. 
Results of Transfection into T-cell Lines 
From the early transfections in which virus production was monitored by observing 
for the presence of syncytia, only two of the ten proviral clones (G.1 and H.1) 
produced syncytia. The remaining eight clones failed to produce syncytia despite 
numerous attempts with many of the constructs and the use of several different 
immortalised cell lines (table 6.5 (i)). 
In later experiments, where virus production was monitored by measuring p24 
production, each of the ten proviral clones produced an initial burst of p24 (ranging 
from between 24.Ong/ml and 44.Ong/ml) into the culture supernatant, and p24-positive 
cells (at greater than 10 %) could be detected 72hr post-transfection. However, 
sustained p24 production was only observed with clones G. 1 and H. 1. The other eight 
clones showed declining levels of p24 in the culture supernatant, which dropped 
below the level of detection (<ing/mi) within 18 days, and no p24-positive staining 
cells could be detected from day 3 post-transfection onwards. 
Syncytia were observed in all cultures transfected with G. 1 and H. 1, but no syncytia 
were observed in cultures transfected with the other eight clones. The first appearance 
of syncytia was slightly delayed in cultures transfected with G.l and H.1, as 
compared to the HXB2 controls. For example, from a set of transfections into C8166 
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cells, syncytia were detected at day 11 for H.1, but at day 6 with pHXB2-SPT, and 
at day 5 with pHXB2-MCS. Similarly, in a second transfection experiment, syncytia 
were detected at day 22 in the H9 cells transfected with H. 1, but at day 7 for 
pHXB2-MCS. 
The infectivity of the virions obtained from G. 1 and H. 1 was confirmed by passaging 
aliquots of the transfected cultures to fresh uninfected C8166 cells, and by initiating 
infections by inoculating C8166 cultures with cell-free supernatants obtained from the 
transfected cultures. In each case, virus was observed to spread and replicate in these 
cultures as determined by an increase in p24 production with time, and the presence 
of p24-staining cells (data not shown). 
All attempts to transmit virus from the other eight clones by cell-to-cell passage, or 
through inoculation with cell-free supernatants into C8166 cells, failed to demonstrate 
the presence of infectious virus: no p24 antigen could be detected, above the 
background levels from the inoculum, and no p24-positive cells could be observed 
(data not shown). 
Transfections with PBMCs 
At this stage of the study it was becoming apparent from studies taking place in other 
laboratories, that many primary isolates are not able to grow in transformed CD4+ 
cell lines (Fenyo et a!, 1989; Tersmette et a!, 1989b; Schuitemaker et al, 1991). In 
these studies, the primary isolates which were unable to grow in transformed CD4+ 
cell lines showed a preference for growth in CD4+ T-lymphocyte cultures, or cultures 
of monocyte-derived macrophages. Many such isolates replicated slowly and to low 
level in primary cell culture and failed to infect T-cell lines productively. Those that 
did grow in T-cell-lines did not induce the production of syncytia in these cell types, 
nor in T-cell cultures or in macrophages. 
At the same time, the differences in the in vitro growth properties of HIV-1 isolates 
were found to be determined by the env gene. These different growth properties could 
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be transferred to recombinant viruses by substitution of the relevant env genes, or 
gene-fragments (Westervelt et al, 1991; Cann et al, 1992; O'Brien et al, 1990). 
By combining these findings, we hypothesised that many of the PBMC-derived env 
genes obtained in this study would confer growth properties similar to the slow-
replicating, non-T-cell-line tropic isolates described. It was perhaps not surprising, 
therefore, that infectious virions could not be recovered from the majority (8/10) of 
PBMC-derived clones when transfecting into T-cell lines. 
The study of Fouchier et al, 1992, and Milich et al, 1993, correlating the presence 
of positively-charged V3 loop with a fast-replicating, T-cell-line tropic syncytium-
inducing viral phenotype, allowed us to make more precise predictions about the 
growth properties of our recombinant proviral clones. The growth properties inferred 
from the charge and amino acid sequence of the V3 loop, has been described in the 
previous chapter (chapter 5, section 5.5.). Eight out of the ten PBMC-derived clones 
are predicted to confer a slowly replicating, non-syncytium-inducing, non-T-cell-line 
tropic phenotype, whilst two clones, G.l and H.1, are predicted to confer a fast-
replicating, syncytium-inducing, T-cell-line tropic phenotype (table 6.5(i)). 
The results of the transfections into immortalised cell-lines are compatible with these 
predictions. The production of infectious virions was observed only in cultures 
transfected with the two predicted-SI clones, G.1 and H.1. No evidence of virus 
infectivity could not found from cultures transfected with the eight predicted-NSI 
clones. 
In the light of this, it appeared likely that culture in donor PBMCs would be required 
to recover and replicate many of the PBMC-derived clones constructed in this study. 
Subsequent transfections were therefore carried out with PHA-stimulated PBMCs as 
the target cells. 
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Results of Transfections into PBMCs 
Each of the ten proviral clones A.1 to 11, was transfected into COS-1 cells, followed 
by co-cultivation with PBMCs, as summarised in table 6.5(i). In each case, an initial 
burst of p24 antigen in the culture supernatant (ranging from between 1 .8ng/ml to 
38ng/ml) was produced, indicating that each transfection had been successful (data 
not shown). However, sustained p24 antigen production over the four-week course 
of infection monitored was only observed from the two clones, GA and H.l, 
previously demonstrated to replicate in T-cell-lines. For the other eight clones, p24-
positive staining PBMCs were not detected at any of the time points monitored, and 
p24-antigen levels in the culture supernatant dropped to below lng/ml within one 
week of culturing (data not shown). Virus from the two clones, G.1 and H.1, could 
be transmitted to the cell-line C8166. This was demonstrated by the production of 
syncytia, the detection of p24 antigen in the supernatant, and the presence of p24.-
positive cells two days after co-cultivation of C8116 cells with the transfected 
PBMCs. The co-cultivation of C8166 cells with the PBMCs taken from the 
transfections of the remaining eight clones, as perhaps expected, did not show any 
evidence of virus replication; no syncytia were observed in the co-cultivated C8166 
cells and no p24-positive cells were detected, nor was any p24 antigen produced into 
the supernatants (data not shown). 
Due to the variability between transfections, we conducted two further transfections 
of three of the clones A.1, E.1 and F.1, that did not produce evidence of virus 
replication on the first attempt propagating with PBMCs. All attempts with clone A. 1 
failed to recover infectious virions; p24 could be detected in the culture supernatant 
immediately following transfection, and similarly >10% of COS-1 cells stained 
positive for p24. However, p24 production declined over the course of infection and 
no p24-positive staining PBMCs were found. 
In the two repeat transfections with F. 1, and in one of the two repeats with E. 1, there 
was an indication of the production of infectious virions from each clone. One of 
these transfections has been described in section 6.2.1 above, given as an illustrative 
example of the time course of a transfection experiment. In this transfection, p24 
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positive PBMCs could be detected up to day 12 with E.1 and up to day 8 with F.1, 
implying that early on in the course of the transfection, virions from these clones was 
capable of infecting PBMCs. Similarly, from examination of the p24 in the 
supernatant, there was an increase in p24 production between days 12 and 14, which 
indicates the presence of actively-replicating viruses. The second repeat transfection 
with these two clones will be described below, in section 6.2.6. 
In summary, with the ten Pfr-amplified proviral clones constructed through exchange 
of cassette- 1, we were able to recover infectious virions from two clones, G.1 and 
H. 1. Of the remaining eight proviral constructs, six (A.1, B. 1, C.1, D.1, 1.1 and J. 1), 
clearly failed to produce infectious virions, and two (E.1 and F.i), showed some 
evidence early on in the course of transfection of low-level infectivity. 
Taq-Polymerase Amplified Clones 
The two infectious clones, G.1 and H.1, each have a V3 loop sequence predictive of 
a T-cell line-tropic/SI-ability. The remaining eight proviral constructs each have V3 
loops predictive of an non-T-cell-line-tropic/NSI-phenotype. It could be hypothesised 
that a predicted SI phenotype is required for the production of infectious virions in 
the pHXB2-MCS expression system that we have developed. If this was so, it would 
be expected that transfections of further SI variants should produce viable virus. 
The only proviral clones available at this stage of the study, predicted to confer an 
SI phenotype, were those amplified from PBMC DNA with Taq polymerase K.1, L.1, 
M.1, and N. 1 (table 6.5(i)). We therefore conducted a series of transfections with 
these constructs, despite the high error rate demonstrated to result from amplifications 
with this enzyme, which may have introduced errors into these clones (chapter 4, 
section 4.2.2). 
Results of Transfections with Taq Amplified Clones 
A single transfection was carried out into COS-1 cells, followed by co-cultivation 
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with PBMCs, with each of the four Taq-derived constructs (table 6.5(i)). However, 
no evidence of virus replication could be found for any of the clones. There were 
clear signs of p24 production following the initial introduction of the DNA into the 
COS 1 cells; both p24-positive-staining cells and p24 antigen in the supernatant could 
be detected. However, following the addition of the PBMCs, the p24 in the 
supernatant declined to <lnglml over a period of one week, and no p24-positive cells 
could be detected from the PBMC cultures at any time points. Transfections 
conducted with the control pHXB2, or G. 1 and H. 1, showed increasing levels of p24 
in the supernatant, and p24-positive cells could be observed, indicating that 
transfection procedures and virus propagation were successful. 
Similarly, transfection of the four Taq-derived constructs with T-cell lines H9 or 
C8166 as the propagating cells, failed to recover infectious virus (table 6.5(i)); no p24 
could be detected in the supernatants, and no p24-positive cells were observed 
beyond those detected immediately following transfection (data not shown). 
Possible Inactivating Mutations in Taq Amplified Clones 
Despite the predicted SI phenotype of these clones, each failed to produce evidence 
of virus replication following transfection into PBMCs or T-cell lines. These clones 
were obtained from the same PBMC DNA sample as the infectious clone G.1 and 
contain very similar env gene sequences to both GA and 11.1 (chapter 5, section 
5.3.2). The most obvious explanation for the failure to recover infectious virus is the 
difference in the amplification procedures used to obtain these clones. The non-
infectious clones were amplified with Taq polymerase, which was demonstrated to 
introduce errors into the env sequences during amplification. The infectious clones 
G. 1 and H. 1 were amplified with Pfu polymerase, an amplification procedure from 
which I could not demonstrate the introduction of errors. It is conceivable, therefore, 
that clones K.1, L. 1, M.1, and N.l contain inactivating mutations introduced during 
amplification. However, further analysis would be required to confirm this. 
M. 
6.2.4 Transfections with Additional PBMC-Derived 
Constructs Exchanging Cassettes -2 and -3 
From the results of the transfections described so far, we have hypothesised that env 
sequences of an NSI-predicted phenotype are unable to form fully-infectious viruses 
in the pHXB2-MCS expression system. In contrast, we have demonstrated that, with 
the exception of the Taq-amplified sequences, predicted SI-sequences are able to form 
infectious viruses. 
One reason for the failure to produce productive infections from predicted-NSI 
sequences is each of the eight clones (A.1 to F.1, 1.1 and 11) contains an inactivating 
mutation. However, we did not detect any inactivating mutations following extensive 
sequencing of the clones. Two of these clones (A.1 and D. 1) have been fully-
sequenced and shown to have an intact reading-frame, with no obvious inactivating 
mutations (chapter 5, section 5.8). 
So we decided to pursue further the hypothesis that there may be something specific 
about inferred-NSI sequences which prevents their production of fully-infectious 
viruses. Firstly, we made two more constructs with predicted NSI-sequences using 
the other two cassettes, cassette-2 which contains the entire env gene, and cassette-3 
which encodes only for gp120. Secondly, we constructed three more SI-clones 
exchanging cassette-2 to examine whether swapping gp160 had any noticeable effects 
on growth kinetics. Finally, we aimed to construct recombinant clones using the env 
genes from two clones of known viability and phenotype, SF2MC and SF162MC, which 
are SI and NSI, respectively (Cheng-Mayer et a!, 1989 & 1990). 
Construction of Clones P.2 and A.3 
Clone P.2 has the 2.5kb fragment (cassette-2) of the vector has been replaced by an 
homologous fragment amplified and cloned from PBMC DNA (chapter 4). The V3 
loop sequence of this clone is of an inferred NSI-phenotype, and shows an intact 
reading-frame over a region sequenced of 1.6kb (chapter 5). 
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The second construct, A.3, was made by the exchange of a 1.4kb fragment (cassette-
3) of the env gene vector and has an identical gpl20-coding region as clone A.1, 
which failed to produce infectious virions upon transfection. The env gene has been 
sequenced and shown to contain an intact reading-frame, and a V3 loop sequence of 
an inferred NSI-phenotype (chapter 5). 
Results of Transfections with Constructs P.2 and A.3 (and A.1, 
E.1 and F.!) 
Three transfections with construct P.2 were conducted into COS-1 cells followed by 
co-cultivation with PBMCs (table 6.5(11)). In addition, in this set of transfections, the 
two constructs, E. 1 and P.1, previously demonstrated to produce minimally infectious 
virus, were also transfected. pHXB2-MCS was used as a control. The data from this 
transfection are given in figure 6.3 and table 6.3. 
On day 4 post-transfection, there were p24-positive staining COS-1 cells produced 
from each transfected culture. However, E. 1. and F.1 had fewer p24-positive cells 
present than the other cultures (table 6.3). 
The transfection with pHXB2-MCS showed evidence of virus replication in the first 
two weeks of culture: supernatant p24 increased to 66ng/ml on day 11, and p24 
positive cells could be detected until day 22. However, a drop in the supernatant p24 
levels were observed until day 25, after which levels increased again to 70 ng/ml 
(figure 6.2). 
Cultures transfected with E.1 showed early evidence of infection, with p24-positive 
cells detected up to day 11 post-transfection. p24 levels in the supernatant increased 
up to day 15 but never reached more than 14 ng/ml, and fell to below lng/ml from 
day 25 onwards. 
Each of the transfections with P.2 (P.2a ,-b and -c, in figure 6.2), showed some 
evidence of viral replication. Within the first week, positive staining PBMCs were 
observed, although P.2b and -c contained fewer positive cells. Each cloned showed 
an increase in supernatant p24 from day 4 to day 8, although the levels in each 
culture varied widely: P.2a showed an increase of 44ng/ml to 60ng/ml; whereas P.2b 
showed an increase of <ing/mi to 4.1ng/ml, and P.2c of 2.8ng/ml to 5.2ng/ml. From 
day 8 onwards, p24 production from P.2b and P.2c declined steadily with time: 
supernatant p24 levels dropped to <lng/ml by day 18, and no p24 positive cells were 
observed. However, in P.2a there was a dramatic increase in supernatant p24 to 
139ng/ml by day 15, despite a small drop to Slng/ml in the previous time point (day 
11). This increase in p24 coincided with the detection of p24 positive cells. However, 
after day 15, a dramatic decrease in supernatant p24 occurred, reaching l6ng/ml on 
day 16. Thereafter a gradual decrease was found reaching 4.6ng/ml at day 32. No p24 
positive cells could be observed beyond day 18, indicating no viral infection. 
F.1 showed a similar pattern of infection as P.2a. Supernatant p24 levels increased 
steadily from 27ngIml to 42ng/ml between days 4 and 8, and then increased 
dramatically to 1 lOng/mi by day 11. After this, a sharp decrease to 28ng/ml occurred 
by day 15 and a steady decrease to 3.6ng.ml  by day 32 was observed. p24 positive 
cells could be observed up to day 11, after which no positive cells could be 
observed.The sharp drop in supernatant p24 levels in P.2a and F. 1, coincided with a 
drop in the p24 level in the supernatant from pHXB2-MCS and a reduction of p24-
positive cells at day 22 and no p24 positive cells on day 25. The magnitude of the 
decrease in p24 production in P.2a and F.1, coincident with a drop in virus 
production in the control, suggests that culture conditions may have deteriorated at 
these time points. The fresh PBMCs added to the cultures at time points 11, 15 and 
18, may have been less able to support viral replication than the PBMCs used at the 
beginning of the experiment, and may have diluted the virus. Despite the decline in 
p24 production, virus from pHXB2-MCS showed an increase in supernatant p24 
production from day 24 onwards, and p24-positive staining cells from day 29 
onwards. 
We attempted to co-culture the viruses obtained from P.2a and F.1 by pooling the 
supernatant and cells from day 8, 11 and 15 from each culture and co-culturing with 
fresh, uninfected PBMCs. However, no virus infection could be detected as 
determined by the absence of p24-antigen staining PBMCs and the inability to detect 
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Figure 6.3 and Table 6.3 p24-Antigen Production after Transfection 
into COS-1 Cells followed by Co-Cultivation with PBMCs for Clones 
pHXB2-MCS, E.1, F.1, and P.2 
Figure 6.3 gives the time course of p24-antigen production in culture supernatants 
Table 6.3 shows the presence p24-positive staining PBMCs in the transfected cultures. 
+ the presence of p24-positive cells at (> 10%) 
w+ cultures with less that 10% cells staining for p24 antigen 
- cultures with no p24 staining above background 
opposite page 202 




Figure 6.3 Transfection into COS-1 cells, 





PBMCs days post transfection 
clone 72hr1  4 8 11 	15 	18 	22 	25 	29 	32 
MCS + + + + + + w+ - + + 
E.1 - w+ + + 	- 	- 	- 	- 	- 	- 
F.1 w+ + w+ + - - - - - - 
P.2a + + + + 	+ 	W+ 	- 	- 	- 	- 
P.2b + - w+ - - - - - - - 
P.2c + w+ - w+ 	- - 	- 	- 	- 	- 
1 COS-1 monolayer 
The three clones, Q.2, R.2 and S.2, were constructed by exchange of cassette 2 from 
sequences amplified from the 1989 PBMC DNA sample (chapter 4). We have 
obtained the V3 sequence from only one of these constructs, R.2, which is predicted 
to confer an SI phenotype. Although the two remaining clones have not been 
sequenced, the majority of proviral sequences from 1989 PBMC sample were found 
to have a D-lineage V3 loop, the majority of which are predicted to confer an SI 
phenotype (see chapter 5). In consequence, we would expect all three clones to show 
an SI phenotype. 
From the results of the transfections carried out so far, inferred-SI clones would be 
expected to produce infectious virus from both T-cell line and PBMC cultures. 
Therefore, two transfections were carried out for each of these constructs, the first 
into COS-1 cells, followed by co-cultivation with PBMCs, the second directly into 
the C8166 cells (table 6.5(u)). 
Results of Transfection with Q.2, R.2 and S.2 
Viral replication was detected from each of the three constructs, in both PBMCs and 
C8166 cells, as determined by the production of p24 antigen in the culture 
supernatant and from the presence of p24-positive staining cells (table 6.5 (ii)). 
Syncytia could be observed in both PBMCs and C8166 cells transfected with each 
clone. 
Figure 6.4 and table 6.4 show a single experiment following transfection of pHXB2-
MCS, Q.2, R.2 and S.2 into C8166 cells. Although the rate of p24 production varied 
widely between each clone, each could be passaged to a variety of T-cell lines and 
PBMCs. 
A comparison of the infectivity properties of these clones with the two other viable 
PBMC-derived recombinant viruses, G.1 and H.1, is described further below (section 
6.2.6). 
204 
Figure 6.4 and Table 6.4 p24-Antigen Production after Transfection 
into C8166 Cells for Clones pHXB2-MCS, Q.2, R.2 and S.2 
Figure 6.4 gives the time course of p24-antigen production in culture supernatants 
Table 6.4 shows the presence p24-positive staining cells in the transfected cultures. 
+ the presence of p24-positive cells at (> 10%) 
w+ cultures with less that 10% cells staining for p24 antigen 
- cultures with no p24 staining above background 
opposite page 205 
Figure 6.4 	

















clone 	721w' 	3 	/ 	IV 	ii 
MCS 39.0 + + + 	+ 	culture stopped 
Q.2 11.0 w+ + + + + 
R.2 	25.0 	+ 	+ 	+ 	+ 	+ 	+ 
S.2 <1 - - - - + + 
1 p24 (ng/nil) in supernatant. 
6.2.5 Recombinant Clones Constructed with SF2MC env 
Sequences 
To address further the possibility of a difference in the ability of the PHXB2-MCS 
expression system to produce infectious virus with NSI, non-T-cell-line tropic env 
genes, compared to SI, T-cell-line tropic env genes, we obtained two infectious 
proviral clones SF2MC and SF162MC, which have opposite in vitro growth properties 
(Cheng-Mayer et al, 1989). 
Virus from SF2MC is syncytium-inducing and capable of growth in a variety of T-cell-
lines, and in PBMCs. In contrast, virus from SF162Mc is non-T- cell-line tropic, non-
syncytium-inducing, but is capable of growth in both PBMCs and cultures of 
monocyte-derived macrophages. 
The determinants of the growth properties of these two proviral clones have been 
mapped to the env gene. Substitution of a region of the SF2MC env gene including the 
V3 loop and the C2 region into the SF162Mc backbone results in a recombinant virus 
with an acquired ability to grow in T-cell- lines and to produce syncytia, but a loss 
of ability to grow in cultures of monocyte-derived macrophages. Similarly, the 
substitution of a region of the SF162MC env gene including the V3 loop, and C2 
region into the SF2MC clone, confers on the recombinant virus, an ability to grow in 
cultures of monocyte-derived, but a loss in the ability to grow in T-cell-lines, and 
an inability to form syncytia (Cheng-Mayer et al, 1988) 
I therefore aimed to utilise the env genes from these two clones to determine the 
ability of our HXB2 expression-system to produce recombinant virus, expressing the 
env genes known to confer either, an SI-phenotype, or an NSI-phenotype. 
However, the cloning sites for the construction of the recombinant viruses of this 
study, include a BstEll site at the 5' end of the three cassettes (chapter 3). The 
presence of a BstEll site complicated the construction of the SF162MC recombinant 
derivative, because it has an additional BstEll site within the env gene region to be 
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exchanged. In consequence, it was not possible under the time constraints of this 
study to clone the SF162MC env gene into PHXB2-MCS. 
I have, however, constructed two recombinant viral clones with the env gene from 
SF2MC. The first of these clones, HXSF2.1 has the 1.7kb (cassette-1) of SF2MC, 
incorporated into PHXB2-MCS. The second, HXSF2.2, incorporates the 2.5kb 
(cassette-2), into PHXB2-MCS (chapter 4). 
These two constructs differ, therefore, only in the length of the SF2MC fragment 
incorporated. The presence of the SF2 env gene in HXSF2.1 and HXSF2.2 should 
confer upon these viruses a T-cell-line tropic, syncytium-inducing phenotype. We 
therefore carried out transfections with these clones into both PBMCs and the cell 
lines H9, C8166 and SupTi. In addition, we carried out a transfection with the two 
parental clones SF2MC and SF162MC with PBMCs (table 6.4(iv)). 
Results of Transfections with SF2MC, SF162MC, HXSF2.1 and 
HXSF2.2 
Transfection of both parental clones, SF2MC and SF162Mc into COS-1 followed by co-
cultivation with PBMCs resulted in the production of infectious virus. There was, 
however, a significant delay in the production of p24 antigen with both clones, 
compared to p24-production from PHXB2-MCS. With SF2MC,  p24 could be detected 
in the supernatants of the transfected COS -1 cells, and remained at detectable but low 
levels in the culture supernatant until day 5. After day 5, no p24 could be detected 
until day 20, when high levels of p24 (>1000ng/ml) could be detected in the 
supernatant and p24-positive cells could be observed. With SF162MC, there were no 
signs of p24 production until day 19 post-transfection when p24-positive cells could 
be observed. At day 23 and onwards, low levels (13ng/ml) of p24 could be detected 
in the supernatant. DNA sequence analysis confirmed the identity of the virus 
produced on transfection (data not shown). 
Virus from the SF2MC  cultures was readily transmitted to T-cell line H9 by co-culture. 
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High levels of p24 (>1000ng/ml) were detected in the supernatant at day 10 post-co-
cultivation, and p24-positive cells were observed. Virus from SF162MC cultures could 
not be transmitted to H9 T-cell line by co-culture; no 24 positive cells were observed 
and only low levels of p24 were detected, probably reflecting cariy-over of virus 
particles and/or infected PBMCs from the co-culturing. The inability to transmit 
SF162MC to H9 cells, is in agreement with the non-T-cell-line tropic phenotype found 
previously with this clone (Cheng-Mayer et al, 1989). 
In contrast, from five transfections with HXSF2.2 and a single transfection with 
HXSF. 1, no infectious virus could be recovered; no p24-positive cells could be 
detected beyond day 4 post-transfection, and the levels of p24 antigen in the 
supernatant declined to below ing/mi after one week of culture (data not shown). 
Lack of Infectivity with HXSF2.1 and HXSF2.1 
The failure to produce viable viruses from HXSF2.1 or HXSF2.2, could be due to 
either a failure in the interaction between SF2MC env sequences and HXB2 
background, or due to the introduction of errors during amplification and cloning. The 
recovery of infectious virus from clone SF162MC demonstrates that our PBMC 
culture-system can successfully propagate virus of an NSI-phenotype. 
Table 6.5 Summary of the Transfections of HIV-1 Recombinant 
Proviral Clones 
a  SI: syncytium-inducing, NSI: non-syncytium-inducing 
opposite page 209 
1) PBMC-derived constructs: cassette-1 with Pji-amplified env sequences: 
clone predicted cell type No. attempts No. attempts 
phenotype'  positive 
A.1 NSI C8166 5 0 
SupTi 1 0 
U937 1 0 
COS:PBMC 2 0 
B.1 NSI COS:PBMC 1 0 
COS:U937 1 0 
C.1 NSI C8166 1 0 
H9 1 0 
PBMC 2 0 
COS:PBMC 1 0 
COS:U937 1 0 
D.1 NSI COS:PBMC 1 0 
COS:U937 1 0 
E.1 NSI COS:PBMC 3 2? 
COS:SupTl 1 0 
F.1 NSI COS:PBMC 3 2? 
COS:SupTl 1 0 
G.1 SI H9 1 1 
SupTi 1 1 
COS:PBMC 2 2 
COS:H9 1 1 
H.1 SI C8166 7 6 
H9 2 1 
PBMC 3 0 
COS:PBMC 2 2 
COS:H9 1 1 
1.1 NSI C8166 1 0 
H9 1 0 
Jurkattatm 1 0 
PBMC 3 0 
J.1 NSI Jurkattatm 1 0 
COS:SupTl 1 0 
COS:PBMC 0 0 
Table 6.5 continued 
with Taq-amplified env sequences: 
clone predicted cell type No. attempts No. attempts 
phenotype'  positive 
K.1 SI COS:PBMC 1 0 
COS:H9 2 0 
L.1 SI C8166 2 0 
COS:PBMC 1 0 
M.1 SI C8166 2 0 
COS:PBMC 1 0 
N.l SI H9 1 0 
COS:PBMC 1 0 
COS:H9 1 0 
ii) PBMC-derived constructs: cassette-2 
clone predicted cell type No. attempts No. attempts 
phenotype   positive 
P.2 NSI COS:PBMC 3 3? 
Q.2 SI? COS:PBMC 1 1 
C8166 1 1 
R.2 SI COS:PBMC 1 1 
C8166 1 1 
S.2 SI? COS:PBMC 1 1 
C8166 1 1 
iii) PBMC-derived constructs: cassette-3 
clone predicted 
phenotype' 
cell type No. attempts No. attempts 
 positive 
A.3 NSI COS:PBMC 1 0 
Table 6.5 continued 
iv) Control Constructs 
clone predicted cell type No. attempts No.attempts 
phenotype  positive 
pHXB2-SPT SI C8166 6 3 
Jurkattatm 1 1 
PBMC 1 0 
COS:PBMC 1 1 
pHXB2-MCS SI C8166 4 4 
H9 2 2 
Jurkattatm 2 2 
SupTi 1 1 
COS:C8166 2 2 
COS:H9 2 1 
PBMC 4 1 
COS:PBMC 6 5 
pHXB2-MCS&nv non- C8166 2 0 
infectious H9 1 0 
COS:H9 1 0 
HXSF2.1_ -  SI COS:C8166 1 0 
HXSF2.2 SI COS:PBMC 1 0 
COS:H9 1 0 
H9 1 0 
COS:SupTl 1 0 
COS:C8166 1 0 
SF2MC SI COS:PBMC 1 1 
SF162MC NSI COS:PBMC 1 1 
6.2.6. In Vitro Growth Properties of the Recombinant 
Viruses 
The following sections describe the results of work carried out to determine in more 
detail the biological properties of the five viable PBMC-derived proviral clones, G. 1, 
H.1, Q.2, R.2, and S.2. The virus propagation was carried out entirely by Dr Robert 
Walker and Mrs Elizabeth Harvey. 
Prior to determining in more detail the biological properties of the infectious clone 
in vitro, I carried out a sequence determination of two of the clones G.1 and H.1, to 
examine whether any sequence changes had occurred during the propagation of the 
clones in vitro. After a prolonged period of culture of 6 weeks in C8166 cells, total 
DNA was extracted from the cultures of G. 1 and H. 1. and PCR-amplified in the V3 
to V5 region (chapter 2). The sequence of the V3 to V5 region comprising of 1kb 
was obtained. No differences could be detected between the sequence obtained after 
6 weeks of culture and the sequence of the original proviral variant (data not shown). 
The Cellular Host-Range and Syncytium-Inducing Ability 
The cellular host-range of the five infectious PBMC-derived recombinant proviral 
clones (G.1, H.1, P.2, Q.2 and R.2) was analysed by infecting transformed cell lines 
with cell-free virus derived from the clones, or by co-cultivation with virus-infected 
cells recovered from the transfection with the proviral DNA. 
Each clone was capable of productively infecting T-cell lines C8188, H9, SupTi, and 
MT2. In addition, each clone induced the production of syncytia in the cell lines 
tested. 
Table 6.6 shows the maximum p24 antigen levels produced with each clone following 
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growth in cell lines H9, C8166 and PBMCs. In H9 and C8166 cells each clone 
analysed produced high levels of p24 in the supernatant, ranging from 700ng/ml to 
over 1000ngIml. These values are comparable to the controls isolates fflV-1 and 
HIV- 1SF2'  although HIV- 1SF2 reached just less than 500ng/ml in C8166 cells. 
By comparison, each viral construct grew to lower levels in PBMCs than T-cell lines, 
with the exception of clone HA which reached levels of >1000ng/ml. There was 
considerable variation in the levels of p24 produced in infections with the same 
construct but where different batches of PBMCs were used. For example, H. 1 showed 
a maximum p24 level of 67ng/ml, despite producing >1000ng/ml with different 
PBMCs. Similarly, R.2 showed 55ng/ml on one occasion, and 212ng/ml with a 
different batch of PBMCs. PBMCs are generally less able to support HIV-1 
replication, which in part, reflects the less robust nature of PBMCs and the lower 
proportion of CD4-positive cells in PBMC cultures compared to T-cell lines. 
Virus Infectivity 
One of the earliest observations made with the PBMC-derived clones, was that 
although each produced similar high levels of p24 in the culture supernatants, the 
infectivity titres of cell-free virus was between two or three orders of magnitude 
lower than the parental virus, pHXB2-MCS and the isolate HIV- l. In contrast, 
virus transmission by co-cultivation appeared to be equally efficient with the PBMC-
derived recombinant virus and pHXB2-MCS and HIV-l; in each case, virus spread 
and amplification, detected as the presence of syncytia throughout the cultures, was 
readily observed two or three days post-co-cultivation. 
To investigate this further, infectivity titres were calculated for both cell-free and cell-
to-cell transmission (table 6.7). Cell-free infectious titres from the two clones 
constructed by the exchange of cassette-1, H. 1 and G.1, were 1.0x102 and 8.3x102, 
respectively. The infectious titres for the three clones constructed through exchange 
of cassette-2, were 10-fold higher for Q.2 at 3.6x103, and greater than 100-fold higher 
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for R.2 and S.2, at 8.0x104 and 2.0x104, respectively. 
The infectivity titres from the PBMC-derived constructs were between 10- and 1000-
fold lower than the control isolate HIV-1, and pHXB2-MCS, which were 1.3x106, 
and greater than iO, respectively. The isolate HIV-lS 2, in our hands, produced a 
relatively low infectious titre of 2.5x103. 
Infectious titres determined from cell-to-cell infection were in the range of lx i0 and 
1x104 for the PBMC-derived clones. These were comparable to the infectious titres 
determined from the control constructs fflV-1 and pHXB2-MCS and HIV-lsF2. 
The low infectivity titres of cell-free virus obtained from the PBMC-derived 
constructs have precluded their use in neutralisation assays, which require large 
amounts of virus at high infectivity titre. 
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Table 6.6. Maximum p24 levels (ng/ml) 
Maximum p24 levels (ng/ml) 
cell type  
virus C8166 H9 PBMCs 
pHXB2.MCS 1446 1224 54 
G.l 1014 >1000 440 
H.1 1079 >1000 67, 1160 
Q.2 1125 1119 27 
R.2 1510 712 55,212 
S.2 n.d. 881 33 
HIV-1 493 >1000 >1000 
HIV-1,11B 856 1430 n.d. 
Table 6.7. Virus infectivity titres 
Virus infectivity titres 
virus TCID501m1 TClD501106cells p24 (ng/ml) 






G.1 8.3x102 2.5x105  380 
H.1 1.0x102 7.0x104 234 
Q.2 3.6x103  4.0x104 1119 
R.2 8.0x104 3.2x105  712 
S.2 2.0x104 4.4x104 889 
HW-1 1  2.5x103  1.4x105  316 
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7.1. The Immune Response to HIV-1 Infection 
One of the most important questions concerning the nature of HIV-infection, is how 
HIV maintains a chronic infection despite the presence of a strong antiviral immune 
response. 
There is evidence that the immune system can control virus replication following 
primary infection when high titres of infectious virus are found. A rapid decrease in 
plasma viraemia occurs within several days to weeks, concomitant with the first 
detectable immune response (Daar et at, 1991; Clark et at, 1991). Cytotoxic T-
lymphocyte (CTh) responses are detected first, before neutralising antibodies (Koup et 
at, 1994; Arendrup et at, 1992; Albert et at, 1990; Ariyosha et at, 1992; Moore et at, 
1994b). Moore et at, 1994b, have noted that although the CTL response occurs first, 
and will kill infected cells, neutralising antibodies are probably responsible for the rapid 
clearance of infectious virus from the plasma at this time point. 
A CTh response to HIV-1 can be detected through out the asymptomatic period 
(Clerichi, 1993). However, in infected individuals there is frequently found a loss of 
function of the T-helper cell subset associated with augmenting the cell-mediated 
immunity (the Th1 subset) and a concomitant activation of the Th2 subset, which 
stimulate humoral immunity and the production of antibodies. This imbalance will 
almost certainly lead to a reduced function of cellular immunity. 
Long term survivors, who show a normal and stable CD4+ T-cell count after 12 to 15 
years of HIV-1 infection, show a strong CTh response and a broad neutralising 
antibody response. This vigorous immune response may be responsible for a low viral 
load and a good clinical prognosis (Cao et at, 1995). However, other factors may be 
important: the CD4 cells on long term survivors may be less susceptible to infection, 
or that they harbour attenuated viruses (Zhang et at, 1996; Iverson et al, 1995; Cocchi 
et at, 1995). 
Moore and Ho, 1995, have postulated that ultimately, the immune response is unable 
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to prevent disease progression, because antibodies are ineffectual against HIV- 1 in the 
lymph nodes and lymphoid tissues, where a large proportion of HIV-1 is harboured.Two 
mechanisms for this have been proposed: firstly, the high cell density in the lymphoid 
tissues reduces the effectiveness of antibodies; secondly, the spread of HIV-1 may occur 
principally by cell-to-cell infection in lymphoid tissues, to which antibodies are less 
efficient at blocking. 
7.2 Antigenic Variation in Infectious Diseases 
Another factor, which forms the basis of the work presented in this study, is that HIV 
maintains a chronic infection by continually producing novel antigenic variants which 
are not recognised by the contemporaneous immune response. In this way, the virus will 
be able to 'escape' destruction by the host's immune system. This phenomenon is 
known as antigenic drift, and has been proposed for chronic infections with other 
lentiviruses (such as Visna virus of sheep and equine infectious anaemia virus of horses; 
Thormar et al, 1983; Lutley et al, 1983), and in a number of bacterial and protozoan 
infections, such as Borrelia recurrentis, African trypanosomes and the malaria parasite 
(Bloom, 1979; Mims, 1986). In these cases the production of antigenic variants during 
the course of a single infection is an important factor promoting their persistence in the 
body. 
With a number of viral infections, antigenic variation does not occur during the course 
of a single infection, but may occur outside the host, and so re-infection with a novel 
antigenic variant can occur at a later stage. This is observed for influenza A and 
influenza B viruses, foot and mouth disease virus, and human rhinoviruses (Mims, 
1982; White and Fenner, 1994). Perhaps the most striking example is that of type A 
influenza virus - in which antigenic variation is responsible for the sporadic occurrence 
of pandemics of influenza within the human population. There are two viral envelope 
proteins haemagglutonin (HA) and neuraminidase (NA), both of which are highly 
glycosylated. Type A influenza virus may be classified into subtypes according to the 
antigenic characteristics of the surface antigens HA and NA. The surface antigens 
undergo two types of antigenic variation: antigenic drift which result from mutation in 
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either the NA or HA genes, which are no longer recognised by the immune system; and 
antigenic shift which results from the acquisition of a novel HA or NA gene, producing 
a new human subtype, which is antigenically distinct. This is thought to arise by 
recombination between different strains of influenza A virus leading to a new 
combination of NA or HA subtypes. It is also thought that a new subtype may arise in 
the human population through acquisition of an avian subtype NA or HA, by 
recombination of avian and human influenza type A strains, facilitated by the segmented 
RNA genome (Webster et al, 1982). Antigenic shift is believed to be responsible for 
pandemic outbreaks of influenza that have occurred in 1918, 1946, 1957 (Asian 'flu), 
1968 (Hong Kong 'flu). 
Viruses which evolve rapidly and produce novel antigenic variants within the infected 
host population, or within an individual host, pose problems for vaccination. This is 
principally because vaccination to one strain may have no effect against another. Much 
research has been vested into quantitating the number of antigenic variants in a given 
geographical area, and in predicting which variants will arise in the future by studying 
the patterns and processes of viral evolution (Webster et al, 1982; Louwagie et al, 1993; 
Holmes et al, 1992; Moore et al, 1996). 
7.3. The Genetic Variation of HIV-1 
REV, in common with other viral species and especially RNA viruses, exists within the 
infected individual as a heterogeneous population of variants. This distribution of 
variants has been termed a 'quasispecies' and is the direct result of a high mutation rate 
and a large population size. Competition between the variants under different 
environmental conditions shapes the distribution. The unusual feature of the 
quasispecies is that the fitness of particular sequences is not just a function of the 
sequence per se but is also related to the mutational distance between them and the 
fittest variants (Eigen et a!, 1988; Domingo et a!, 1993; Nowak, 1992). 
This distribution of variants is thought to allow FHV to adapt quickly to new 
environments, such as those formed by the host's evolving immune response where 
antigenic variants may be selected (Albert et a!, 1990), or following the administration 
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of drug therapy where drug resistant forms of the virus may be selected (Larder et al, 
1989), or in the adaptation of HIV-1 to a particular cell or tissue type, where env 
mutations confer different cellular host-ranges (Korber et al, 1994; Cheng-Mayer et al, 
1989). 
7.4 The Principal Targets of Neutralising Antibodies elicited 
following HIV-1 Infection 
For laboratory strains, the principal target of neutralising antibodies found in natural 
infection with HIV-1 is an epitope in the third hypervariable region of the surface 
protein gpi20, which forms a stem-loop structure - 'the V3 loop' (figure 1.5, chapter 
1) (Rusche et al, 1988; Javaherian et a!, 1989; Zwart et a!, 1994. A second important 
target of neutralising antibodies is a complex epitope which makes up the binding-site 
for the cellular receptor molecule, CD4 (Chamat et a!, 1992; Kang et a!, 1991). The 
CD4 binding-site epitope is formed from residues in the conserved regions C2, C3 and 
C4 of gpl2O (Lasky et a!, 1987; Olshevsky et al, 1990), and interacts with the V3 loop 
(Wyatt et al, 1992; Moore et al, 1993a). 
7.4.1 The Function of the V3 loop 
The V3 loop as well as being defined as the principal neutralising determinant of HIV-
1, is also an important determinant of the in vitro viral phenotype: the cellular host-
range, replication-rate and syncytium-inducing ability (Hwang et al, 1991; De Jong et 
a!, 1993a, 1993b; Stamatatos et al, 1994). In general, HIV-1 isolates fall into two 
groups: slower replicating variants that can grow in macrophages and CD4 T-
lymphocytes, but are non-syncytium-inducing (NSI) and are unable to replicate in T 
cell-lines (Schuitemaker et a!, 1992; Connor et al, 1993b); the other group consists of 
faster replicating variants which can grow in macrophages, T-lymphocytes and T-cell 
lines, these variants can usually induce the formation of syncytia (syncytium-inducing 
or SI) (Connor et a!, 1993b; Tersmette et a!, 1989a and 1989b). It is the amino acid 
sequence and charge of the V3 loop which determines these phenotypes: a low net 
charge and a limited sequence diversity from the subtype B consensus sequence predicts 
a non-syncytium-inducing phenotype and a non-T-cell-line tropic phenotype; a high net 
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charge and a high sequence diversity from the subtype B consensus sequence confer a 
syncytium-inducing phenotype and an ability to replicate in T-cell-lines (Milich et al, 
1993; Fouchier et al, 1992; Chesebro et al, 1992). 
There is considerable natural variation in the amino acid sequence of the V3 loop both 
within an individuals and between individuals (Simmonds et al, 1991; Holmes et al, 
1992; Wolfs et al, 1991; Fouchier et a!, 1992; Cichutek et al, 1992; Leigh Brown and 
Holmes, 1994; Leigh Brown, 1991). Many of the variable sites in the V3 loop alter 
antibody binding to synthetic peptides representing the V3 epitope (Wolfs et al, 1991; 
Moore et al, 1995), and can give rise to variants with different sensitivities to 
neutralisation by serum antibodies (Moore et al, 1996; Looney et al, 1988). In vitro 
studies with HIV- 1 clones have shown that resistant forms can arise de novo under 
selection from neutralising antibodies to both the V3 loop and the CD4 binding-site 
epitope (McKeating et al, 1989, 1993; Yoshiyama et al, 1994; Masuda et al, 1990; 
Robert-Guroff et a!, 1988). With the V3 loop, single amino acid substitutions within the 
loop, or at sites distant from the loop have been shown to confer resistance (McKeating 
et a!, 1989; Wahlberg et a!, 1991). 
However, as described above, the variation in the V3 loop also influences the in vitro 
viral phenotype: early On in infection viral isolates tend to be of non-syncytium-
inducing phenotype, whereas later in infection faster-replicating, syncytium-inducing 
variants also emerge (Connor et a!, 1993b and 1994; Schuitemaker et a!, 1992). These 
phenotypic changes correlate with amino acid changes in the V3 loop (Fouchier et a!, 
1992; Connor et a!, 1993a), and may be one of the forces of selection acting upon the 
virus population in vivo. 
7.4.2 Characterising the Evolution of the V3 Loop 
Despite extensive studies of sequence variation, we are still uncertain of the role of 
selection in driving the evolution of the HIV- 1 env gene, and in particular the V3 region 
(Leigh Brown and Holmes, 1994; Domingo et al, 1993; Moore and Ho, 1995; 
Donaldson et a!, 1994b). 
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the proportion of synonymous (Ks) versus nonsynonymous (Kj nucleotide substitutions 
within the V3 region over a 7-year period from a single individual (patient 82 of this 
study). In year 3 post-infection, there was a ten fold higher mean number of 
nonsynonymous substitutions (Ka), which is indicative of positive selection for amino 
acid change. By year 5, the ratio of K to K8, had increased to greater than 1, indicating 
weak negative selection against amino acid changes. This increase in KJKa  correlated 
with a low CD4 count, is consistent with a role for the immune system in selecting 
variants. 
However, other investigations have failed to show consistent KJKa  ratios in the V3 
region of less than 1, suggesting a random element in the sequence evolution (Zhang 
et al, 1996). Similarly, a variable KJKa  ratio (of between 0.2 to 2) was found by 
Lukashov et al, 1995, in an extensive study of 44 individuals. In each of these studies, 
a significant difference in the rates of evolution was found between the patients. This 
is consistent with specific host factors, such as differing immune responses, in driving 
the evolution. 
Leigh Brown (1996) has applied the neutral theory to data from patient 82, to determine 
whether the pattern of variation in the V3 region fits that expected for selectively 
neutral sequences, whose evolution will be governed by mutation rate and random drift, 
or whether the pattern of variation is significantly different from that of selective 
neutrality. If so, this would indicate that selection was driving the evolution of the V3 
region. At only two time points out of six (year 4 and year 6) did amino acid sequences 
show a level of diversity greater than expected from neutrality, suggesting a role for 
selection. Further analysis showed that only the V3 loop itself showed a significant 
departure from neutrality, the regions flanking the V3 loop did not show a departure 
from neutrality. From this analysis, only the V3 loop is under selection in this patient. 
Interestingly, the diversity in the V3 loop in years 4 and 6 from patient 82 is at sites 
important in determining cell tropism, which may be the selective force acting upon the 
V3 loop. (This was described in chapter 5, section 5.5). 
So we have some evidence that selection is acting upon the V3 loop; selection may be 
from the immune response, or for variants with a different cellular host-range. It may 
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from the immune response, or for variants with a different cellular host-range. It may 
be difficult to determine which is the most important, as the same amino acid changes 
can alter both the neutralising sensitivity and the cell tropism. 
However, other factors aside from selection, may be important in shaping the evolution 
of HIV- 1: the clonal activation of individual T-cells harbouring HIV- 1, or random drift 
of selectively neutral variants (Domingo et al, 1993). Indeed, Leigh Brown (1996) has 
estimated that the effective population size (NJ of HIV-1 in the host is sufficiently 
small that random drift may have a significant effect upon viral evolution. 
7.5. A Model of Antigenic Diversity in HIV-1 Pathogenesis 
The extensive variation displayed by HIV-1 in vivo has been the basis of mathematical 
model: the 'antigenic diversity threshold' model which examines the role of antigenic 
variation upon HIV-1 pathogenesis (Nowak et al, 1990). 
During the early stages of HIV infection, prior to the development of the immune 
response, there will be an outgrowth of the fastest-replicating variants, reducing the 
observed variation of the population. A reduction in variation in the env gene upon 
primary infection has been demonstrated by a number of groups (Zhu et al, 1993; 
Zhang et al, 1993; Delwart et al, 1993). 
Following seroconversion, the model states that the immune response will select for 
antigenic variants that have escaped neutralisation. With time, this process will give rise 
to virus diversification and variation will accumulate in epitopes recognised by the 
immune response. Diversification in the env gene has been observed by a number of 
groups (Holmes et al, 1992; Wolfs et al, 1990 and 1992; McNearney et at, 1992; 
Kuiken et at, 1993), but the role of immune selection remains undetermined (see 
above). 
With time, there will be an increase in antigenic diversity which the immune system 
will find more and more difficult to control. The model proposes that an imbalance 
between immunological and viral diversity will develop, on the assumption that each 
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The antigenic diversity will increase until it reaches a certain level, or a 'diversity 
threshold', at which there are too many variants for the immune system to contain. 
Once this threshold is reached the immune system will collapse and the patient will 
progress to AIDS. Viral replication in AIDS will escalate due to the absence of immune 
control. In the absence of selection for antigenic variants, the fastest replicating variants 
will predominate and this will reduce the variation observed. A low sequence diversity 
in AIDS has been observed by some groups (McNearney et al, 1990) but not by others 
(Donaldson et at, 1994b). 
The degree of genetic diversity has been examined with respect to the rate of disease 
progression. Lukashov et al, 1995, observed that in a large data set of 44 individuals, 
non-progressors accumulated a greater number of amino acid changes in the V3 loop, 
than those who progressed rapidly to AIDS. In a second study, Delwart et al, 1994, 
found that long-term infected asymptomatics showed the highest levels of genetic 
complexity in the env gene. A rapid CD4-cell decline and progression to AIDS was 
often associated with lower complexity. It may be that a strong immune response is 
present in the non-progressors and this may drive env and V3 sequence evolution, 
leading to a greater genetic complexity. Individuals progressing rapidly to AIDS may 
have a weaker immune response, thus weakening the selective pressure for antigenic 
diversification. 
However, in contrast to this, a study of two long-term non-progressors, (who showed 
a normal and stable CD4 count over a 5 years of infection with HIV-1), showed each 
to have a very low viral sequence diversity and viral load throughout this period of 
asymptomatic infection (Haigwood et al, 1993). The low diversity is presumably due 
to immune control of viral replication, which also results in a very low viral load. 
Thus, it may be argued that a strong immune response will lead to a low viral load and 
a low viral diversity, and a good disease prognosis, as was seen by Haigwood et al, 
1993 and Strunnikova et al, 1995. However, it may also be argued that the extensive 
diversity seen in slower-progressors is due to a strong immune response, which selects 
for escape mutants - as was seen by Lukashov et al, 1995. However, this is in contrast 
to the predictions of the antigenic diversity threshold model. According to the model 
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the antigenic sites of lily-i evolve more rapidly in individuals progressing rapidly to 
AIDS, as the antigenic diversity threshold will be reached quicker. In contrast, in 
individuals who do not progress, who remain asymptomatic for longer, evolution of 
antigenic sites should be slower, and so it will take longer to reach the antigenic 
diversity threshold. 
7.6. Characterising the Immune Response to the V3 Loop 
using Synthetic Peptides 
The antibody response to HIV infection has been extensively examined by determining 
the reactivity of sera to in vitro synthesised peptides representing specific epitopes of 
gp 120 or gp4 1. This approach has been widely used to characterise the antibody 
responses to the V3 loop. For example, this method has been used in the 
characterisation of virus isolates found in different geographical locations to determine 
the different V3 serotypes (Moore et al, 1994c). Peptide studies have also been used to 
investigate HIV transmission, for example, by mother-to-child transmission, or through 
sexual contact, with the aim of determining the correlates of transmission and non-
transmission (Fiore et al, 1994). Peptides have also been used to analyse the humoral 
immune response during the course of natural infection - in cross-sectional and 
longitudinal studies, or to study the humoral immune response following vaccination 
of humans and animals (Wahlberg et al, 1991; Wolfs et a!, 1991; Zwart et a!, 1992). 
There are a number of draw-backs to the use of peptides for characterising the immune 
responses to HIV-1 infection. Firstly, V3 peptides do not measure the neutralising 
antibody response to the V3 loop, but measure the binding of serum antibodies to the 
peptides and these may not have a neutralising property. Secondly, it has been shown 
that V3 peptides do not reproduce the antigenicity of the V3 loop when present on the 
native envelope protein complex (Moore, 1993). Although the V3 loop is a linear 
epitope (one which requires the correct linear amino acid sequence to bind antibody and 
may be mimicked by short peptide sequences), the binding of antibodies is influenced 
by the conformation of the loop, which may vary according to the sequence and 
conformation of the rest of the protein molecule (McKeating et a!, 1989; Klasse et al, 
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1993; Haigwood et at, 1993). Ideally, the envelope protein should be assayed as an 
oligomeric complex, not as gp120 monomers, as many of the antigenic sites are more 
exposed on gp120 monomers than on the native envelope protein complex, which 
consist of oligomers of gp120 in association with gp41 (Moore et at, 1995; Sullivan et 
al, 1995). Indeed, to express and assay the native envelope protein complex of variants 
of HIV-1 found in vivo, was the principal aim of the work described in this thesis. 
Studies with V3 peptides have, however, shown a number of important results about the 
antibody-specificity during the course of natural infection. Antibodies to the V3 loop 
elicited early in infection have been shown to be type-specific - that is will only react 
with a limited number of peptides of different sequence (Zwart et at, 1992). Wolfs et 
al, 1991, have shown that in one individual the V3 sequences that emerge during the 
course of infection were accompanied by the emergence of a new population of V3-
specific antibodies. In a longitudinal study of forty-six seroconverters, Zwart et al, 1992, 
found that in the majority of patients the specificity of antibody response to V3 peptides 
did not change during the course of infection. In a few patients, the later antibody 
response had a broader activity. Only three patients developed a completely new serum 
specificity. 
V3 peptides have been used to adsorb anti-V3 antibodies present in HIV- l-positive sera, 
which can then be eluted and used in neutralisation assays. These types of studies have 
shown that a large proportion of neutralising activity in sera is directed to the V3 loop 
(Zwart et al, 1994; Profy et al, 1990; Wolfs et al, 1991). These antibodies are type-
specific and will only neutralise a limited number of strains. 
7.7 Examination of the Neutralising Antibody Response to 
HIV-1 Infection 
7.7.1 Differing sensitivities to neutralising antibodies of primary isolates 
and laboratory strains 
Up until recently, the majority of neutralisation studies have been carried out with 
laboratory-adapted strains such as HIV-1NY5, IllV-1, }llV-i and have used T-cell 
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lines to passage the virus and conduct the neutralisation assays (Zwart et a!, 1994; 
McKeating et al, 1989). However, more recent studies have shown that there are 
significant differences between the in vitro properties of laboratory-adapted strains and 
those of primary isolates, particularly in their sensitivities to neutralising antibodies 
(Moore et al, 1995; Sullivan et a!, 1995; Wrin et al, 1995; Bou-Habib et al, 1994). 
Although there is not a strict definition of primary isolates, they are those which have 
been obtained by limited cultivation of patient PBMCs, or plasma, with uninfected 
PBMCs (Fenyo et a!, 1989; Tersmette et al, 1988; Schuitemaker et al, 1991; Gao et a!, 
1996; Ho et al, 1989). In contrast, laboratory isolates are those that have been 
extensively passaged in human T-lymphoid cell lines, such as the 'prototype' isolates 
HIV-1, HIV-1, I-HV-1, HIV-lsFj6i (Shaw et al, 1984; Cheng-Mayer et al, 1991). 
The majority of primary isolates are non-syncytium-inducing and replicate in T-
lymphocytes and monocyte-derived macrophages. However, most primary isolates do 
not grow well in cell lines; those that can be passaged in T-cell lines, generally show 
a syncytium-inducing phenotype (Fouchier et a!, 1992; Koot et a!, 1992). In contrast, 
and by definition, laboratory-adapted isolates generally grow well in a variety of T-cell 
lines and are generally of a syncytium-inducing phenotype. 
Moore et al, 1995b, found that primary isolates are more resistant to neutralisation by 
HIV-1 anti-sera, and certain monoclonal antibodies (MAbs). This is similar to earlier 
findings showing that laboratory-adapted isolates show a 100 to 1000 fold increased 
sensitivity to neutralisation by sCD4, a property that correlates with increased shedding 
of gp120 on exposure to sCD4 (Daar et a!, 1990). By contrast, primary isolates are 
relatively resistant to neutralisation by sCD4, which in part, explains the inefficacy of 
the administration of sCD4 to patients as an anti-viral agent. 
The relative resistance of primary isolates to antibodies has been confirmed by the work 
of Sullivan et a!, 1995. In this study, the envelope protein complexes of three primary 
isolates were more resistant to monoclonal antibodies to the CD4 binding-site and the 
V3 loop, than the envelope complexes from two laboratory-adapted strains. In addition, 
the primary isolates had a higher density of envelope glycoprotein spikes on the virions, 
which may contribute to their increased resistance to neutralising antibodies. 
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Further to this, the adaption of a primary isolate to growth in a T-cell line, which 
involved sequence changes in the V2, C2 and V3 regions of the surface protein gpl20, 
also increased the susceptibility to neutralisation by V3-specific MAbs (Wrin et a!, 
1995). In another study, it was found that the V3 neutralising-epitope on the primary 
isolate HIV- 'F  is presented in a form where it is less-accessible to V3-directed 
antibodies. The V3 loop epitope was said to be of a 'cryptic' nature. Adaptation of 
FHV- 1JR-CSF  to a T-cell line resulted in amino acid changes to the V3 region, which 
increased the net charge of the loop, and rendered the virus more susceptible to 
neutralisation by V3 monoclonal antibodies (Bou-Habib et al, 1994). 
7.7.2 A Dual Configuration Proposed for the HIV-1 Envelope 
Protein 
Based upon this evidence, Moore and Ho (1995) have proposed that the envelope 
protein complex of primary isolates has a configuration that is fundamentally different 
to that of laboratory-adapted strains. They suggest that the configuration of the envelope 
complex of primary isolates is such that it shields the major neutralising epitopes, 
especially the V3 loop and the CD4 binding-site, from access to neutralising antibodies. 
The CD4 binding-site of primary isolates is described as being predominantly in a 
'closed' configuration (figure 7.1). In contrast, the envelope protein complex of 
laboratory-adapted isolates will have evolved during their extensive propagation in vitro, 
to a configuration which enhances their in vitro replicative ability but renders them 
more susceptible to neutralisation by sCD4, monoclonal antibodies and HIV-1 positive 
sera. In this case, the CD4 binding-site is described as being predominantly in an 'open' 
configuration. 
Specifically, Moore and Ho, 1995, have predicted that the amino acid changes 
producing a T cell-line adapted virus, alter the association between the V3 loop and 
residues in C3 and C4 which contribute to the CD4 binding-site. These changes are 
believed to move the V3 loop into a more exposed position and uncover the CD4-
binding site. Amino acid changes in the V3 loop, and elsewhere in gpl2O or gp41, have 
been shown to exert an effect on viral phenotype (Andeweg et at, 1993; Boyd et at, 
ipm 
Figure 7.1. Schematic Representation of the Change in Configuration of the 
Envelope Proteins of HIV-1 following Adaptation of Primary Isolates to growth 
in T-Cell Lines. 
This figure is adapted from Moore and Ho, 1995. 
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1993; Groenink et al, 1992). This may be mediated through exposing the V3 loop and 
CD4 binding-site. 
7.7.3 The Implications of the dual configuration hypothesis 
upon neutralisation studies 
The dual configuration hypothesis has a number of important implications: firstly, that 
the V3 loop may not be the principal neutralising determinant (PND) of the viruses 
found in vivo. Indeed, the V3 loop was defined as the PND following the experimental 
inoculation of animals with synthetic peptides representing the V3 loop (Ruche et al, 
1988). Many of the neutralising assays used the 'neutralisation-sensitive' isolates such 
as HIV-1. It may be that other neutralising epitopes are more important targets of 
neutralisation in vivo. In one study, a primary isolate was found to be more sensitive 
than a laboratory-adapted strain to neutralising antibodies directed to the V2 region 
(Gorny et al, 1994). 
Secondly, the hypothesis suggests that studies on the immune response to HIV infection 
should be conducted using primary isolates. The properties of primary isolates have 
been examined in a number of recently published work (Iversen et at, 1995; Gao et al, 
1996; Sullivan et al, 1995) and has formed the basis of the work described in this 
thesis. 
Thirdly, the evolution of the V3 loop of HIV-1 in vivo may be restricted by the 
presence of a strong immune system which selects for a V3 loop which is less 
accessible to neutralising antibodies, ie. has a 'closed' configuration. Recent studies 
have shown that the V3 loop sequences early in infection, and those in non-lymphoid 
tissues, show a restricted sequence variation, a low net charge, and are predicted to 
confer a macrophage, NSI phenotype (Zhang et at, 1993; Zhu et al, 1993; Donaldson 
et al, 1994b; Korber et at, 1994; Milich et at, 1993). However, a number of researchers 
have shown that highly divergent V3 loops may be found within the plasma of a single 
individual, during the asymptomatic phase (Leigh Brown and Clelland, 1996). 
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Moore and Ho, 1995, have suggested that syncytium-inducing isolates only appear later 
in infection, because a strong neutralising antibody response to these variants selects 
against these variants during the early stages of infection. During the latter stages of 
HIV- 1-infection, a compromised immune system with a reduction in titres of 
neutralising antibodies, will allow viruses with a higher replication rate but increased 
sensitivity to neutralising antibodies to emerge. With respect to this, Bonhoeffer et a!, 
1995, have found that the V3 sequences with an inferred SI phenotype from patient 82, 
have a significantly lower K.JKa  (ie. that selection is stronger) than sequences of an 
inferred NSI phenotype. This supports the hypothesis that the immune system has a 
greater effect against SI-type viruses than NSI/macrophage-tropic viruses. 
7.7.4 Approaches to Examining Autologous Neutralising 
Antibody Responses 
There are two main experimental approaches taken to study autologous neutralising 
antibody responses to the evolving virus population found in vivo. 
The first, is to obtain viral isolates from sequential peripheral blood samples, and to 
examine the neutralising properties of autologous serum samples taken at time points 
before and after the isolates were obtained. Such an approach has been taken by Albert 
et al, 1990; Arendrup et a!, 1992; Tremblay et a!, 1990; Moore et al, 1994b, Cao et a!, 
1995) These studies have shown that isolate-specific neutralising antibodies to 
autologous viral strains arise after seroconversion, and that in some cases, subsequent 
isolates are resistant to neutralisation from early sera. In one study, neutralising 
antibodies to the resistant forms developed, however, the titre of these antibodies was 
lower than to the earlier isolates (Arendrup et a!, 1992) 
However, most viral isolates are genetically heterogeneous (Hahn et a!, 1986; 
Meyerhans et a!, 1989; Delwart et a!, 1993), as such, the neutralising antibody titres 
obtained will be to a mixture of variants which may have different neutralising 
sensitivities, and not to a specific variant. In these cases it will not be possible to 
correlate resistance with a specific env sequence. Another source of difficulty is 
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obtaining isolates in the early stages of infection when viral load is very low and 
isolation difficult. 
A second approach is to engineer recombinant viruses expressing the env sequences 
whose neutralising sensitivities are to be examined. This approach has been taken to 
examine the autologous neutralising responses following the accidental infection of a 
laboratory worker with lilV-1 (Di Marzo Varonese et al, 1993), and following the 
experimental infection of monkeys with HIV-1 and SlVmac (Burns et al, 1993; Back 
et a!, 1993; Reitz et al, 1994). 
Di Marzo Varonese et al, 1993, examined the neutralising response following the 
accidental infection of a laboratory worker with HIV- 1. A predominant env variant, 
detected one year after infection, was introduced into the pHXB2 clone (an infectious 
clone derived from the HIV-1.,isolate, Shaw et al, 1984, and used in this study), and 
this clone was found to be resistant to a panel of monoclonal antibodies directed to the 
V3 loop, and to neutralisation by autologous sera. However, this variant was detected 
after the development of a neutralising response capable of neutralising the variant and 
persisted in all subsequent isolates (Reitz et al, 1994). This suggests that a variant 
specific neutralising antibody response did not select this variant. The predominance of 
this resistant variant may have occurred by chance, or by antibody-enhancement of 
infection (Sanchez-Palomino et al, 1993; Domingo et a!, 1993). Also, infection was 
with the laboratory strain HIV-1, which may not be representative of the immune 
response to infection with primary isolates, which as described above, are less sensitive 
to antibody neutralisation. 
The recombinant approach was used by Burns et a!, 1993, who studied the sequence-
specific immune response in rhesus monkeys infected with the pathogenic clone 
''mac239 Two variant env sequences, arising at 69 and 93 weeks post-infection, 
respectively, were substituted back intothe parental clone SIVm9  to generate two 
variant viral clones. Sequential sera from the monkey infected with SIVm9 showed 
much stronger neutralising titres to the parental virus, than to either of the two variants. 
Experimental infection of naive monkeys with the two variants generated high titres of 
type-specific neutralising antibodies, showing that the two variants were not inherently 
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less immunogenic. The authors concluded that SIVmC9 mutants resistant to serum 
neutralisation arise during the course of infection in rhesus monkeys. 
Similarly, following the experimental infection of chimpanzees with HIV-1, 
recombinant viruses chimeric for the env gene, were generated to examine the sequence-
specific neutralising antibody responses (Nara et al, 1990; Back et al, 1993). These 
studies have shown that viruses resistant to V3 antibodies arise during infection in 
response to a V3-specific neutralising antibody response. In one instance, the mutation 
conferring resistance mapped to gp4l (Back et al, 1993). However, these studies were 
of the experimental infection of chimpanzees with the laboratory-adapted isolate FHV-
l. Again, such a result with the laboratory-adapted isolate may not be representative 
of the immune response to primary isolates. 
In more recent work by Sullivan et al, 1995, recombinant viruses were generated to 
examine the structure and neutralising sensitivity of different env genes: two from 
laboratory isolates, and three from primary isolates. These studies did not address the 
question of the development of 'escape' mutants to neutralising antibodies, but 
confirmed the greater sensitivity of laboratory-adapted isolates to neutralisation. 
7.8 Summary of the Results of this Study 
An HIV-1 cassette-vector has been made to allow examination of the functional 
properties of variants of the env gene. The vector, pHXB2-MCS, is modified from the 
infectious proviral clone pHXB2-D (Fisher et al, 1985), and has unique cloning sites 
for exchange of the env gene. 
Initially, ten recombinant clones were constructed by replacing a 1 ;7kb fragment of 
pHXB2-MCS with ten variants of the env gene. The env sequences were cloned directly 
from the peripheral blood samples of a single infected individual. The sequences are 
from four time points and are representative of the spectrum of variants within this 
individual. 
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On transfection into T-cell lines and COS-PBMCs, virions recovered from two clones 
(G.1, H.1) were able to replicate. Each transfected culture showed a burst of p24. 72hr 
post-transfection, a transient decrease and subsequent increase in p24 over a period of 
30 days. Each induced the formation of syncytia and could be passaged in a variaety 
of T cell lines and in PBMCs. Virions recovered from another two clones (E.l, F.l) 
showed evidence of low level replication. An increase in p24 could be detected in the 
first week of culturing, but this level declined to <lng/ml by the second week. Virions 
from clones E. 1 and F. 1 could not be passaged in PBMCs or a Variety of T-cell lines. 
In contrast, virus replication could not be detected from the remaining six clones (A. 1, 
B.l, C.1, D.l, 1.1, J.1). After an initial burst of p24 72hr post-transfection, levels 
dropped to below <lng/ml within a week. Virus replication could not be detected 
following passage in either T-cell lines or PBMCs. 
The remaining work of this study has been directed towards understanding why such 
a small proportion of clones are replication competent. 
7.9 Discussion of Results 
Perhaps the most obvious explanation for the low frequency of replication-competent 
clones is that the non-productive clones contain inactivating mutations. However, 
extensive sequencing has been carried out for each clone, including across each of the 
five hypervariable regions and across part of gp4l (chapter 5; section 5.4). This totalled 
16kb of sequencing but did not reveal any inactivating mutations. It is, however, 
conceivable that mutations lie within the unsequenced regions of the env gene. But if 
there is a high incidence of inactivating mutations, we would expect these to show a 
random distribution across the env gene and not be limited to the unsequenced regions. 
To investigate further the presence of inactivating mutations, the full sequence of two 
of the non-infectious clones (A.1 and C. 1) was obtained (chapter 5; section 5.4). Each 
was found to encode a full open reading-frame with no obvious inactivating mutations. 
A more detailed examination of the possibility of inactivating mutations in these clones, 
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is described separately below (section 7.10). 
Closer inspection of the deduced amino acid sequences of the third hypervariable region 
(V3) from each of the ten clones, reveals an interesting result: the two fully-infectious 
clones have V3 loops predicted to confer an SI and a T-cell-line tropic phenotype. In 
contrast, the non-infectious clones and the two partially infectious clones have V3 loop 
sequences predicted to confer an NSI and a non-T-cell-line phenotype (chapter 5; 
section 5.5). Firstly, this result goes against the hypothesis that the majority of the non-
infectious clones contain inactivating mutations - if there are inactivating mutations in 
these clones, we would not expect these mutations to be limited to clones of an NSI-
type. In addition, the non-infectious clones are derived from the early (1987) blood 
sample and the later sample (1990). The infectious clones are both from 1989 samples. 
Again, it would be difficult to see why inactivating mutations should limited to clones 
these two sample dates. 
Isolates that are 'NSI' have a number of biological properties that are different from 
'SI' isolates (Asjo et al, 1986; Fenyo et al, 1989). In general, NSI isolates can grow in 
monocyte-derived macrophage cultures, T-cells, but not T-cell-lines. They frequently 
have a lower replicative ability, that is, produce p24, or reverse transcriptase (RT), at 
a lower rate in vitro than SI isolates. In contrast, SI isolates generally grow poorly in 
monocyte-derived macrophages, but replicate well in T-cells and particularly well in T-
cell-lines. 
It is conceivable, then, that a similar difference in replicative capacity exists between 
the 'NSI-like' clones and the SI clones of this study, which renders the NSI-like clones 
very slow growing in vitro. Slow/low viruses that grow in T-cells but cannot be 
passaged, have been described by Asjo et al, 1986 and Fenyo et al, 1989. These viruses 
may be similar to the three poorly-growing clones of this study (E.1, F.1 and P.2). 
However, the remaining NSI-like viruses of this study, did not show convincing 
evidence of virus replication. 
It may be that the vector, pHXB2-MCS, is unable to support the growth of NSI-like 
sequences. One way to examine whether pHXB2-MCS is able to produce replication- 
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competent viruses with NSI sequences, would be to substitute the env gene from a well-
characterised NSI clone such as YU2, ADA, SF162 or 89.6 (Li et al, 1992; Cheng-
Mayer et al, 1991, Coilman et a!, 1992) into pHXB2-MCS. We were, however, unable 
to do this, partly due to the unavailability of these clones, but also due to technical 
difficulties with cloning into pHXB2-MCS. In addition, many well-characterised NSI 
isolates are studied because of their high replicative ability, and may not represent NSI-
like primary isolates. 
If such an incompatibility exists between NSI-like sequences and pHXB2-MCS, we 
hypothesised that it may be due to the formation of a hybrid envelope protein arising 
from the substitution of the 1.7kb env fragment (cassette 1). In the ten '1.7kb' clones, 
the gp4l transmembrane protein is hybrid between the pHXB2-MCS and the patient 
sequences (chapter 3: figure 3.2); residues from the HXB2 gp41 part may be unable to 
interact correctly with the patient gp4l and gpl20 sequences. 
To prevent a hybrid gp4l, two further clones with patient-derived NSI-like sequences 
were constructed. The first (P.2), has the whole of the env gene derived from the 
patient, and the second (A.3), has just gpl2O derived from the patient (chapter 4; 
sections 4.2.4. and 4.2.5). Each has a V3 loop predicted to confer an NSI phenotype. 
The latter clone (A.3) was found to be non-infectious, but clone P.2 was minimally-
infectious, but could not be passaged. 
To test further the hypothesis that SI-like sequences can form infectious viruses with 
pHXB2-MCS, four more clones, this time with SI-like sequences, were constructed 
(K.1, L.1, M.1, N.1; chapter 4, section 4.2.3). These were constructed with Taq 
amplified env sequences from the 1989A DNA sample. However, virus replication could 
not be detected following transfection into COS-PBMCs or T-cell lines. Although these 
results do not support the 'SIINSI' hypothesis, these clones may have incorporated 
inactivating mutations due to the high rate of mutations associated with Taq polymerase. 
Three clones (Q.2, R.2, S.2) were generated by exchanging the whole of the env gene 
for sequences obtained from the 1989A DNA sample. Each of these produced infectious 
viruses. The V3 loop of one (R.2) has been obtained and shows an SI-like sequence 
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(chapter 5; section 5.5) supporting the hypothesis that only SI sequences are replication 
competent. 
However, in a final set of experiments we were unable to detect infectious viruses from 
two clones incorporating a 1.7kb fragment of the env gene of the infectious, SI, 
molecular clone SF2MC. Similarly, the 2.5kb provial fragment from SF2MC expressed on 
the pHXB2-MCS background failed to support virus replication, even though this 
fragment contains the entire env gene from SF2MC. An inactivating mutation may have 
been introduced during the cloning, or there may be a requirement for accessory genes 
absent in pHXB2-MCS. 
Indeed, with each of the non-infectious clones, a deficiency may reside with pHXB2-
MCS, which has inactivating mutations in vpu, vpr and nef genes (Myers et al, 1991). 
These 'accessory' genes may be required to form infectious particles with the NSI-like 
env sequences of this study and with 52MC  env gene. The role of accessory genes is 
discussed further in section 7.11, below. The most direct way to test this hypothesis 
would be to express the env genes on another full-length HIV- 1 clone, such as FIIV-
1Y'J2' HIV4SF162, HIV-1869, HIV-'. F (Li et a!, 1992; Cheng-Mayer et a!, 1990; 
Coffman et al, 1992). Again this was thwarted due to cloning difficulties, time restraints 
and poor accessibility of published molecular clones. 
7.10 Discussion on the Functional Ability of env Genes 
Amplified Directly from PBMC DNA 
Although no inactivating mutations were found by sequence analysis, if the non-
productive clones contain inactivating mutations then it will be important to recognise 
where these came from. There are two main sources of inactivating mutations: firstly, 
mutations could have been introduced into the env genes during the process of PCR 
amplification and cloning (ie artefactual error), or secondly, the env variants as they 
were present in the PBMCs prior to amplification, could be defective (ie. defective 
proviruses). 
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7.10.1 Artefactual Error 
One of the most obvious sources of artefactual error is the error-prone process of PCR-
amplification used to amplify the env genes from PBMC DNA. Errors may have arisen 
by nucleotide mis-incorporation, or by the production of artefactual hybrid molecules 
by recombination in vitro (Meyerhans et al, 1990). In this study, the mis-incorporation 
of nucleotides was reduced through the use of Pfu DNA polymerase in place of the 
more commonly used Taq DNA polymerase. The error rate of Pfu polymerase, 
calculated in this study, was less than one error in 16kb of amplified and cloned DNA. 
This error-rate was considered low enough to allow the amplification of env gene 
sequences from PBMC DNA without the introduction of errors. The production of 
artefactual recombinant molecules was reduced by amplifying each proviral sequence 
in a separate reaction tube (chapter 4). 
Artefactual errors could also occur through the two cloning steps subsequent to the PCR 
amplification, that is, the cloning of the amplified env gene sequences into the 
subcloning vector (pNBXXenv), and the transfer of the cloned env genes to the 
proviral vector (pHXB2-MCS). There are two main sources of error associated with 
cloning: firstly, the exposure of the DNA to mutagenic UV light - required in this study 
to isolate the cloned env gene sequences prior to cloning into the proviral vector; and 
secondly, the propagation of the cloned sequences in E.coli, where it has been shown 
that HIV- 1 proviral sequences can often be unstable and may contain bacterial insertion 
sequences (Kusumi et al, 1992). 
Point mutations introduced during the cloning steps may have gone unnoticed, although 
large DNA re-arrangements would have been detected following the restriction-mapping 
of each clone. In this study, the E.coli strain DL655F' (chapter 2, section 2.4) was 
found to be capable of stably propagating both env gene subclones, and the larger full-
length proviral clones. 
7.10.2 Defective Proviruses 
It is also possible that the cloned env gene variants were derived from a subset of 
defective proviral sequences that were present in the original PBMC sample. It has 
often been argued from the frequent detection of stop codons from clones amplified 
from PBMC DNA, that many of the proviral sequences found in vivo are defective 
(Meyerhans et al, 1989; Kusumi et al, 1992; Li et al, 1992; Sabino et a!, 1994). 
However, most of these reports used Taq polymerase to amplify the sequences, which 
as has been described above, is associated with a high error rate. In other studies, very 
few inactivating mutations were found in the PBMC population (Balfe et a!, 1990, 
Burns and Desrosiers, 1991). 
It has also been argued from the observation of the long term survival of HIV- 1 variants 
in the PBMC population, that these may be defective proviruses (Simmonds et al, 1991; 
Haigwood et al, 1993; Zhang et al, 1993; Kusumi et al, 1992). For example, in the 
analysis of Simmonds et al, 1991, of the V4 and V5 hypervariable regions of the env 
gene from sequential PBMC and plasma samples, it was found that proviral variants 
may be found for up to three years after they were found in the plasma (see chapter 5). 
From this observation, the authors have argued that many PBMCs represent long-term 
infected cells, which survive infection because they harbour defective proviruses. 
Indeed, as described in chapter 5, many of the cloned variants obtained in this study 
were cloned from PBMC DNA samples at time-points when the corresponding variants 
were not found in the plasma. It could be argued, therefore that these clones were 
derived from defective proviral sequences. However, three of the viable clones 
constructed in this study: 82.24 (G.1), 123.14 (H.1) and 82.04 (R.2), were cloned from 
PBMC samples taken at dates in which the equivalent sequence was not found in the 
plasma. Therefore, at least in these cases, this argument does not hold. 
There have been a number of investigations determining the proportion of infectious 
proviruses in PBMCs (Brinchman et a!, 1991; Simmonds et a!, 1990a; Bienasz et a!, 
1993). These studies were carried out by measuring the infectious viral load in PBMCs 
by limiting-dilution culture, and comparing this figure to the number of proviral DNA 
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copies in the original sample, calculated by a quantitative PCR method. By assuming 
that each infected PBMC harbours a single provirus, (the figure estimated by Simmonds 
et al, 1990a and Brinchman et a!, 1991), it is possible to produce a ratio of the number 
of infectious proviruses to the number of proviral sequences. In the study of Brinchman 
et al, 1991 and Simmonds et a!, 1990a, the ratio was found to be high - ranging from 
between one infectious provirus to every five proviral DNA copies (1:5), to one 
infectious copy for each proviral sequence (1:1). From these studies it would appear that 
a high proportion of proviruses found in PBMCs are infectious. However, in a more 
extensive study of Bienasz et a!, 1993, a much wider variation was found, of between 
one infectious provirus to each proviral copy (1:1), to one infectious copy for every 
1000 proviral copies (1:1000). Clearly, therefore, it is possible that the large majority 
of proviruses are incapable of producing infectious viruses. However, the number of 
infectious proviruses calculated by limiting-dilution culture, may be an underestimate. 
It may be the case that not all viable viruses can replicate to detectable levels in culture. 
In addition, the presence of CD8+ T lymphocytes in the PBMC cultures, has been 
shown to suppress the expression of Hill-i (Cocchi et a!, 1995). This would lead to an 
underestimate of the number of infectious proviruses present. 
7.10.3 Alternative Approaches to Obtaining Env Genes from 
Patient Material 
If the majority of PBMC-derived proviral genomes are defective, then it may be 
necessary, in future work, to screen the cloned env genes for an intact-reading frame, 
or indeed, clone the env genes from another source. 
It may be possible to screen for an intact reading-frame using in vitro 
transcription/translation systems (as described in chapter 4). Alternatively, eukaryotic 
expression vectors such as pSVIIIenvCAT (Helseth et al, 1990a), or a vaccinia virus 
expression vectors could be used to screen for a full-length gp160. 
PBMCs may be cultured for a limited number of passages, in order to increase the 
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proportion of infectious proviruses prior to cloning (Groenink et al, 1991). Culturing 
should stimulate virus replication and increase the proportion of viable viruses. 
However, a major disadvantage of this approach is that culturing greatly reduces the 
variation of the virus population (Kusumi et al, 1992; Sabino et al, 1994). Therefore, 
following culturing, it is unlikely that the full-spectrum of variants will be represented. 
An alternative approach would be to carry out limiting-dilution culturing, as has been 
described by Schuitemaker et a!, 1992; Connor et al, 1993a and Bienasz et al, 1993. 
Through limiting-dilution, each HIV- 1 positive culture should be initiated from a single 
infectious unit, and this should reduce competition between variants and the selection 
of the fastest-replicating viruses. However, this method selects those variants best 
adapted to culture conditions. Very low replicating variants may be missed. 
Another source of env genes is the virion-associated RNA found in the plasma. It has 
been argued that plasma variants will represent actively replicating sequences, and 
therefore, should contain a higher proportion of infectious viruses (Simmonds et al, 
1991). However, it is currently, exceedingly difficult to amplify and clone long stretches 
of genomes from an RNA source. 
7.11 Discussion on the use of pHXB2-MCS as a Cassette-
Vector 
If the sequences of env genes must be SI-like to produce rapidly-growing viruses in the 
recombinant system developed in this study, then this may be due to the choice of 
vector (pHXB2-D). pHXB2 is a laboratory-adapted, SI-virus (Fisher et al, 1985), so it 
may be expected to support only the growth of SI-variants. 
It is conceivable that certain env sequences, and in particular NSI-types, may not 
interact with the genetic elements provided by pHXB2-MCS required to form infectious 
virions. 
One of the most obvious problems of pHXB2 as an expression vector, is that it has 
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inactivating mutations in three accessory genes: vpu, nef and vpr. The Vpr protein is 
truncated - 25 amino acids shorter than other subtype B isolates due to a frameshift 
mutation. The vpu gene has no start codon, and the nef gene contains a premature 
termination codon (Myers et al, 1991). As has been demonstrated in this study, these 
three accessory genes are dispensable for the growth of HIV-1 viruses in cultures of 
PBMCs, CD4-positive T-cell-lines, and in CD4-positive T-lymphocytes (Fisher et al, 
1985; Westervelt et al, 1992b). However, recombinant studies have shown that the vpu 
and vpr genes are essential for growth in monocyte-derived macrophage cultures (Gibbs 
et al, 1994; Westervelt et a!, 1992b). These two genes have a complementary function 
in macrophage culture, such that a functional copy of only either of these genes is 
sufficient for productive infection. Vpr contains a nuclear localisation signal, which 
connects the pre-integration complex to the cell nuclear import pathway, which is 
necessary for replication in non-dividing cells, such as the macrophage (Heinzinger et 
al, 1994). 
It could be hypothesised that the lack of vpu and vpr in pHXB2-MCS, will prevent 
productive infection with certain env variants, if these variants are only capable of 
productive infection in monocyte-derived macrophages. However, the majority of 
primary isolates are 'dual tropic' and can productively infect both macrophage cultures 
and PBMCs and CD4+ T-lymphocytes (Connor et a!, 1993b, 1994; Schuitemaker et a!, 
1991, 1992 and Valentin et a!, 1994). Therefore, it is unlikely that the absence of vpu 
and vpr will have prevented the replication of the viruses in this study which have 
predicted NSlJmacrophage-tropic phenotype, because these should grow in PBMCs, and 
as such, should not show a requirement for vpu and vpr. 
The proviral clone pHXB2 has been used quite extensively by other groups to generate 
recombinant clones to examine the function of the accessory genes (Westervelt et a!, 
1992b; Fisher et a!, 1986), and properties of various lilY-i env genes (Sullivan et a!, 
1995; De Jong et a!, 1992a and 1992b). Several of these have shown that pHXB2 can 
generate infectious viruses with full-length env gene sequences of an NSlJmacrophage 
(non-T-cell-line) tropic phenotype, without altering the defective genes vpr, vpu and nef 
(Westervelt et al, 1992b; Sullivan et a!, 1995). For example, the env gene from the 
prototype macrophage-tropic clone 'ADA', when expressed on an HXB2-background, 
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forms recombinant viruses that grow well in PBMCs but not macrophages (Westervelt 
et al, 1992b). Sullivan et al, 1995, used a defective virus pHXBenvCAT - an env gene-
defective derivative of pHXB2 (Helseth et al, 1990a), to assess the ability of a number 
of envelope glycoproteins (from both primary and laboratory-adapted strains), to 
complement virus entry. When the env genes were transfected together with 
pHXBenvCAT, recombinant viruses capable of infecting CD4+ T-lymphocytes, and 
SupTi cells, were generated. Five envelope glycoproteins were used: two from primary 
macrophage-derived/NSI clones 'ADA', 'YU2' (Li et al, 1992), and two from 
laboratory-adapted isolates HXB2, 'MN' (Shaw et al, 1984; Fisher et at, 1985), and one 
from an unusual cytopathic macrophage-tropic isolate '89.6' (Coliman et al, 1992). 
Although this study used the env gene of primary isolates, each clone was selected for 
its high replicative ability to facilitate the production of virus stocks, and may not be 
representative of the majority of viruses found in vivo. 
Iversen et al, 1995, exchanged the entire env gene of molecular clone pNL4-3 (which 
is also from the same isolate as pHXB2-D: HIV- l) with four sequences amplified 
directly from PBMC DNA, and this resulted in the production of four non-infectious 
viruses. Replication could not be detected in peripheral blood lymphocytes nor 
monocyte-derived macrophages. Each clone had an open reading frame in gpl60, but 
an attenuating point mutation in the rev gene contained within the exchanged region. 
In this study, the cassette-vector pHXB2-MCS was designed specifically to allow 
exchange a 1.7kb fragment of the env gene. This fragment does not include any open 
reading frames of rev, tat, vpu or nef (chapter 3). 
In our pHXB2-MCS system, PBMC-derived SI-sequences produced rapidly-growing 
viruses when the whole env gene was replaced (cassette-2) and when the env gene was 
hybrid (cassette-2 - with gpl20 and the N-terminal third of gp4l exchanged). The non-
infectious or slowly-growing viruses were constructed with either a hybrid env gene 
(cassette-1 and -3) or a full env gene (cassette-2) from an NSI variant (chapter 6). In 
this case, it would appear that the region exchanged (cassette- 1, -2 or -3) is not a major 
factor contributing to the infectivity of the resultant recombinant viruses. 
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The Cellular Host-Range of NSI Variants 
It could also be argued that the recombinant viruses expressing predicted-NSI sequences 
are not capable of growth in the cell types in which we have attempted to propagate 
them, namely PBMCs and transformed CD4+ cell lines. 
We have no information concerning the cell type in the PBMCs from which the 
sequences were derived. The DNA used to obtain the sequences was extracted from 
unfractionated buffy-coat. The cell types infected in vivo in peripheral blood appear to 
be mainly CD4+ T lymphocytes of the memory cell subtype (Schnittman et al, 1989 
and 1990). Other reports have indicated the presence of HIV-1 sequences in monocytes 
and dendritic cells but only at very low levels (Knight et al, 1990). It is conceivable 
therefore, that the env sequences obtained in this study, were derived from viruses 
showing exclusive tropism for monocytes, or for dendritic cells. These cells may form 
such a low proportion of PBMCs that viral replication cannot occur to detectable levels. 
With the recent discovery of the co-receptors required for HIV-1 infection, CD4+ cell 
lines expressing these receptors may facilitate virus infection and replication. 
Whilst it is clear from the work described in this thesis, that the construction of viable 
recombinant viruses with env genes taken directly from PBMC is difficult, this type of 
approach will be necessary in studying the property of viruses, especially where the 
isolation through cell culturing is not possible or is undesirable. 
For example, to study virus found in different organs at post-mortem from which virus 
isolation is difficult. It is, similarly, difficult to obtain viral isolates from patients with 
low viral load, such as is frequently found in patients at the early asymptomatic stage 
of infection, or in long-term non-progressors where proviral load is often measured as 
below 1 copy per 20,000 PBMCs (Haigwood et al, 1993; Cao et al, 1995). These 
viruses may show interesting in vitro properties, which confer a low level replication 




Appendix A Solutions and Media 
2xTY-broth 
Per liter: 
16g tryptone (Oxoid) 
lOg yeast extract (Oxoid) 
5g NaCl (Sigma) 
Adjust to pH 7.0 with 10M NaOH 
For 2xTY-agarose plates: 
lOg agarose (BRL) 
TE 
10mM Tris, pH 8.0 
1mM EDTA, pH 8.0 
TBE lOx 
89mM Tris-base 
89 mM boric acid 
3mM EDTA 
TfbI 
30m mM potassium acetate 
100 mM RbCl 
10 mM CaCl2 
50 mM MnC12 
15 % glycerol 
adjust to pH 5.8 with 0.2 M acetic acid and sterilise by filtration. 
TfbII 
10 mM PIPES 
10 mM RbC1 
75 mM CaCl2 
15% glycerol 
Adjust to pH 6.5 woth KOH and sterilise by filtration. 
STET 
8% w/v sucrose 
0.5% v/v Triton X-100 (Sigma) 
50 mM EDTA pH8.0 
50 mM Tris pH 8.0 
Ficoll Stop Buffer (FSB) 
100 mM EDTA 
20% w/v Ficoll Type 400 
0.05% w/v bromophenol blue 
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6% Polyacrylamide Sequencing gel 
Ligase lOx buffer (Boehringer) 
500mM Tris, pH 7.6 
100 MM  MgC12 
10 m ATP 
KGB W Glutamate Buffer) lOx (McClelland et al, 1988) 
1M potassium glutamate 
100mM Mg acetate 
500ug/ml bovine serum albumen 
5mM -mercaptoethanol 
filter sterilise and store at 4°C 
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Appendix B Restriction Sites of HXB2R 
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HXB2R RESTRICTION SITES 
SEQUENCE RANGE: 1 to 9265 
Enzyme #Cuts Positions 
Aatl 2 4953 6380 
Acci 8 506 1225 2474 3936 4377 4624 	4879 	5333 
Acc3 1 8939 
Af12 4 63 4289 5180 9148 
Afl3 3 5601 6051 7044 
Ahal 3 1402 6428 8868 
Aha3 11 790 886 1336 2088 3133 3262 	4080 	4330 
6156 6795 8614 
A1wN1 6 693 4938 7462 7546 8237 9052 
Apal 1 1556 
Apall 1 6160 
Asel 2 5043 6651 
Asp718 4 3372 3700 5893 8561 
Aval 3 7939 8443 8926 
Ava3 6 797 2437 3601 3927 6084 6292 
Avr2 3 1557 4977 5207 
Ball 2 2167 4099 
BamHl 1 8021 
Ban3 1 377 
Bbel 1 187 
Bell 1 1975 
Bg12 6 19 1642 6587 7167 8597 9104 
Bsml 3 1177 7606 
BspMl 2 3864 4592 
BspM2 1 8939 
BssH2 1 257 
BatXI 5 1181 1920 2550 2778 3954 
Bau361 4 1800 5502 6862 8557 
Cori 1 8443 
Cfrl 3 1403 2165 4097 
CfriOl 2 1228 4139 
Gal 1 377 
Cviii 4 1800 5502 6862 8557 
Dral 11 790 886 1336 2088 3133 3262 	4080 	4330 
6156 6795 8614 
Dra3 2 6146 8843 
EcoNi 2 5517 7182 
EcoRl 2 4194 5289 
EcoR5 3 2525 8666 8745 
EcoT221 6 797 2437 3601 3927 6084 6292 
Espi 1 8410 
Hinc2 4 3044 3067 6334 6348 
Hund3 6 77 631 1258 5573 7687 9162 
Hphi 10 301 769 2441 2553 3487 4129 	4520 	4616 
7003 7899 
Kpnl 4 3376 3704 5897 8565 
Mrol 1 8939 
Mst2 4 1800 5503 6852 8557 
Narl 1 184 
Ncol 1 5221 
Ndei 2 4669 5950 
Nhel 1 6806 
Nail 6 797 2437 3601 3927 6084 6292 
PaeR71 1 8443 
Pfiml 2 3038 4849 
PflM1 2 3038 4849 
Pstl 1 965 
Pvu2 6 693 2847 3891 6631 8592 9066 
Sad 4 37 228 5550 9122 
Sall 1 5332 
Saul 4 1800 5502 6862 8557 
Scal 7 2299 2418 3771 6949 6964 6973 	8946 
Spel 1 1053 
Sphl 1 993 
Sspl 4 2571 5705 7114 8153 
Sstl 4 37 228 5550 9122 
Stul 2 4953 6380 
Xhol 	1 	8443 






























Appendix C Fragment sizes produced upon single-enzyme 
digestion of full-length recombinant proviral clones 
Key of restriction patterns following sinlge digest with BsmI, HindIll, KpnI, SspI 
clone BsmI Hinciffi KpnI SspI 
pHXB2.MCS H H H H 
A 2A H H H 
B 2A H H H 
C H H H H 
D 2A 1A 1A H 
E 2A H H H 
F 2A 1A H H 
G 1A 1A H H 
H 1A 1A H H 
I H H lB 1A 
V H 1A H lB 
J lB H H H 
P 2A 1A H 2A 
Q 2A 1A H 2A 
R 1A 1A 1A 2A 
S 2A 1A H 2A 
H, 1A, lB and 2A are (arbitrary) names for restriction-fragment patterns. (Patterns 
labelled H are identical to pHXB2-MCS. 1A and lB are patterns produced when 
there is a single site within the cassette-region, and patterns labelled 2A are those 
generated when their are two sites within the cassette). 
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B sml 
H 1A lB 2A 
6429 	(V) "-6100 	(C) 8929 	(V) -'-6100 	(C) 
"-6100 (C) 5004 (V) -6100 (C) 5004 (V) 




4315 (C)/-4300 	(C) 	doublet 4315 (C)/-4300 	(C) 	doublet 
-2500 (C) -2500 (C) 
2114 (V) "-1800 (C) 
-1800 (C) 1599 (V) 
1475 (C) 1475 (C) 
627 (V) 627 (V) 
-550 (C) --550 (C) 
531 (V) 
Kpn I 
H 1A lB 
-10050 	(C) -10050 	(C) -10050 	(C) 
2668 (V) 4885 (V) 3161 (V) 
2193 	(V) 328 	(C) 1641 	(V) 
328 (C) 1 1 	328 (C) 
Ssp I 
H 1A lB 2A 
-3300 (C) -3300 (C) -3300 (C) -3300 (C) 
3134 (C) 3134 (C) 3134 (C) 3134 (C) 
--2500 (C) -2500 (C) -2500 (C) -2500 (C) 
-1800 (C) --1800 (C) 	/1870 	(V) 	doublet 2448 (V) -1800 (C) 
1409 (V) -600 (V) --1800 (C) 1409 (V) 
1039 (V) -550 (C) -550 (C) 650 (V) 
-550 (C) -550 (C) 
--350 (V) 
(V) Vector: are restriction-fragments mapping outside the cassette, and are therefore 
constant. 
(C) Cassette: are the variable, restriction-fragments contained entirely within, or 
spanning, the cassette. 
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Appendix D Nucleotide Sequences of the env Gene Clones 
Taq-amplified sequences: 
V4-C4 (primer 407 sense) 
clone 1 50 
P0821013407 CTTGGAATTC APCATGGGAT TTAACACAAC TTAATAGTAC TCAGAATAAA 
P0821022407 CTTGGAATTC AACATGGGAT TTAACACAAC TTAATAGTAC TCAGAATAAA 
P0820611407 .......... ..... gggat ttaacacaac ttaatagtac ccagaataaa 
P0820612407 .......... ..... GGGAT TTAACACAAC TTAATAGTAC CCAGAATAAA 
51 * * 	100 
P0821013407 GAAGAAAATA TCACACTCCC ATGTAGAATA AAACAAATTA TAAACATGTG 
P0821022407 GAAGAAAATA ACACACTCCC ATGTAGAATA AAACAAATTA TAAACATGTG 
P0820611407 gaagaaaata tcacactccc atgtagaata aaacaaatta taaacatgtg 
P0820612407 GAAGAAAATA TCACACTCCC ATGTAGAATA AAACAAATTA TTAACATGTG 
101 150 
P0821013407 GCAGGAAGTA GGAAAAGCAA TGTATGCCCC TCCCATCAGA GGACAAATTA 
P0821022407 GCAGGAAGTA GGAAAAGCAA TGTATGCCCC TCCCATCAGA GGACAAATTA 
P0820611407 gcaggaagta ggaaaagcaa tgtatgcccc tcccatcaga ggataaatta 
P0820612407 GCAGGAAGTA GGAAAAGCAA TGTATGCCCC TCCCATCAGA GGACAAATTA 
151 200 
P0821013407 GATGTTCATC ATATTACA GGGCTACTAT TAACAAGAGA TGGTGGTAAT 
P0821022407 GATGTTCATC AAATATTACA GGGCTACTAT TAACAAGAGA TGGTGGTAAT 
P0820611407 gatgttcatc aaatattaca gggctactat taacaagaga tggtggtaat 
P0820612407 GATGTTCATC APTATTACG GGGCTACTAC TAACAAGAGA TGGTGGTAAT 
201 250 
P0821013407 AGTGGTAACA AAAGCAPCG. .......... .......... 	.......... 
P0821022407 AGTGGTAACA PAGCAACGA CACCACCGAG ACCTTCAGAC CTGGGGGAGG 
P0820611407 agtggtaaca aa ...................................... 
P0820612407 AGTGGTAACA AAAGCA 	................................. 
251 276 
P0821013407 
P0821022407 AGATATGAGG GACAATTGGA GAAGAG 
P0820611407 
P0820612407 
V3 region (primer 307 antisense) 
clone 	1 	 * 	50 
P0820612307 TCTTAATTTT ATAACTATCT GTTTTAAAGT TTCATTCCAT TTTGCTCTAC 
P0820611307 TCTTAATTTT ATAACTATCT GTTTTAAAGT TTCATTCCAT ATTGCTCTAC 
51 	 * 	 100 
P0820612307 TAATGTTACA ATGTGCTTGT CTTATATTTC CTATTATTTG TTCTGTTGTA 
P0820611307 TAATGTTACA ATGTGCTTGT CTTATATTTC CTATTATTCG TTCTGTTGTA 
101 	 150 
P0820612307 TAP.ACTGCTC TCCCTGGTCC TATATATATC CTTTTTCTTG TATTGTTGTT 
P0820611307 TAAACTGCTC TCCCTGGTCC TATATATATC CTTTTTCTTG TATTGTTGTT 
151 	 168 
P0820612307 GGGTCTTGTA CAAGTAAT 
P0820611307 GGGTCTTGTA CAAG. 
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Pfi4-amplified sequences: 
a) The V1-V2 hypervariable regions (primers 402 and 403) 
clone 	1 	 50 
P1081827402 . . gttaaccc cactctgtgt tactttaaat tgcactgatt gggggaatgc 
P1081828402 .......... ..... TGTGT TACTTTAAAT TGCACTGATT GGGGGAATGC 
P1081103402 .......ccc cactctgtgt tactttaaat tgcactgatt gggggaatgc 
P1081107402 .......ccc ctctctgtgt tactttaaat tgcactgatt gggggaatgc 
P1081006402 .......... .... ctgtgt tactttaaat tgcactgatt tggggaatgc 
P1081007402 . . . ttaaccc cactctgtgt tactttaaat tgcactgatt tggggaatgc 
P1081501402 .......ccc cactctgtgt tactttaaat tgcactgatt tgaggaatgc 
P1081504402 .......CCC CACTCTGTGT TACTTTAAAT TGCACTGATT TGAGGAATGC 
P1081733402 AAATTAACCC CACTCTGTGT TACTTTAAAT TGCACTGATT TGGGGAATGC 
P1081906402 .......... ......... t tactttaaat tgcactgatt tgaggaatgc 
P0120810402 .......ccc cactctgtgt tactttaaat tgcactgatt gggggaatgc 
P0121604402 	.......... .......... 	....... ................agaatgc 
P0121614402 .......... .......... ...... aaat tgcactgatt gggagaatgc 
P0822407402 AAATTAACCC CACTCTGTGT TACTTTAAAT TGCACTGATG TGAGGAATGC 
P1231410402 .AATTAACCC CACTCTGTGT TACTTTAAAT TGCACTGATG TGAGGAATGC 
P1231411402 	.......... .......... .......... . gcactgatg tgaggaatgc 
51 	 100 
P1081827402 tactaatacc aatag ..... .......... ......... t agtagtgggg 
P1081828402 TACTAATACC AATAG ..... .......... ......... T AGTAGTGGGG 
P1081103402 tactaatatc aataa ..... .......... ......... t agtagtgggg 
P1081107402 tactaatatc aataa ..... .......... ......... t agtagtgggg 
P1081006402 tactaatatc aataa ..... .......... ......... t agtagtgggg 
P1081007402 tactaatatc aataa ..... .......... ......... t agtagtgggg 
P1081501402 tactaatacc aataatgc.. .tactaat.c ca .atagt agtagttggg 
P1081504402 TACTAATACC AATAATGC.. .TACTAATAC CA. .ATAGT AGTAGTTGGG 
P1081733402 TACTAATATC AATAA ..... .......... ......... T AGTAGTGGGG 
P1081906402 tactaatacc aataatgc.. .tactaatac ca .atagt agtagttggg 
P0120810402 tactaatatc aatag ..... .......... ......... t agtagtgggg 
P0121604402 tactaatacc . . .aatgc.. .tactaatac ca .atagt agtagtgggg 
P0121614402 tactaatgct actaatacca atgctactaa taccaatagt agtagtgggg 
P0822407402 TACTAATGCC AATAATGC.. .TACTATAC CACTAGTAGT AGTATTGGGA 
P1231410402 TACTAATGCC AATAATGC.. .TACTAATAC CAC .TAGT AGTATTGGGG 
P1231411402 tactaatgcc aataatgc.. .tactaatac cac .tagt agtattgggg 
101 	 150 
P1081827402 aaacgatgag aggagaaata aaaaactgct cTttcaatat caccacaagt 
P1081828402 AAACGATGAG AGGAGAAATA AAAAACTGCT CTTTCAATAT CACCACAAGT 
P1081103402 aaccgatgag aggagaaata aaaaactgct ctttcaatat caccacaagt 
P1081107402 aaccgatgag aggagaaata aaaaactgct ctttcaatat caccacaagt 
P1081006402 aaccgatgag aggagaaata aaaaactgct ctttcaatat caccacaagt 
P1081007402 aaccgatgag aggagaaata aaaaactgct ctttcaatat caccacaagt 
P1081501402 aaaagatgag aggagaaata aaaaactgct ctttcaatat caccacaagt 
P1081504402 AAAAGATGAG AGGAGAAATA AAAAACTGCT CTTTCAATAT CACCACAAGT 
P1081733402 AACCGATGAG AGGAGAAATA AAAAACTGCT CTTTCAATAT CACCACAAGT 
P1081906402 aaCCGATGAG AGGAGAAATA AAAAACTGCT CTTTCAATAT CACCACAAGT 
P0120810402 aaccgatgag aggagaaata aaaaactgct ctttcaatat caccacaagt 
P0121604402 aagagatgag aggagaaata aaaaactgct ctttcaatat caccacaagt 
P0121614402 aagagatgag aggagaaata aaaaacagct cttcaatat. .......... 
P0822407402 AAGAGATGAG AGGAGAAATA AAAAACTGCT CTTTCAATAT CACCACAAGT 
P1231410402 AAGAGATGAG AGGAGAAATA AAAAACTGCT CTTTCAATAT CACCACAAGT 
P1231411402 aagagatgag aggagaaata aaaaactgct ctttcaatat caccacaagt 
151 	 200 
P1081827402 ataagagata aggtgCagaa agaatatgca cttttttata aacttgatgt 
P1081828402 ATAAGAGATA AGGTGCAGAA AGAATATGCA CTTTTTTATA AACTTGATGT 
P1081103402 ataagagata aggtgcaaaa agaatatgca cttttttata aacttgatgt 
P1081107402 ataagagata aggtgcaaaa agaatatgca cttttttata aacttgatgt 
254 
P1081006402 ataagagata aggtgcagaa agaatatgca cttttttata aacttgatgt 
P1081007402 ataagagata aggtgcagaa agaatatgca cttttttata aacttgatgt 
P1081501402 ataagagata aggtgcagaa agaatatgca cttttttata a......... 
P1081504402 ATAAGAGATA AGGTGCAGAA AGAATATGCA CTTTTTTATA ACTTGATGTA 
P1081733402 ATAAGAGATA AGGTGCAGAA AGAATATGCA CTTTTTTATA AACTTGATGT 
P1081906402 ATAAGAGATA AGGTgCAGAA AGAATATGCA CTTTTTTATA AACTTGATGT 
P0120810402 	ataag ..... 	.......... 	.......... 	.......... 	.......... 
P0121604402 ataagagata aggtgcagaa agaatatgca cttttttata aacttgatgt 
P0121614402 
P0822407402 ATAAGAGATA AGGTGCAGAA AGAATATGCA CTTTTTTata aacttgatgt 
P1231410402 ATAAGAGATA AGGTTGCAGA AAGAATATCA CTTTTTTATA AACTTGATGT 
P1231411402 ataagagata aggtgcagaa agaatatgca cttttttata aacttgatgt 
201 	 250 
P1081827402 	agtaccaa .......................................... 
P1081828402 AGTACCAATA GATGAGGATA ATaCTAAT ...................... 
P1081103402 agtaccaata gatgaggata atactaatac cagctatagg ttata ..... 
P1081107402 agtaccaata gatgaggata atactaatac cagctatagg ttgatagttg 
P1081006402 agtaccaata gatgaggata atactaatac cagctatggt tgataag... 
P1081007402 agtaccaata gatgaggata atactaatac cagctatagg ttg....... 
P1081501402 
P1081504402 
P1081733402 AGTACCAATA GATGAGGATA ATACTAATAC CAGCCAGCTA TAGGTT. 
P1081906402 AGTACCAATA GATGAGGATA ATACTAATAC CAGCTATAGG TTgATAAGTT 
P0120810402 
P0121604402 agtaccaata gatgaggata atactaatac cagctatagg ttgataagtt 
P0121614402 
P0822407402 agtaccaata gatgaggata atactaatac cagctatagg ttgataagtt 
P1231410402 AGTATTAATA GATGAGGATA ATACTAATAC CACCGCTATA GGTTGATAA. 
P1231411402 agtaccaata gatgaggata at ............................ 










P1081906402 GTAATACCTC AGTCATTACA CAGG... 
P0120810402 
P0121604402 gtaatacctc agtcattaca caggcct 
P0121614402 
P0822407402 gtaatacctc agt .............. 
P1231410402 
P1231411402 
1 	 50 
P1081828403 
P1081501403 





51 	 100 
P1081828403 .GGGATACCT TTGGACaggc ctgtgtaatg actgaggtat tacaatttat 
P1081501403 .....tatct ttggccaggc ctgtgtaatg actgaggtat tacaacttat 
P1081504403 cataatactg gagaaaatat cacactccca tgtagaataa aacaaattat 
P0120810403 .......... ......... c ctgtgtaatg actgaggtat tacaacttat 
P0121604403 	.......... .......... .......... . ctgaggtat tacaacttat 
P1390610403 
255 
P1396b09403 	 . ctgaggtat tacaacttat 
101 	 150 
P1081828403 caacctatag ctggtattag tattatcctc atctattggt actacatcaa 
P1081501403 caacctatag ctggtattag tattatcctc atctattggt actacatcaa 
P1081504403 aaacatgtgg caggaagtag gaaaacgaat gtatgcccct cccatcagag 
P0120810403 caacctatag ctggtattag tattatcctc atctattggt actacatcaa 
P0121604403 caacctatag ctggtattag tattatcctc atctattggt actacatcaa 
P1390610403 cctcatgagc taggtattag tattatcctc atctattggt actacatcaa 
P1396b09403 caacctatag ctggtattag tattatcctc atctattggt actacatcaa 
151 
P1081828403 gtttataaaa aagtgcatat 
P1081501403 ctttataaaa aagtgcatat 
P1081504403 gacaaattag atgttcatca 
P0120810403 gtttataaaa aagtgcatat 
P0121604403 gtttataaaa aagtgcatat 
P1390610403 gtttataaaa aagtgcatat 
P1396b09403 gtttataaaa aagtgcatat 
201 
200 
tctttctgca ccttatctct tatactt... 
tctttctgca ccttatctct tatacttgtg 
aatattacgg gctactatta acaagagatg 
tctttctgca ccttatctct tatacttgtg 
tctttctgca ccttatctct tatacttgtg 
tctttctgca ccttatctct tatacttgtg 
tctttctgca ccttatctct tatacttgtg 
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P1081828403 
P1081501403 gtgatattga aagagcagtt ttttatttct cctctcatc ......... 
P1081504403 	gtggtaacaa gaac .................................. 
P0120810403 gtgatattga aagagcagtt ttttatttct cctctcatcg gtttcccc 
P0121604403 gtgatattga aagagcagtt ttttatttct cctctcatct cttcccc. 
P1390610403 gtgatattga aagagcagtt ttttatttct cctctcatct ctgcccc. 
P1396b09403 gtgacattga aagagcagtt ttttatttct cctctcatct ctgcccc. 
b) The V3 hypervariable region (primer 307 antisense) 
clone 	 1 	 50 
P1081827307 .......... ...... gttt tattcccaaa ttgttctctt aattttataa 
P1081828307 .........g actattgttt tattcccaaa ttgttctctt aattttataa 
P1081103307 
P1081107307 	.......... .......... .......... ..gttctcct aattttataa 
P1081006307 .......... ...... gttc tattcccaaa ttgttctcct aattttataa 
P1081007307 
P1081501307 	.......... .......... .......... .. GTTCTCCT AATTTTATAA 
P1081904307 .........g actattgttt tattctcaaa ttgttctctt aattttataa 
P1081906307 .......... ....... TTT TATTCTCAAA TTGTTCTCTT AATTTTATAA  
P0120810307 	.......... .......... .... cccaaa ttgttctcct aattttataa 
P0121603307 
P0121604307 .......... ...... gctt tatgcccaaa ttgttctctt aattttataa 
P0822407307 TTACTTAAAG ACTATTGTTT TATTCTCAAA TTGTTCTCTT AATTTTATAA 
P1231409307 .......AAG ACTATTGTTT TATTCTCAAA TTGTTCTCTT AATTTTATAA 
P1231410307 .......AAG ACTATTGTTT TATTCTCAAA TTGTTCTCTT AATTTTATAA 
P1231411307 .......AAG ACTATTGTTT TATTCTCAAA TTGTTCTCTT AATTTTATAA 
P1390516307 .......... ...... gttt tatTctcaaa ttgttctctt aattttataa 
P1390520307 .......... ...... GTTT TATTCTCAAA TTGTTCTCTT AATTTTATAA 
P1390501307 .......... ..... tgttt tattctcaaa ttgttctctt aattttataa 
P1390503307 .......... ..... tgttt tattctcaaa ttgttctctt aattttataa 
P1390608307 .......... ...... gttt tattctcaaa ttgttctctt. aattttataa 
P1390610307 	.......... .......... .... CTCAAA TTGTTCTCTT AATTTTATAA 
P1390611307 
P1396b09307 	.......... .......... .... CCCAPA TTGTTCTCTT AATTTTGTAA 
P1396b12307 ......gact attgttttat tattcccaaa ttgttctctt aattttgtaa 
51 	 100 
P1081827307 ctatctgtct taaagtttca ttccattttg ctctactaag gttacaatgt 
P1081828307 ctatctgtct taaagtttca ttccattttg ctctactaag gttacaatgt 
P1081103307 ctatctgtct taaagtttca ttccattttg ctctactaag gttacaatgt 
P1081107307 ctatctgtct taaagtttca ttccattttg ctctactaag gttacaatgt 
256 
P1081006307 ctatctgttt taaagtttca ttccattttg ctctactaag gttacaatgt 
P1081007307 ctatctgttt taaagtttca ttccattttg ctctactaag gttacaatgt 
P1081501307 CTATCTGTCT TAAAGTTTCA TTCCATTTTG CTCTACTAAG GTTACAATGT 
P1081904307 ctatctgttt taaagtttca ttccattttg ctctactaat gttacaatgc 
P1081906307 CTATCTGTTT TAAAGTTTCA TTCCATTTTG CTCTACTAAT GTTACAATGC 
P0120810307 ctatCTGTCT TAAAGTTTCA TTCCATtTTG CTCTACTAAG GTTACAATGT 
P0121603307 ........TT TTAAGTTTCA TTCCATTTTG CTCTACTAAG GTTACAATGT 
P0121604307 ctatctgttt taaagtttca ttccattttg ctctactaag gttacgatgt 
P0822407307 CTATCTGTTT TAAAGTTTCA TTCCATTTTG CTCTACTAAT GTTACAATGT 
P1231409307 CTATCTGTTT TAAAGTTTCA TTCCATTTTG CTCTACTAAT GTTACAATGT 
P1231410307 CTATCTGTTT TAAAGTTTCA TTCCATTTTG CTCTACTAAT GTTACAATGT 
P1231411307 CTATCTGTTT TAAAGTTTCA TTCCATTTTG CTCTACTAAT GTTACAATGT 
P1390516307 ctatctgttt taaagtttca ttccattttg ctctactaat gttacAatgt 
P1390520307 CTATCTGTTT TAAAGTTTCA TTCCATTTTG CTCTACTAAT GTTACAATGT 
P1390501307 ctatctgttt taaagtttca ttccattttg ctctactaat gttacaatgt 
P1390503307 ctatctgttt taaagtttca ttccattttg ctctactaat gttacaatgt 
P1390608307 ctatctgttt taaagtttca ttccattttg ctctactaat gttacaatgt 
P1390610307 CTATCTGTTT TAAAGTTTCA TTCCATTTTG CTCTACTAAT GTTACAATGT 
P1390611307 CTATCTGTTT TAAAGTTTCA TTCCATTTTG CTCTACTAAT GTTACAATGT 
P1396b09307 CTATCTGTTT TAAAGTTTCA TTCCATTTTG CTCTACTAAT GTTACAATGT 
P1396b12307 ctatctgttt taaagtttca ttccattttg ctctactaat gttacaatgt 
101 	 150 
P1081827307 gcttgtctta tatctcctat tatttctcct gttgtataaa atgctctccc 
P1081828307 gcttgtctta tatctcctat tatttctcct gttgtataaa atgctctccc 
P1081103307 gcttgtctta tatctcctat tatatctcct gttgtataaa atgctctccc 
P1081107307 gcttgtctta tatctcctat tatatctcct gttgtataaa atgctctccc 
P1081006307 gcttgtctta tatctcctat tatttgtcct gttgtataaa atgctccccc 
P1081007307 gcttgtctta tatctcctat tatttgtcct gttgtataaa atgctccccc 
P1081501307 GCTTGTCTTA TATCTCCTAT TATTTGTCCT GTTGTATAAA ATGCTCTCCC 
P1081904307 gcttgtctta tatctcctat tattcctcct gttgtataaa atgctctccc 
P1081906307 GCTTGTCTTA TATCTCCTAT TATTCCTCCT GTTGTATAAA ATGCTCTCCC 
P0120810307 GCTTGTCTTA TATCTCCTAT TATGTCTCCT GTTGTATAAA ATGCTCTCCC 
P0121603307 GCTTGTCTTA TATCTCCTAT TATGTCTCCT GTTGCATAAA ATGCACTCCC 
P0121604307 gcttgtctta tatctcctat tatgtctcct gttgcataaa atgcactccc 
P0822407307 GCTTGTCTTA TATTTCCTAT TATTTGTTCT GTTGTATAAA CTGCTCTCCC 
P1231409307 GCTTGTCTTA TATTTCCTAT TATTTGTTCT GTTGTATAAA CTGCTCTCCC 
P1231410307 GCTTGTCTTA TATTTCCTAT TATTTGTTCT GTTGTATAAA CTGCTCTCCC 
P1231411307 GCTTGTCTTA TATTTCCTAT TATTTGTTCT GTTGTATAAA CTGCTCTCCC 
P1390516307 gcttgtctta tatctcctat tatTcctcct gttgcataaa atgcactccc 
P1390520307 GCTTGTCTTA TATCTCCTAT TATTCCTCCT GTTGCATAAA ATGCACTCCC 
P1390501307 gcttgtctta tatctcctat tattcctcct gttgcataaa atgcactccc 
P1390503307 gcttgtctta tatctcctat tattcctcct gttgcataaa atgcactccc 
P1390608307 gcttgtctta tatctcctat tattcctcct gttgcataaa atgcactccc 
P1390610307 GCTTGTCTTA TATCTCCTAT TATTCCTCCT GTTGCATAAA ATGCACTCCC 
P1390611307 GCTTGTCTTA TATCTCCTAT TATTCCTCCT GTTGCATAAA ATGCACTCCC 
P1396b09307 GCTTGCCTTA TATCTCCTAT TATGTCTCCT GTTGCATAAA ATGCACTCCC 
P1396b12307 gcttgcctta tatctcctat tatgtctcct gttgcataaa atgcactccc 
151 	 200 
P1081827307 tggtcctata tgtatacttt ttcttgtatt gttgttggg . .......... 
P1081828307 tggtcctata tgtatacttt ttcttgtatt gttgttgggt cttgtacaat 
P1081103307 tggtcctata tgtatacttt ttcttgtatt gtt.ttggtc tgtacatatt 
P1081107307 tggtcctata tgtatacttt ttcttgtatt gttgttgggc tgtacattat 
P1081006307 tggtcctata tgtatacttt ttcttgtatt gttgttgggt cttgtacaat 
P1081007307 tggtcctata tgtatacttt ttcttgtatt gttgttgggt cttgtacaat 
P1081501307 TGGTCCTATA GGTATACTTT TTCTTGTATT GTTGTTGGGT CTTGTACAAT 
P1081904307 tggtcctata tgtatacttt ttcttgtatt gttgttgggt cttgtacaat 
P1081906307 TGGTCCTATA TGTATACTTT TTCTTGTATT GTTGTTGGGT CTTGTACAAT 
P0120810307 TGGTCCTATA GGTATACTTT TTCTTGTGTT GTTGTTGGGT CTTgTACAAT 
P0121603307 TGGTCCTATA TGTATACCTT TTCTTGTATT GTTGTTGGGT CTTGTACAAT 
P0121604307 tggtcctata tgtatacctt ttcttgtatt gttgttgggt cttgtacaat 
P0822407307 TGGTCCTATA TATATCCTTT TTTT .......................... 
P1231409307 TGGTCCTATA TGTATCCTTT TTCTTGTATT GTTGTTGGGT CTTGTACAAT 
P1231410307 TGGTCCTATA TGTATCCTTT TTCTTGTATT GTTGTTGGGT CTTGTACAAT 
P1231411307 TGGTCCTATA TGTATCCTTT TTCTTGTATT GTTGTTGGGT CTTGTACAAT 
P1390516307 tggtcctata tgtatacctt ttcttgtatt gttgttgggt cttgtacaat 
P1390520307 TGGTCCTATA TGTATACCTT TTCTTGTATT GTTGTTGGGT CTTGTACAAT 
257 
P1390501307 tggtcctata tgtatacctt ttcttgtatt gttgttgggt cttgtacaat 
P1390503307 tggtcctata tgtatacctt ttcttgtatt gttgttgggt cttgtacaat 
P1390608307 tggtcctata tgtatacctt ttcttgtatt gttgttgggt cttgtacaat 
P1390610307 TGGTCCTATA TGTATACCTT TTCTTGTATT GTTGTTGGGT CTTGTACAAT 
P1390611307 TGGTCCTATA TGTATACCTT TTCTTGTATT GTTGTTGGGT CTTGTACAAT 
P1396b09307 TGGTCCTATA TGTATACCTT TTCTTGTATT GTTGTTGGGT CTTGTACAAT 
P1396b12307 tggtcctata tgtatacctt ttcttgtatt gttgttgggt cttgtacaat 
201 	 250 
P1081827307 
P1081828307 taatttctac agattccttc agctgtacta ttatt ............... 
P1081103307 	ctc ............................................... 
P1081107307 tctc .............................................. 
P1081006307 	taattct ........................................... 
P1081007307 taattct ........................................... 
P1081501307 TAATTACTAC AGATTCCTTC AGCTGTACTA TTATGGTTTT AGCATT. 
P1081904307 taattactac agattcattc agctgtac ...................... 
P1081906307 TAATTACTAC AGATTCATTC AGCTGTACTA TTATgGTTTT .......... 
P0120810307 TAATTTCTAC AGATTCCTTC AGCTGtacta ttatggtttt .......... 
P0121603307 TAATTACTAC AGATTCATTC AGCTGTACTA TTATGGTTT ........... 
P0121604307 	taattactac agattcatt ............................... 
P0822407307 
P1231409307 TAATTACTAC AGATTCATTC AGCTGTACTA TTATG ............... 
P1231410307 	TAA ............................................... 
P1231411307 TAATTACTAC AGA ....... .......... .......... .......... 
P1390516307 taattactac agattcattc agctgtacta tatgtttt ............ 
P1390520307 TAATTACTAC AGATTCATTC AGCTGTACTA TATGTTTTAG CAT ....... 
P1390501307 taattactac agattcattc agctgtacta tatgttttag .......... 
P1390503307 taattactac agattcattc agctgtacta tatgttt ............. 
P1390608307 taattactac agattcattc agtgtactat tatggtttta gcattgtctg 
P1390610307 TAATTACTAC AGATTCATTC AGCTGT ........................ 
P1390611307 TAATTACTAC AGATTCATTC AGCG ...... .......... .......... 
P1396b09307 TAATTACTAC AGATTCATTC AGCTGTACTA TTATGGTTTT AGCATTGTCT 
P1396b12307 	taattacta ......................................... 
























P1396b0 9307 GTGAAATTGC TAGATCTAAT TACTACCCC 
P1396b12307 
258 
c) V4-C4-V5 regions (primers 407 sense) 
clone 1 50 
P1081827407 .......... 	.......... ..... gtact tggaattcac cacaacttaa 
P1081828407 .......... ....... GTT TAATAGTACT TGGAATTCAC CACAACTTAA 
P1081103407 .......... 	.......... .. CTTGGAAT TATTCTAATG ATACTTGGAG 
P1081107407 .......... .......... .......... .......... ... cttggag 
P1081004407 .......... 	.......... ..... ggaat tattctaatg gtacttggat 
P1081006407 .......... ......... g tacttggaat tattctaatg gtaattggag 
P1081007407 .......... 	......... g tacttggaat tattctaatg gtaattggag 
P1081504407 .......... . GTTTAATAG TACTTGGAAT TATTATAATG GTACTTGGAA 
P1081904407 .......... 	.......... ..... ggaat tattctaatg gtacttggat 
P1081906407 .........C TGTTTAATAG TACTTGGAAT TATTCTAATG GTACTTGGAT 
P0120810407 .......... 	......... G TACTTGGATC TATTCTAATG GTACTTGGAA 
P0121603407 
P0121604407 . . . CTGTTTA ATAGTACTTG GAATTCAACA TGGGATTTAA CACAACTTAA 
P0121614407 CACTGTTTA ATAGTACTTG GAATTCAACA TGGGATTTAA CACAACTTAA 
P0822407407 CAACTGTAAA ATAGTACTTG GAATTCAACA TGGGATTTAA CACAACTTAA 
P1231409407 .......... 	...... CTTG GAATTCAACA TGGGATTTAA CACAACTTAA 
P1390501407 .......... .......... .......... ........ aa cacaacttaa 
P1390516407 ........TA ATAGtACTTG GAATTCAACA TGGGATTTAA CACAACTTAA 
P1390520407 .......... 	...... CTTG GAATTCAACA TGGGATTTAA CACAACTTAA 
P1390503407 ........TA ATAGtACTTG GAATTCAACA TGGGATTTAA CACAACTTAA 
P1390603407 .......... 	.......... .......... ....... TAA CACAACTTAA 
P1390604407 ......................................AA CACAACTTAA 
P1390606407 ......................................AA CACAACTTAA 
P1390608407 .......... 	...... CTTG GAATTCAACA TGGGATTTAA CACAACTTAA 
P1390610407 .....GTTTA ATAGTACTTG GAATTCAACA TGGGATTTAA CACAACTTAA 
P1390611407 .......... 	...... CTTG GAATTCAACA TGGGATTTAA CACAACTTAA 
P1396b07407 .......... .......... .......... ........ aa cacaattt.. 
P1396b09407 .......... 	... GAACTTG GAATTCAACA TGGGATTTAA CACAATTT.. 
P1396b12407 .......... .......... ...........gggatttaa cacaattt.. 
P1396b12407 .......... 	... GTACTTG GAATTCAACA TGGGATTTAA CACAATTT.. 
51 	 100 
P1081827407 taatacttgg aataatactg aagaaaatat cacactccca tgtagaataa 
P1081828407 TAATACTTGG ATAATACTG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1081103407 TTCAACACAA CATAATACTG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1081107407 ttcaacacaa cataatactg aagaaaatat cacactccca tgtagaataa 
P1081004407 ttcaacacaa cataatactg aataaaatat cacactccca tgtagaataa 
P1081006407 TTCAACACAA CATAATACTG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1081007407 ttcaacacaa cataatactg aagaaaatat cacactccca tgtagaataa 
P1081504407 TTCAACACAA CATAATACTG GAGAAAATAT CACACTCCCA TGTAGAATAA 
P1081904407 ttcaacacaa cataatactg aagaaaatat cacactccca tgtagaataa 
P1081906407 TTCAACACAA CATAATACTG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P0120810407 TCCAACACAA CATAATACTG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P0121603407 .......... ..TAA ... AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P0121604407 TAGTACTCGA AATAA ... AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P0121614407 TAGTACTCGG AATAA ... AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P0822407407 TAGTACTCAG AATAA.. .AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1231409407 TAGTACTCAG GATAA ... AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1390501407 tagtactcag aataa ... ag aagaaaatat cacactccca tgtagaataa 
P1390516407 TAGTACTCAG AATAA ... AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1390520407 TAGTACTCAG AATAA ... AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1390503407 TAGTACTCAG AATAA.. .AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1390603407 TAGTACCCAG AATAA.. .AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1390604407 TAGTACCCAG APTAA.. AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1390606407 TAGTACCCAG AATAA ... AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1390608407 TAGTACTCAG AATAA ... AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1390610407 TAGTACTCAG AATAA ... AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1390611407 TAGTACTCAG AATAP ... AG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1396b07407 .......cag aatga.. .ag aagaaaatat cacactCCCA TGTAGAATAA 
P1396b09407 ..........CAGAATGAAG AAGAAAATAT CACACTCCCA TGTAGAATAA 
P1396b12407 .......cag aatga ... ag aagaaaatat cacactccca tgtagaataa 
P1396b12407 ..........CAGAATGAAG AAGAAAATAT CACACTCCCA TGTAGAATAA 
259 
101 	 150 
P1081827407 aacaaattat aaacatgtgg caggaagtag gaaaagcaat gtatgcccct 
P1081828407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1081103407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCC 
P1081107407 aacaaattat aaacatgtgg caggaagtag gaaaagcaat gtatgccccc 
P1081004407 aacaaattat aaacatgtgg caggaagtag gaaaagcaat gtatgcccct 
P1081006407 AACAAATTAT AAACATGTGG CAGGGAGTAG GAAAAGCAAT GTATGCCCCT 
P1081007407 aacaaattat aaacatgtgg cagggagtag gaaaagcaat gtatgcccct 
P1081504407 AACAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1081904407 aacaaattat aaacatgtgg caggaagtag gaaaagcaat gtatgcccct 
P1081906407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P0120810407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P0121603407 AACAAATTAT AAATATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P0121604407 AACAAATTAT AAATATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P0121614407 AACAAATTAT AAATATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P0822407407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAP.AAGcAAt gtatgcccct 
P1231409407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1390501407 aacaaattat aaacatgtgg caggaagtag gaaaagcaat gtatgcccct 
P1390516407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1390520407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1390503407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1390603407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1390604407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1390606407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1390608407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1390610407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1390611407 AACAAATTAT AACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1396b07407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1396b09407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAAGCAAT GTATGCCCCT 
P1396b12407 aacaaattat aaacatgtgg caggaagtag gaaaagcaat gtatgcccct 
P1396b12407 AACAAATTAT AAACATGTGG CAGGAAGTAG GAAAA ............... 
151 	 200 
P1081827407 cccatcagag gacaaattag atgttcatca aatattacag ggctactatt 
P1081828407 CCCATCAGAG GACAAATTAG ATGTTCATCA AATATTACAG GGCTACTATT 
P1081103407 CCCATCAGAG GACAAATTAG ATGTTCATCa AATATTACAG GGCTACTATT 
P1081107407 cccatcagag gacaaattag atgttcatca aatattacag ggctactatt 
P1081004407 cccatcagag gacaaattag atgttcatca aatattacag ggctactatt 
P1081006407 CCCATCAGAG GACAAATTAG ATGTTCATCA AATATTACAG GGCTACTATT 
P1081007407 cccatcagag gacaaattag atgttcatca aatattacag ggctactatt 
P1081504407 CCCATCAGAG GACAAATTAG ATGTTCATCA AATATTACAG GGCTACTATT 
P1081904407 cccatcagag gacaaattag atgttcatca aatattacag ggctactatt 
P1081906407 CCCATCAGAG GACAAATTAG ATGTTCATCA AATATTACAG GGCTACTATT 
P0120810407 CCCATCAGAG GACAAATTAG ATGTTCATCA AATATTACAG GGCTACTATT 
P0121603407 CCCATCAGAG GACAAATTAG ATGTTCATCA AATATTACag GGCTATTGTT 
P0121604407 CCCATCAGAG GACAAATTAG ATGTTCATCA ATATTACAG GGCTATTATT 
P0121614407 CCCATCAGAG GACAAATTAG ATGTTCATCA AATATTACAG GGCTATTATT 
P0822407407 cccatcagcg gacaaattag atgttcatca aatattcaag ggctactatt 
P1231409407 CCCATCAAAG GACAAATTAG ATGTTCATCA AATATTACAG GGCTACTATT 
P1390501407 cccatcagag gacaaattag atgttcatca aatattacag ggctattatt 
P1390516407 CCCATCAGAG GACAAATTAG ATGTTCATCA AATATTACAG GGCTATTATT 
P1390520407 CCCATCAGAG GACAAATTAG ATGTtCATCA AATATTACAG GGCTATTATT 
P1390503407 CCCATCAGAG GACAAATTAG ATGTTCATCA AATATTACAG GGCTATTATT 
P1390603407 CCCATCAGAG GACAAATTAG ATGTTCATCA AATATTACAG GGCTATTATT 
P1390604407 CCCATCAAAG GACAAATTAG ATGTTCATCA ACTATTACAG GGCTACTATT 
P1390606407 CCCATCAGAG GACAAATTAG ATGTTCATCA AATATTACAG GGCTATTATT 
P1390608407 CCCATCAAAG GACAAATTAG ATGTTCATCA ACTATTACAG GGCTACTATT 
P1390610407 CCCATCAAAG GACAAATTAG ATGTTCATCA ACTATTACAG GGCTACTATT 
P1390611407 CCCATCAAAG GACAAATTAG ATGTTCATCA ACTATTACAG GGCTACTATT 
P1396b07407 CCCATCAGAG GACAAATTAG aTGTTCATCA AATATTACAG GGCTACTATT 
P1396b09407 CCCATCAGAG GACAAATTAG ATGTTCATCA AATATTACAG GGCTACTATT 
P1396b12407 cccatcagag gacaaattag atgttcatca aatattacag ggctactatt 
P1396b12407 
201 	 250 
P1081827407 	aacaagagat ggtggtaaca cg ............................ 




P1081004407 aacaagagat ggtggtaatg gtggtaacaa aagcaacg .. .......... 
P1081006407 AACAAGAGAT GGTGGTAACA ACACGAACGG GACCGAGATC TTCAGACCTG 
P1081007407 aacaagagat ggtggt .................................. 
P1081504407 AACAAGAGAT GGTGGT .................................. 
P1081904407 aacaagagat ggtggtaatg gtggtaacaa aagcaacg .. .......... 
P1081906407 AACAAGAGAT GGTGGTAATG GTGGTAACAA AAGCAACGAC ACCACCGAGA 
P0120810407 AACAAGAGAT GGTGGTAACA AGAGCGAGAC CGACCCC ............. 
P0121603407 AACAAGAGAT GGTGGTAATG GTGGTA .... 	.......... .......... 
P0121604407 AACAAGAGAT GGTGGTAATG GTGGTAACAA A ......... .......... 
P0121614407 AACAAGAGAT GGTGGTAATG GTGGTAACAA A ......... .......... 
P0822407407 aacaagagat ggtggtaata gtggtaacaa aagcaacgac accaccgaga 
P1231409407 AACAAGAGAT GGTGGTAATA GTGGTAACAA AAGCAACG .. .......... 
P1390501407 aacaagagat ggtggtaatg gtggtaacaa aa ........ .......... 
P1390516407 AACAAGAGAT GGTGGTAATG GTGGTAACAA AAGCAACGAC ACCACCGAGA 
P1390520407 AACAAGAGAT ........................................ 
P1390503407 AACAAGAGAT GGTGGTAATG GTGGTAACAA AAGCAACGAC ACCACCGAGA 
P1390603407 AACAAGAGAT GGTGGTAATG GTGGTAACAA AA.................. 
P1390604407 AACAAGAGAT GGTGGTAATA GTGGTAACAA AA.................. 
P1390606407 AACAAGAGAT GGTGGTAATG GTGGAACAAA AGCAAC .... .......... 
P1390608407 AACAAGAGAT GGTGGTAATA GTGGTAACAA AAGCAACGAC ACCACC.... 
P1390610407 AACAAGAGAT GGTGGTAATA GTGGTAACAA AAGCAACGAC ACCACCGAGA 
P1390611407 AACAAGAGAT GGTGGTAATA GTGGTAACAA AAGCAACGAC ACCACCGAGA 
P13 96b07 407 AACAAGAGAt GGTGGTGACA CGAGC ..... 	.......... ...... 	.... 
P1396b09407 AACAAGAGAT GGTGGTGACA C ............................. 
P1396b12407 aacaagagat ggtggtgaca cgag ...... .......... .......... 
P1396b12407 















P0822407407 ccttcagacc tgggg 
P1231409407 
P1390501407 
P1390516407 CCTTCAGACC TGGGGGAGGA GATATGA 
P1390520407 










































d) gp4l (primer 367 antisense) 
clone 1 50 
P1081827367 .......... . CCAAGGCAC AGTAGTGGTG CAAATGAGTT TTCCAGAGCA 
P1081828367 .......... . ccaaggcac agtagtggtg caaatgagtt ttccagagca 
P1081107367 . . . CTAGCAT TCCAAGGCAC AGCAGTGGTG CAAATGAGTT TTCCAGAGCA 
P1081501367 .......... ..... ggcac agcagtggtg caaatgagtt ttccagagca 
P1081504367 ......GCAT TCCAAGGCAC AGCAGTGGTG CAAATGAGTT TTCCAGAGCA 
P1081906367 .......... ..... ggcac agcagtggtg caaatgagtt ttccagagca 
P0120810367 .......... . ccaaggcac agcagtggtg caaatgagtt ttccagagca 
P0121603367 ......GCAT TCCAAGGCAC AGCAGTGGTG CAAATGAGTT TTCCAGAGCA 
P0121604367 ggcttagcat tccaaggcac agcagtggtg caaatgagtt ttccagagca 
P0121614367 ........................................TTCCAGAGCA 
P1231409367 .......GTA TCCAAGGCAC AGCAGTGGTG CAAATGAGTT TTCCAGAGCA 
P1390516367 .......GTA TCCAAGGCAC AGCAGTGGTG CAAATGAGTT TTCCAGAGCA 
P1390520367 .......GTA TCCAAGGCAC AGCAGTGGTG CAAATGAGTT TTCCAGAGCA 
P1390501367 .......GTA TCCAAGGCAC AGCAGTGGTG CAAATGAGTT TTCCAGAGCA 
P1390503367 .......GTA TCCAAGGCAC AGCAGTGGTG CAAATGAGTT TTCCAGAGCA 
P1390608367 ......GCAT TCCAAGGCAC AGCAGTGGTG CAAATGAGTT TTCCAGAGCA 
P1390610367 ......GCAT TCCAAGGCAC AGCAGTGGTG CAAATGAGTT TTCCAGAGCA 
P1390611367 ......GCAT TCCAAGGCAC AGCAGTGGTG CAAATGAGTT TTCCAGAGCA 
P1396b09367 .......... ..... GGCAC AGCAGTGGTG CAAATGAGTT TTCCAGAGCA 
P1396b12367 ......gtat tccaaggcac agcagtggtg caaatgagtt ttccagagca 
51 	 100 
P1081827367 ACCCCWTC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACAGCCA 
P1081828367 accccaaatc cctaggagct gttgatcctt taggtatctt tccacagcca 
P1081107367 ACCCCAAATC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACAGCCA 
P1081501367 accccaaatc cctaggagct gttgatcctt taggtatctt tccacagcca 
P1081504367 ACCCCAAATC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACAGCCA 
P1081906367 accccaaatc cctaggagct gttgatcctt taggtatctt tccacagcca 
P0120810367 accccaaatc cctaggagct gttgatcctt taggtatctt tccacagcca 
P0121603367 ACCCCAAATC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACAGCCA 
P0121604367 accccaaatc cctaggagct gttgatcctt taggtatctt tccacagcca 
P0121614367 ACCCCAAATC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACAGCCA 
P1231409367 ACCCCAAATC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACAGCCA 
P1390516367 ACCCCAAATC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACaGCCA 
P1390520367 ACCCCAAATC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACAGCCA 
P1390501367 ACCCCAAATC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACaGCCA 
P1390503367 ACCCCAAATC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACAGCCA 
P1390608367 ACCCCAAATC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACAGCCA 
262 
P1390610367 ACCCCAAATC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACAGCCA 
P1390611367 ACCCCAAATC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACAGCCA 
P1396b09367 ACCCCAAATC CCTAGGAGCT GTTGATCCTT TAGGTATCTT TCCACAGCCA 
P1396b12367 accccaaatc cctaggagct gttgatcctt taggtatctt tccacagcca 
101 	 150 
P1081827367 GGACTCTTGC CTGGAGCTGC TTGATGCCCC AGACTGTGAG TTGCAACAGA 
P1081828367 ggactcttgc ctggagctgc ttgatgcccc agactgtgag ttgcaacaga 
P1081107367 GGACTCTTGC CTGGAGCTGC TTGATGCCCC AGACTGTGAG TTGCAACAGA 
P1081501367 ggactcttgc ctggagctgc ttgatgcccc agactgtgag ttgcaacaga 
P1081504367 GGACTCttGC CTGGAGCTGC TTGATGCCCC AGACTGTGAG TTGcAACAGA 
P1081906367 ggactcttgc ctggagctgc ttgatgcccc agactgtgag ttgcaacaga 
P0120810367 ggactcttgc ctggagctgc ttaatgcccc agactgtgag ttgcaacaga 
P0121603367 GGACTCTTGC CTGGAGCTGC TTGATGCCCC AGACTGTGAG TTGCAACAGA 
P0121604367 ggactcttgc ctggagctgc ttgatgcccc agactgtgag ttgcaacaga 
P0121614367 GGACTCTTGC CTGGAGCTGC TTGATGCCCC AGACTGTGAG TTGCAACAGA 
P1231409367 GGACTCTTGC CTGGAGCTGC TTGATGCCCC AGACTGTGAG TTGCAACAGA 
P1390516367 GGACTCTTGC CTGGAGCTGC TTAATGCCCC AGACTGTGAG TTGCAACAGA 
P1390520367 GGACTCTTGC CTGGAGCTGC TTAATGCCCC AGACTGTGAG TTGCAACAGA 
P1390501367 GGACTCTTGC CTGGAGCTGC TTAATGCCCC AGACTGTGAG TTGCAACAGA 
P1390503367 GGACTCTTGC CTGGAGCTGC TTAATGCCCC AGACTGTGAG TTGCAACAGA 
P1390608367 GGACTCTTGC CTGGAGCTGC TTGATGCCCC AGACTGTGAG TTGCAACAGA 
P1390610367 GGACTCTTGC CTGGAGCTGC TTGATgCCCC AGACTGTGAG TTGCAACAGA 
P1390611367 GGACTCTTGC CTGGAGCTGC TTGATGCCCC AGACTGTGAG TTGCAACAGA 
P1396b09367 GGACTCTTGC CTGGAGCTGT TTGATGCCCC AGACTGTGAG TTGCAACAAA 
P1396b12367 ggactcttgc ctggagctgt ttgatgcccc agactgtgag ttgcaacaaa 
151 	 200 
P1081827367 TGCTGTTGCG CCTCAATAGC CCTCAGCAGA TTGTTCTGCT GTTGCACTAT 
P1081828367 tgctgttgcg cctcaatagc cctcagcaga ttgttctgct gttgcactat 
P1081107367 TGCTGTTGCG CCTCAATAGC CCTCAGCAAA TTGTTCT ............. 
P1081501367 t ................................................. 
P1081504367 TGCTGTTgcG CCTCAATAGC CCTCAGCAAA TTGTTCTGCT GTTGCACTAT 
P1081906367 tgctgttgcg cctcaatagc cctcagcaaa ttgttctgct gctgcactat 
P0120810367 tgctgttgcg cctcaatagc cctcagcaaa ttgttctgct gttgcactat 
P0121603367 	TGCTGTTGCG CCT ..................................... 
P0121604367 tgctgttgcg cctcaatagc cctcagcaaa ttgttctgct gttgc ..... 
P0121614367 TGCTGTTGCG CCTCAATAGC CCTCAGCAAA TTGTTCTGCT GTTGCACTAT 
P1231409367 TGCTGTTGCG CCTCAATAGC CCTCAGCAAA TTGTTCTGCT GTTGCACTAT 
P1390516367 TGCTGTTGCG CCTCAATAGC CCTCAGCAAA TTGTTCTGCT GTTGCACTAT 
P1390520367 TGCTGTTGCG CCTCAATAGC CCTCAGCAAA TTGTTCTGCT GTTGCACTAT 
P1390501367 TGCTGTTGCG CCTCAATAGC CCTCAGCAAA TTGTTCTGCT GTTGCACTAT 
P1390503367 TGCTGTTGCG CCTCAATAGC CCTCAGCAAA TTGTTCTGCT GTTGCACTAT 
P1390608367 TGCTGTTGCG CCTCAATAGC CCTCAGCAAA TTGTTCTGCT GTTGCACTAT 
P1390610367 TGCTGTTgcG CCTCAATAGC CCTCAGCAAA TTGTTCTGCT GTTGCACTAT 
P1390611367 TGCTGTTGCG CCTCAATAGC CCTCAGCAAA TTGTTCTGCT GTTGCACTAT 
P1396b09367 TGCTGTTGCG CCTCAATAGC CCTCAGCAAA TTGTTCTGCT GTTGCACTAT 
P1396b12367 tgctgttgcg cctcaatagc cctcagcaaa ttgttctgct gttgcactat 
P 10818273 67 
P 108182 83 67 
P1081107367 
P1081501367 
P 108 15 043 67 
P 108 190 63 67 
P0 12 08 103 67 
P0 12 16033 67 
P0 12 16043 67 
P 0 12 16 143 67 
P 12 3 14 0 93 67 
P 13 905163 67 
P 13 90 52 03 67 
P 13 9050 13 67 
P 13 905 033 67 
P 13 90 60 83 67 
P 13 90 6103 67 
P 13 90 6113 67 
201 	 250 
ACCAGACAAT AATAGTCTGG CCTGTACCGT CAGCGCCATT GACGCTGCGC 
accagacaat aatagtctgg cc ............................ 
ACCAGACAAT AATAG ..... .......... .......... .......... 
accagacaat aatagtctgg cctgt ......................... 
accagacaat aatagtctgg cctgtaccgt cagcgccatt gacgctgcgc 
ACCAGACAAT AATAGTCTGG CCTGTACC.. 
CCAGACATAT GATCTGG ... .......... 
ACCAGACAAT AATAGTCTGG CC ........ 
ACCAGACAAT AATAGTCTGG CC ........ 
ACCAGACAAT AATAGTCTGG CC ........ 
ACCAGACAAT AATAGTCTGG CC........ 
ACCAGACAAT AATAGTCTGG CCTGTACC.. 
ACCAGACAAT AATAGTCTGG CCTGTACCGT 
ACCAGACAAT AATAGTCTGG CCTGTACCGT 
263 
P1396b09367 ACCAGACAAT AATAGTCTGG CCTGTACCGT CAGCGCCATT GACGCTGCGC 
P1396b12367 	accagacaat aatag ..... .......... .......... .......... 
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